Page last updated: 2024-09-28

Absence Seizure

Synonyms(53)

Synonym
Epileptic Seizures
Tonic Clonic Seizure
Generalized Absence Seizure
Convulsive Seizure
Seizures, Epileptic
Single Seizure
Partial Seizures
Generalized Absence Seizures
Convulsive Seizures
Seizures, Focal
Convulsions
Seizures, Generalized
Seizures, Gustatory
Seizures, Convulsive
Seizures, Clonic
Non-Epileptic Seizure
Non-Epileptic Seizures
Partial Seizure
Seizures, Motor
Seizures, Olfactory
Seizures, Sensory
Nonepileptic Seizure
Seizures, Somatosensory
Nonepileptic Seizures
Epileptic Seizure
Convulsion
Seizures, Tonic
Seizures, Tonic-Clonic
Seizures, Vertiginous
Seizures, Auditory
Seizures, Vestibular
Seizures, Visual
Tonic-Clonic Seizures
Absence Seizure
Absence Seizures
Clonic Seizure
Convulsion, Non-Epileptic
Jacksonian Seizure
Myoclonic Seizure
Myoclonic Seizures
Seizure
Clonic Seizures
Petit Mal Convulsion
Tonic-Clonic Seizure
Complex Partial Seizures
Complex Partial Seizure
Generalized Tonic-Clonic Seizures
Tonic Seizure
Tonic Seizures
Atonic Absence Seizure
Atonic Absence Seizures
Atonic Seizure
Atonic Seizures

Research Excerpts

Overview

ExcerptReference
"Convulsions are stopped after anaesthesia with pentobarbitone."( Damas, J; Lecomte, J; Lecomte, JH; Piette, JL, 1978)
"Seizures are also accompanied by significant reductions in extracellular Ca2+ activity (aCa) to as low as 0."( Heinemann, U; Lux, HD, 1978)
"Type II (tonic) seizures are invariably associated with profound transient bradycardia, recovery from which begins about the time the tonic seizure phase ends."( Beaver, RW; Brauer, RW; Fuquay, J, 1979)
"(Time to convulsions is referred to as the induction period, and time between convulsions as the interictal period."( Segerbo, BE, 1979)
"Included in the convulsions are wild running, tonic-clonic activity, and occasionally death."( Philo, R; Reiter, RJ, 1978)
"Generalized clonic-tonic seizures are induced by higher volume injections (50 microliter) associated with wider distribution of ouabain, including the cerebellum and brainstem."( Barbeau, A; Davidson, DL; Tsukada, Y, 1978)
"The hypothesis that convulsions are means to reduce the changes of physical dependence in the central nervous system was not refuted by the present experiments."( Wahlström, G, 1976)
"The seizures are characterized by running, hopping, and vocalizing and are mixed with shorter-duration tonic episodes."( Doerr, JK; Konkol, RJ; Madden, JA, 1992)
"Cocaine-induced seizures are common and appear to be due to the local anaesthetic actions of this compound."( Djenderedjian, AH; Giombetti, R; Mena, I; Miller, BL; Villanueva-Meyer, J, 1992)
"Experimental seizures are followed by an especially rapid and massive induction of brain ornithine decarboxylase (ODC), an enzyme which catalyses the rate-limiting step in the synthesis of polyamines."( de Belleroche, JS; Herberg, LJ; Mintz, M; Rose, IC, 1992)
"Seizure is a common problem evaluated in pediatric emergency departments."( Davis, AT; Nypaver, MM; Reynolds, SL; Tanz, RR, 1992)
"Spinal cord seizures are infrequently reported."( Cross, LL; Meythaler, JM; Tuel, SM, 1991)
"Seizures are a recognized manifestation of neurosarcoidosis, but their clinical relevance is not well established."( Krumholz, A; Stern, BJ; Stern, EG, 1991)
"We emphasize that convulsions are not infrequent side effect of conditioning regimens including high dose busulfan, and efficient anticonvulsant prophylactic regimens should be used."( Berberana, M; De La Camara, R; Fernandez-Rañada, JM; Figuera, A; Tomas, JF, 1991)
"Treating seizures is a major part of a neurologic practice."( Bernstein, AL, 1990)
"Experimental seizures are more readily produced in infant than adult rats, possibly related to a developmental predominance of NMDA receptor-mediated effects."( Pasternak, JF; Trommer, BL, 1990)
"Eclamptic seizures are clinically and electroencephalographically indistinguishable from generalized tonic-clonic seizures."( Fisher, RS; Hanley, DF; Kaplan, PW; Lesser, RP; Repke, JT, 1990)
"Seizures are common in acute exacerbations of hepatic porphyria, even though the etiology is not identified in most cases."( Deeg, MA; Rajamani, K, 1990)
"Seizures are a less frequent, but important complication."( Kieburtz, K; Moxley, RT; Ricotta, JJ, 1990)
"When partial seizures are identified they are attributed to preceding brain damage, head trauma or stroke."( Baulac, M; Laplane, D, 1990)
"Convulsive seizures are a potential side effect of antidepressant drug treatment and can be produced by all classes of antidepressants."( Ikeda, M; Knapp, RJ; Malatynska, E; Yamamura, HI, 1988)
"Pilocarpine seizures are characterized by a sequential development of behavioral patterns and electrographic activity."( Bortolotto, ZA; Cavalheiro, EA; Ikonomidou, C; Turski, L; Turski, WA, 1989)
"L-allylglycine seizures are associated with generalized decreases in regional GABA levels, and increases in regional glutamine levels."( Chapman, AG, 1985)
"Neocortical focal seizures are characterized by motor jerks in one limb (Jacksonian type), head turning (adversive attack), or localized sensory manifestations, and limbic or psychomotor attacks by brief impairment of consciousness and often by motor automatisms."( Hess, CW, 1988)
"Febrile seizures are common in children."( Wright, SW, 1987)
"Tetanic convulsions are not uncommon among severely dehydrated children in the developing countries."( Aperia, A; Butt, KS; Khan, SR; Lindblad, BS; Murtaza, A, 1988)
"The occurrence of convulsions is not in keeping with the results of animal experiments, studies of epileptic patients treated with nomifensine or observations made following overdoses of this drug."( Edwards, JG; Glen-Bott, M, 1987)
"Convulsions are characteristic of magnesium deficiency and hypocalcemia."( Chaistitwanich, R; Hendricks, DG; Mahoney, AW; Sisson, DV, 1987)
"The seizures are characterized by one or two wild running fits which terminate in a tonic dorsiflexion with open mouth, followed by a catatonic state."( Depaulis, A; Kiesmann, M; Marescaux, C; Micheletti, G; Vergnes, M; Warter, JM, 1987)
"Bilateral seizures are obtained after about 15 stimulations of the amygdala in the rat."( LeGal La Salle, G; Papy, JJ; Rougier, I; Vion-Dury, J, 1986)
"Febrile seizures are a common problem."( Ater, SB; Bettis, DB, 1985)
"These seizures are characterized by tonic spasm in the extremities, often accompanied by painful dysesthesias, and are fleeting, usually lasting no more than two minutes."( Cherrick, AA; Ellenberg, M, 1986)
"Seizures are an occasional manifestation of phenytoin toxicity, particularly when levels are high."( Masdeu, JC; Stilman, N, 1985)
"Her seizures are now treated successfully with phenytoin."( Soman, M; Swenson, C, 1985)
"L-Allylglycine seizures are associated with generalized decreases in GABA concentrations (-32 to -54%), increases in glutamine concentrations (+10 to +53%), and a decrease in cortical aspartate concentration (-14%)."( Chapman, AG; Meldrum, BS; Premachandra, M; Westerberg, E, 1984)
"The occurrence of convulsions is not in keeping with the results of animal experiments and of clinical trials in which epileptic patients were included, both of which suggest that viloxazine does not have epileptogenic properties and may have anticonvulsant actions."( Edwards, JG; Glen-Bott, M, 1984)
"Seizures are a common occurrence in patients who are dependent on alcohol."( McMicken, D, 1984)
"Penicillin induced seizures are not affected by furosemide."( Kariv, N; Noy, S; Rubinstein, E; Schtacher, G, 1984)
"These convulsions are tonic-clonic."( Colombo, R; Ossi, C; Pinelli, A; Spazzi, L; Tofanetti, O, 1984)
"The 'typical' T4-T7 seizure is a scratch reflex followed by the tonic-clonic seizure lasting for 20-30 s and ending with a scratch afterdischarge lasting for several minutes."( Chambers, WW; Chen, WP; Herdman, SJ; Liu, CN; Yu, J, 1984)
"These seizures are indistinguishable in quality from those induced by pentylenetetrazol (PTZ), and pretreatment with low doses of caffeine potentiates PTZ-induced seizures."( Marangos, PJ; Martino, AM; Paul, SM; Skolnick, P, 1981)
"Sound-induced seizures are suppressed by the i."( Croucher, MJ; Krogsgaard-Larsen, P; Meldrum, BS, 1983)
"Brainstem-triggered convulsions are generalized convulsive seizures produced by direct electrical stimulation of the mesencephalic reticular formation."( Burnham, WM; Chiu, P, 1982)
"Febrile seizures are a common pediatric problem, yet there is a great deal of disagreement about the appropriate diagnostic evaluation of a child with this disorder."( Berliner, BC; Gerber, MA, 1981)
"Kynurenine seizures are suggested to be related to the action of kynurenine on glycine receptors in the central nervous system."( Lapin, IP, 1981)
"Catamenial seizures are defined as epileptic seizures occurring during distinct phases of the menstrual cycle (i."( Bauer, J; Elger, CE; Hocke, A, 1995)
"Drug-induced seizures are a potentially serious adverse effect."( Chatel, DM; Dahdal, WY; Franson, KL; Grossberg, GT; Hay, DP; Kotegal, S; Mirza, WU; Neppe, V; Szwabo, PA, 1995)
"Initially seizures are discrete, then undergo waxing-and-waning of convulsive/electroencephalographic severity."( Handforth, A; Treiman, DM, 1995)
"Stimuli that evoke seizure are capable of inducing structural changes in the hippocampus."( Bauer, J; Fischer, B; Platt, D; Popa-Wagner, A; Retchkiman, I, 1995)
"Seizures are a recognized complication of human immunodeficiency virus (HIV)-type-1 infection."( Bodian, C; Maker, H; Van Paesschen, W, 1995)
"Audiogenic seizures are evoked by acoustic stimulation in susceptible (S) but not in resistant (R) rats."( Antunes-Rodrigues, J; Garcia-Cairasco, N; Oliveira, JA; Reis, LC; Terra, VC, 1994)
"Amygdala-kindled seizures are more potently inhibited by phenytoin than by magnesium sulfate."( Cotton, DB; Irtenkauf, SM; Mason, B; Standley, CA; Stewart, L, 1994)
"Since limbic seizures are a more injurious stimulus, the KROX-20 expression profile was investigated in adult rats subjected to kainic acid induced limbic epilepsy at postictal intervals up to 48 h."( Bravo, R; Gass, P; Herdegen, T; Kiessling, M, 1994)
"Convulsions are described as an infrequent complication with this therapy in the non-pregnant population."( DeChazal, R; Halligan, A; Nan, A; Taylor, D, 1993)
"The mechanisms of convulsions are not clear."( Andou, Y; Koyama, K; Matsuo, H; Saruki, K, 1994)
"Seizures are a rare complication after myelography with the current nonionic contrast agents and have not been previously reported in the emergency medicine literature."( Olsen, J, 1994)
"Such seizures are more likely in the elderly, in the presence of pre-existing neurological disease, and when theophylline is given with certain antibiotics and cimetidine."( FitzGerald, MX; Hutchinson, J; Hutchinson, M; O'Riordan, JI, 1994)
"Seizures are uncommon, but serious, adverse effects of antidepressant drugs."( Jacobs, SC; Nelson, JC; Rosenstein, DL, 1993)
"These seizures are characterized by running/bouncing clonus and tonic extensor convulsions."( Bettendorf, AF; Browning, RA; Burger, RL; Jobe, PC; Mishra, PK, 1994)
"Most such seizures are related to acute abstinence from chronic, high doses of alcohol use."( Earnest, MP, 1993)
"Convulsions are frequently observed in severe, acute cyanide intoxication."( Cassel, GE, 1995)
"Generalised or partial seizures are a common problem with many supratentorial gliomas."( Beaumont, A; Clarke, M; Whittle, IR, 1996)
"Epileptic seizures are thought to terminate largely as a result of the extracellular accumulation of the purinergic neuromodulator, adenosine, released by discharging neurons."( Engelbrecht, AH; Herberg, LJ; Kellaway, L; Lamm, MC; Mintz, M; Russell, VA; Taljaard, JJ, 1996)
"Altitude convulsion is a rather specific form of experimental convulsion which is induced by acute exposure to a hypobaric hypoxic condition."( Chen, AC; Chen, CH; Liu, HJ, 1997)
"Convulsive seizures are among the most common problems involving the central nervous system."( Kraus, D; Schmolke, M; Thomasius, R, 1997)
"Pilocarpine-induced seizures are initiated via muscarinic receptors and further mediated via NMDA receptors."( Ebinger, G; Khan, GM; Manil, J; Michotte, Y; Smolders, I, 1997)
"Seizures are common in patients infected with human immunodeficiency virus (HIV)."( Dasgupta, A; McLemore, JL, 1998)
"The SNR effects on seizures are site-specific within the SNR and developmentally regulated."( Löscher, W; Moshé, SL; Velísková, J, 1998)
"In rodents these seizures are readily triggered by sound (audiogenic seizures)."( Faingold, CL; N'Gouemo, P; Riaz, A, 1998)
"Generalized epileptic seizures are underlied by specific circuits where GABAergic synapses are involved at different levels."( Depaulis, A; Deransart, C; Marescaux, C; Vergnes, M, 1997)
"Seizures are commonly encountered in patients who do not have epilepsy."( Delanty, N; French, JA; Vaughan, CJ, 1998)
"Because cocaine seizures are relatively uncommon, they should be diagnosed by exclusion and a neurological workup to rule out central nervous system (CNS) catastrophe should be made."( Blaho, K; Geraci, S; Logan, B; Winbery, S, 1998)
"Partial seizures are usually due to a structural cerebrocortical lesion and may be simple or complex."( March, PA, 1998)
"Seizure is the primary adverse reaction associated with bupropion overdoses."( Paris, PA; Saucier, JR, 1998)
"Whereas neonatal seizures are a predictor of adverse neurological outcome, there is controversy regarding whether seizures simply reflect an underlying brain injury or can cause damage."( Ben-Ari, Y; Chevassus-Au-Louis, N; Gairsa, JL; Holmes, GL, 1998)
"New-onset seizures are infrequent in patients with HIV."( Barrio, JL; Domingo, P; Escartin, A; Fuster, M; Iranzo, A; Marti-Fàbregas, J; Pascual-Sedano, B; Sambeat, MA, 1999)
"Seizures are common after severe cerebral ischemia."( Kim, DC; Todd, MM, 1999)
"Epileptic seizures are associated with increases in hippocampal excitability, but the mechanisms that render the hippocampus hyperexcitable chronically (in epilepsy) or acutely (in status epilepticus) are poorly understood."( Basbaum, AI; Cao, Y; Liu, H; Mazarati, AM; Sankar, R; Wasterlain, CG, 1999)
"Partial onset seizures are more frequent among hazardous drinkers than hitherto recognized."( Bovim, G; Bråthen, G; Brodtkorb, E; Helde, G; Sand, T, 1999)
"Seizures are a frequent problem confronting EMS personnel."( Nicholl, JS, 1999)
"Tonic and clonic seizures are abolished at 15 min (ED(50s) 0."( Chapman, AG; Meldrum, BS; Nanan, K; Yip, P, 1999)
"Although seizures are very common in neonates and are often the harbinger of poor neurologic outcome, there is controversy regarding the degree of brain damage induced by seizures during early development."( Holmes, GL; Schmid, R; Stafstrom, CE; Tandon, P, 1999)
"Nicotine-induced seizures are centrally mediated and involve the activation of alpha7 along with other nicotinic receptor subunits."( Damaj, MI; Dukat, M; Glassco, W; Martin, BR, 1999)
"Conclusion Atypical absence seizures are common in glucose transporter type 1 deficiency and should alert the clinician to the possibility of this treatable disorder when present in a young child with developmental delay."( Boles, RG; Kollros, PR; Mitchell, WG; Mofidi, S; Novotny, EJ; Seashore, MR, 1999)
"Postoperative epileptic seizures are recognised but rare."( Enright, SM; Goulding, PJ; Reuber, M, 2000)
"All patients' seizures are fully controlled on once-a-day low-dose phenobarbital with no side effects."( Lerman, P; Lerman-Sagie, T, 1999)
"Seizures are a well known consequence of human cocaine abuse, and in rodent models, sensitivity to cocaine seizures has been shown to be strongly influenced by genotype."( Belknap, JK; Bergeson, SE; Crabbe, JC; Hain, HS, 2000)
"Seizures is a major toxicity of theophylline."( Gupta, YK; Malhotra, J, 1998)
"Seizures are also often associated with tics and compulsions, which likewise involve cortical-limbic hyperactivity."( Burton, FH; Campbell, KM; McGrath, MJ; Veldman, MB, 2000)
"Experimental absence seizures are associated with perturbations in the presynaptic release of GABA and glutamate within thalamocortical circuitry."( Banerjee, PK; Burnham, M; Hampson, D; Snead, OC, 2000)
"The threshold for seizures is lowered by tramadol."( Levine, BS; Pestaner, JP; Ripple, MG; Smialek, JE, 2000)
"Epileptic seizures are often not the main problem in atypical rolandic epilepsies like CSWS or LKS and the amelioration of cognitive dysfunction by epileptic discharge is the prominent aim of an AED therapy."( Rating, D, 2000)
"Although neonatal seizures are quite common, there is controversy regarding their consequences."( Cha, BH; Cilio, MR; Holmes, GL; Liu, X; McCabe, BK; Silveira, DC; Sogawa, Y, 2001)
"Convulsions are well-known complications of local anesthetics."( Alardo, JP; Bisschop, DY; Germain, ML; Just, BY; Millart, HG; Razgallah, B; Trenque, TC, 2001)
"Febrile seizures are the most common seizures in childhood and, like all seizures, can be frightening to witness."( Baumann, RJ, 2001)
"Subtle seizures are mild paroxysmal alterations in motor or autonomic activity and are unique to the neonatal period."( Aggarwal, R; Deorari, AK; Paul, VK; Upadhyay, A, 2001)
"Seizures are associated with pronounced changes in regional cerebral blood flow."( Borbély, K, 2001)
"Seizures are commonly associated with hypoxic-ischemic encephalopathy."( Armstrong, DL; Battin, MR, 2001)
"Convulsions are a common complication of severe malaria in children and are associated with poor outcome."( Crawley, J; Edwards, G; Kokwaro, GO; Marsh, K; Muchohi, SN; Newton, CR; Ogutu, BR; Otieno, GO, 2002)
"Epileptic seizures are followed by dynamic alterations in neurological function in the postictal period."( Baumgartner, C; Leutmezer, F, 2002)
"Other childhood seizures are also responsive to ACTH."( Burnham, WM; Edwards, HE; Vimal, S, 2002)
"Pilocarpine-induced seizures are mediated by the M(1) subtype of muscarinic acetylcholine receptor (mAChR), but little is known about the signaling mechanisms linking the receptor to seizures."( Berkeley, JL; Decker, MJ; Levey, AI, 2002)
"Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis."( Chan, KW; Choroszy, M; Koontz, S; Mullen, CA; Slopis, J; Tran, H; Worth, LL, 2002)
"The new onset seizure is then the manifestation of this abnormality."( Martinus, I; Modi, G; Modi, M; Vangu, M, 2002)
"Flurothyl-induced convulsions are associated with GABA receptors; hence, benzodiazepine (BDP) suppression may result from the strong relation between BDP and GABAnergic neurons."( Araki, H; Futagami, K; Gomita, Y; Hashimoto, Y; Kawasaki, H; Kobayashi, Y, 2002)
"Seizures are an uncommon but serious complication of hyponatremia which can lead to permanent brain damage and even death."( Tokeshi, J; Youn, KS, 2002)
"Severity of tonic convulsive seizures is a determinant of disordered cardiac autonomic regulation and directly influences the duration of cardiac arrhythmia during the immediate postictal state following MES."( Casebeer, D; Darbin, O; Naritoku, DK, 2003)
"Epileptic seizures are associated with neuronal hyperactivity."( Bikson, M; Fox, JE; Hahn, PJ; Jefferys, JG, 2003)
"Such seizures are more common among adolescents."( Bailine, SH; Doft, M; Lui, G; Petrides, G, 2003)
"The seizures are resistant to conventional anticonvulsants."( Akre, B; Lundby, R; Rasmussen, M, 2004)
"Some electrographic seizures are generated intracortically."( Grenier, F; Steriade, M; Timofeev, I, 2004)
"Generalized seizures are commonly thought to involve the entire brain homogeneously."( Blumenfeld, H; McNally, KA, 2004)
"Convulsions are major and life-threatening signs of organophosphate (OP) nerve agents induced neurotoxicity."( Auta, J; Costa, E; Davis, J; Guidotti, A, 2004)
"Second, that the seizure is not inherently harmful but is, instead, associated with massive intracerebral circulatory changes that are intended to restore impaired mitochondrial function."( Doman, G; Pelligra, R, 2004)
"Seizures are reported to occur more frequently among children with diagnoses of autism and pervasive developmental disorder (PDD), and some reports indicate a frequency as high as 30%."( Castello, FV; Mehta, UC; Patel, I, 2004)
"Hypocalcemic seizures are uncommon and underdiagnosed complications of long-term therapy with AEDs."( Al-Busairi, WA; Al-Bustan, MA; Al-Mulla, FA; Ali, FE, 2004)
"Neonatal seizures are the most common manifestation of underlying cerebral dysfunction."( Armstrong, EA; Jaharus, C; Saucier, DM; Wirrell, EC; Yager, JY, 2004)
"Seizures are both caused by and induce a complex set of neurobiological alterations and adaptations."( Post, RM, 2004)
"Convulsions are common complications of shigellosis in children."( Ashkenazi, S; Chrousos, GP; Ovadia, H; Weizman, A; Yuhas, Y, 2004)
"Experimental seizures are often accompanied by the generation of free radicals that cause lipid peroxidation (LPO), which may subsequently cause neurodegeneration observed in certain types of human epilepsy."( Rajasekaran, K, 2005)
"Generalized tonic-clonic seizures are a rare complication of levofloxacin therapy."( Christie, MJ; Sikaneta, TG; Tam, PY; Ting, RH; Wong, K, 2005)
"Dyskinesias and seizures are both medically refractory disorders for which cannabinoid-based treatments have shown early promise as primary or adjunctive therapy."( Adrian, R; Baratta, J; Giuffrida, A; Piomelli, D; Solbrig, MV, 2005)
"Seizures are an important adverse effect of bupropion and care is needed when used in other conditions or with other medication that can lower the seizure threshold."( Ross, S; Williams, D, 2005)
"The induction of a seizure is a core event in successful ECT."( Amiaz, R; Aronov, S; Etchin, A; Grunhaus, L; Vishne, T, 2005)
"Diagnosis of epileptic seizures is largely dependent on the clinical history."( Mackay, M, 2005)
"Centrally mediated seizures are a common consequence of exposure to organophosphates (OP) despite conventional treatment with atropine and an oxime."( Chapman, S; Gilat, E; Kadar, T, 2006)
"Seizures are a common complication of primary (PBT) and metastatic (MBT) brain tumors, affecting approximately 50% of all patients during the course of their illness."( Goldlust, SA; Newton, HB; Pearl, D, 2006)
"Seizures are a common neurologic symptom of tuberous sclerosis complex."( Chuck, G; Collins, JJ; Franz, DN; Leonard, JM; Tudor, C, 2006)
"Seizures are the most common clinical manifestation and may be exacerbated by phenobarbitone."( Appleton, DB; Bowling, FG; Burke, CJ; Coman, DJ; De Vivo, DC; McGill, JJ; O'Neil, CM; Pelekanos, JT; Sinclair, KG; Wallace, GB; Wang, D, 2006)
"Most neonatal seizures are triggered by acute illness such as hypoxic-ischemic encephalopathy, stroke, or infection; rarely are they triggered by epilepsy per se."( Clancy, RR, 2006)
"Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors."( Bomprezzi, C; Formica, F; Iacoangeli, M; Mauro, AM; Morresi, S; Provinciali, L; Scerrati, M, 2007)
"Neonatal seizures are most commonly incited by serious acute illnesses such as hypoxic-ischemic encephalopathy, birth trauma, or infection."( Clancy, RR, 2006)
"Seizures are a common complication of metastatic brain tumors (MBT), affecting approximately 27-50% of all patients during the course of their illness."( Dalton, J; Goldlust, S; Newton, HB; Pearl, D, 2007)
"Seizures are a rare complication during cerebral angiographic procedures."( Nwagwu, CI; Westhout, FD, 2007)
"Kindled seizures are widely used to model epileptogenesis, but the molecular mechanisms underlying the attainment of kindling status are largely unknown."( Dunoiu, C; Ioana, M; Mogoantă, L; Petcu, EB; Pirici, D; Popa-Wagner, A, 2007)
"Seizures are a common occurrence in the neonatal intensive care unit, especially among low-birth-weight infants."( Rotenberg, JS; Shoemaker, MT, 2007)
"Sevoflurane-induced seizures are most often described during mask induction of anesthesia when high concentrations of the volatile agent are administered concomitant with alveolar hyperventilation."( Iqbal, Z; Kumar, V; Markan, S; Mohanram, A; Pagel, PS, 2007)
"Seizures are a major complication of viral encephalitis."( Campbell, IL; Getts, DR; Getts, MT; King, NJ; Matsumoto, I; Müller, M; Radford, J; Shrestha, B, 2007)
"A potential role in seizures is suggested by Newton et al."( Atassi, H; Croll, SD; Elkady, A; Goodman, JH; Hylton, D; McCloskey, DP; Nicoletti, JN; Rudge, JS; Scharfman, HE; Shah, SK, 2008)
"Although seizures are very common during early brain development, consequences of seizures during this age period are less severe than in the mature brain."( Stafstrom, CE, 2007)
"Prevention of seizures is needed when HBO is used as preconditioning method."( Li, J; Liu, K; Liu, W; Sun, X; Tao, H; Xu, W; Zhang, JH, 2008)
"Early onset of seizures is linked to the combined MECP2 and BDNF genotypes."( Bahi-Buisson, N; Bienvenu, T; Chelly, J; Coste, J; De Roux, N; Guellec, I; Nectoux, J; Rosas, H; Tardieu, M, 2008)
"Tardive seizure is a serious adverse reaction of electroconvulsive therapy (ECT)."( Isse, K; Nakamura, M; Saito, T; Watari, M, 2008)
"Epileptiform seizures are most common during the neonatal period, affecting at least 0."( Bari, F; Domoki, F; Zimmermann, A, 2008)
"Whereas propagated seizures are known to disrupt cerebral activity, little work has been done on remote network effects of seizures that do not propagate."( Blumenfeld, H; Englot, DJ; Herman, P; Hyder, F; Mansuripur, PK; Mishra, AM, 2008)
"Seizures are a recognized complication of citalopram overdose."( Graham, A; Gray, JA; Waring, WS, 2008)
"Generalized seizures are an important manifestation of citalopram toxicity, and cannot be explained solely by electrolyte disturbances or co-ingestion of other drugs or ethanol."( Graham, A; Gray, JA; Waring, WS, 2008)
"Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures."( Barbaro, N; Burt, M; Chakalian, L; Chang, E; Chang, S; Lamborn, KR; Lim, DA; McDermott, MW; Tarapore, P, 2009)
"Neonatal seizures are one of the most common neurological disorders in infants."( Blume, HK; Christakis, DA; Garrison, MM, 2009)
"Seizure is the most common paediatric neurological disease which occurs in ten percent of children."( Fallah, R; Karbasi, SA; Mosadegh, MM, 2009)
"Epileptic seizures are a common clinical problem in children with brain tumors."( Attinà, G; Battaglia, D; Mastrangelo, S; Riccardi, R; Rizzo, D; Ruggiero, A, 2010)
"Seizures are a recognized complication of acute overdose with the racemic (1:1 ratio of R- and S-enantiomers) selective serotonin reuptake inhibitor antidepressant citalopram."( Bauer, K; Ceschi, A; Gerber-Zupan, G; Hackl, E; Hoffmann-Walbeck, P; Kullak-Ublick, GA; Kupferschmidt, H; Prasa, D; Rauber-Lüthy, C; Sauer, O; Seidel, C; Stedtler, U; Wilks, M; Yilmaz, Z, 2010)
"Seizures are a frequently reported adverse effect of bupropion in therapeutic oral doses; however, there are limited data about the consequences of nasal insufflation of bupropion."( Kim, D; Steinhart, B, 2010)
"Neonatal seizures are associated with a high likelihood of adverse neurological outcomes, including mental retardation, behavioral disorders, and epilepsy."( Holmes, GL; Isaev, D; Isaeva, E; Khazipov, R; Savrasova, A, 2010)
"Seizures are a common phenotype in all of these neurological disorders, yet the underlying molecular mechanism(s) of seizure induction and propagation remain largely unknown."( Malter, JS; Westmark, CJ; Westmark, PR, 2010)
"EEG seizures are associated with prolonged deep hypothermic circulatory arrest and with adverse long-term neurodevelopmental outcomes."( Andropoulos, DB; Dickerson, HA; Fraser, CD; Heinle, JS; Hrachovy, RA; McKenzie, ED; Meador, MR; Mizrahi, EM; Stark, AR; Stayer, SA, 2010)
"EEG seizures are infrequent in neonates undergoing surgery with high-flow CPB."( Andropoulos, DB; Dickerson, HA; Fraser, CD; Heinle, JS; Hrachovy, RA; McKenzie, ED; Meador, MR; Mizrahi, EM; Stark, AR; Stayer, SA, 2010)
"A Prolonged convulsive seizure is the most common neurological medical emergency with poor outcome."( Ashrafi, MR; Bavarian, B; Karimi, P; Khosroshahi, N; Kompani, F; Malamiri, RA; Mirzaei, M; Zarch, AV, 2010)
"Subtle seizures are the commonest type of seizures occurring in the neonatal period."( Agarwal, R; Deorari, A; Paul, VK; Sankar, JM, 2010)
"Seizures are a common sequela of self-poisoning."( Eddleston, M; Shah, AS, 2010)
"Seizures are reported as an uncommon side effect of interferon therapy."( Ahmed, F; Albert, C; Brand, M; Brass, C; Brown, R; Fixelle, AM; Herrera, JL; Jacobson, IM; Rustgi, VK; Wasserman, RB, 2011)
"Neonatal seizures are common, especially in prematurity."( Dinger, J; Ikonomidou, C; Ramantani, G; Rating, D; Walter, B, 2011)
"Eating-induced seizures are an uncommon presentation of reflex epilepsy, a condition characterized by seizures provoked by specific stimuli."( Friedman, DE; Kung, DH; Manyam, SC; Newmark, ME; Rhodes, LB, 2010)
"Considering that seizures are precipitated by common infections in children with GA-I, we investigated whether lipopolysaccharide (LPS) modifies GA-induced electrographic and neurochemical alterations in 21 days-old rats."( Ferreira, J; Fighera, MR; Furian, AF; Magni, DV; Mello, CF; Oliveira, AP; Oliveira, MS; Royes, LF; Santos, AR; Souza, MA, 2011)
"Neonatal seizures are often refractory to treatment with initial antiseizure medications."( Abend, NS; Clancy, RR; Dlugos, DJ; Gutierrez-Colina, AM; Monk, HM, 2011)
"Both types of seizures are suppressed by VB(6)."( Ohtahara, S; Ohtsuka, Y; Yamatogi, Y, 2011)
"Acute seizures are readily recognizable episodes requiring urgent treatment."( Chen, YI; Chiang, LM; Chou, ML; Deng, ST; Hung, PC; Lin, KL; Shen, HH; Tseng, CH; Wang, HS, 2011)
"Seizures are induced in some patients even at low doses."( Beasley, DM; Gee, P; Schep, LJ; Slaughter, RJ; Vale, JA, 2011)
"While early-life seizures are considered a major cause for cognitive impairment, it is not known whether it is the seizures, the underlying neurological substrate or a combination that has the largest impact on eventual learning and memory."( Holmes, GL; Lenck-Santini, PP; Lucas, MM; Scott, RC, 2011)
"In these models epileptic seizures are triggered either by external stimuli (reflex epilepsies) or by internal fluctuations."( Kalitzin, S; Koppert, MM; Lopes da Silva, FH; Viergever, MA, 2011)
"The incidence of seizures is particularly high in the early ages of life."( Briggs, SW; Galanopoulou, AS, 2011)
"Seizures are a common symptom of brain tumours."( Grant, R; Kerrigan, S, 2011)
"An epileptic seizure is reported in a 38-year-old woman, known to be an epileptic patient."( Skalli, S; Soulaymani Bencheikh, R, 2011)
"Psychogenic nonepileptic seizures are clinical events that mimic epileptic seizures but are not associated with electroencephalographic discharges."( Dubois-Teklali, F; Spitz, MA; Vercueil, L, 2012)
"Seizures are common in critically ill patients and can impact morbidity and mortality."( Cherry, S; Elzawahry, H; Judd, L; LaRoche, S; Muniz, JC, 2012)
"The incidence of seizures is generally accepted to be greater in patients with multiple sclerosis (MS) than in the general population, and rarely, MS can initially present as seizure."( Kendrick-Adey, AC; Sponsler, JL, 2011)
"Seizures are a common complication in patients with central nervous system (CNS) tumors."( O'Reilly, M; Twomey, M; Wallace, EM, 2012)
"Conversely, seizures are sensitive to changes in sex hormone levels, which in turn may affect the seizure-induced neuronal damage."( Desantis, KA; Velíšková, J, 2013)
"Seizures are markedly drug resistant and few reports have suggested the efficacy of some antiepileptic drugs."( Auvin, S; Bellavoine, V; Delanoë, C; Mahfoufi, N; Merdariu, D, 2013)
"Neonatal seizures are common and often reflect a severe underlying neurologic dysfunction in neonates."( Huang, LT; Lai, MC; Tain, YL; Yang, SN, 2012)
"Drug-induced seizures are in view of a constantly ageing population and increasingly frequent polypharmacotherapy an increasing problem in daily routine praxis."( Block, F; Dafotakis, M, 2013)
"Seizures are the manifestation of highly synchronized burst firing of a large population of cortical neurons."( Abramowitz, J; Birnbaumer, L; Flockerzi, V; Freichel, M; Gottschall, PE; Howell, MD; Phelan, KD; Rhee, SW; Shwe, UT; Wu, H; Zheng, F, 2013)
"Seizures are a potentially devastating complication of resection of brain tumors."( Forman, A; Graham, S; Heimberger, AB; Hess, K; Lang, FF; McCutcheon, IE; Prabhu, SS; Qiao, W; Sawaya, R; Suki, D; Trinh, VT; Wang, X; Weinberg, JS; Wu, AS, 2013)
"When (sub)clinical seizures are treated, there is no consensus about the most appropriate treatment for neonatal seizures and how to assess the efficacy of treatment."( de Vries, LS; Hellström-Westas, L; van Rooij, LG, 2013)
"While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC."( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013)
"Neonatal seizures are a naturally occurring source of neuronal overactivation and can lead to long-term epilepsy and cognitive deficits."( Jensen, FE; Klein, PM; Kosaras, B; Sun, H, 2013)
"On the one hand, seizures are associated with excessive neuronal activity that can spread across the brain, suggesting run-away excitation."( Grasse, DW; Karunakaran, S; Moxon, KA, 2013)
"Its effect on seizures is complex."( Bråthen, G; Brodtkorb, E; Helde, G; Reimers, A; Samsonsen, C, 2013)
"Tardive seizures are typically associated with electroencephalographic evidence of ictal activity and motor manifestations of the tonic-clonic activity."( Karim, Y; McCormick, LM; Thisayakorn, P; Yamada, T, 2014)
"Neonatal seizures are common in the first month of life and may impair neurodevelopmental outcome."( Cipriani, C; Crisp, E; Khan, O; Kirmani, B; Wright, C, 2013)
"Febrile seizure is common in young children, and the use of non-steroidal anti-inflammatory drugs for febrile seizure is not recommended."( Baik, EJ; Chung, JI; Kim, AY; Lee, SH, 2013)
"Neonatal seizures are a potentially life-threatening pediatric problem with a variety of causes, such as birth trauma, asphyxia, congenital anomalies, metabolic disturbances, infections, and drug withdrawal or intoxication."( Chen, L; Langhan, ML; Thornton, MD, 2013)
"Seizure is estimated to be the presenting symptom of pulmonary embolism (PE) < 1% of the time."( Jasani, N; Volz, EE, 2014)
"Although seizures are known to be harmful, recent evidence indicates that they can also lead to adaptations that protect neurons from further insult."( Friedman, L; Hu, S, 2014)
"Neonatal seizures are often refractory to treatment with initial antiseizure medications."( Ariguloglu, EA; Koklu, E; Koklu, S, 2014)
"Seizures are rare but well known side-effects of carbapenems, especially imipenem."( Beovic, B; Maticic, M; Soštaric, N, 2014)
"Epileptic seizures are well-known neurological complications following stroke, occurring in 3% of patients."( Chen, JG; Guan, XL; He, JG; Hu, ZL; Luo, Y; Wang, F; Wu, PF; Xiao, W; Zhang, JT; Zhou, J, 2014)
"Seizures are currently defined by their electrographic features."( Bennet, KE; Blaha, CD; Bower, MR; Chang, SY; Goerss, SJ; Kim, I; Lee, KH; Marsh, WR; Meyer, FB; Stead, M; Van Gompel, JJ; Worrell, GA, 2014)
"Convulsive seizures are a serious postoperative complication after cardiac surgery."( Carroll, J; Djaiani, G; Garrido-Olivares, L; Jerath, A; Katznelson, R; Rao, V; Sharma, V; Wasowicz, M, 2014)
"Animal modeling of seizure is invaluable to contribute to the mechanistic understanding of punctual seizure event, and those that triggered in an immature neural network could alter the mature brain physiology."( Da Silva, RS; Menezes, FP; Rico, EP, 2014)
"Seizures are a common manifestation of acute neurologic insults in neonates and are often resistant to the standard antiepileptic drugs that are efficacious in children and adults."( Kahle, KT; Kaila, K; Puskarjov, M; Ruusuvuori, E, 2014)
"Seizures are the primary clinical manifestation which could be acute (secondary to active lesions) or remote symptomatic (due to calcified lesions)."( Chakrabarty, B; Gulati, S; Gupta, AK; Jain, P; Kumar, A; Pandey, RM; Sachan, D, 2014)
"Flurothyl induced seizures are clinically as effective without the memory effects associated with electricity."( Cooper, K; Fink, M, 2014)
"Seizures are a frequent complication of brain injury, including intracerebral hemorrhage (ICH), where seizures occur in about a third of patients."( Colbourne, F; Dickson, CT; Klahr, AC, 2015)
"Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled."( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015)
"Clinical seizures are common intraoperative and postoperative complications of supratentorial craniotomies with intraoperative brain mapping."( Bello, L; Carrabba, G; Colombo, A; Conte, V; L'Acqua, C; Magni, L; Magnoni, S; Stocchetti, N, 2015)
"Kainate-induced seizures are accompanied by leukotriene formation, and are reduced by inhibitors of LOX/COX pathway."( Arroyo, DS; Iribarren, P; Jesse, AC; Lenz, QF; Marafiga, JR; Masson, CJ; Mello, CF; Poersch, AB; Reschke, CR; Temp, FR, 2014)
"Seizures are a common cause of neurologic disease, and phenobarbital (PB) is the most commonly used antiepileptic drug."( Barnes Heller, HL; Delamaide Gasper, JA; Robertson, M; Trepanier, LA, 2015)
"Anxiety and seizures are closely similar neurobehavioral disorders and are regulated by limbic system."( Gulati, K; Ray, A, 2014)
"Seizures are common but are self-limited."( Albertson, TE; Ford, JB; Lewis, JC; Owen, KP; Sutter, ME, 2014)
"Seizures are a known adverse effect of clozapine therapy."( Park, SH; Williams, AM, 2015)
"Seizures are a known co-occurring symptom of Alzheimer's disease, and they can accelerate cognitive and neuropathological dysfunction."( Harrison, FE; Kang, JQ; Kennard, JA; Warner, TA, 2015)
"Seizures are accompanied by cardiovascular changes that are a major cause of sudden unexpected death in epilepsy (SUDEP)."( Bhandare, AM; Farnham, MM; Mohammed, S; Pilowsky, PM, 2015)
"SSRI-induced seizures are rare and are more likely to be associated with larger doses and severe symptoms such as those present in serotonin syndrome."( McKean, J; Mokszycki, R; Watts, H, 2015)
"Postoperative seizures are more common in the first month after cranial surgery."( Boza, FM; Gumà I Padró, J; Peralta Muñoz, S; Taberner Bonastre, MT, 2015)
"In epilepsy, seizures are generated by abnormal synchronous activity in neurons."( Alberto, MV; Anne, S; Laura, MC; Xóchitl, FP, 2015)
"Seizures are common during the neonatal period, often due to hypoxic-ischemic encephalopathy and may contribute to acute brain injury and the subsequent development of cognitive deficits and childhood epilepsy."( Boylan, GB; Dunleavy, M; Henshall, DC; Jimenez-Mateos, EM; Rodriguez-Alvarez, N; Waddington, JL, 2015)
"In newborns, seizures are most commonly associated with hypoxic-ischemic encephalopathy (HIE)."( Raol, YH; Sampath, D; Shmueli, D; White, AM, 2015)
"Neonatal seizures are commonly associated with hypoxic-ischemic encephalopathy."( Johnston, MV; Kadam, SD; Kang, SK, 2015)
"Febrile seizures are the most common type of convulsive events in children."( Blumberg, MS; Kaila, K; Pospelov, AS; Puskarjov, M; Yukin, AY, 2016)
"Convulsion is one of the most common problems in children and hypocalcemia is one the most frequent etiological items in children's convulsion."( Haghi Ashtiani, MT; Keihani Douste, Z; Shariat, M; Tehrani, F, 2015)
"Epileptic seizures are generally unpredictable and arise spontaneously."( Beniczky, S; Caciagli, L; Koepp, MJ; Lehnertz, K; Pressler, RM, 2016)
"Myoclonic seizures are a hallmark of feline audiogenic seizures (FARS)."( Bessant, C; Garosi, L; Harvey, RJ; Lowrie, M; Sparkes, A; Thomson, S, 2017)
"Neonatal seizures are associated with long term disabilities including epilepsy and cognitive deficits."( Benke, TA; Bernard, PB; Castano, AM; O'Leary, H, 2016)
"Generally, seizures are accompanied by changes in brain function leading to uncontrolled nerve activity causing high blood pressure, rapid heart rate, and abnormal heart rhythm."( Bhandare, AM; Farnham, MM; Kapoor, K; Pilowsky, PM, 2016)
"Seizures are accompanied by an exacerbated activation of cerebral ion channels."( Aldana, BI; Reed, RC; Sitges, M, 2016)
"The odds ratio of seizure is 5."( Lin, Z; Xiaoyi, Z, 2016)
"Seizures are common following perinatal asphyxia and may exacerbate secondary neuronal injury."( Berg, M; Soll, R; Young, L, 2016)
"Seizures are common complications for patients with brain tumors."( Nasr, ZG; Paravattil, B; Wilby, KJ, 2016)
"Post-stroke seizures are considered as a major cause of epilepsy in adults."( Lei, Z; Liang, Y; Xu, ZC; Zhang, H, 2016)
"Epileptic seizures are network-level phenomena."( Casteels, C; Cleeren, E; Goffin, K; Janssen, P; Premereur, E; Van Paesschen, W, 2016)
"Seizures are bursts of excessive synchronized neuronal activity, suggesting that mechanisms controlling brain excitability are compromised."( Bassell, GJ; Danielson, SW; Danzer, SC; Engel, T; Gross, C; Henshall, DC; Jimenez-Mateos, EM; Pun, RYK; Rowley, S; Schroeder, LM; Thomas, KT; Tiwari, D; Xing, L; Yao, X, 2016)
"Convulsive seizures are due to abnormal synchronous and repetitive neuronal discharges in the central nervous system (CNS)."( Asadi, S; Fereidoni, M; Kordi Jaz, E; Moghimi, A; Roohbakhsh, A; Shamsizadeh, A, 2017)
"Neonatal seizures are a common problem in the neonatal intensive care unit and are frequently treated with antiepileptic drugs."( Ahmad, KA; Ahmad, SF; Bennett, MM; Clark, RH; Desai, SJ; Ng, YT; Tolia, VN, 2017)
"These seizures are caused by sudden which may vary from a brief lapse of attention or muscle jerks, to severe and prolonged convulsions."( Jain, N; Jaiswal, J; Pathak, A; Singour, PK, 2018)
"Seizures are more common in patients with early onset or progressive forms of the disease and prognosticate rapid progression to disability and death."( Binder, DK; Hasselmann, JPC; Khalaj, AJ; Lapato, AS; Szu, JI; Tiwari-Woodruff, SK, 2017)
"A seizure is a sustained increase in brain electrical activity that can result in loss of consciousness and injury."( Beattie, CE; Berberoglu, MA; Duy, PQ; Hall, CW, 2017)
"Postoperative seizure is a common complication of cranioplasty, especially in patients with preoperative or postoperative abnormal EEG with spikes or sharp waves."( Ding, P; Liang, S; Wu, Y; Zhang, J; Zhang, S, 2017)
"Seizures are very common in children."( Julliand, S; Moretti, R; Rinaldi, VE; Titomanlio, L, 2019)
"In conclusion, seizures are generally the most common complication by a spectrum of seizure types, and sometimes cause symptomatic epilepsy."( Arslan, M; Güngör, S; Kılıç, B; Selimoğlu, MA; Yılmaz, S, 2017)
"Posttraumatic seizures are a medical problem affecting patients with traumatic brain injury."( Cao, Y; Liao, Z; Lu, XM; Mountney, A; Shear, DA; Tortella, FC, 2017)
"Seizure is the most common presentation of neurological disorder in the pediatric emergency care setting."( Demir, E; Gucuyener, K; Gurkas, E; Havali, C, 2019)
"Seizures are epileptic manifestations that are intrinsically modulated through different neurotransmitters and receptor systems."( Arzhang, A; Elahdadi Salmani, M; Goudarzi, I; Lashkarbolouki, T, 2017)
"Seizures are a common early presentation in infants with tuberous sclerosis complex (TSC) and can be preceded by electrographic changes on electroencephalography (EEG) before clinical seizure onset."( Jan, S; McCoy, B; Whitney, R; Zak, M, 2017)
"LGS type of seizures is epilepsy which is due to abnormal vibrations occurring in seizures."( Natchimuthu, V; Ramalingam, M; Ravi, S; Thomas, S, 2017)
"Neonatal seizures are the most common clinical manifestation of Central Nervous System (CNS) dysfunction and are associated with various neurological sequelae."( Agrawal, A; Banergee, A, 2017)
"Seizures are the commonest manifestation of brain parenchymal cysticercosis."( Sharma, R; Singh, G, 2017)
"Seizures are typically not responsive to conventional antiepileptic drugs, but they cease after parental pyridoxine administration."( Corsello, G; Falsaperla, R, 2017)
"Epileptic seizures are rare in nonalcoholic WE."( Chen, H; Chen, X; Hong, H; Li, X; Shang, W; Tang, S, 2017)
"Seizures are rare manifestation of thalamic disorder."( Brohi, H; Kumar, R; Mughul, A, 2017)
"History of seizure is an important risk factor for seizure occurrence in patients with mCRPC, particularly in those with a history of anticonvulsant use."( Bonafede, M; Dharmani, C; Krivoshik, A, 2017)
"Seizure is a serious complication of stroke, indicating poor prognosis."( An, XF; Liu, XJ; Yang, GS; Yu, D; Zhang, YJ; Zhou, XY, 2017)
"Seizures are common in infants with HIE undergoing TH and may worsen outcome."( Aronowitz, E; Hutton, A; Krishna, S; Moore, H; Vannucci, SJ, 2018)
"Epileptic seizures are short episodes of abnormal brain electrical activity."( Choi, BY; Choi, HC; Hong, DK; Jeong, JH; Kho, AR; Lee, SH; Lee, SY; Song, HK; Suh, SW, 2017)
"The risk of seizure is increased following brain surgery such as cranioplasty."( Liu, Y; Wang, Z; Zhang, B; Zhang, Z, 2018)
"Seizures are the most common neurological complication in neonatal intensive care units."( Lancaster, S; Manganas, LN; McHugh, DC, 2018)
"Epileptic seizures are refractory to treatment in approximately one-third of patients despite the recent introduction of many newer antiepileptic drugs (AEDs)."( Dash, A; Desudchit, T; Leung, H; Lim, KS; Tiamkao, S; Tsai, JJ; Wu, T, 2018)
"Incidence of seizure is similar in patients with mCRPC and similar seizure risk factors with or without enzalutamide exposure."( Carles, J; Clark, W; George, D; Krivoshik, A; Park, JW; Slovin, S; Wang, F, 2018)
"Neonatal seizures are treated with phenobarbital and prolonged treatment does not prevent postneonatal epilepsy."( Beatty, CW; Gust, J; Hamiwka, L; Natarajan, N, 2018)
"Currently, an epileptic seizure is considered to involve a temporary network that exists for a finite period of time."( Bragin, A; Engel, J; Kriukova, K; Li, L, 2018)
"Seizures are important complications following a subarachnoid hemorrhage (SAH)."( Buxton, J; Mahmoud, SH, 2017)
"An early onset of seizures is common in MLC."( Boschert, U; Brouwers, E; Bugiani, M; Dubey, M; Hamilton, EMC; Koch, H; Kole, MHP; Mansvelder, HD; Min, R; Stiedl, O; van der Knaap, MS; Wykes, RC, 2018)
"Seizures are present in over 90% of infants and children with Wolf-Hirschhorn syndrome (WHS)."( Battaglia, A; Carey, JC; Ho, KS; Lortz, A; Markham, LM; Newcomb, T; Olson, LM; Sheng, X; Twede, H; Wassman, ER; Weng, C, 2018)
"Catamenial seizures are believed to be a neurosteroid withdrawal symptom, and it was hypothesized that exogenous administration of progesterone to maintain its levels high during luteal phase will treat catamenial seizures."( Joshi, S; Kapur, J, 2019)
"Seizures are common in newborns after asphyxia at birth and are often refractory to anti-seizure agents."( Bennet, L; Davidson, JO; Draghi, V; Galinsky, R; Gunn, AJ; Lear, CA; Unsworth, CP, 2018)
"Seizures are controllable with antiepileptic drugs (AEDs) in about 70% of epilepsy patients, however, there remains about 30% of patients inadequately medicated with these AEDs, who need a satisfactory control of their seizure attacks."( Kondrat-Wróbel, MW; Łuszczki, JJ, 2018)
"Seizure is one of the important symptoms of tramadol poisoning, but its causes are still unknown."( Ahmadimanesh, M; Ahsani Nasab, S; Ghazi-Khansari, M; Rouini, MR; Shadnia, S; Sheikholeslami, B, 2018)
"The pathogenesis of epileptic seizures is not satisfactorily explored, and hence more effective anti-convulsive therapies are indispensable."( El-Azab, MF; Moustafa, YM; Tawfik, KM, 2018)
"Such early-life seizures are associated with language deficits and autism that can result from aberrant development of the auditory cortex."( Hensch, TK; Jensen, FE; Lippman-Bell, JJ; Sun, H; Takesian, AE; Wang, TT, 2018)
"Persistent seizures are associated with physical injury, reduced quality of life, and psychosocial impairment."( De Rosendo, J; Howard, D; Patel, V; Tremblay, G; Tsong, W, 2018)
"Neonatal seizures are harmful to the developing brain and are associated with mortality and long-term neurological comorbidities."( Carter, BM; Kadam, SD; Kharod, SC, 2018)
"Neonatal seizures are frequent in neonatal intensive care and the most common cause is perinatal asphyxia."( Cools, F; Demeulemeester, V; Lefevere, J; Van Hautem, H, 2018)
"Epileptic seizures are associated with increased astrocytic Ca2+ signaling, but the fine spatiotemporal kinetics of the ictal astrocyte-neuron interplay remains elusive."( Åbjørsbråten, KS; Enger, R; Heuser, K; Jensen, V; Nagelhus, EA; Nome, CG; Pettersen, KH; Sprengel, R; Tang, W; Taubøll, E, 2018)
"Seizures are sustained neuronal hyperexcitability in brain that result in loss of consciousness and injury."( Han, L; He, Q; Ji, X; Jin, M; Liu, K; Sheng, W, 2018)
"Epileptic seizure is the result of uncontrollable neural excitation in the brain."( Bayraktutan, OF; Ceylan, M; Laloglu, E; Yalcin, A, 2018)
"Seizures are common in term infants with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia."( Chanlaw, T; Cho, A; Garg, M; Hussain, SA; Rao, LM; Sankar, R; Zaki, T, 2018)
"Seizures are easily controlled by AEDs."( Kalita, J; Kumar, V; Misra, UK; Parashar, V, 2019)
"Symptoms during seizure are very important to diagnose."( Zhou, W; Zhu, Q, 2018)
"Seizures are commonly thought to occur in a spontaneous, unpredictable manner."( Hassan, I; Hrazdil, CT; Randhawa, J, 2019)
"Seizures are a feature not only of the many forms of epilepsy, but also of global metabolic diseases such as mitochondrial encephalomyopathy (ME) and glycolytic enzymopathy (GE)."( Barile, ZJ; Fogle, KJ; Gutierrez, AC; Hertzler, JI; McCardell, CS; Novak, MO; Palladino, MJ; Satterfield, SL; Shon, JH; Smith, AR, 2019)
"Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary."( Bergner, C; Hörnschemeyer, J; Kirschstein, T; Köhling, R; Krause, BJ; Lange, F; Linnebacher, M; Mullins, CS; Porath, K; Weßlau, K, 2019)
"Febrile seizure is a common neurological disorder observed in neonates."( Moghimi, A; Roohbakhsh, A; Zandi, N; Zaniani, NR, 2019)
"Neonatal seizures are different from adult seizures, and many antiepileptic drugs that are effective in adults often fail to treat neonates."( Bai, Y; Chen, G; Dong, F; Feng, M; Huo, Q; Li, ST; Long, C; Lüscher, B; Ren, L; Wang, GL; Wang, Y; Wu, G; Wu, Z, 2019)
"However, seizures are not typical and the majority of them were seizure-free."( Goji, A; Imoto, I; Ito, H; Kagami, S; Kohmoto, T; Mori, K; Mori, T; Toda, Y, 2019)
"The prevalence of seizures is reported to be 1."( Basha, MM; Bernitsas, E; Marawar, R; Sriwastava, S; Yarraguntla, K; Zutshi, D, 2019)
"Acute seizures are common in pediatric cerebral malaria (CM), but usual care with phenobarbital risks respiratory suppression."( Abdel Baki, SG; Birbeck, GL; Capparelli, EV; Dzinjalamala, FK; Gardiner, JC; Herman, ST; Mallewa, M; Postels, DG; Seydel, KB; Taylor, TE; Toto, NM, 2019)
"Unlike in children, seizures are unusual in adult patients with eucalyptus oil poisoning."( George, GR; Ittyachen, AM; Joy, Y; Radhakrishnan, M, 2019)
"Seizures are uncommon among younger children with exploratory ingestions."( Gosen, J; Levine, M; Offerman, S; Thomas, SH, 2020)
"Epileptic seizures are frequent in patients with glioma, and anticonvulsive treatment is often indicated."( Kirschstein, T; Köhling, R; Krause, BJ; Lange, F; Mayer, J; Porath, K; Resch, T, 2020)
"Seizures are induced when subjects are exposed to severe hypoxia."( Fukushi, I; Horiuchi, J; Kurita, Y; Mori, Y; Okada, Y; Okazaki, S; Pokorski, M; Takeda, K; Uchiyama, M; Yokota, S, 2020)
"Drug-resistant seizures are life-threatening and contribute to sustained hospitalization."( Capra, S; Narayan, SW; Parratt, K; Patanwala, AE, 2020)
"Controlling seizures is essential during GBM treatment because they are often present and closely associated with the quality of life of GBM patients."( Chang, MJ; Min, KL; Ryu, JY, 2019)
"Paradoxical seizure is an unusual reaction of seizure aggravation or change in its pattern due to antiepileptics."( Radhakrishnan, A; Sudarsan, P; Suresh, A; Varghese, R, 2021)
"Epileptic seizures are characterized by synchronized discharges of neurons, leading to the activation of inflammatory responses that in turn contributes to seizure progression."( Ji, X; Jin, M; Liu, K; Sik, A; Wang, L; Zhang, B; Zhang, S, 2020)
"Neonatal seizures are difficult to diagnose and, when they are, tradition dictates first line treatment is phenobarbital."( Alix, JJP; Gossling, L; Hart, AR; Stavroulakis, T, 2020)
"Seizures are a combination of electrical and behavioral events that can induce biochemical, molecular, and anatomic changes."( Adem, A; Alachkar, A; Frank, A; Ojha, SK; Sadek, B; Sadeq, A; Stark, H, 2020)
"Seizures are a morbid complication of intracerebral hemorrhage (ICH) and increase the risk for herniation, status epilepticus, and worse patient outcomes."( Naidech, AM; Pinto, D; Prabhakaran, S; Tipton, E, 2020)
"Seizures are known to trigger a neuroinflammatory response to promote neuronal damage and increase the risk of epilepsy."( Fox, P; Koh, S; Mithal, DS; Sanchez, RM; Somogyi, JR; Vien, AC, 2020)
"Focal-onset or partial seizures are localized to a specific brain area or areas of the cerebral hemisphere."( Dhir, A, 2020)
"As seizures are precipitated in children with GA-I and the mechanisms underlying this disorder are not well established, we decided to investigate the role of nitric oxide (NO) in GA-induced convulsive behaviour in pup rats."( Bortolatto, CF; Brüning, CA; Magni, DV; Nogueira, CW; Nonemacher, NT; Quines, CB; Rosa, SG, 2020)
"Acute symptomatic seizures are possible in patients with COVID-19 disease."( Bhimraj, A; George, P; Hantus, S; Hepburn, M; Mullaguri, N; Newey, CR; Punia, V, 2021)
"Seizure is a common acute and severe disease in infants and children."( Hu, QP; Huang, XY; Peng, F; Wu, C; Yang, H, 2020)
"As seizures are commonly associated with autonomic manifestations, we believe that biomarkers for diseases affecting autonomic functions such as epilepsy can be found in vagus nerve signals."( Cury, J; Delbeke, J; Doguet, P; Hermans, E; Nielsen, TN; Nonclercq, A; Sevcencu, C; Smets, H; Stumpp, L; Tahry, RE; Vespa, S, 2020)
"Various types of generalized seizures are most prevalent, with most common types are myoclonic and atypical absence."( Samanta, D, 2021)
"Neonatal seizures are frequently encountered in the neonatal intensive care unit and may be associated with serious long-term neurological sequelae."( Darwich, M; Hanneyan, S; Hnaini, M; Jaafar, F; Koleilat, N; Maalouf, FI; Mikati, IE; Nabout, R; Obeid, M; Rahal, S; Shbarou, RM, 2020)
"A seizure is an uncontrolled electrical activity in the brain that can cause different levels of behavior, emotion, and consciousness."( Ahn, JH; Ahn, SH; Bae, MA; Chae, JS; Cho, JH; Hwang, KS; Jang, IS; Joo, J; Kan, H; Kim, CH; Kim, SS; Shin, DS; Shin, J; Yang, JY, 2020)
"Neonatal seizures are one of the most common comorbidities of neonatal encephalopathy, with seizures aggravating acute injury and clinical outcomes."( Engel, T; Menéndez Méndez, A; Smith, J, 2020)
"First unprovoked seizures are not influenced by the lunar cycle."( Boston, R; Lawn, N; Seneviratne, U; Wang, S, 2022)
"Epileptic seizures are automatic, excessive, and synchronized neuronal activities originating from many brain regions especially the amygdala, the allocortices and neocortices."( Chou, P; Hsueh, SW; Kuo, CC; Wang, GH; Yang, YC, 2021)
"Neonatal seizures are the most frequent type of neurological emergency in newborn infants, often being a consequence of prolonged perinatal asphyxia."( Ala-Kurikka, T; Gailus, B; Hampel, P; Johne, M; Kaila, K; Löscher, W; Römermann, K; Theilmann, W, 2021)
"Seizures are a threat to the host brain and body and can even cause death in epileptic children."( Eor, JY; Kim, SH; Kwak, MJ; Son, YJ; Tan, PL, 2021)
"Epileptic seizures are considered to be a brain network dysfunction, and chronic recurrent seizures can cause severe brain damage."( Chen, C; Li, F; Liang, Y; Xu, P; Yao, D; Yu, L, 2020)
"Epileptic seizures are characterized by imbalanced inhibition-excitation cycle that triggers biochemical alterations responsible for jeopardized neuronal integrity."( Mishra, P; Rajput, SK; Sinha, JK, 2021)
"Since seizures are highly unlikely to be detected in a routine scalp EEG, the primary diagnosis depends heavily on the visual evaluation of Interictal Epileptiform Discharges (IEDs)."( Cash, SS; Chaudhari, R; Dauwels, J; Jing, J; Karia, S; Peh, WY; Rathakrishnan, R; Saini, V; Shah, N; Srivastava, R; Tan, YL; Thangavel, P; Thomas, J; Westover, B; Yuvaraj, R, 2021)
"Sevoflurane-induced seizures are most often caused by high concentrations of sevoflurane during anesthesia induction."( Du, L; Zhang, L; Zheng, J, 2021)
"Epileptic seizures are the most common neurological diseases that change the function of neurovascular unit at molecular levels accompanied by activation of a wide variety of neurodegenerative cascades."( Darabi, S; Faghihi, N; Mohammadi, MT; Sarahian, N, 2021)
"Seizures are a common manifestation of toxic exposures requiring immediate and possibly ongoing management."( Alunday, RL; Fletcher, ML; Nash, J; Sarangarm, P; Seifert, SA; Smolinske, SC; Warrick, BJ, 2021)
"Seizures are physically burdensome and emotionally distressing for patients, families, caregivers, and clinicians."( Besbris, JM; Daly, FN; Jones, CA; Kramer, NM; Mehta, AK; Sharma, A; Singhal, D, 2021)
"First seizures are always challenging for physicians."( Carrizosa-Moog, J; Jiménez-Villegas, MJ; Lozano-García, L, 2021)
"Seizures are common in patients with gliomas; however, the mechanisms of epileptogenesis in gliomas have not been fully understood."( Abe, M; Hirose, Y; Inamasu, J; Kumon, M; Kuwahara, K; Murayama, K; Nakae, S; Ohba, S; Sasaki, H; Yamada, S, 2021)
"Myoclonic seizures are the most common seizure type, and 56."( Cao, D; Fahlke, C; Guzman, RE; He, H; Peng, J; Sierra-Marquez, J; Stauber, T; Yin, F, 2021)
"Neonatal seizures are significant cause of neonatal mortality and morbidity."( Aggarwal, A; Banerjee, BD; Batra, P; Famra, K, 2022)
"Epileptic seizures are core symptoms in focal cortical dysplasia (FCD), a disease that often develops in infancy."( Akiyama, T; Inoue, Y; Kada, A; Kato, M; Nakagawa, E; Saito, AM; Shiraishi, H; Takahashi, Y; Tohyama, J, 2021)
"Seizures are common in neonates recovering from birth asphyxia but there is general consensus that current pharmacotherapy is suboptimal and that novel antiseizure drugs are needed."( Ala-Kurikka, T; Kaila, K; Kurki, S; Pospelov, AS; Voipio, J, 2021)
"The risk of seizures is 10-fold higher in patients with Alzheimer's disease than the general population, yet the mechanisms underlying this susceptibility and the effects of these seizures are poorly understood."( Barbour, AJ; Eberwine, G; Gourmaud, S; Irwin, DJ; Jensen, FE; O'Brien, WT; Roberts, N; Stewart, DA; Talos, DM; Vassar, R, 2022)
"Seizures are common in newborn infants with hypoxic-ischemic encephalopathy and are highly associated with adverse neurodevelopmental outcomes."( Bennet, L; Cho, KHT; Davidson, JO; Drury, PP; Gunn, AJ; Lear, CA; McDouall, A; Zhou, KQ, 2021)
"Absence seizures are associated with generalised synchronous 2."( Leitch, B; Lyons, NMA; Panthi, S, 2021)
"Seizures are the outward manifestation of abnormally excessive or synchronous brain activity."( Abas, F; Choo, BKM; Faudzi, SMM; Kundap, UP; Samarut, É; Shaikh, MF, 2021)
"Reflex seizures are consistently evoked by a specific afferent stimulus or by patient activity."( Parente, E; Rebessi, E; Riva, A; Romeo, A; Striano, P; Viri, M, 2022)
"Epileptic seizures are increasingly recognized as part of the clinical phenotype of patients with Alzheimer's disease (AD)."( Larner, AJ; Marson, AG, 2022)
"These seizures are paroxysmal events that result from abnormal neuronal discharges and are categorized into various types based on the clinical manifestations and localization."( Karthick, PA; Mathew, J; Ramakrishnan Manuskandan, S; Sivakumaran, N, 2021)
"Seizures are common in NBIA, particularly in PLAN and BPAN."( Emamikhah, M; Fasano, A; Mohammadzadeh, N; Rohani, M; Saiyarsarai, P; Schneider, SA, 2023)
"NAC effects on absence seizures are still not uncovered, and considering its clinical use as a mucolytic in patients with lung diseases, people with epilepsy are also likely to be exposed to the drug."( Citraro, R; Constanti, A; De Caro, C; De Sarro, G; Guarnieri, L; Leo, A; Nicoletti, F; Russo, E; Tallarico, M; Zito, MC, 2022)
"Pediatric seizures are a common reason for emergency department visits."( Case, SD; Tsao, HS, 2022)
"Seizures are a disorder caused by structural brain lesions, life-threatening metabolic derangements, or drug toxicity."( Andrade, AR; Barbas, LAL; Ferreira, LO; Hamoy, AO; Hamoy, M; Jóia de Mello, V; Leitão, DS; Lopes, DCF; Martins, MFC; Medeiros, NCL; Muto, NA; Santos, VC, 2022)
"Focal seizures are associated with various co-morbidities."( Bhattacharyya, A; Mahajan, SS; Medhi, B; Niraj, N; Prakash, A; Sarma, P, 2022)
"Epileptic seizures are associated with the overproduction of free radicals in the brain leading to neuronal cell death."( Dehdashtian, E; Hosseinzadeh, A; Jafari-Sabet, M; Mehrzadi, S, 2022)
"Seizures are a common complication that leads to neurological deficits and affects outcomes after aneurysmal subarachnoid haemorrhage (aSAH)."( Chen, Y; Fang, M; Hu, X; Li, Y; Pang, B; Sun, B; Wu, H; Wu, P; Wu, Q; Xie, Z; Xu, S; You, C; Zhang, J; Zheng, N, 2022)
"Neonatal seizures are one of the most challenging problems for experts across the globe."( Deshmukh, L; Joshi, A; Londhe, A; Susnerwala, S, 2022)
"Seizure is a rare side effect of enzalutamide."( Demir, O; Demirag, G, 2023)
"Seizures are the main neurological emergency during the neonatal period and are mostly acute and focal."( Bedetti, L; Berardi, A; Casa Muttini, ED; Cavalleri, F; Ferrari, F; Guidotti, I; Lugli, L; Ori, L; Pugliese, M; Roversi, MF; Stefanelli, F, 2022)
"Seizures are more common in the neonatal period than at any other stage of life."( Allison, BJ; Bennet, L; Boyd, BJ; Castillo-Melendez, M; Fahey, MC; Hirst, JJ; Hunt, RW; Jenkin, G; Malhotra, A; McDonald, C; Mihelakis, J; Miller, SL; Nitsos, I; Pham, Y; Sutherland, AE; Walker, DW; Wong, F; Yawno, T, 2022)
"Seizures are a common clinical manifestation in neuropsychiatric lupus, and our work identifies anti-BC autoantibody activity as a mechanistic cause."( Berardi, V; Ginzler, EM; Hanly, JG; Muslimov, IA; Stephenson, S; Tiedge, H, 2022)
"Seizures are a frequent and diagnostically relevant symptom of ab + AE."( Angstwurm, K; Bergh, FT; Bien, CG; Bogarin, Y; Doppler, K; Finke, A; Geis, C; Gerner, ST; Handreka, R; Häusler, M; Hellwig, K; Kaaden, T; Kaufmann, M; Kellinghaus, C; Koertvelyessy, P; Kraft, A; Kunze, A; Lewerenz, J; Leypoldt, F; Madlener, M; Malter, M; Melzer, N; Menge, T; Mues, S; Paliantonis, A; Prüss, H; Rauer, S; Reimann, G; Ringelstein, M; Rostásy, K; Schirotzek, I; Schwabe, J; Sokolowski, P; Suesse, M; Sühs, KW; Surges, R; Tauber, SC; Thaler, F; Urbanek, C; von Podewils, F; Wandinger, KP; Wildemann, B; Zettl, U, 2022)
"The seizures are generally resistant to traditional antiepileptic drugs and show a dramatic response to high-dose pyridoxine."( Çavdartepe, BE; İpek, R; Kor, D; Okuyaz, Ç, 2022)
"A seizure is a significant in-flight medical emergency event."( Asadi-Pooya, AA; Hosseini, SA, 2022)
"Seizure is paroxysmal abnormal electrical discharges in the cerebral cortex."( Amini-Khoei, H; Bijad, E; Dehkordi, HT; Korrani, MS; Saghaei, E, 2023)
"Absence seizures are hyperexcitations within the cortico-thalamocortical (CTC) network, however the underlying causative mechanisms at the cellular and molecular level are still being elucidated and appear to be multifactorial."( Adotevi, NK; Hassan, M; Leitch, B, 2022)
"Seizures are a complex of transient signs and symptoms resulting from abnormal, simultaneous, and excessive activity of a population of neurons, and they can be both a cause and a consequence of oxidative stress."( López-Meraz, ML; Pérez-Severiano, F; Ramos-Riera, KP, 2023)
"Seizures are suspected to be side effects of antipsychotics."( Efthimiou, O; Leucht, S; Reichelt, L; Schneider-Thoma, J, 2023)
"A post stroke seizure is a period of neurological dysfunction caused by abnormal neuronal activity."( Lidetu, T; Zewdu, D, 2023)
"Seizures are common in palliative care patients and its control is essential in the management of these patients as it helps to reduce suffering at the end of life."( Diaz-Forero, AF; Estrada, J; Gaviria-Carrillo, M; Mora-Muñoz, L; Rodríguez, JH; Torres-Ballesteros, V; Vargas-Osorio, J; Vélez Van Meerbeke, A, 2023)
"This motor seizure is irrelevant to the therapeutic action of the treatment."( Andrade, C, 2023)
"Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the drug-induced seizure cases."( El-Bassyouni, GT; Elgohary, R; ElShebiney, SA; Hamzawy, EMA; Kenawy, SH, 2023)
"Seizures are a frequent pathophysiological feature of malignant glioma."( Aiba, I; Cervantes, A; Cocito, C; Curry, RN; Deneen, B; Gavvala, J; Greenfield, JP; Huang-Hobbs, E; Jalali, A; Ko, Y; Lozzi, B; McDonald, MF; Meyer, J; Mohila, C; Noebels, J; Rao, G; Rosenbaum, A; Serin Harmanci, A, 2023)
"Seizures are life-threatening complications of neuropsychiatric systemic lupus erythematosus (NPSLE) and are often associated with poor outcomes."( Jiang, W; Shi, Y; Wu, J; Zhang, J; Zhang, L, 2023)
"Seizures are common neurological emergencies in the elderly that are frequently provoked."( Alattiya, MK; Hammamy, RA; Joudeh, AI, 2023)
"Seizures are among the most common clinical signs in people with glioblastoma."( Cole, AJ; Dietrich, J; Sokolov, E, 2023)
"Neonatal seizures are severe pathologies which may result in long-term neurological consequences."( Gataulina, E; Gerasimova, E; Khalilov, I; Kurmashova, E; Sitdikova, GF; Yakovlev, AV, 2023)
"Urgent seizures are a medical emergency for which new therapies are still needed."( Asensio, M; Campos, D; Castillo, A; Chavarria, B; Escalza, I; Falip, M; Fernández-Cabrera, A; Garcés, M; García-Morales, I; Gifreu, A; Giménez, J; Guillén, V; Hampel, K; Hernández Pérez, G; Juiz-Fernández, Á; Martínez, AB; Massot, M; Montoya, J; Parejo-Carbonell, B; Rocamora, R; Rodriguez-Osorio, X; Rubio-Nazábal, E; Ruiz-Giménez, J; Santamarina, E; Sayas, D; Villanueva, V, 2023)
"Seizures are a common neurological disorder that affects people of all ages."( Fathi, E; Panahi, Y; Shafiian, MA, 2023)
"Seizures are common in neonates, but there is substantial management variability."( Abend, NS; Auvin, S; Boylan, G; Brigo, F; Cilio, MR; De Vries, LS; Elia, M; Espeche, A; Hahn, CD; Hartmann, H; Inder, T; Jette, N; Kakooza-Mwesige, A; Mader, S; Mizrahi, EM; Moshé, SL; Nagarajan, L; Noyman, I; Nunes, ML; Pressler, RM; Samia, P; Shany, E; Shellhaas, RA; Subota, A; Triki, CC; Tsuchida, T; Vinayan, KP; Wilmshurst, JM; Yozawitz, EG, 2023)
"Classically, seizures are assumed to occur at random."( Anderson, C; Bagshaw, AP; Cook, MJ; D'Souza, W; Lightman, SL; Marinelli, I; Seneviratne, U; Terry, JR; Walker, JJ; Woldman, W, 2023)
"Seizures are associated with a decrease in γ-aminobutyric type A acid receptors (GABAaRs) on the neuronal surface, which may be regulated by enhanced internalization of GABAaRs."( Huang, H; Li, S; Lu, Y; Ma, M; Sun, L; Wei, X; Wu, Y; Ye, L, 2023)

Context

ExcerptReference
"Epilepsy-like convulsive seizures have been induced by cholera toxin administration into the rat amygdaloid complex."( Kakita, K; Kuriyama, K, 1979)
"Six major convulsions have been seen among 555 patients who had therapeutic second trimester abortion by intra-amniotic prostaglandin F2alpha (PGF2alpha)."( Itzkowic, D; Lyneham, RC; Shearman, RP; Shutt, DA; Walsh, JC, 1975)
"(1) Induced seizures have an hippocampal origin for MCD and two different origins, situated in the cortex and in the limbic system, for DTX1."( Bidard, JN; Gandolfo, G; Gottesmann, C; Lazdunski, M; Mourre, C; Schweitz, H; Widmann, C, 1989)
"A history of seizures has been cause for exclusion from clinical trials."( Van Stone, JC, 1989)
"In humans, partial seizures have been the most extensively studied, with 18F-fluorodeoxyglucose and positron emission tomography."( Ackermann, RF; Engel, J; Phelps, ME, 1986)
"Convulsions have failed to result from intravenous PGF2 alpha even when infused at doses high enough to provoke significant side-effects, including pyrexia, the latter presumably resulting from a central cerebral effect."( Craft, I, 1973)
"Seizures have not previously been described in association with verapamil therapy or poisoning."( Crespin, FH; Passal, DB, 1984)
"Metabolic causes of seizures have received little attention."( Bodian, C; Maker, H; Van Paesschen, W, 1995)
"Chemically provoked seizures have proved to serve as useful model to investigate long term neuronal responses collectively termed as neuronal plasticity."( Kaczmarek, L; Kamińska, B; Lukasiuk, K, 1994)
"Kainate-induced epileptic seizures have been shown to induce gene expression of trophic factors, particularly members of neurotrophin or fibroblast growth factor families, in the hippocampus."( Bektesh, S; Collins, F; Hoffer, B; Humpel, C; Olson, L; Strömberg, I, 1994)
"No such convulsion has been described to date in pregnancy."( DeChazal, R; Halligan, A; Nan, A; Taylor, D, 1993)
"Alcohol-related seizures have been recognized since the time of Hippocrates."( Earnest, MP, 1993)
"Seizures have been reported in several large studies of patients treated with imipenem/cilastatin."( Norrby, SR, 1996)
"Seizures have been reported as a late complication of medically treated prolactin-producing macroadenomas with lateral extension."( Hashi, K; Niwa, J; Tanabe, S, 1996)
"Prolonged seizures have long been known to be associated with cell injury and cell death in brain."( Graham, SH; Simon, RP; Tanaka, K, 1996)
"Gelastic seizures have not previously been discussed in the literature of aerospace medicine."( Feeks, EF; Murphy, GL; Porter, HO, 1997)
"Seizures have been shown to regulate neurotrophin expression in adult mammalian brain."( Gall, CM; Kornblum, HI; Sankar, R; Shin, DH; Wasterlain, CG, 1997)
"Seizures have many causes, and physicians should try not to be shortsighted when an apparent cause seems to leap out."( Cohen, MR, 1997)
"Drug-induced seizures have occurred and will continue to occur as healthcare professionals exceed recommended dosing guidelines to treat critically ill patients."( Hunter, WJ, 1993)
"Early childhood convulsions have been correlated with the finding of subsequent hippocampal neuronal loss and memory impairment in patients with intractable temporal lobe epilepsy."( Cole, AJ; Koh, S; Mian, AY; Santos, TC; Storey, TW, 1999)
"A high frequency of seizures has been reported in family members of persons with SEL."( Bhatia, RC; Kaushal, RK; Kaushal, V; Kumar, S; Raizada, N; Ram, S; Singh, G, 2000)
"Only 61 cases of convulsions have been reported with levofloxacin, with 33 of those affected having received NSAIDs."( Yagawa, K, 2001)
"Focal clonic seizures have a better prognosis as compared to myoclonic seizures for long-term neuro-developmental outcome."( Aggarwal, R; Deorari, AK; Paul, VK; Upadhyay, A, 2001)
"Tonic-clonic seizures have not been reported as a manifestation of this condition."( Boylan, GB; Guerra, MP; Rennie, JM; Wilson, GA, 2002)
"Conversely, epileptic seizures have led to the anomalous sprouting of mossy fibers, a process thought to induce hyperexcitation of granule cells."( Ashida, H; Kanda, M; Maru, E, 2002)
"Spontaneous seizures have been observed in several baboon species housed at the Southwest National Primate Research Center (SNPRC), including Papio hamadryas anubis and cynocephalus/anubis, hamadryas/anubis, and papio/anubis hybrids."( Haines, R; Leland, MM; Mahaney, MA; Restrepo, S; Szabó, CA; Sztonák, L; Williams, JT, 2004)
"Epileptic seizures have been reported in patients on imipenem/cilastatin (Imi/Cil) therapy."( Lovic, OS; Susic, V; Zivanovic, D, 2004)
"Seizures have been shown to promote the proliferation of granule cell precursors in the adult brain, but the underlying mechanisms remain largely unknown."( Huang, YG; Jiang, W; Wolfe, K; Xiao, L; Zhang, X; Zhang, ZJ, 2004)
"Epileptic seizures have been shown to increase the proliferation of granule cell precursors in the adult brain, but the underlying mechanisms remain largely unknown."( Huang, YG; Jiang, W; Wang, JC; Xiao, L; Zhang, X, 2004)
"Whether febrile seizures have detrimental consequences on the brain is still controversial."( Leung, LS; Tsai, ML, 2006)
"Seizures have several different aetiologies, but in police reports a person known to have seizures is most likely to be reported as suffering from epilepsy."( Christoffersen, S, 2007)
"Seizures have been reported in patients receiving fluoroquinolones, including levofloxacin (LVFX)."( Ishiwata, Y; Itoga, Y; Son, K; Yasuhara, M, 2007)
"Relapses of seizures have occurred in 19-33% of patients, especially when tapering of dose."( Kälviäinen, R; Parviainen, I; Ruokonen, E, 2007)
"Epileptic seizures have been shown to stimulate the proliferation rate of neuronal progenitor cells in adult animals, which may be related to epileptogenesis."( Choi, ES; Jeong, SW; Kim, DW; Kwon, YS; Son, BK, 2008)
"Seizures have both local and remote effects on nervous system function."( Blumenfeld, H; Englot, DJ; Herman, P; Hyder, F; Mansuripur, PK; Mishra, AM, 2008)
"Although seizures have been described in the literature, delayed seizure onset has not been reported."( Kleinschmidt, KC; Wax, PM; Young, AC, 2009)
"Hypermotor seizures have not been seen for 1."( Itakura, T; Miki, J; Nishibayashi, H; Ogura, M; Taguchi, M; Uematsu, Y, 2009)
"Early control of seizures has a crucial role in preventing subsequent epileptic encephalopathy, and in reducing the cognitive/behavioural consequences of seizures, but does not guarantee for a normal mental outcome in children with TSC."( Bombardieri, R; Cerminara, C; Curatolo, P; Moavero, R; Pinci, M, 2010)
"Neonatal seizures have devastating consequences for brain development and are inadequately treated by available antiepileptics."( Barnett, SM; Kahle, KT; Sassower, KC; Staley, KJ, 2009)
"Delayed seizures have been reported with overdoses of bupropion extended-release (XL)."( Ekleberry, SE; Kern, P; Klein-Schwartz, W; Kunkel, S; Spiller, H; Starr, P, 2009)
"Seizures have been reported with lidocaine at its lowest effective dose (1."( Guay, J, 2009)
"Dystonia and seizures have been associated with ondansetron in a few case reports."( Manchanda, S; Mittal, S; Patel, A; Puliyel, JM, 2011)
"No hypertension or convulsions have been detected on the control examinations, and she has now been followed-up without any symptoms or findings."( Akbayram, S; Ariyuca, S; Cesur, Y; Dogan, M; Dogan, ŞZ; Ozdemir, O; Peker, E, 2012)
"Seizures have been reported with tramadol monotherapy in animal and human studies, both at recommended and high doses."( Bekjarovski, N; Chaparoska, D; Radulovikj-Bekjarovska, S, 2012)
"Drug-induced seizures have often been seen as a complication of psychopharmacological therapy, but its occurrence has also been described in response to a great diversity of compounds such as antibiotics, sympathomimetics and anaesthetics."( Block, F; Dafotakis, M, 2013)
"Reflex seizures have been reported in patients with Dravet syndrome provoked by body temperature elevation, looking at visual patterns, or under intermittent photic stimulation."( Patiño-Garcia, A; Sanchez-Carpintero, R; Urrestarazu, E, 2013)
"Although seizures have been reported in interferon-treated patients with multiple sclerosis and in a variety of malignancies, the epileptogenic potential of interferon-α in the treatment of HCV infection is considered minimal."( Antinori, S; Cattaneo, D; Falvella, FS; Gervasoni, C; Magni, C; Milazzo, L; Peri, AM; Vidale, S, 2013)
"Absence seizures have a significant impact on quality of life."( Posner, E, 2013)
"Seizures have been shown to upregulate the expression of numerous extracellular matrix molecules."( Arriaga-Avila, V; Guevara-Guzmán, R; Landgrave-Gómez, J; Mercado-Gómez, O; Nebreda-Corona, A, 2014)
"The 6 Hz model of focal seizures has been increasingly used to identify anticonvulsant compounds with potential activity against therapy-resistant epilepsy, but the protective response to anticonvulsants in this model could be dependent on experimental conditions and selection of mouse strains."( Kaminski, RM; Leclercq, K, 2015)
"Seizures have never been reported with ranolazine use or abuse."( Akil, N; Bottei, E; Kamath, S, 2015)
"Olanzapine-related seizures have rarely been reported despite associated proconvulsant risk factors described in the literature: myoclonic status, increased frequency of seizures, tonic-clonic seizures, as well as fatal status epilepticus."( Anzellotti, F; Capasso, M; Frazzini, V; Onofrj, M, 2016)
"Neonatal seizures have an incidence of 3."( Carter, BM; Kadam, SD; Landers, JR; Sullivan, BJ, 2018)
"While seizures have been reported with its use, the risk in clinical practice has not been well characterised."( Dormuth, CR; Gomes, T; Juurlink, DN; Mamdani, MM; Morrow, RL; Paterson, M, 2019)
"Seizures have severe implications in the intraoperative period, as it can instigate an increase in cerebral metabolism and oxygen demand, thus causing cerebral hypoxia."( Ajayan, N; Hrishi, AP; Prathapadas, U, 2021)
"Seizures have not been directly reported as a part of COVID-19 outside of patients with previously known brain injury or epilepsy."( Bhimraj, A; George, P; Hantus, S; Hepburn, M; Mullaguri, N; Newey, CR; Punia, V, 2021)
"No seizures have been observed since the antiepileptic drug was administered."( Ishii, K; Muroi, A; Tamaoka, A; Tozaka, N; Tsutsumi, S, 2020)
"TBM-related seizures have been categorized into early (< 1 month) or late (> 1 month) seizures."( Kalita, J; Misra, UK; Tripathi, A, 2021)
"Posterior cortex seizures have a complex semiologic presentation that is especially challenging in the pediatric population."( Čokolić Petrović, D; Kukuruzović, M; Malenica, M; Šeparović, I, 2021)
"Posterior cortex seizures have a complex semiologic presentation that is especially challenging in the pediatric population."( Čokolić Petrović, D; Kukuruzović, M; Malenica, M; Šeparović, I, 2021)
"Posterior cortex seizures have a complex semiologic presentation that is especially challenging in the pediatric population."( Čokolić Petrović, D; Kukuruzović, M; Malenica, M; Šeparović, I, 2021)
"In ZF, seizures have been induced through a variety of chemoconvulsants, primarily pentylenetetrazol (PTZ), kainic acid (KA), and pilocarpine."( D'Amora, M; De Angelis, F; Faraguna, U; Galgani, A; Giorgi, FS; Marchese, M; Tantussi, F, 2023)
"While seizures have long been recognized as a potential cause of hormonal imbalances, recent research has shed new light on the link between seizures and prolactin."( Fathi, E; Panahi, Y; Shafiian, MA, 2023)
"No seizures have occurred in more than one year since doxepin discontinuation."( Burns, MM; Watson, CJ; Whitledge, JD, 2023)

Actions

ExcerptReference
"The most extensive seizures affected all limbs and trunk, sometimes with falling (generalised seizures)."( Hiscock, JJ; Mackenzie, L; Medvedev, A; Willoughby, JO, 1995)
"Domoic acid-induced convulsions affects limbic structures such as hippocampus and entorhinal cortex, and different anatomic markers can detect these neurotoxic effects to varying degrees."( Appel, NM; Bell, JM; Freed, LM; O'Callaghan, JP; Rapoport, SI, 1997)
"In contrast, 1-h convulsions affected many neurons and caused swelling of astrocytic processes and neuronal dendrites (excitotoxic neuropil)."( Csordás, A; Gallyas, F; Mázló, M; Schwarcz, A, 2005)
"Treatment-resistant seizures affect about a third of patients suffering from epilepsy."( Afrikanova, T; Buenafe, OE; Crawford, AD; De Prins, A; de Witte, PA; Esguerra, CV; Kaminski, RM; Langlois, M; Leclercq, K; Rospo, CC; Smolders, I; Van Eeckhaut, A, 2015)
"As seizures affect ribosome biogenesis without long-term effects on the total ribosome content, such a requirement may be associated with a need to produce specialized ribosomes that promote pro-epileptic plasticity."( Hetman, M; Kolikonda, M; Naik, SP; Parlato, R; Pietrzak, M; Slomnicki, LP; Smith, SC; Vashishta, A, 2018)
"Seizures affect about 50 million people around the world."( Arrifano, GPF; Carvalho, JCT; Crespo-López, ME; Farina, M; Lichtenstein, MP; Rogez, H; Souza-Monteiro, JR; Suñol, C, 2018)
"Seizure-affected pregnancies were more frequent in the VPA changed pregnancies than in the VPA unchanged ones (46."( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJE, 2020)
"The type of focal seizures may affect the outcome of participants with seizures."( Chen, J; Guan, H; Huang, Y; Jin, L; Lin, N; Liu, Q; Lu, Q, 2021)
"New-onset seizures affect up to 10% of people over their lifetime, however, their health economic impact has not been well-studied."( Ademi, Z; Au Yong, HM; Carney, PW; Carrillo de Albornoz, S; Chen, Z; D'Souza, W; Foster, E; Kwan, P; Liew, D; Nicolo, JP; O'Brien, TJ; Pellinen, J; Tailby, C; Vaughan, DN, 2022)
"Seizures affect 35%-60% of patients diagnosed with mitochondrial diseases."( Faller, DV; Glavas, IP; Kanara, I; Kodukula, K; Moos, WH; Pernokas, J; Pernokas, M; Pinkert, CA; Powers, WR; Sampani, K; Steliou, K; Vavvas, DG, 2023)

Treatment

ExcerptReference
"The pattern of daily convulsions evoked by cocaine MCD changed from multiple episodes of intermittent tonic-clonic convulsions, which occurred during the earlier stage (1--2 months) of chronic treatment, to a single episode of sustained tonic-clonic convulsion."( Matsuzaki, M, 1978)
"The initial seizure was induced by the cortical suprafusion of PGE1 over the left visual cortex of PG transport inhibitor-pretreated rabbits."( Bito, LZ; Wallenstein, MC, 1979)
"Thiopental was administered for seizure control in 2 patients with uncontrollable seizures."( Cloyd, JC; Perrier, D; Wright, BD, 1979)
"Withdrawal seizures were evident on cessation of CZP administration."( Congdon, WC; DuCharme, LL; Levy, RH; Lockard, JS; Salonen, LD, 1979)
"The effect of each drug on seizures (tonic, tonic-clonic, clonic, myoclonic or myoclonic-atonic, atonic and atypical absences) during the first month of each treatment is discussed."( Lison, MP; Speciali, GG, 1977)
"Epilepsy-like convulsive seizures have been induced by cholera toxin administration into the rat amygdaloid complex."( Kakita, K; Kuriyama, K, 1979)
"Eight patients developed grand mal seizures during intravenous theophylline therapy."( Cohn, WM; Matthay, RA; Neff, TA; Sutton, FD; Weinberger, MM; Zwillich, CW, 1975)
"Twenty-seven children with uncontrolled seizures, predominantly akinetic and myoclonic, were treated with this drug."( Botsford, E; Freeman, JM; Vining, EP, 1979)
"Thirty children with simple febrile convulsions were treated with sodium valproate following their second convulsion."( Evans-Jones, LG; Groom, PJ; Kindley, AD; Williams, AJ, 1979)
"Metrizamide-induced seizures could be prevented by intramuscular preadministration of diazepam."( Davis, JP; Eldevik, OP; Gager, WE; Harris, GJ; Haughton, VM, 1979)
"The thresholds of twitch and clonic convulsion induced by intravenous infusion of pentylenetetrazol (PTZ) were measured in rats treated with 6-hydroxydopamine (6-OHDA)."( Fukuda, T; Oishi, R; Suenaga, N, 1979)
"Early treatment (convulsions less than or equal to 15 minutes) had effect in 96%, and late treatment (convulsions greater than 15 minutes) in 57% of cases."( Knudsen, FU, 1979)
"When the convulsions were protected by pretreatment with AOAA, the decreased GABA releases in both the conditions rose to or above the normal levels."( Asakura, T; Hoshino, M; Matsuda, M, 1979)
"A 4-year-old girl who developed convulsions after an accidental ingestion of excessive dosage (50 mg/kg) of nalidixic acid, while treated with the drug (50 mg/kg/day) over 30 days for a urinary tract infection, was reported."( Jo, M; Shinoda, M; Tachi, N, 1979)
"Clonic convulsions after intracranial administration of NMGI in dogs occurred when NMGI was given into the parenchyma but not when given into the ventricle."( Wakabayashi, K, 1977)
"When seizures developed, intravenous phenytoin sodium therapy was begun."( Bivins, BA; Blouin, R; Bustrack, J; Griffen, WO; Rapp, RP, 1978)
"A Tanzanian man with a known seizure disorder was admitted to hospital for treatment of schistosomiasis mansoni."( Keystone, JS, 1978)
"During the convulsions by TSC 16hr after the AOAA-pretreatment, the GABA content in synaptosomes was less than that from the group treated with AOAA alone, though its GABA level was higher than the normal level."( Abe, M, 1978)
"during epileptic seizures and after amphetamine-administration, protein leakage in the brain is more pronounced than in hypertension per se."( Johansson, BB; Lund, S, 1978)
"Before the onset of lignocaine-induced seizures in non-treated animals, the animals appeared to be drowsy."( Ausinsch, B; Malagodi, MH; Munson, ES, 1976)
"The effect of electrically induced convulsions was tested on the tolerance to hexobarbital after chronic barbital treatment in male rats."( Wahlström, G, 1976)
"When premidication is needed or when convulsions occur after Amipaque examinations, combined diazepam and phenobarbital therapy ought to be instituted in order to achieve the best control of epileptic reactions."( Brucher, JM; Gonsette, RE, 1977)
"If both minimal and maximal seizures are considered, the reserpine and combined treatment groups do not differ from one another, but do show a lower threshold as compared to ECS or control groups."( Blank, DL, 1976)
"The behavioral convulsions decrease in severity and then disappear after the long-term administration of delta9-tetrahydrocannabinol."( Consroe, P; Martin, P, 1976)
"Diazepam pretreatment raised the seizure threshold of bupivacaine."( Jenkins, LC; Robinson, WM, 1975)
"Attempts were made to control prolonged seizures with rapid intravenous administration of either diazepam or methohexitone in relatively small doses under electroencephalographic (EEG) monitoring."( Da Costa, AA; Pampiglione, G, 1975)
"Audiogenic seizures in DBA/2 mice have been studied after administration of drugs believed to act as dopamine agonists."( Anlezark, GM; Meldrum, BS, 1975)
"Hyperreflexia and periodic convulsions were controlled by initial intramuscular injections of 30 mg diazepam and 2 g methocarbamol, followed at 6-hour intervals with intramuscular injections of 30 mg diazepam each, for 2 additional treatments."( Peavy, GM, 1975)
"Successful treatment of partial complex seizures (and the epilepsies in general) is a process of management over time and involves several factors."( Booker, HE, 1975)
"That convulsion and other symptoms were due to cephaloridine was confirmed when the second intrathecal administration produced the same symptom."( Fujita, M; Nambu, H; Uehara, H; Yoshioka, H, 1975)
"On day 30 of life, seizure-treated rats had smaller brains (-56 mg, P less than ."( Wasterlain, CG, 1976)
"Diazepam pretreatment decreased the tonic seizure time following ECS in a dose-dependent manner."( Mathé, AA; Srinivasan, GR; Stenfors, C; Theodorsson, E, 1992)
"Tacrine elicited seizures and brain damage in 90% of the rats treated."( Bagetta, G; Iannone, M; Nisticò, G; Scorsa, AM, 1992)
"In mice, tonic convulsive seizure induced by intravenous administration of caffeine (adenosine A1, A2 receptors antagonist) was significantly potentiated by any one of L-PIA (adenosine A1 receptor agonist), NECA (adenosine A2 receptor agonist) and 2-ClAd (adenosine A1, A2 receptors agonist)."( Inano, S, 1992)
"Despite phenytoin administration, the seizure-like activity subsided only after discontinuing ganciclovir."( Barton, TL; Dever, LL; Roush, MK, 1992)
"Since clinical data indicate a seizure enhancing interaction between FQ and theophylline (THEO) we studied the influence of concurrent FQ-THEO administration in kindled rats."( Schwark, WS; Vancutsem, PM, 1992)
"Twenty-two patients had grand mal seizures during the administration periods."( Hori, M; Koizumi, J; Sasaki, M; Shiraishi, H; Suzuki, T, 1992)
"Withdrawal Seizure Prone (WSP) mice, genetically selected to develop severe handling-induced convulsions after withdrawal from chronic ethanol treatment, were exposed to ethanol vapor for 24 h."( Crabbe, JC, 1992)
"Withdrawal seizure prone (WSP) and withdrawal seizure resistant (WSR) mice were treated with 5 mg/kg lorazepam for 7 days via implanted osmotic mini pumps."( Allan, AM; Baier, LD; Zhang, X, 1992)
"administration to audiogenic seizure-susceptible DBA/2J mice."( Baron, BM; Harrison, BL; McDonald, IA; Meldrum, BS; Palfreyman, MG; Salituro, FG; Siegel, BW; Slone, AL; Turner, JP; White, HS, 1992)
"An eclamptic seizure occurring at 32+2 weeks of gestation was treated with magnesium sulfate."( Bleker, OP; Schutte, MF; Swartjes, JM, 1992)
"To evaluate the role of the acute seizures and associated hippocampal structural alterations in the development of this long-lasting susceptibility, rats that received intraventricular kainic acid were cotreated with phenobarbital (60 mg/kg, s."( Cavazos, J; Golarai, G; Sutula, T, 1992)
"One rat that developed seizures after CPX pretreatment needed a considerably reduced dose of thiopental to induce the silent-second."( Broholm, KA; Schliamser, SE; Wahlström, G, 1992)
"Spinal seizures in mice induced by handling following pretreatment with a subconvulsive dose of strychnine could be blocked by competitive N-methyl-D-aspartate (NMDA) receptor antagonists (D-, L-, DL-CPPene (CPPene = (E)-4-(3-phophonoprop-2-enyl)-piperazine-2-carboxylic acid), D-AP5 (D-2-amino-5-phophonovalerate)) and compounds acting at receptor-coupled modulatory sites (R-HA 966, ifenprodil)."( McAllister, KH, 1992)
"There were no convulsions subsequent to treatment, although the study was too small to assess anticonvulsant efficacy."( Chongsuphajaisiddhi, T; Holloway, P; Kuile, F; Maelankirri, L; Nosten, F; White, NJ, 1992)
"We compared the seizure frequency in the 3 months before and after methylphenidate with the seizure frequency during methylphenidate treatment, using the Wilcoxon signed-rank test."( Leary, JM; Manning, K; Phelan, AM; Whyte, J; Wroblewski, BA, 1992)
"Only 4 patients had greater seizure frequency during methylphenidate treatment, and 3 of these 4 were receiving tricyclic antidepressants."( Leary, JM; Manning, K; Phelan, AM; Whyte, J; Wroblewski, BA, 1992)
"Although electrical seizure activity in response to opioids such as fentanyl has been well described in animals, scalp electroencephalographic (EEG) recordings have failed to demonstrate epileptiform activity following narcotic administration in humans."( Bernardo, KL; Edwards, I; Modica, PA; Tempelhoff, R, 1992)
"EtOH withdrawal seizures of WSP mice were significantly increased by chronic and acute corticosterone treatment, whereas those of the WSR mice were unaffected."( Chu, HP; Crabbe, JC; Keith, LD; Roberts, AJ, 1991)
"Mice were observed for convulsions for 90 minutes after the administration of temafloxacin HCl (100 mg/kg orally [p."( Giardina, WJ, 1991)
"In fact, no convulsions were observed in the first week of treatment, but all the animals became sensitized to PTZ by the 12th week."( Biggio, G; Corda, MG; Giorgi, O; Longoni, B; Orlandi, M, 1990)
"In neonatally drug-treated rats, seizures during adulthood were found to occur with significantly higher incidence and severity."( Pierson, M; Swann, J, 1991)
"The incidences of both seizure and death for strychnine and death for picrotoxin were enhanced by treatment with GES, whereas the latency of pentetrazole-induced tonic extensor was prolonged."( Araki, H; Sano, M; Shimada, C; Tanaka, S, 1991)
"We report a patient with a seizure disorder on anticonvulsant therapy, who developed systemic reactive histiocytosis."( Galetta, SL; Hicks, DG; Oberholtzer, JC; Plock, G; Raps, EC; Stadtmauer, EA, 1991)
"In the present study, we examined the clonic seizure immediately preceding head-weaving behaviour elicited by 8-OH-DPAT (40 mg/kg, ip) administration in mice."( Fujii, E; Nomoto, T, 1991)
"The incidence of lidocaine-induced convulsions was decreased by treatments with alpha-MPT and disulfiram, while that of PTZ was increased by either treatment."( Dohi, T; Takada, K; Tanaka, S; Tsujimoto, A; Yoshimura, Y, 1991)
"AOAA also induced clonic convulsions in mice subjected to intracerebroventricular administration of the drug with a CD50 of 0."( Calderazzo-Filho, LS; Cavalheiro, EA; Dziki, M; Turski, WA; Urbanska, E, 1991)
"Initially, a dose sufficient to cause convulsions (CD) was given followed by twice the CD (2 x CD), which was administered 48 h later."( Arthur, GR; Covino, BG; Doucette, AM; Feldman, HS; Hurley, R; Pitkanen, M, 1991)
"Changes in inhibition during seizure development were monitored by administering pulse pairs at regular intervals."( Ivy, GO; Khurgel, M; Milgram, NW; Racine, R; Yearwood, T, 1991)
"Both PTX and Ro 5-4864 produced myoclonic seizures, primarily between 15-40 min after administration; myoclonus was followed by more severe seizures after PTX."( Dai, KS; Woolley, DE, 1991)
"Pretreatment were pancuronium prevented convulsions and hyperthermia, but had no effect on acidemia or changes in cardiovascular parameters after intravenous (i."( Davis, WM; Hackett, RB; Obrosky, KW; Waters, IW, 1991)
"Generalized convulsion appeared after intraperitoneal administration of 50 mg/kg PTZ with a latency of 68."( Fujimoto, H; Hashiguchi, S; Kawai, H; Masuda, T; Saito, S, 1990)
"To determine the adequacy of seizure control and the adverse effects of administering an IV loading dose of phenytoin by constant infusion pump."( Cline, D; Donovan, PJ, 1991)
"On the other hand, BIC-induced seizures in both groups were suppressed by IPR pretreatment."( Mutoh, F, 1991)
"Treatment of hyponatremic seizures with routine anticonvulsants may be ineffective and is associated with a considerable incidence of apnea."( Fleischmann, L; Hackbarth, R; Meert, K; Sarnaik, AP, 1991)
"Clonic seizures induced in mice by intracerebral administration of N-methyl-D-aspartate, kainate or quisqualate were used to study the anti- and proconvulsant potential of antiepileptic drugs and beta-carbolines."( Niemann, W; Stephens, DN; Turski, L, 1990)
"Studies of the treatment of intractable seizures (unsatisfactory control of seizure) indicate that more complex cases may require the data obtained with EEG video monitoring."( Erlichman, M, 1990)
"In the present study, limbic seizures induced by systemic administration of kainic acid resulted in substantial increases in the TRH content of posterior cortex and of dorsal and ventral hippocampus, and in moderate elevations in anterior cortex, amygdala/piriform cortex and corpus striatum."( Kreider, MS; Winokur, A; Wolfinger, BL, 1990)
"MK-801 treatment reduced overall seizure score and proportion of rats seizing."( Janowsky, DS; Morrisett, RA; Overstreet, D; Rezvani, AH; Swartzwelder, HS; Wilson, WA, 1990)
"When administered i."( Kanai, Y; Manabe, S; Wada, O, 1990)
"Treating seizures is a major part of a neurologic practice."( Bernstein, AL, 1990)
"In contrast, generalized motor seizures evoked by [NMe-Phe3-D-Pro4]morphiceptin were potentiated and prolonged in colchicine-pretreated animals as status epilepticus (sustained clonus of forepaws and head for more than 1 h) was observed in both unilateral and bilateral colchicine-pretreated animals but not in control rats."( Hong, JS; Lee, PH, 1990)
"NMDA-induced convulsions were antagonized in a dose-related manner by prior administration of the NMDA antagonists cis-(+/- )-4-phosphonomethyl-2-piperidine carboxylic acid (CGS19755), cis-(+/- )-4-(2H-tetrazol-5-yl)methyl-piperidine-2-carboxylic acid (LY233053), (+/- )3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), D,L-2-amino-5-phosphonovalerate (D,L-AP5) and MK801."( Gamble, AY; Johnson, BG; Ornstein, PL; Salhoff, CR; Schoepp, DD, 1990)
"Pilocarpine seizures were blocked by systemic administration of benzodiazepines, barbiturates, valproate and trimethadione, while diphenylhydantoin did not affect, and ethosuximide increased the susceptibility of rats to such seizures."( Andrews, JS; Bortolotto, ZA; Bressler, K; Calderazzo-Filho, LS; Cavalheiro, EA; Löschmann, PA; Turski, L, 1990)
"Normeperidine-induced seizures in patients with porphyria may be treated by withdrawal of meperidine therapy and selective use of anticonvulsants."( Deeg, MA; Rajamani, K, 1990)
"Both convulsions and mortality percentages are more significantly reduced in treated animals with these two substances in combination rather than separately."( Bertelli, A; Bertelli, AA; Giovannini, L; Spaggiari, P, 1990)
"However, the seizures initiated 1 day after drug administration were dose-dependently suppressed."( Abraham, WC; Bilkey, DK; Takazawa, A, 1990)
"In contrast to the potent effect on the seizure threshold, the severity or duration of seizures, evoked in phenytoin-pretreated rats by increasing the current, was not reduced."( Hönack, D; Löscher, W; Rundfeldt, C, 1990)
"By using a rat seizure model, a comparison of the antiseizure activity of 12 dihydropyridine calcium channel antagonists (administered i."( Morón, MA; Stevens, CW; Yaksh, TL, 1990)
"The odds ratios of seizure induction in the CsA-treated groups versus placebo group were 1."( Christenson, M; Fisher, RS; Fivush, B; McCrindle, BW; Racusen, LC, 1990)
"Protection against convulsions induced by cyanide was observed after treatment with alpha-ketoglutarate, either alone or in combination with sodium thiosulfate, a classical antagonist for cyanide intoxication."( Yamamoto, H, 1990)
"A 93-year-old woman without a known seizure history, while on ciprofloxacin and theophylline combined therapy, experienced a grand mal seizure."( Bentley, DW; Karki, SD; Raghavan, M, 1990)
"Generalized tonic clonic seizures continued despite conventional therapy."( Dean, BS; Goetz, CM; Krenzelok, EP; Lopez, G, 1990)
"The duration of seizure was shorter with propofol in both treatments but there was significant drug-time interaction."( Boey, WK; Lai, FO, 1990)
"The role of seizure-induced cell death was investigated by recording the EEG in monkeys and in rats treated with phenobarbital."( Dasheiff, RM; Ramirez, LF, 1985)
"This seems to imply that seizures become harder to suppress as they recur--a possibility which argues for the early initiation of anticonvulsant therapy."( Burnham, WM; Mace, JA, 1987)
"Convulsive seizures are a potential side effect of antidepressant drug treatment and can be produced by all classes of antidepressants."( Ikeda, M; Knapp, RJ; Malatynska, E; Yamamura, HI, 1988)
"Knowledge of a strain's seizure susceptibility to the GABA antagonist or of its sensitivity to the hypnotic effects of ETOH were of no predictive value in estimating the outcome of coadministration studies, suggesting at least partially separate genetic influences on each phenotype."( Dudek, BC; Phillips, TJ, 1989)
"The incidence of convulsions increased 3 days after starting GES administration, and this effect continued throughout the 6 months of drug administration."( Edamatsu, R; Higashihara, Y; Hiramatsu, M; Kabuto, H; Mori, A, 1989)
"Focal, limbic seizures were produced by systemically administered pilocarpine (200 mg/kg, i."( Barone, P; Campanella, G; Chase, TN; Marin, C; Palma, V; Parashos, SA, 1989)
"In order to investigate the effects of seizures on manganese distribution in the body, rats were treated with kainic acid to produce spontaneous seizures which were quantitated for number and severity."( Carl, GF; Critchfield, JW; Gallagher, BB; Holmes, GL; Hurley, LS; Keen, CL; McGinnis, LS; Thompson, JL; Wheeler, GA, 1989)
"Five patients with seizures related to imipenem administration are described."( Chmel, H; Eng, RH; Munsif, AN; Smith, SM; Yangco, BG, 1989)
"We favor treatment of a single seizure in patients with HIV infection."( Holtzman, DM; Kaku, DA; So, YT, 1989)
"The potentiation of seizures and death by 2 mg/kg nifedipine pretreatment was further shown by challenge with three different doses of cocaine."( Albertson, TE; Derlet, RW, 1989)
"In animals that presented convulsion a stereotyped gnawing and/or licking behavior was observed immediately after the ictus activity as a consequence of the combined acute administration of haloperidol and picrotoxin."( Palermo-Neto, J; Sandoval, MR, 1989)
"Four adult men with resistant partial seizures underwent an intensive open-label protocol designed to evaluate long-term add-on lamotrigine (LTG) therapy."( Ashworth, M; Keally, M; Kupferberg, H; Mikati, MA; Osborne-Shafer, P; Schachter, SC; Schomer, DL; Seaman, CA; Sheridan, PH; Valakas, A, 1989)
"The effects of seizures induced by an acute administration of bicuculline have been investigated on the central benzodiazepine and adenosine receptors in developing rats and in adults."( Daval, JL; Sarfati, A, 1987)
"At a dose of 70 pmol seizures occurred for half of the treated rats."( Bidard, JN; Gandolfo, G; Gottesmann, C; Lazdunski, M; Mourre, C, 1987)
"Thus, myoclonic seizures were observed in 30% and 80% of the animals by the third and the eighth day of treatment, respectively."( Biggio, G; Corda, MG; Giorgi, O; Mele, S, 1987)
"Hyponatremia should be considered when seizures or mental changes occur in patients treated with DDP."( Ritch, PS, 1988)
"Definition of other pathways of seizure development and the effects of pharmacologic treatments on discrete brain regions await further research efforts."( Gale, K, 1988)
"Soman (100 micrograms/kg; sc) produced convulsions in 63% of the saline-pretreated rats, whereas with LiCl pretreatment all rats exposed to 100 micrograms/kg of soman had tonic-clonic convulsions."( Nelson, SR; Pazdernik, TL; Samson, FE; Savolainen, KM, 1988)
"Kindled seizures were almost completely blocked by treatment with carbamazepine, whereas the effect of valproic acid was partial, suppressing only generalized seizures."( Higuchi, T; Igarashi, Y; Kato, N; Minatogawa, Y; Nagaki, S; Ohshima, H; Takazawa, A; Watanabe, N; Yamazaki, J; Yamazaki, O, 1986)
"The analgesic treatments lowered the seizure threshold considerably in 5 out of 6 dogs, and fentanyl and pentazocine led to an increased incidence of clonic-tonic seizures after the end of the pentetrazole infusion."( Czuczwar, SJ; Frey, HH; Scherkl, R, 1986)
"Postdecapitation convulsions were analyzed in rats after the administration of a variety of adrenergic and serotonergic agents."( Gonzales, DA; Peroutka, SJ; Shapiro, M, 1987)
"Reasons for the occurrence of these seizures despite treatment are discussed within the context of the differential potency that exists among benzodiazepines in binding to central and peripheral benzodiazepine receptors."( Pawluczyk, S; Schneider, LS; Syapin, PJ, 1987)
"RO 15-3505 induced seizures in mice treated with a subconvulsant dose of pentylenetetrazole, the most efficient doses being 3 and 6 mg/kg."( Belzung, C; Misslin, R; Vogel, E, 1988)
"We conclude that 1) bicuculline-induced seizures result in pial arteriolar dilation and increased CBF; 2) CSF levels of prostanoids increase during seizures; and 3) pretreatment with indomethacin severely blunts increases in CBF during seizures."( Busija, DW; Leffler, CW, 1989)
"In kindled rats, 31 days after the last seizure, the number of GABA-immunoreactive cells that could be observed after AOAA-treatment was significantly lower (35% ipsilateral and 25% contralateral) when compared to AOAA-treated controls."( Huisman, E; Kamphuis, W; Lopes da Silva, FH; Wadman, WJ, 1989)
"In the work reported here, audiogenic seizure susceptibility and brain tryptophan and serotonin concentrations were measured in DBA/2J mice after administration of three doses of L-tryptophan or p-chlorophenylalanine."( Lack, DB; Peters, RI, 1985)
"Pentylenetetrazole and picrotoxin seizure thresholds, measured during constant rate iv infusion, were significantly lowered by pretreatment with diazepam (250 mg/kg) and Ro 15-1788 (20 mg/kg) administered 30 and 20 minutes, respectively, before seizure threshold measurement."( Bourn, WM; Garrett, RL, 1985)
"Like 1 and 2, tonic-clonic seizures were induced when trans-3 or -4 were administered to mice intracerebroventricularly."( Enna, SJ; Fung, YK; Patch, RJ; Witiak, DT, 1986)
"Fluid restriction and treatment of seizures with phenobarbital are widely used therapies."( Donn, SM; Goldstein, GW; Schork, MA, 1988)
"Protection against sound-induced seizures was observed after intraperitoneal administration of flunarizine (5-40 mg/kg)."( De Sarro, GB; Meldrum, BS; Nistico, G, 1986)
"By contrast, pentylenetetrazol seizures' characteristics were significantly changed in response to the intraperitoneal administration of the norepinephrine antagonist, 6-hydroxydopamine, by abolishing the tonic and clonic phases of the seizure."( Abed, WT, 1986)
"The electrographic seizure produced by GBL was significantly prolonged and more severe in the 6-OHDA-treated animals."( Snead, OC, 1987)
"Protection against sound-induced seizures was observed after intraperitoneal administration of denzimol (3-15 mg/kg)."( Ascioti, C; De Sarro, GB; Libri, V; Nistico, G; Testa, R, 1987)
"A decrease of the triggered seizure duration occurred during the high-dose treatment."( Kurachi, M; Minabe, Y; Tsutsumi, M, 1988)
"Children with seizure disorders frequently are treated with anticonvulsant medications such as clonazepam, valproic acid, carbamazepine, and ethosuximide, which cannot be given parenterally."( Laney, SM; Woody, RC, 1988)
"The threshold of the generalized clonic convulsions induced by intravenous infusion of pentylenetetrazol (PTZ) was significantly increased by the intraperitoneal administration of noradrenaline (NA) neurotoxin, 6-hydroxydopamine, which produced no changes in the levels of catecholamines in discrete areas of rat brain, but the effect was accompanied by spinal depletion of NA."( Abed, WT, 1988)
"The pharmacotherapy of minor seizures depends on the type of epileptic manifestation."( Hess, CW, 1988)
"Eleven children with seizures were treated with clonazepam by rectal route."( Bildstein, G; Cano, JP; Chateauneuf, R; Fornaris, M; Netter, JC; Petrus, M, 1988)
"Both seizures and sprouting were seen in 32% of the treated animals."( Cronin, J; Dudek, FE, 1988)
"Theophylline can cause life-threatening seizures when administered in excessive doses."( Levy, G; Yasuhara, M, 1988)
"Protection against sound-induced seizures was given after intraperitoneal administration of AVM (30 and 50 mg/kg)."( Ammendola, D; De Sarro, A; De Sarro, GB; Germanà, G; Naccari, F; Rotiroti, D, 1988)
"The effect of bicuculline-induced convulsive seizures on lipid metabolism has been studied in four brain areas (cerebellum, cerebral cortex, hippocampus, and brainstem) using [2-3H]glycerol and [1,2-14C]ethanolamine as radioactive lipid precursors administered simultaneously with bicuculline."( Arienti, G; Corazzi, L; Marku, N; Piccinin, GL, 1988)
"In rats, caerulein failed to affect the seizures caused by intraventricular administration of quinolinic acid."( Allikmets, LKh; Prakh'e, IB; Ryzhov, IV; Soosaar, AKh; Vasar, EE, 1988)
"The average time to onset of seizures induced by fluorothyl in control mice was 510 sec; pretreatment with oral doses of 1000, 1500 and 2000 mg/kg of aspartame 1 hr earlier significantly reduced the time required to elicit seizures (394, 381 and 339 sec, respectively)."( Maher, TJ; Pinto, JM, 1988)
"The incidence and severity of convulsions were monitored in individual rats until they were sacrificed by focused microwave irradiation of the head at the following time points after soman administration: 4 min, a time prior to the onset of convulsions; 10 min, the time of onset of convulsions; 1 h, the time of peak convulsive activity; and 6 h, a time at which rats were recovering from convulsions."( Ho, IK; Hoskins, B; Liu, DD; Ueno, E, 1988)
"Five neonates treated with PB alone for seizures were studied."( Bhargava, VO; Garrettson, LK, 1988)
"The convulsive-seizure-increasing effect of AT II was enhanced after multiple administration of pimozide and particularly after its withdrawal for 21 days."( Georgiev, V; Kambourova, T; Petkova, B, 1988)
"Peak inhibition of severity of seizures occurred at 1 hr after administration with an ED50 of 17."( Heit, MC; Schwark, WS, 1988)
"The behavioral topography of the convulsions and the neuroanatomical distribution and nature of the subsequent pathology closely resemble that observed with systemic administration of these compounds."( McDonough, JH; McLeod, CG; Nipwoda, MT, 1987)
"Bicuculline and picrotoxin convulsions were not significantly affected by MPTP treatment."( Castorina, M; DeMattei, M; Fariello, RG; Ferraro, TN; Golden, GT, 1987)
"In an infant with neonatal seizures, CSF GABA levels were determined before and after treatment with vitamin B6."( Dominick, HC; Kurlemann, G; Löscher, W; Palm, GD, 1987)
"Because seizures may follow ingestion of certain amounts, appropriate treatment is needed, including the use of anticonvulsants."( Siegel, E; Wason, S, 1986)
"CNS excitation and seizures, manifestations of organochlorine intoxication, can occur following ingestion or inappropriate application of the 1 per cent topical formulation of lindane used to treat scabies and lice."( Mortensen, ML, 1986)
"Male Long-Evans rats experienced three convulsions induced by intravenously administered pentylenetetrazol (PTZ) and were then kindled by electrical stimulation of the olfactory bulb or amygdala."( Gramlich, CA; Stripling, JS, 1987)
"Four cases of convulsive seizures occurring during treatment with nomifensine have been notified to the Committee on the Safety of Medicines of the United Kingdom, and 22 cases have been reported from other countries."( Edwards, JG; Glen-Bott, M, 1987)
"The resistance of seizures produced by PILO in rats to antiepileptic drugs reaffirms the clinically obvious lack of effective treatments for limbic convulsions."( Cavalheiro, EA; Coimbra, C; da Penha Berzaghi, M; Ikonomidou-Turski, C; Turski, L; Turski, WA, 1987)
"Prevention of convulsions with phenobarbitone administered immediately before diazinon, resulted in neither the development of lactic acidosis nor mobilization of muscle glycogen or activation of glycogen phosphorylase."( Husain, K; Matin, MA; Mirza, MA, 1987)
"Management of seizures requires prompt medical attention to prevent morbidity and mortality and to clarify the etiology of the event so that proper long-range therapy can be planned."( Bean, SC, 1986)
"Both compounds antagonized MES-induced seizures after administration to mice; oral ED50 values for 3 and 4 were 3."( Beedle, EE; Clark, CR; Lawson, R; Leander, JD; Parli, CJ; Potts, BD; Robertson, DW, 1987)
"One child treated with FB exhibited seizures on the second day and six children showed drowsiness and bradycardia on the last two days, that were attributable to high levels of FB."( Chunga, F; Durán, JA; Serrano, JS; Valls, A; Vela, F, 1987)
"Unlike kainate, TMT produced seizures in only a subset of treated animals and with a latency of days rather than minutes."( Dempster, DW; Sloviter, RS; von Knebel Doeberitz, C; Walsh, TJ, 1986)
"The thresholds for inducing the maximal seizure by pentylenetetrazole (PTZ) were compared for BDF1 mice of both sexes with varying ages after intraperitoneal administration of various doses of PTZ."( Kanai, S; Kitani, K; Masuda, Y; Nokubo, M; Ohta, M; Sato, Y, 1986)
"At age 16 to 17 days, seizures were induced in the cannulated rats and naive (intact) controls by exposure to flurothyl following pretreatment with the GABA agonist, muscimol, or vehicle."( Moshe, SL; Okada, R; Sperber, EF; Wong, BY; Zhao, DY, 1986)
"A patient with seizures, coma and respiratory depression after pentazocine overdose was treated successfully with naloxone and artificial ventilation."( Bear, R; Gesztes, T; Roytblat, L, 1986)
"Seven neonatal patients with severe seizures unresponsive to conventional anticonvulsant therapy were treated with lorazepam."( Deshmukh, A; Mangurten, HH; Schnitzler, E; Wittert, W, 1986)
"Duration of freedom from seizures following acute therapy was independent of LOR dosage."( Crawford, TO; Mitchell, WG; Snodgrass, SR, 1987)
"Generalized convulsive seizures can be triggered by sensory stimuli in animals treated with subthreshold levels of convulsant drugs."( Caspary, DM; Faingold, CL; Hoffmann, WE, 1985)
"Psychosis and/or seizures following the administration of intramuscular penicillin G procaine have not been reported in the pediatric literature to our knowledge."( D'Angelo, L; Silber, TJ, 1985)
"We studied 15 children with complex partial seizures in whom one or more seizure type was exacerbated during treatment with carbamazepine."( Hosey, LC; Snead, OC, 1985)
"In this model, tonic-clonic seizures are easily elicited by handling and the effects of administration of carbamazepine (CBZ), phenytoin (DPH), phenobarbital (PB), diazepam, valproic acid (VPA) and ethosuximide were quantitatively evaluated."( Abbott, LC; Bennett, GD; Finnell, RH; Taylor, SM, 1985)
"Three adolescent patients with severe seizure disorders were treated with phenacemide."( Baska, RE; Duggan, E; Hellerstein, S; Hoffman, L; Lea, K, 1986)
"However, the incidence of convulsions was increased by FLA-63 in rats pretreated with the catecholamine precursor L-dihydroxyphenylalanine."( Blask, DE; Stockmeier, CA, 1986)
"In four patients the seizure followed the institution of maprotiline therapy by less than three weeks."( Bryan, GE; Gunderson, CH; Jabbari, B; Marsh, EE, 1985)
"The appearance of convulsion induced by I-nicotine in mice was also inhibited by pretreatment with d-nicotine."( Ishikawa, T; Nagata, M; Osumi, Y, 1985)
"The binding sites from seizure sensitive and resistant mice were equally affected by treatment with dithiothreitol, trypsin or heat."( Collins, AC; Marks, MJ; Miner, LL, 1985)
"The latency to clonic convulsion was dramatically affected by prior shock treatment, and the direction of this change depended upon the escapability/inescapability of the shock."( Alpern, HP; Drugan, RC; Maier, SF; McIntyre, TD, 1985)
"These prolonged seizures remained with chronic (10 days) treatment but an anticonvulsant effect of phenytoin (40 and 75 mg/kg) also emerged, shown by a decrease in the incidence of seizures."( File, SE; Pellow, S; Wilks, L, 1985)
"Grand mal seizures were observed in unanesthetized animals (+/-SD) 133+/-37 min after administration of insulin, at a time when brain glucose was normal, but brain tissue content of Na(+), K(+), osmoles, and water was significantly greater than normal."( Arieff, AI; Doerner, T; Massry, SG; Zelig, H, 1974)
"The treatment was found to prevent seizures induced by pentylenetetrazol."( Mizutani, A; Sano, M; Seto-Ohshima, A, 1984)
"The rise in seizure threshold still occurred when animals were pretreated with alpha-methyl-p-tyrosine (200 mg ."( Cowen, PJ; Green, AR; Nutt, DJ, 1981)
"Changes in leptazol (pentetrazol) seizure susceptibility after successive treatments of mice with tryptophol, a neutral metabolite of indoleamine, in combination with ethanol have been examined."( Fukumori, R; Kitagawa, H; Minegishi, A; Satoh, T, 1981)
"In mice, running, clonic and tonic convulsions and lethality were assessed following transcorneal (electroshock) current or convulsant drugs, each administered alone and after cannabidiol (CBD) pretreatment."( Benedito, MA; Carlini, EA; Consroe, P; Leite, JR; Mechoulam, R, 1982)
"tremor, myoclonus and convulsions, successively appear, have been studied in fed and fasted rats with and without pretreatment with 2-amino-7-phosphonoheptanoic acid (180 mg/kg)."( Halsey, MJ; Meldrum, BS; Wardley-Smith, B, 1984)
"Generalized tonic-clonic convulsions appeared with typical changes in the electroencephalogram 7-35 s after administration of the epileptogenic drugs."( Goitein, KJ; Shohami, E, 1983)
"Except for single seizure episodes in five patients, GAG therapy was well tolerated."( Agid, Y; Böhlen, P; Bonnet, AM; Chazot, G; Coquillat, G; Fischer, C; Koch-Weser, J; Schechter, PJ; Tell, G, 1981)
"Following these treatments, seizure thresholds to these drugs were measured by an IV infusion method to minimise problems of systemic uptake and metabolism of the drugs."( Batts, CC; Cowen, PJ; Grahame-Smith, DG; Green, AR; Nutt, DJ, 1982)
"Electroconvulsive seizures administered during the period of fetal benzodiazepine (BZ) binding site proliferation (days 16, 18 and 20 in gestation) significantly decreased the density of cerebral cortical benzodiazepine binding sites in exposed pups up to 21 days postnatal age."( Gallager, DW; Wakeman, EA, 1982)
"Administration of THC during the seizure-insensitive period resulted in genotype-dependent alternations in photocell activity and sprawling."( Consroe, P; Fish, BS, 1983)
"We think this decline is caused by seizures since phenobarbital pretreatment prevented the appearance of limbic seizures and blocked the receptor decline."( Dasheiff, RM; Fanelli, RJ; Kraus, VM; McNamara, JO, 1983)
"These electrographic seizures were not opiate specific since this activity occurred undiminished in naltrexone-pretreated animals and was even potentiated in animals pretreated for 6 days with increasingly higher doses of systemic morphine."( Frenk, H; Mayer, DJ; Miller, J; Watkins, LR, 1984)
"More animals with clonic seizures were seen in the DPA-treated group which had been subjected to selective depletion of spinal serotonin or treated with methysergide than in DPA-treated controls."( Bendotti, C; Lazarova, M; Samanin, R, 1983)
"The role of forebrain noradrenaline in seizures induced by electrical stimulation of the anterior neocortex (kindling) was investigated in control rats and rats pretreated with bilateral injections of 6-hydroxydopamine (6-OHDA) into the mesencephalic trajectory of the dorsal tegmental noradrenergic bundle."( Altman, IM; Corcoran, ME, 1983)
"Six cases of convulsive seizures occurring during treatment with viloxazine notified to the Committee on Safety of Medicines (CSM) and two other cases from Japan were reviewed."( Edwards, JG; Glen-Bott, M, 1984)
"In the case of picrotoxin induced convulsive seizures where there is an alteration at the GABA receptor level, ther is a lack of efficiency after nDPA treatment which increases GABA at the synaptic level."( Ciesielski, L; Mandel, P; Simler, S, 1981)
"Six cats with stable seizure thresholds were treated with 150 mg/kg of chloramphenicol or its cogener, thiamphenicol, at 12-h intervals over a 30-h period."( Belsito, O; Bowersox, SS; Shouse, MN, 1984)
"Using treatments which produce generalized seizures (electroconvulsive shock, strychnine, and flurothyl) and gamma amino-butyric acid (GABA) antagonists (picrotoxin, bicuculline, and pentylentetrazol), the ED50 for seizures was determined in the selected lines."( Crabbe, JC; McSwigan, JD; Young, ER, 1984)
"In animals displaying lidocaine-kindled convulsions there were marked increases in glucose utilization in either the hippocampus and amygdala or in perirhinal cortical areas during the seizure administration; these animals also displayed long-lasting increases in irritable behavior."( Ingvar, DH; Kennedy, C; Miyaoka, M; Post, RM; Shinohara, M; Sokoloff, L; Squillace, K; Suda, S, 1984)
"A study of the effects of MNPC on convulsions induced by chemicals which interfere with GABA-mediated neurotransmission was carried out in the mouse, with MNPC being administered by subcutaneous injection 30, 60 or 90 min prior to challenge with bicuculline."( Crider, AM; Hinko, CN; Seibert, K, 1984)
"In the maximal pentetrazol seizures test in rats denzimol showed a profile similar to that of phenytoin and carbamazepine, but different from that of barbiturates and benzodiazepines so that it is suggested that its clinical application would be that of "grand mal" and psychomotor type seizures therapy."( Barbadoro, E; Graziani, G; Testa, R; Tirone, F, 1983)
"The intensity of sound-induced convulsions in the genetically epilepsy-prone rat (GEPR) was reduced in a dose related fashion by intracerebroventricular administration of dobutamine, (beta 1 agonist), terbutaline (beta 2 agonist) or phenylephrine (alpha 1 agonist)."( Dailey, JW; Jobe, PC; Ko, KH, 1984)
"Protection against sound-induced seizures occurred after intraventricular administration of (+/-)cis-2,3-piperidine dicarboxylic acid (0."( Collins, JF; Croucher, MJ; Meldrum, BS, 1984)
"In the same animals the occurrence of clonic seizures was scored as to time of onset and severity for 20 min after drug administration."( Carney, JM; Johnson, P; Rennert, OM; Seale, TW, 1984)
"Amygdaloid kindled generalized convulsion was reversibly blocked despite continued afterdischarge generation by amygdaloid stimulation for about 60 h following intracerebral administration of gabaculine, a GABA-transaminase inhibitor, into the substantia innominata (SI) ipsilateral to the side of amygdaloid kindling."( Okamoto, M; Wada, JA, 1984)
"A progressive development of seizure activity after this treatment was observed."( Diehl, RG; Gotwo, T; Smialowski, A, 1984)
"Electrographic seizure activity was recorded shortly following naxolone injections in artificially ventilated, methadone-treated stump-tailed macaques."( Beck, EC; Dustmann, RE; Shearer, DE; Snyder, EW, 1980)
"Methionine alone did not induce convulsions when administered by various routes in dosages of 250--13,000 mg/kg, although larger doses of methionine (500--4,000 mg/kg) decreased behavioral activity."( Freed, WJ; Gillin, JC; Luchins, DJ; Taylor, SP; Wyatt, RJ, 1980)
"These seizures are indistinguishable in quality from those induced by pentylenetetrazol (PTZ), and pretreatment with low doses of caffeine potentiates PTZ-induced seizures."( Marangos, PJ; Martino, AM; Paul, SM; Skolnick, P, 1981)
"The sensitivity to insulin hypoglycemic convulsions has been shown to decrease at early times (16 and 24 hr) and increase at later times (1 week) after gold thioglucose (GTG) treatment."( Fish, KW; Holliday, JF; Luby, JL; Marrazzi, MA, 1981)
"We also treated a single case of tonic-clonic seizure after intracranial spill of metrizamide in a patient without a history of seizure disorder, and a case of myoclonus following a thoracic metrizamide myelogram that showed a highgrade block."( Hayward, JN; Killebrew, K; Scatliff, JH; Whaley, RA, 1983)
"5 Factors that might predispose to seizures include relevant family and past medical history, starting treatment, a change in dose, benzodiazepine withdrawal and concomitant treatment with other drugs that have epileptogenic properties."( Edwards, JG; Glen-Bott, M, 1983)
"The slowed rate of seizure development was not significant if the kindling stimuli were initiated 6 days posthaloperidol treatment nor if 10-mg doses of haloperidol were used for 30 days."( Gee, KW; Hollinger, MA; Killam, EK, 1983)
"Since the effectiveness of seizure prophylaxis has not been established, the authors suggest that anticonvulsant drugs be administered only after an early seizure has occurred."( Bean, JR; Haack, D; Norton, JA; Rapp, RP; Tibbs, PA; Young, B, 1983)
"It appeared to inhibit seizure activity, subsequently allowing the patient to be treated with hyperbaric oxygen."( Weaver, LK, 1983)
"On day 3 a convulsion was induced by electricity in half of the rats (controls and barbital-treated) and 1 h later the sensitivity to hexobarbital was determined with a threshold test."( Wahlström, G, 1983)
"During seizure threshold determinations, aminophylline pretreatment markedly prolonged afterdischarge durations without significantly changing seizure severity or threshold."( Albertson, TE; Bowyer, JF; Joy, RM; Stark, LG, 1983)
"A total of 26 neonates with seizures had an EEG while on phenobarbital therapy."( Bickford, RB; Coen, RW; Scholl, ML; Staudt, F, 1982)
"No significant changes in seizure-grade distribution, as compared to controls, were observed in any of the TCT- or TPhT-treated groups at any of the time points examined."( Doctor, SV; Fox, DA, 1982)
"As a seizure was observed in two of our cases after administration of this barbiturate, an EEG study was performed."( Ginet, J; Meigner, M; Nogues, B; Souron, R; Vecchierini-Blineau, MF, 1982)
"Furthermore, post-decapitation convulsions were eliminated in DSP-4 treated animals."( Asin, KE; Fibiger, HC; Wirtshafter, D, 1982)
"Prominal reduced the severity of convulsions in pp'DDT-treated animals."( Jaffery, FN; Matin, MA; Siddiqui, RA, 1981)
"Epileptiform seizures resistant to treatment with diazepam and barbiturates were frequent and probably not solely caused by cerebral ischaemia."( Holm, HA; Kittang, E; Laake, K; Refstad, SO, 1981)
"The maximal seizure was induced by administering an electric shock through the eyes."( Fujii, T; Hironaka, T; Morimoto, S; Nakanishi, H; Ohtaki, Y, 1981)
"Behavioral seizures reappeared 2 to 3 days after termination of GAG treatment."( Myslobodsky, MS; Valenstein, ES, 1980)
"The rate and pattern of seizure development provoked by repeated electrical stimulation of the amygdala (kindling) was assessed in rats that had been pretreated with intracerebral injections of the selective catecholaminergic neurotoxin 6-hydroxy-dopamine."( Corcoran, ME; Mason, ST, 1980)
"Convulsive seizures occurred only after the im doses that were lethal, but they were observed after administration of iv doses that were nonlethal."( Henry, MC; Levine, BS; Port, CD; Rosen, E, 1980)
"A progression from encephalopathy to seizures was observed following aminophylline administration."( Chu, NS, 1981)
"When seizures were preceded by antihypertensive treatment with the alpha-adrenergic antagonist, phentolamine, peak blood pressure tended to remain near the baseline level and lower than sham-injected controls."( Kanter, RK; Sauro, MD; Strauss, JA, 1995)
"El mouse convulsions were inhibited by oral administration of citalopram for 2 weeks."( Kabuto, H; Kurimoto, T; Mori, A; Takei, M; Yokoi, I, 1994)
"Felbamate was also potent to prevent seizures induced by administration of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), an AMPA/kainate receptor agonist (ED50 = 11."( Aguglia, U; Bertorelli, R; De Sarro, A; De Sarro, G; Ongini, E, 1994)
"The kainate-elicited convulsions and NO formation were attenuated in animals pretreated with either 7-nitroindazole, a specific inhibitor of neuronal NO synthase, or diazepam."( Busse, R; Mordvintcev, PI; Mülsch, A; Nielsen, EO; Olesen, SP; Scheel-Krüger, J; Vanin, AF, 1994)
"There was no difference in seizure duration before or after D-NA administration."( Albrecht, RF; Baughman, VL; Pelligrino, DA; Theard, MA; Wang, Q, 1995)
"We investigated whether the severity of convulsions evoked by kainic acid and pilocarpine is modified in nitric oxide synthase inhibitor-treated rats."( Barbier, P; Corsini, GU; Donati, E; Fumagalli, F; Maggio, R; Racagni, G; Riva, M, 1995)
"Behavioral characteristics of seizures have age-dependent features, which suggests that effective treatment of seizures may be age-specific as well."( Moshé, SL; Ortíz, J; Ptachewich, Y; Shinnar, S; Velísek, L; Velísková, J, 1995)
"A newborn girl with seizures was, after repeated conventional anticonvulsive treatment, cured by pyridoxine administration."( Bosschaart, AN; Hageman, G; Tummers, RF; van Waarde, WM, 1995)
"The fluoxetine effect on HIP seizures was also assessed following long-term treatment with gepirone, a 5-HT1A receptor agonist."( Hasegawa, H; Nakamura, M; Shiraishi, J; Wada, Y, 1995)
"In patients without seizures before therapy, seizures occurred during therapy in 5 of 82 patients (6%) receiving meropenem and in 1 of 86 patients (1%) receiving cefotaxime (95% confidence interval: -0."( Dagan, R; Klugman, KP, 1995)
"Patients with ALL and seizures were identified retrospectively by review of the records of all pediatric ALL patients who were diagnosed and treated during the years 1983 through March 1993 in a large tertiary-care hospital."( Eviatar, L; Grossman, R; Karayalycin, G; Lanzkowsky, P; Maytal, J; Schaul, N; Shende, AC; Yusuf, FH, 1995)
"We compared the duration of seizure activity and cognitive recovery profiles after different doses of methohexital, propofol, and etomidate administered to induce hypnosis prior to ECT."( Avramov, MN; Husain, MM; White, PF, 1995)
"PTZ-induced convulsions were partly antagonized by the GVG treatment."( Sayin, U; Timmerman, W; Westerink, BH, 1995)
"Spontaneous recurrent seizures are registered during the long-term period following the systemic administration of PILO in rats."( Cavalheiro, EA; Leite, JP, 1995)
"This was indicated by a higher mean convulsion score, increased number of mice responding with convulsions, and induction of seizures in animals pretreated with a subepileptic dose of pentylenetetrazol."( Ashkenazi, S; Dinari, G; Weizman, A; Yuhas, Y, 1995)
"administration."( Baron, BM; Chapman, AG; Dürmüller, N; Harrison, BL; Meldrum, BS; Parvez, N, 1995)
"We report two cases of seizures and one case of hand cramping and finger paresthesia after starting foscarnet therapy with no evidence of predisposing risk factors, such as serum laboratory abnormalities, renal dysfunction, or known central nervous system (CNS) involvement."( Liu, YQ; Lor, E, 1994)
"To assess whether electrically induced seizures are indeed required for the appearance of the blunted pineal response to isoproterenol, pineal and serum melatonin levels were measured after isoproterenol stimulation in rats treated with ECS (80 mA, 0."( Amaro, S; d'Istria, M; De Luca, B; Maj, M; Monteleone, P; Serino, I, 1994)
"Five of 6 patients developing seizures received anticonvulsant and supportive treatment with resolution of neurologic abnormalities."( Bernaudin, F; Bunin, N; Johnson, FL; Lenarsky, C; Ohene-Frempong, K; Powars, D; Souillet, G; Sullivan, KM; Vannier, JP; Walters, MC, 1995)
"Generalized and partial seizures with secondary generalization were observed during ifosfamide-mesna (IFO) treatment in a patient with lung epidermoid carcinoma."( Farisse, P; Somma-Mauvais, H; Viallat, JR, 1994)
"Pentylenetetrazole-induced seizure thresholds were similar in mice treated for 14 days with lorazepam or alprazolam, 2 mg/kg/day."( Byrnes, JJ; Greenblatt, DJ; Miller, LG; Shader, RI, 1993)
"The latency of the audiogenic seizures was prolonged by bromocriptine treatment."( Akarsu, ES; Kayaalp, SO; Uzbay, IT, 1994)
"Infusions were started 5 min before seizures were induced with flurothyl 3% administered for either 45 (n = 10) or 75 (n = 10) min."( Ahdab-Barmada, M; Clyde, C; Kofke, WA; Nemoto, E; Rose, M, 1993)
"Reliable clonic seizures were obtained by administering the proconvulsive dopamine D1 agonist SKF 38393 (10 mg/kg i."( Alam, AM; Starr, MS, 1994)
"The mRNA levels were increased during seizures in the order of c-fos > jun-B > c-jun > jun-D in the hippocampus and jun-B > c-fos > c-jun > jun-D in the cortex, and were increased for a longer duration as well as to a greater extent than after administration of pilocarpine alone."( Jope, RS; Williams, MB, 1994)
"Despite insignificant changes in seizure latency, chronic pretreatment with CPA increased the incidence of clonic/tonic episodes and end-point mortality."( Carter, M; Jacobson, KA; Ji, XD; Paul, IA; Von Lubitz, DK, 1994)
"In L-NAME-treated rats, seizure activity occurred about 10 min sooner than in control rats, and status epilepticus was inevitably followed by a flat electroencephalogram and sudden death."( Borredon, J; Pinard, E; Rigaud-Monnet, AS; Seylaz, J, 1994)
"He had been treated with valproate for seizures since the age of 2 years."( Brichard, B; Cornu, G; Ninane, J; Scheiff, JM; Vermylen, C, 1994)
"However, seizures associated with clozapine treatment occur at a rate of about three percent."( Frankenburg, FR; Toth, P, 1994)
"Four patients had generalized seizures only with meperidine administration, all of whom had nonfocal EEG and radiological studies."( Ballas, SK; Gzesh, DJ; Liu, JE, 1994)
"Ten (5 men, 5 women) had at least one seizure during clozapine treatment."( Claussen, AM; Wilson, WH, 1994)
"The frequency of spontaneous recurrent seizures was monitored during and after phenobarbital therapy."( Chronopoulos, A; Gatt, A; Holmes, GL; Hyde, P; Liu, Z; Mikati, MA; Stafstrom, CE; Thurber, S; Werner, S, 1994)
"Two patients developed seizure immediately after flumazenil administration that aimed to reverse the prolonged sedative effect of diazepam."( Hseu, SS; Hsing, CH; Lee, TY; Ng, KO; Tang, GJ, 1994)
"He had a single grand mal seizure 37 days following retreatment with quinine intravenously, which resulted in rapid clearance of fever and parasitemia, in addition to mefloquine."( Aoki, M; Kamei, K; Miyashita, T; Nishiya, H; Ohyatsu, I; Ono, Y; Shibuya, T; Sugiyama, H; Tokumura, Y; Yamaguchi, M, 1994)
"The anti-seizure efficacy of intraperitoneally administered anticonvulsants and Ca++ antagonists to CF-1 mice was tested using these models."( Cramer, CL; Knowles, MA; Palmer, GC; Stagnitto, ML, 1994)
"Phenytoin is frequently used to treat seizure episodes in critically ill patients."( Kronfol, NO; Lau, AH, 1994)
"Mice selectively bred to be Withdrawal Seizure-Prone (WSP) or Seizure-Resistant (WSR) after chronic ethanol administration have been reported to be differentially sensitive to the anticonvulsant and proconvulsant effects on alcohol withdrawal of drugs interacting with glutamate receptors."( Crabbe, J; Dorow, J; Young, ER, 1994)
"However, DOPS significantly potentiated seizures induced by imipramine in disulfiram-pretreated animals."( Amabeoku, GJ, 1993)
"The behavioral pattern of convulsion produced by pentylenetetrazol was similar to that produced by systemic administration of BW373U86."( Chang, KJ; Comer, SD; De Costa, BR; Hoenicke, EM; McNutt, RW; Mosberg, HI; Sable, AI; Woods, JH, 1993)
"Development of kindled seizures was significantly faster in the intermittently treated group (P < 0."( Allerup, P; Barry, DI; Bolwig, TG; Bruhn, T; Glenthøj, B; Hemmingsen, R, 1993)
"F-721 was effective against MES seizures following oral administration to mice (ED50: 31."( Albertson, T; Drust, EG; Pong, SF; Skeen, GA; Stark, LG; Swinyard, EA; White, HS; Wolf, HH, 1993)
"Isolated seizures can be treated with phenytoïne or phenobarbital, while active seizures must be treated with diazepam."( Floret, D, 1993)
"1S,3R-ACPD-induced seizures were antagonized by systemic administration of dantrolene, an inhibitor of intracellular calcium mobilization, but not by the ionotropic glutamate antagonists MK-801 or GYKI-52466."( Fix, AS; McDonald, JW; Schoepp, DD; Tizzano, JP, 1993)
"Age, sex, race, seizure type, seizure focus, age at onset, duration of epileptic illness, reasons for discontinuing treatment, other medications, and response to treatment of seizures, psychiatric symptoms, and behavioral symptoms were recorded."( Burns, RL; Jenkins, PL; Vallini, AD, 1993)
"Meperidine has been associated with seizure activity when administered via traditional routes."( Hagmeyer, KO; Mauro, LS; Mauro, VF, 1993)
"This case report describes seizures and encephalopathy in a nine year-old boy treated with iodoquinol for amebiasis."( Fisher, AK; Szabo, S; Walter, FG, 1993)
"Susceptibility to generalized seizures was then tested using the volatile convulsant flurothyl; at both doses of MK801, flurothyl seizure latency was significantly greater in pretreated animals."( Holmes, GL; Stafstrom, CE; Thompson, JL, 1993)
"In pargyline pretreated GEPR-9s, seizure severity fell and the fraction of animals exhibiting an anticonvulsant response increased progressively as the dose of norepinephrine was increased."( Bettendorf, AF; Dailey, JW; Jobe, PC; Kahle, EH; Mishra, PK, 1993)
"To report a case of reversible seizures and mental status changes in a dialysis patient given preventive isoniazid therapy."( Asnis, DS; Bhat, JG; Melchert, AF, 1993)
"Using this novel method of seizure threshold determination, it was found that systemically administered diphenylhydantoin and carbamazepine elevated the threshold for ATPA and had negligible effects on the threshold for kainate and NMDA."( Steppuhn, KG; Turski, L, 1993)
"Theophylline-induced seizures have significant morbidity and mortality and are difficult to treat."( Glenn, GM; Kelly, P; Krober, MS; McCarty, J; Weir, M, 1995)
"However, the tonic seizures induced by L-Cysteine were prevented by pretreatment with N(G)-nitro-L-arginine."( Yamamoto, H, 1996)
"To isolate seizure-related genes, we applied differential screening technique to the cDNA library which constructed from primary cultured cerebral cortical cells treated with pentylenetetrazol (PTZ)."( Kajiwara, K; Kimura, M; Nagawawa, H; Ookuri, T; Shimizu-Nishikawa, S; Sugaya, E, 1996)
"Acute treatment of breakthrough seizures and clusters of seizures at home with rectal BZDs (usually DZP, 0."( Mitchell, WG, 1996)
"Epileptic seizures (ES) and nonepileptic seizures (NES) often coexist in patients with treatment-refractory seizures."( Alper, K; Devinsky, O; Kothari, M; Luciano, D; Sanchez-Villaseñor, F; Vazquez, B, 1996)
"However, the limbic seizures induced by 1 were blocked by systemically administered 2a in a dose-dependent manner (EC50 = 271 mg/kg, ip)."( Bond, A; Campbell, JB; Griffey, K; Howe, T; Johnson, BG; Lodge, D; Monn, JA; Paschal, JW; Salhoff, CR; Schoepp, DD; Spangle, LA; Tizzano, JP; Valli, MJ; Wright, RA, 1996)
"However, the incidence of seizures induced by potassium cyanide was significantly inhibited by preadministration of melatonin (20 mg/kg, s."( Tang, HW; Yamamoto, H, 1996)
"Further evaluation of the postictal seizure suppression immediately after a fully kindled seizure demonstrated that morphine-pretreated rats had a decreased sensitivity to subsequent kindling stimulations."( Ackermann, RF; Engel, J; Rocha, L, 1996)
"A similar increase in seizure prevalence, noted as a kindling effect, was observed in cocaethylene-treated animals tested with cocaethylene in that 90% of the mice exhibited status epilepticus on the last test day."( Meehan, SM; Schechter, MD, 1996)
"Rotational behavior and convulsions were prevented by intrastriatal preadministration of MK-801 and attenuated by preadministration of succinate."( Begnini, J; da Costa, E; de Bastiani, J; de Mello, CF; Jiménez-Bernal, RE; Rubin, MA; Wajner, M, 1996)
"The treatment had no effect on the seizure threshold for picrotoxin."( Chiu, TH; Rosenberg, HC; Zhao, TJ, 1996)
"Cocaine use can reduce seizure threshold in patients with underlying epilepsy as a direct toxic effect or indirectly by contributing to poor compliance with antiepileptic drug treatment, poor diet, or poor sleep habits."( Daras, M; Koppel, BS; Samkoff, L, 1996)
"In all seizure paradigms, KYNA levels in the dialysate began to rise within 1 h and gradually reached a plateau approximately 4 h after administration of the convulsants."( Schwarcz, R; Wu, HQ, 1996)
"L-NA (100 mg/kg, IP) suppressed clonic seizure as well as tonic seizure in bicuculline-treated (3."( Endo, T; Hara, S; Iwata, N; Kano, S; Kuriiwa, F; Mukai, T, 1996)
"Subjects with a seizure history were prophylactically treated with tapering doses of chlordiazepoxide."( Worner, TM, 1996)
"During medical treatment, symptomatic seizures occurred in three cases."( Hashi, K; Niwa, J; Tanabe, S, 1996)
"Starting vigabatrin treatment reduced seizure frequency by > 50%, from six to seven per month to three."( Behar, KL; Mattson, RH; Petroff, OA; Rothman, DL, 1996)
"The increase in seizure severity was evidenced by a significant increase in the incidence of tonic convulsions in 5,7-DHT treated animals (53% in treated animals compared to 0% in vehicle treated controls) over the testing period."( Browning, RA; Clough, RW; Dailey, JW; Jobe, PC; Maring-Smith, ML; Statnick, MA; Wang, C, 1996)
"However, other side effects of seizures, sedation, neuroleptic malignant syndrome and cardiovascular, hematologic, endocrinological, and weight gain problems remain as clinical management challenges posed by existing antipsychotic drug therapy."( Casey, DE, 1996)
"Audiogenic seizures could be induced in all treatment groups 12 h after withdrawal."( Davidson, M; Matsumoto, I; Otsuki, M; Wilce, PA, 1996)
"Treatment was dictated by the cat's seizure frequency and by the underlying cause."( McDonell, W; Parent, JM; Quesnel, AD, 1997)
"Results suggest that severity of seizure disorder in cats is not a good predictor of outcome and that aggressive treatment is often rewarding, even in the most severe cases."( McDonell, W; Parent, JM; Quesnel, AD, 1997)
"On the other hand, no difference in seizure susceptibility was found between homozygous and heterozygous mutants when strychnine was administered."( Miyakawa, T; Niki, H; Tateishi, K; Yagi, T, 1996)
"A saline-treated group gave a 100% seizures response, while the group treated with NR1 antisense probe gave a 7% seizure response to the sound stimulus."( Chapman, AG; Meldrum, BS; Woodburn, VL; Woodruff, GN, 1996)
"In one patient with intractable seizures, the therapy was not effective."( Aihara, M; Hatakeyama, K; Hinohara, Y; Kamiya, Y; Kanemura, H; Nakazawa, S; Sata, Y; Shimoda, C, 1997)
"Nicardipine remarkably inhibited epileptic seizures induced by combined treatment with enoxacin (p."( Kamei, C; Kitazumi, K; Ohishi, H; Okumura, Y; Sugimoto, Y, 1996)
"Limbic seizures were provoked in freely moving rats by intrahippocampal administration of the muscarinic receptor agonist pilocarpine via a microdialysis probe (10 mM for 40 min at 2 microliters/min)."( Ebinger, G; Michotte, Y; Smolders, I; Van Belle, K, 1997)
"Furthermore, seizure latencies after the administration of an ED100 dose of NMDA (150 mg/kg) were significantly higher in antisense treated animals compared to vehicle controls."( Adan, J; Capdevila, JL; Martínez, JM; Piulats, J; Tarrason, G; Trullas, R; Zapata, A, 1997)
"In adults without a seizure history, seizures were observed only in patients treated with high dose chlorambucil; however, in adults with a seizure history, lower doses as used in pulse therapy also caused seizures."( Cooper, DL; Khan, KK; Salloum, E, 1997)
"Intrastriatal injection of ET-1 caused seizures and barrel rolling which were prevented by pretreatment with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 and attenuated by the nitric-oxide synthase inhibitor N omega-nitro-L-arginine (L-NNA)."( Morton, AJ; Reynolds, DS; Sullivan, AM; Thomas, KL, 1996)
"Pretreatment with diazepam blocked the seizures as well as the elevation of BDNF mRNA."( Gall, CM; Kornblum, HI; Sankar, R; Shin, DH; Wasterlain, CG, 1997)
"To compare treatment of ongoing seizures using intramuscular (IM) midazolam versus intravenous (IV) diazepam."( Altieri, MA; Chamberlain, JM; Futterman, C; Ochsenschlager, DW; Waisman, Y; Young, GM, 1997)
"The decrease in the seizure threshold for pentylenetetrazole during diazepam withdrawal was inhibited by pretreatment with MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cycloheptan-5,10-imine maleate), 7-chlorokynurenic acid and ifenprodil."( Misawa, M; Suzuki, T; Tsuda, M, 1997)
"Generalized tonic-clonic seizures observed in EP mice were inhibited by valproate, administered 1 h prior to testing, in a dose-response fashion."( Alexiuk, NA; Vriend, JP, 1996)
"The overall frequency of seizures during muromonab-CD3 administration is 6%."( Lawrence, KR; Monaco, AP; Rahamtulla, AF; Seifeldin, RA, 1997)
"The incidence of seizures in rats receiving cocaine or lidocaine individually was significantly reduced by pre-treatment with dextromethorphan but not DNQX."( Abdel-Rahman, MS; Barat, SA, 1997)
"Propofol consistently reduces the seizure duration during electroconvulsive therapy, its use has been successful in controlling refractory status epilepticus and in animals it offers a strong protection against lignocaine- or pentylene-tetrazol-induced epilepsy."( Borgeat, A, 1997)
"One patient experienced a seizure immediately after administration of naloxone."( Anderson, DL; Benson, BE; Gorman, SE; Ruskosky, DR; Spiller, HA; Stancavage, MM; Villalobos, D, 1997)
"Opinions vary as to which 'neonatal seizures' should be treated and which should not be."( Caballar-Gonzaga, FJ; Dierkes, T; Koenigsberger, MR, 1997)
"Two patients died following seizures, but three patients recovered following prompt treatment with parenteral midazolam infusions and rotation to alternative opioids."( Hagen, N; Swanson, R, 1997)
"I report the occurrence of seizure activity after the inadvertent administration of 4 mg/kg of tramadol to a child."( Tobias, JD, 1997)
"In rats susceptible to audiogenic seizures, intraperitoneal administration of both GABAB receptor antagonists, at doses which suppressed absence seizures, facilitated the elicitation of sound-induced tonic seizures."( Bernasconi, R; Boehrer, A; Marescaux, C; Simler, S; Vergnes, M, 1997)
"The phrase alcohol withdrawal seizures (AWS) refers to seizures that result from the withdrawal of alcohol after a period of chronic alcohol administration."( Tan, CY; Weaver, DF, 1997)
"After initiation of therapy, seizures resolved after 2."( Bai, AN; Cao, YM; Chui, W; Gao, DY; Ge, ZL; Jiao, FY; Li, HR; Lieu, NS; Liu, SB; Liu, ZY; Takuma, Y; Wu, S; Zhang, XK, 1997)
"However, the seizure-producing dose of cocaine was decreased dose dependently in rats that received naltrindole, regardless of the route of administration, naloxone, or naltrexone."( Gordon, FJ; Holtzman, SG; Patterson, AB, 1997)
"(2) Neurophysiologically, the increased seizure susceptibility to pentylenetetrazol treatment reached a maximum at four days post-trimethyltin and then declined after five days post-trimethyltin."( Akaike, M; Ishida, N; Kanai, H; Kato, N; Kuroda, Y; Masui, A; McEwen, BS; Sadamatsu, M; Tsutsumi, S; Watanabe, Y, 1997)
"Although seizures may be a feature of the disease being treated, antibiotics should be considered possible causes of seizures, particularly if suggested by temporal relationships between seizure activity and drug administration."( Wallace, KL, 1997)
"rats with a pentylenetetrazole-induced seizure score of 3 or more on a seizure scale ranging from 0 to 6) and death rate compared with those obtained for rats pre-treated with an equivalent intraperitoneal dose (140 mg kg-1) of acepifylline ('equivalent dose' referred to here denotes the theophylline content of the two preparations)."( Chakrabarti, A; Garg, SK; Saini, HK, 1997)
"This treatment controlled seizures in 86% of patients (49/57), on average within 40 minutes (median, 30 min; range, 10-120 min), at a mean infusion rate of 0."( Banerjee, S; Singhi, P; Singhi, S, 1998)
"The lidocaine levels at seizure threshold were increased in the propofol-treated rats: 16."( DiFazio, CA; Lee, VC; Moscicki, JC, 1998)
"The potential for convulsions induced by the coadministration of ciprofloxacin (CPFX) and foscarnet (PFA) may be due not to a change in the distribution of CPFX to the brain but to a potential CPFX-induced inhibition of gamma-aminobutyric acid (GABA)-GABA(A) receptor binding in the presence of PFA."( Iga, T; Kawakami, JI; Matsuo, H; Nagata, A; Ryu, M; Sawada, Y; Uchida, T; Yamamoto, K, 1998)
"Pentylenetetrazol (PTZ) seizure threshold was determined in the rat during recovery from anesthesia induced by intravenous administration of propofol (20 mg/kg) or thiopentone (30 mg/kg)."( Hasan, Z, 1997)
"The increase in seizure sensitivity of repeatedly withdrawn mice was prevented by treatment with the NMDA receptor antagonist CGP 39551 (20 mg/kg, i."( Dunworth, SJ; Stephens, DN, 1998)
"Drug-induced exacerbation of seizures is a serious and common clinical problem that is often unrecognized or overlooked by the treating physician."( Avanzini, G; Dulac, O; Gram, L; Perucca, E, 1998)
"The suppression of the convulsions by 7-nitroindazole was not reversed by the pretreatment of L-arginine."( Masukawa, T; Nakanishi, K; Natsuki, R, 1998)
"One child presented with a seizure and cortical venous drainage that were treated immediately."( Balousek, PA; Ciricillo, SF; Dowd, CF; Edwards, MS; Halbach, VV; Higashida, RT, 1998)
"These results show that tonic or tonic-clonic seizures induced by TMPP administration (0."( Jung, AE; Lindsey, JW; Narayanan, TK; Ritchie, GD, 1998)
"long-term occurrence of spontaneous, generalized seizures and motor convulsions) following a latent period after the initial treatment."( Buckmaster, PS; Dudek, FE; Hellier, JL; Patrylo, PR, 1998)
"A case of tonic-clonic seizures following chloroquine treatment for leprosy reactions in a Nigerian male is reported."( Ebenso, BE, 1998)
"To do so, the maximal electroshock seizure test in mice (an experimental model predicting drug efficacy in the treatment of human generalized tonic-clonic seizures) was employed to (1) quantify changes in the protective efficacy and potency of felbamate produced by adjunct drugs and (2) assess the ability of aminophylline and caffeine to affect protective efficacy afforded by a submaximal protective dose of felbamate against maximal electroshock-induced seizures."( Borowicz, K; Czuczwar, SJ; Gasior, M; Kleinrok, Z; Przybyłko, M; Swiader, M; Turski, WA, 1998)
"During the first 4 weeks of therapy seizure recurrence was seen in 9."( Baranwal, AK; Khandelwal, N; Singhi, PD; Singhi, SC, 1998)
"Audiogenic seizures caused a marked induction of c-fos messenger RNA (mRNA) in septal nucleus, bed nucleus of stria terminalis, amygdaloid nuclei, peripeduncular nucleus, and inferior colliculus, which was almost completely blocked by the pretreatment with MK-801."( Higashiyama, A; Ishida, N; Kato, N; Kuroda, Y; McEwen, BS; Nishimura, T; Yasuda, S, 1998)
"Successful treatment of seizure disorders in small animals requires proper patient assessment, understanding the principles of antiepileptic drug (AED) therapy, designing a strategy for pharmacotherapy, and plans for emergency treatment."( Podell, M, 1998)
"The clonic convulsions were not modified by MgCl2 treatment."( Lazarini, CA; Vassilieff, I, 1998)
"Chemically kindled clonic seizures were observed in 100% of TMPP or FG-7142 and 50% of PTZ treated rats by the thirtieth dosing."( Cassell, J; Lin, J; Nordholm, AF; Ritchie, GD; Rossi, J, 1998)
"Diastat treatment reduced median seizure frequency (p = 0."( Cereghino, JJ; Kriel, RL; Mitchell, WG; Murphy, J; Rosenfeld, WE; Trevathan, E, 1998)
"We describe four infants whose seizures were treated with intravenous fosphenytoin."( Caviness, VS; Krishnamoorthy, KS; Soman, TB; Takeoka, M, 1998)
"Treatment was with anti-seizure, anti-viral, and immunomodulating medication."( Stübgen, JP, 1998)
"These audiogenic seizures were differently modified by MK-801 and NBQX; while intraperitoneal MK-801 equally inhibited running fit (RF) and generalized tonic-clonic seizure (GTCS), NBQX administered into cisterna ambiens significantly inhibited RF but not GTCS."( Higashiyama, A; Ishida, N; Kato, N; Yasuda, S, 1998)
"Dizocilpine alone had no effect on seizure induction and did not potentiate the anticonvulsive effect of lorazepam when coadministered with lorazepam."( Fahey, JM; Greenblatt, DJ; Pratt, JS; Pritchard, GA; Shader, RI, 1999)
"Because of the convulsions, the treatment was discontinued."( Bouvy, M; Heeringa, M; Kuster, JA; Meyboom, RH, 1998)
"Continuous seizures of more than 5 min duration were randomly treated with buccal midazolam or rectal diazepam."( Besag, FM; Neville, BG; Scott, RC, 1999)
"Buccal midazolam was used to treat 40 seizures in 14 students, and rectal diazepam 39 seizures in 14 students."( Besag, FM; Neville, BG; Scott, RC, 1999)
"All children who presented in a convulsion, including convulsive status epilepticus, to the accident and emergency department over a 12-month period and who required treatment, were reviewed retrospectively to identify the effectiveness and safety of a specific treatment protocol."( Appleton, RE; Garr, RE; Molyneux, EM; Robson, WJ, 1999)
"A newborn infant with seizures of unknown etiology that were refractory to treatment with phenobarbitone, phenytoin, midazolam, clonazepam, and vigabatrin is reported."( Antony, JH; Barr, PA; Buettiker, VE, 1999)
"The most important factor determining seizure recurrence was continued therapy, which was the case for barbiturates, phenytoin and valproate."( Chadwick, D, 1999)
"Drug-induced seizures have occurred and will continue to occur as healthcare professionals exceed recommended dosing guidelines to treat critically ill patients."( Hunter, WJ, 1993)
"Furthermore, the latency of convulsions in mice induced by administration of theophylline at a higher dose (240 mg/kg, i."( Chisaki, K; Hayashi, H; Komatsu, Y; Sanae, F, 1999)
"By measuring the latency to generalized seizures after beta-CCM administration to A/J and C57BL6/J mice and their progeny, we estimated a heritability of 0."( Gershenfeld, HK; Li, X; Neumann, PE; Paul, SM; St Jean, PL, 1999)
"administration in relief of seizures, e."( Bechgaard, E; Gizurarson, S; Gudbrandsson, FK; Jónsson, H, 1999)
"All 30 of the control mice had seizures followed by death compared to 11 seizures and 7deaths in the 15 treatment mice."( Brubacher, JR; Hoffman, RS; Lachmanen, D; Ravikumar, PR, 1999)
"Isoniazid-induced seizures respond poorly to anticonvulsants but well to pyridoxine (Vitamin B6); theophylline produces difficult-to-treat seizures with substantial morbidity and mortality."( Bonner, AB; Peterson, SL; Weir, MR, 1999)
"Rats presenting partial seizures showed no alterations in the immunostaining pattern compared with saline-treated animals."( Cavalheiro, EA; Funke, MG; Naffah-Mazzacoratti, MG; Sanabria, ER, 1999)
"Neonates whose seizures were not controlled by the assigned drug were then treated with both drugs."( Alvin, J; Armatti, S; Gardiner, JC; Minnigh, B; Painter, MJ; Paneth, N; Scher, MS; Stein, AD; Wang, Z, 1999)
"When combined treatment is considered, seizure control was achieved in 17 (57 percent) of the neonates assigned to receive phenobarbital first and 18 (62 percent) of those assigned to receive phenytoin first (P=0."( Alvin, J; Armatti, S; Gardiner, JC; Minnigh, B; Painter, MJ; Paneth, N; Scher, MS; Stein, AD; Wang, Z, 1999)
"Compounds 4a,b and 5a-c antagonize seizures induced by AMPA and kainate (KA) and their anticonvulsant activity is reversed by pretreatment with aniracetam."( Baraldi, M; De Micheli, C; De Sarro, A; De Sarro, G; Grasso, S; Micale, N; Puia, G; Zappalà, M, 1999)
"Electroconvulsive shock (ECS) seizures provide an animal analog of electroconvulsive therapy (ECT)."( Burnham, WM; Cottrell, GA; Gombos, Z; Mendonça, A, 1999)
"Medical records were reviewed for seizure and medication history, diagnostic test results, types of treatment, hospitalization costs, and outcome of hospital visits."( Bateman, SW; Parent, JM, 1999)
"The authors believe that diencephalic seizures can present with a spectrum of autonomic features, and treatment should be tailored with the appropriate pharmacologic blockade."( Conway, EJ; DaRosso, RC; Epstein, FJ; Goh, KY; Muszynski, CA, 1999)
"In saline-treated controls, hypoxic seizures were most frequent at 15 days (80% of pups) and 20 days (60%) of age."( Allred, E; Holtzman, D; Jensen, F; Khait, I; Kraft, R; Mulkern, R; Rand, T, 1999)
"In contrast to the seizure activity and wide-spread neuronal degeneration following kainate treatment, injections of lidocaine did not produce neuronal death within three days."( Chae, HJ; Cho, SB; Gwag, BJ; Jin, BG; Kang, JS; Kim, HR; Won, SJ, 1999)
"Interestingly, convulsions which were observed in the NMDA-treated rats were almost totally suppressed by bilobalide."( Chatterjee, SS; Hilgert, M; Klein, J; Lehr, M; Weichel, O, 1999)
"Vigabatrin improves seizure control as add-on therapy for refractory partial seizures and may produce therapeutic benefits in the treatment of infantile spasms."( Gidal, BE; Gilman, JT; Privitera, MD; Sheth, RD, 1999)
"All animals developed seizures following this treatment."( Copeland, T; McDonough, JH; McMonagle, J; Shih, TM; Zoeffel, D, 1999)
"Sensitivity to PTZ-induced seizures and lethality was not affected in mice with a history of repeated treatment with ganaxolone, diazepam, or valproate."( Beekman, M; Carter, RB; Gasior, M; Ungard, JT; Witkin, JM, 2000)
"Cocaine-induced convulsions were observed following pretreatment with various doses of the following 5-HT(2) antagonists: mianserin, metergoline, MDL 11939, and methiothepin."( George, FR; Kreifeldt, MJ; O'Dell, LE; Ritz, MC, 2000)
"PD 123319 did not change the seizure threshold both in theophylline-untreated and -treated mice."( Georgiev, V; Kambourova, T; Tchekalarova, J, 2000)
"Potentiation of convulsions by BSO treatment was recovered by supplying GSH (10 nmol, i."( Abe, K; Nakanishi, K; Saito, H, 2000)
"We report convulsions induced by short-term metronidazole therapy used in conventional doses for Clostridium difficile colitis in an elderly patient with chronic renal failure."( Beloosesky, Y; Grinblat, J; Grosman, B; Marmelstein, V, 2000)
"It is noteworthy that the antiseizure potency of the combined treatment (diazepam 1."( Borowicz, KK; Czuczwar, SJ; Kleinrok, Z, 2000)
"Bupivacaine seizure doses in 7-NI and L-NAME pretreated animals were similar to control but significantly different from each other."( Heavner, JE; Shi, B, 2000)
"Sound induced convulsions in DBA/2 mice were dose-dependently inhibited by all compounds (administered intraperitoneal, i."( Dalby, NO, 2000)
"To study the seizure-induced activation of glutamate decarboxylase, we investigated the expression of both embryonic and adult glutamate decarboxylase messenger RNAs in the adult rat hippocampus after kainic acid administration by semi-quantitative reverse transcription-coupled polymerase chain reaction, in situ hybridization and immunoblotting."( Hoertnagl, B; Kartarova, Z; Somogyi, R; Sperk, G; Szabó, G, 2000)
"The tonic convulsions appeared 5-6 h after MSO administration, without brain glycogen content variations during the preconvulsive period."( Ardourel, M; Bernard-Helary, K; Cloix, JF; Hévor, T; Lapouble, E, 2000)
"Treatment with oral L-serine abolished seizures and improved psychomotor development, hyperexcitability, head growth, cortical and subcortical hypotrophy, and hypomyelination of the brain on MRI scans."( Aracil, A; Artuch, R; García González, MM; Jaeken, J; Pineda, M; Santos, S; Van Schaftingen, E; Vilaseca, MA, 2000)
"A significant decrease in seizure susceptibility could be observed in BCCA treated mice compared with sham-operated controls."( Kleinrok, Z; Rejdak, K; Rejdak, R; Sieklucka-Dziuba, M, 2000)
"Most children with symptoms of convulsions are taken to the health center, but are more likely than children with simple malaria to receive traditional treatments as well."( Baume, C; Helitzer, D; Kachur, SP, 2000)
"In one dog, seizures kept recurring after periods of successful control following administration of propofol."( Grasmueck, S; Steffen, F, 2000)
"However, the attenuation of severe seizures by a single PRA, PHEN, DZP, or PHB cotreatment was accompanied by a decrease in the brain COCA concentration."( Fukui, Y; Hayase, T; Yamamoto, K; Yamamoto, Y, 2000)
"ICV administered DHEAS induced seizures in a dose-dependent way."( Bidziński, A; Członkowska, AI; Krzaścik, P; Płaźnik, A; Siemiatkowski, M; Sienkiewicz-Jarosz, H; Szyndler, J, 2000)
"The authors reviewed the occurrence of seizures in patients with epilepsy who had all their antiepileptic medications discontinued during an 8-week period, converted to gabapentin monotherapy, and observed for 26 weeks as part of the gabapentin trial #945-082."( DeToledo, JC; Garofalo, EA; Greiner, M; Lowe, MR; Ramsay, RE, 2000)
"In a general population, risk of seizure may be associated with long-term therapy with tramadol or the presence of cofactors, or confined to a small sensitive population subset."( Alderfer, R; Anderson, G; Blough, D; Drinkard, CR; Gardner, JS; Graham, D; Shatin, D, 2000)
"Animals which developed seizures were treated for 3 days with rofecoxib (10 mg/kg, i."( Kunz, T; Oliw, EH, 2001)
"To report development of a seizure after administration of ropivacaine."( Alardo, JP; Bisschop, DY; Germain, ML; Just, BY; Millart, HG; Razgallah, B; Trenque, TC, 2001)
"High rate of seizure recurrence mandates therapy of solitary seizure in patients with HIV infection."( Chadha, DS; Handa, A; Sharma, SK; Singh, AP; Varadarajulu, P, 2000)
"However, the increase in convulsion thresholds and lethal doses was much greater for GABAergic antagonists (PIC, BIC, and PTZ) than non-GABAergic convulsants (STY, 4AP, and NMDA) following 2000 mg/kg TCE administration."( Chen, HH; Chiu, TH; Shih, CL, 2001)
"We experienced a case of convulsion following the combination of single oral administration of enoxacine before an emergency operation and single postoperative intravenous administration of flurbiprofen axetil."( Kaneko, A; Machida, K; Mizuno, J; Sugimoto, S; Tsutsui, T; Zushi, N, 2001)
"The drug significantly reduced seizure frequency compared with placebo in children with partial-onset epilepsy after 16 weeks of double-blind adjunctive treatment (33."( McClellan, K; Ormrod, D, 2001)
"VNS effectively reduced seizure severity in both capsaicin- and vehicle-treated rats as compared with their non-VNS baselines."( Handforth, A; Krahl, SE; Senanayake, SS, 2001)
"She presented repetitive generalized convulsions with metabolic acidosis, treated with diazepam and 7."( Hamabe, Y; Kiyota, K, 2001)
"MP administration (150 mg/kg, i."( Giraldez, L; Girardi, E; Rodríguez de Lores Arnaiz, G; Vanore, G, 2001)
"All rats had stage 5 convulsions 24 hr after cessation of the administration of dipotassium clorazepate and diazepam."( Amano, K; Deshimaru, M; Katsuragi, S; Miyakawa, T; Miyazaki, C; Ogata, A; Takamatsu, J, 2001)
"Six dogs with partial seizures or partial seizure-like activity were treated with the antiepileptic drug felbamate between 1993 and 1998."( March, P; Podell, M; Ruehlmann, D, 2001)
"Phenylephrine increased seizure duration in ECS-treated rats, and also enhanced recall in both true and sham ECS groups."( Anand, A; Andrade, C; Guido, S; Sudha, S; Venkataraman, BV, 2001)
"We describe a prolonged seizure occurring during the first treatment of a course of ECT in an adult patient receiving long-term bupropion therapy, lithium, and venlafaxine."( Conway, CR; Nelson, LA, 2001)
"Furthermore, seizure activity on kainic acid administration was markedly increased in mutant mice and was accompanied by heightened immediate early gene (c-fos) expression throughout the brain."( Davies, B; Davies, CH; Kearns, IR; Lathe, R; Ure, J, 2001)
"The interval until convulsion due to picrotoxin was also prolonged by the administration of DMP combined with diazepam and valproic acid (VPA)."( Aoyagi, Y; Ohta, A; Watanabe, Y; Yamada, K, 2001)
"Sixteen patients with pharmacoresistant partial seizures undergoing presurgical evaluation were randomized in this double-blind, placebo-controlled, parallel-group Losigamone monotherapy study under continuous video-EEG monitoring."( Dienel, A; Feichtinger, M; Hopp, P; Kerling, F; Kirchner, A; Pauli, E; Stefan, H; Wang, Y; Zhou, D, 2001)
"To report two cases of seizures following administration of levofoxacin and ciprofloxacin."( Kushner, JM; Peckman, HJ; Snyder, CR, 2001)
"As generalized seizures such as absence and myoclonus were counted in only one trial, results do not address the treatment of these seizure types."( Marson, AG; Tudur Smith, C; Williamson, PR, 2001)
"During limbic status epilepticus, only seizures in the sensorimotor cortex were markedly attenuated a few minutes after 14C-ZNS administration."( Akaike, K; Fukumoto, S; Imamura, S; Takigawa, M; Tanaka, S; Tojo, H, 2001)
"To provide data on the incidence of seizures and response to anticonvulsant therapies, a cohort of 90 term infants with hypoxic-ischemic encephalopathy treated at our institution between January 1, 1995, and July 1, 1999, was reviewed."( Armstrong, DL; Battin, MR, 2001)
"Control had initial "drop-off" seizure burst rates over time; seizure bursts in the treatment groups were compared to these rates."( Engebretsen, KM; Harris, CR; Holger, JS, 2002)
"Rate of seizure occurrence after initial treatment was higher in infants with cortical hypometabolism on the second PET, but the difference was not statistically significant."( Ishigaki, T; Itomi, K; Natsume, J; Negoro, T; Okumura, A; Tadokoro, M; Takada, H; Watanabe, K, 2002)
"These seizures were completely abolished by the simultaneous administration of melatonin (20 mg/kg, ip), a potent scavenger of hydroxyl radical."( Mohanan, PV; Yamamoto, HA, 2002)
"The reduced seizure threshold confirm the modulatory role exerted by progesterone on central nervous system excitability, and may be relevant in epileptic patients undergoing antifungal therapy."( Acevedo, X; Bustamante, D; Miranda, HF; Pesce, ME; Pinardi, G, 2001)
"Furthermore, brain seizure activity recorded following 1 h MCAo and 72 h of recovery in injured rats was either completely blocked (30 min pre-MCAo treatment) or significantly reduced (30 min post-MCAo treatment) with RS100642 (1."( Tortella, FC; Williams, AJ, 2002)
"Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine."( Ali, I; Casey, PB; Cassidy, N; Tracey, JA, 2002)
"Clinical seizures after venlafaxine treatment have occasionally been reported when the drug was used at very high doses or in combination with other medications."( Agustine, PE; Do Monte, FH; Lanziotti, VM; Russi, M; Santos, JG, 2002)
"Propofol anesthesia increases the seizure threshold of patients receiving electroconvulsive therapy."( Nishihara, F; Saito, S, 2002)
"In the other 10 babies electrographic seizures increased after treatment, whereas electroclinical seizures reduced."( Binnie, CD; Boylan, GB; Morton, M; Pressler, RM; Rennie, JM; Wilson, G, 2002)
"Here, we report a case who sustained convulsion immediately after administration of epidural ropivacaine."( Cherng, CH; Ho, ST; Wong, CS, 2002)
"Higher prevalence of seizures in large dogs, compared with smaller dogs, may be caused by administration of larger total volumes of contrast agent per volume of CSF."( Barone, G; Shofer, FS; Steinberg, SA; Ziemer, LS, 2002)
"Specifically, seizure induction by KA injection into the amygdala induces tPA activity and cell death in both hippocampi, and unilateral treatment of rats with neuroserpin, a natural inhibitor of tPA in the brain, enhances neuronal survival in both hippocampi."( Bugge, TH; Coleman, TA; Lawrence, DA; Mitola, D; Moore, E; Sandkvist, M; Wu, JY; Yepes, M, 2002)
"Seventy three patients presenting with seizures and showing SSECTL on cranial CT scans (plain and contrast) were randomized into group A (6 months therapy) and group B (2 years therapy)."( Arora, A; Lal, V; Prabhakar, S; Sawhney, IM; Thussu, A, 2002)
"A pentylenetetrazole seizure test was administered 15 min after the injections."( Burnham, WM; Likhodii, SS, 2002)
"The thresholds for the clonic seizures induced after intravenous administration of pentylenetetrazole (PTZ) or bicuculline were assessed in mice weighing 23-30 g."( Dehpour, AR; Homayoun, H; Khavandgar, S, 2002)
"In another experiment, WDS and seizures were monitored after KA treatment alone or in combination with L-NA."( Koylu, EO; Manev, H; Pogun, S; Uz, T, 2002)
"Of the 56 seizures treated, 30 received lorazepam, 19 diazepam, and seven both drugs."( Dooley, JM; Harrison, R; Stewart, WA, 2002)
"Furthermore, it antagonized in vivo seizures induced by icv administration of AMPA or kainate (KA)."( De Micheli, C; De Sarro, A; De Sarro, G; Ferreri, G; Grasso, S; Micale, N; Puja, G; Toma, L; Zappalà, M, 2002)
"Cocaine kindled seizures were developed in male, Swiss-Webster mice by daily administration of 60 mg/kg cocaine for 5 days."( Gasior, M; Hartman, T; Schad, C; Shippenberg, T; Slusher, BS; Witkin, JM; Zapata, A, 2002)
"Cefoselis (50 microg/animal)-induced convulsions were prevented by pretreatment with 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), diazepam and phenobarbital (ED(50) values (mg/kg) of 0."( Matsuoka, N; Mochizuki, Y; Mutoh, S; Sugimoto, M; Terai, T; Uchida, I; Yamazaki, S, 2002)
"Neurotoxicity manifesting as convulsions is a recognised complication of the administration of local anaesthetic drugs as part of a regional anaesthetic technique."( Pirotta, D; Sprigge, J, 2002)
"To determine the risk of seizure recurrence after a first seizure due to neurocysticercosis (NC) and to evaluate risk factors for seizure recurrence, including the influence of antihelminthic treatment."( Carpio, A; Hauser, WA, 2002)
"Gastrodin reduced the seizure score in the treated group, although the immunoreactivities of GABA synthetic enzymes and GABA transporters were unaltered in gastrodin-treated animals."( An, SJ; Baek, NI; Choi, SY; Hwang, IK; Jung, SJ; Kang, TC; Kim, SK; Kwon, OS; Lee, HY; Park, SK; Won, MH, 2003)
"GM1 pretreatment decreased MMA-induced convulsions (GM1-MMA: 6."( Bonini, JS; de Oliveira, TG; Dutra-Filho, CS; Fighera, MR; Frussa-Filho, R; Mello, CF; Rocha, JB; Rubin, MA, 2003)
"This subset experiences more seizures prior to the initiation of treatment, is more likely to be treated initially with a noncarbamazepine medication, and tends to have a higher frequency of associated conditions."( Al-Twajri, WA; Shevell, MI, 2002)
"Overall, 59% of the animals had seizures terminated within 30 min of the biperiden administration."( Byers, CE; Capacio, BR; Caro, ST; McDonough, JH, 2003)
"Whether better control of neonatal seizures leads to a reduction in neurodisability in childhood cannot be determined until more effective treatments are found."( Boylan, GB; Rennie, JM, 2003)
"Moreover, seizure duration was not dependent on the time of ECT administration in the time window between one and 6 minutes after loss of consciousness."( Brock-Utne, JG; Debattista, C; Lemmens, HJ; Levi, DC, 2003)
"To report a seizure occurring secondary to meperidine treatment despite normal renal and central nervous system (CNS) function, and to provide a review of meperidine's role in pain management, including its use in pancreatitis and sphincter of Oddi dysfunction."( Hubbard, GP; Wolfe, KR, 2003)
"Five minutes after the start of EEG seizures, animals were treated im with different doses of anticholinergics or benzodiazepines and observed for seizure termination."( Duniho, SM; McDonough, JH; Shih, TM, 2003)
"Garenoxacin did not induce any convulsions at intravenous doses up to 60 mg/kg in combination with 200 mg/kg oral administration of fenbufen in mice, and its convulsant activity was weaker than those of enoxacin, norfloxacin, ciprofloxacin, alatrofloxacin and ofloxacin."( Fukuda, H; Kawamura, Y; Morita, Y; Nakamura, T; Soumi, K, 2003)
"We report a case of postpartum convulsions due to a benign cerebral angiopathy occurring after bromocriptine therapy to suppress lactation."( Burckard, E; Combourieu, E; Escarment, J; Felten, D; Patrigeon, RG, 2003)
"Guanosine prevented seizures in 40% and death in 50% on mice treated with i."( Elisabetsky, E; Frizzo, ME; Izquierdo, I; Schmidt, AP; Souza, DO; Vinadé, ER, 2003)
"Nicotine-induced seizures were blocked by cotreatment with either the nonselective antagonist mecamylamine or the alpha7*-selective antagonist methyllycaconitine."( Collins, AC; Dobelis, P; Hutton, S; Lu, Y, 2003)
"The antiseizure potency of the ketamine/carbamazepine combination was comparable to that of carbamazepine alone administered at 20 mg/kg, while the effect of ketamine/valproate was comparable to the efficacy of valproate alone at 100 mg/kg."( Borowicz, KK; Czuczwar, SJ, 2003)
"Treatment of seizures in pediatric patients is complicated by the fact that the etiology of the disorder and the pharmacokinetics, efficacy, and safety of antiepileptic drugs (AEDs) may differ from that in adults."( Dulac, O; Glauser, TA, 2003)
"Patients who achieved adequate seizure control with levetiracetam as add-on therapy in a double-blind, placebo-controlled study entered a monotherapy phase of the trial in which the baseline AED was gradually withdrawn."( Ben-Menachem, E, 2003)
"The proportion of children who had seizures was significantly lower in the treated group compared with the control group at 3 months (10% versus 32%; P=."( Dua, T; Kalra, V; Kumar, V, 2003)
"The risk for oxygen-induced convulsions during routine hyperbaric treatment of most routine conditions is extremely low."( Atik, D; Hampson, N, 2003)
"Two groups of children with salaam seizures were studied-16 treated with routine anticonvulsants (control group) and 20 who had hydrocortisone added to their routine medication (Cortef-plus group)."( CROWTHER, DL, 1964)
"Since convulsions associated with the concurrent administration of enoxacin and fenbufen were reported in 1986, the concurrent administration of quinolones and anti-inflammatory drugs has been regulated to be contraindicated or carefully administered."( Hori, S; Igarashi, T; Iida, N; Kaneda, M; Kizu, J; Tajima, H; Tsuda, J, 2003)
"With pentylenetetrazol (PTZ) induced seizures pre-treated by CBZ, or SR-3, both CBZ and SR-3 were equally effective in providing seizure control and both were superior to the saline control."( Mostofsky, DI; Rabinovitz, S; Yehuda, S, 2004)
"Measures to treat seizures, hypoglycaemia, electrolyte anomalies and hyperthermia are the therapeutic goals."( Refstad, S, 2003)
"We have shown that electroconvulsive seizure (ECS), used for the treatment of severe depression, induces proliferation of both neuronal and nonneuronal cells in the adult rat hippocampus."( Ekdahl, CT; Hellsten, J; Tingström, A; Wennström, M, 2003)
"After several reports of new-onset seizures in children treated with oral baclofen at our institution, we reviewed our experience regarding possible effects of baclofen on seizure induction in a childhood movement disorders program over a 2-year period."( Hansel, CR; Hansel, DE; Hoon, AH; Johnston, MV; Levey, EB; Madden, L; Reinhardt, EM; Shindle, MK, 2003)
"In this population of adults with seizure disorders, CBZ-ERC twice daily was well tolerated during 12 to 36 months of open-label treatment,with no increase in seizure frequency or decrease in quality of life."( Garnett, WR; Hogan, RE; Thadani, VM, 2003)
"An 8 year old boy with partial seizures developed maculopapular rashes with itching on day 15 of carbamazepine therapy."( Kalita, J; Misra, UK; Rathore, C, 2003)
"In patients with seizures due to viable parenchymal cysts, antiparasitic therapy decreases the burden of parasites and is safe and effective, at least in reducing the number of seizures with generalization."( Del Brutto, OH; Evans, CA; Garcia, HH; Gilman, RH; Gonzalez, AE; Herrera, G; Martinez, SM; Moulton, LH; Pretell, EJ, 2004)
"After 3 years seizure-free period, he had repeated HMS, seven to eight attacks per day, after initiation L-thyroxine treatment."( Aydin, A; Baklan, B; Cemeroglu, AP, 2004)
"To report a case of seizure activity following gatifloxacin administration during treatment of urosepsis in an intensive care unit."( Lederman, JR; Quigley, CA, 2004)
"The alterations in clonic seizure threshold, induced by pentylenetetrazole, following the induction of intestinal inflammation by the administration of two consecutive daily oral doses of croton oil, was evaluated in mice."( Bahadori, M; Dehpour, AR; Demehri, S; Homayoun, H; Honar, H; Riazi, K, 2004)
"Rats treated with ketamine following seizure onset were virtually indistinguishable from nonepileptic controls on a variety of behavioral tasks that included tests on learning, memory, and anxiety."( Fournier, NM; Persinger, MA, 2004)
"Electroconvulsive seizures, an animal model for electroconvulsive treatment, induce a strong increase in neurogenesis in the dentate gyrus of adult rats."( Bengzon, J; Hellsten, J; Mohapel, P; Tingström, A; Wennström, M, 2004)
"In naloxone-treated group, the rats' seizure duration and seizure grade [(5."( Chang, XZ; Qin, J; Shan, Y; Yang, ZX, 2004)
"The antiseizure activity of progesterone in PRKO mice was reversed by pretreatment with finasteride, a 5alpha-reductase inhibitor that blocks the metabolism of progesterone to allopregnanolone."( Castaneda, DC; O'Malley, BW; Reddy, DS; Rogawski, MA, 2004)
"The prediction of seizure thresholds in electroconvulsive therapy (ECT) remains problematic."( Kiyama, S; Nakaoji, T; Ochiai, R; Takeda, J; Yamada, T, 2004)
"Repeated seizures were induced in male Wistar rats by daily administration of 3-mercaptopropionic acid (MP) 45 mg/kg i."( Brusco, A; García-Rivello, H; Girardi, E; Lazarowski, A; Ramos, AJ, 2004)
"Epileptic seizures have been reported in patients on imipenem/cilastatin (Imi/Cil) therapy."( Lovic, OS; Susic, V; Zivanovic, D, 2004)
"At our institution, new-onset seizures in children on chemotherapy are treated with gabapentin, a nonhepatic enzyme inducer."( Hunt, DL; Khan, RB; Thompson, SJ, 2004)
"To report a case of loss of seizure control due to hypocalcemia resulting from long-term treatment with phenytoin and phenobarbital."( Al-Busairi, WA; Al-Bustan, MA; Al-Mulla, FA; Ali, FE, 2004)
"Hypocalcemic seizures are uncommon and underdiagnosed complications of long-term therapy with AEDs."( Al-Busairi, WA; Al-Bustan, MA; Al-Mulla, FA; Ali, FE, 2004)
"The sustained seizures were subsequently treated with diazepam (10 mg/kg) and pentobarbital (30 mg/kg) and finally terminated 25 min after onset."( Aas, P; Andersen, JM; Myhrer, T; Nguyen, NH, 2004)
"Differentiation of pseudoseizures from epileptic seizures and hysterical stridor from asthma is key to the treatment of patients."( Kaufman, KR; Mohebati, A; Sotolongo, A, 2004)
"Nonconvulsive seizures (NCSs) after traumatic and ischemic brain injury are often refractory to antiepileptic drug therapy and are associated with a decline in patient outcome."( Hartings, JA; Lu, XM; Moreton, JE; Tortella, FC; Williams, AJ, 2004)
"We used "two-hit" rodent seizure model to study the long-term effect of perinatal hypoxia on later kainate (KA) seizure-induced neuronal damage and investigated the therapeutic efficacy of a postseizure treatment protocol in reversing the conditioning effect of early-life seizures."( Jensen, FE; Koh, S; Simpson, JN; Tibayan, FD, 2004)
"There were three seizures in the first week after initiating glargine therapy."( Buckingham, B; Tan, CY; Wilson, DM, 2004)
"Age, number of seizures, duration of AED therapy, occurrence of breakthrough seizures, administration of albendazole, and presence of a calcific residue of the SCCG on the CT scan were studied as prognostic factors to predict recurrence of seizures."( Jeyaseelan, L; Rajshekhar, V, 2004)
"When fed to seizure-prone Mongolian gerbils (Meriones unguiculatus) in a model of epilepsy, hispidulin (10 mg kg(-1) body weight (BW) per day) and diazepam (2 mg kg(-1) BW per day) markedly reduced the number of animals suffering from seizures after 7 days of treatment (30 and 25% of animals in the respective treatment groups, vs 80% in the vehicle group)."( Baur, R; Kavvadias, D; Qaiser, MZ; Rausch, WD; Rice-Evans, C; Riederer, P; Sand, P; Schreier, P; Sigel, E; Youdim, KA, 2004)
"The authors report a case of convulsion during intra-arterial selective infusion of fasudil hydrochloride (FSD) for treatment of vasospasm following subarachnoid hemorrhage (SAH)."( Date, I; Nakashimia, H; Ohmoto, T; Ono, S; Sasahara, W; Sugiu, K; Tokunaga, K, 2004)
"The clinical seizures resolved after administration of phenobarbital with normalization of the EEG several days later."( Goodkin, HP; Tramonte, JJ, 2004)
"Human seizure disorders are a major health concern due to the large number of affected individuals, the potentially devastating consequences of untreated seizure occurrences, and the lack of an effective treatment for all patients."( Lin, F; Tan, JS; Tanouye, MA, 2004)
"The threshold for the clonic seizures (CST) induced by acute intravenous administration of gamma-aminobutyric acid (GABA)-antagonist pentylenetetrazole (PTZ) was assessed in male and female mice."( Dehghani, M; Dehpour, AR; Gaskari, SA; Homayoun, H; Honar, H; Rashidi, N; Riazi, K; Sadeghipour, H, 2004)
"Three children being treated for seizures with vigabatrin showed definite clinical findings of peripheral retinal nerve fiber layer atrophy, with relative sparing of the central or macular portion of the retina and relative nasal optic nerve atrophic changes."( Buncic, JR; Logan, WJ; MacKeen, LD; Munn, JR; Panton, CM; Westall, CA, 2004)
"To report a case of seizure activity associated with oral codeine phosphate administered for analgesia in an elderly woman with end-stage renal disease."( Kao, SM; Kuo, SC; Lin, YC; Yang, YH, 2004)
"The numbers of spontaneous seizures per day during a 15 min observation interval were recorded for each rat during the treatment period and during an additional 30 days when only tap water was given."( Peredery, O; Persinger, MA, 2004)
"One of them, soman, can induce severe epileptic seizures and brain damage for which therapy is incomplete."( Carpentier, P; Dorandeu, F; Foquin, A; Lallement, G, 2004)
"Compared to vehicle, seizures were dramatically reduced in cultures treated with NR2B selective antagonists and slightly increased in cultures treated with moderate-affinity uncompetitive or high-affinity competitive antagonists."( Bausch, SB; Wang, XM, 2004)
"Soman induced profound limbic convulsions and 30% mortality, leading to increased blood-brain barrier permeability, neural injuries, learning and memory impairments, and physical incapacitation of survived rats pretreated with HI-6."( Che, JH; Choi, EK; Ha, YC; Hur, GH; Hwang, SY; Jang, JY; Kim, DJ; Kim, J; Kim, JC; Kim, YB; Park, D; Seong, YH; Shin, S; Yon, JM, 2004)
"Seven days post-seizure, the ECS group showed significantly more locomotion following intraperitoneal administration of apomorphine (0."( Burnham, WM; Sahebgharani, M; Zarrindast, MR, 2004)
"He developed generalized tonic clonic seizures just before the biopsy and was treated with IV midazolam 1 mg and thiopental 60 mg."( Agarwal, A; Dhiraaj, S; Pandey, R; Raza, M; Saxena, R; Singh, PK, 2005)
"If epilepsy developed, the seizures were less frequent in DZP-treated animals compared to the vehicle group (median 16."( Kharatishvili, I; Lukasiuk, K; Narkilahti, S; Nissinen, J; Pitkänen, A, 2005)
"The emergency treatment of seizures is an important practical issue, in particular the therapy of status epilepticus."( Peters, CN; Pohlmann-Eden, B, 2005)
"The therapeutic goal was persistent seizure control, defined as successful interruption of clinical seizure activity within less than 15 min, followed by seizure freedom during intravenous therapy for at least 12h."( Peters, CN; Pohlmann-Eden, B, 2005)
"One year later he again suffered from convulsions and was treated with carbamazepine in another hospital."( Matsushita, H; Sugama, Y; Uji, M, 2005)
"The duration and frequency of seizure activities and electrographic seizure onset of 41 patients totally withdrawing from CBZ monotherapy (n = 20), LTG monotherapy (n = 10) and CBZ + LTG combined therapy (n = 11) were intensively studied by therapeutic intensive seizure analysis (TISA) method."( Koebnick, C; Pauli, E; Stefan, H; Tilz, C; Wang, B; Wang-Tilz, Y, 2005)
"Generalized tonic-clonic seizures are a rare complication of levofloxacin therapy."( Christie, MJ; Sikaneta, TG; Tam, PY; Ting, RH; Wong, K, 2005)
"After treatment, 8 patients were seizure-free, and 11 others had > or =50% improvement in seizure control, including 11 of the 28 patients for whom treatment with six or more antiepileptic drugs was insufficient."( Brotherton, T; Santos, CC, 2005)
"The reduction in seizure frequency using ELB138 in dogs with newly diagnosed idiopathic epilepsy was comparable to the reduction in dogs treated either with phenobarbital or primidone."( Rieck, S; Rundfeldt, C; Tipold, A, 2006)
"The antiseizure effect of tested combinations was not sex-dependent and not reversed by hydrocortisone pretreatment."( Borowicz, KK; Czuczwar, SJ, 2005)
"The thresholds for the clonic seizures induced by the intravenous administration of gamma-aminobutyric acid (GABA)-antagonist, pentylenetetrazole (PTZ) were assessed in mice."( Dehpour, AR; Ebrahimkhani, MR; Ghaffari, K; Homayoun, H; Honar, H; Jannati, A; Kiani, S; Noorian, AR; Rashidi, N; Riazi, K, 2005)
"Dyskinesias and seizures are both medically refractory disorders for which cannabinoid-based treatments have shown early promise as primary or adjunctive therapy."( Adrian, R; Baratta, J; Giuffrida, A; Piomelli, D; Solbrig, MV, 2005)
"Electroconvulsive seizure (ECS)-treatment, a model for electroconvulsive therapy (ECT) has been shown to induce proliferation of endothelial cells in the dentate gyrus (DG) of adult rats."( Arvidsson, A; Ekstrand, J; Hellsten, J; Jansson, L; Tingström, A; Wennström, M; West, MJ, 2005)
"The latency and incidence of seizures were recorded by an observer who was uninformed of the estrous cycle and dietary treatment conditions of the rats."( Frye, CA; Harney, JP; Rhodes, ME; Talluri, J, 2005)
"The relative incidence of seizures during the first 28 days of treatment was 3."( Britton, J; Farrington, P; Godfrey, C; Hubbard, R; Lewis, S; Smeeth, L; Smith, C; West, J, 2005)
"Furthermore, the inhibition of seizure expression in SERs was still apparent 5 weeks after termination of LEV treatment."( Ishihara, K; Ji-qun, C; Nagayama, T; Sasa, M; Serikawa, T; Yan, HD, 2005)
"QA administration induced seizures in rats and was able to stimulate synaptosomal L-[3H]glutamate release."( Abud, J; Schmidt, AP; Souza, DO; Tasca, CI; Tavares, RG, 2005)
"Propofol may decrease seizure duration in electroconvulsive therapy."( Akcaboy, EY; Akcaboy, ZN; Bayam, G; Dikmen, B; Dilbaz, N; Gogus, N; Yigitbasł, B, 2005)
"access at the time of convulsions were randomised into 2 groups and treated with either intramuscular midazolam or intravenous diazepam for control of seizures."( Deshmukh, CT; Shah, I, 2005)
"There were no seizures in the treated group."( Coulter-Smith, SD; Geary, M; O'Donovan, M; Singh, J, 2005)
"All animals developed seizures subsequent to this treatment."( Li, JX; Liu, KL; Liu, YQ; Ruan, JX; Wang, YA; Yue, YJ; Zheng, JQ; Zhou, WX, 2005)
"There was no evidence of any seizure-like convulsions when ARD-353 was administered to mice either i."( Chang, KJ; Gengo, PJ; Gross, GJ; Holt, JD; O'Neill, SJ; Pendergast, W; Watson, MJ; Wei, K, 2006)
"10/15 patients remained seizure-free on the ketogenic diet in monotherapy."( Binder, S; Gertsen, E; Hertzberg, C; Klepper, J; Leferink, M; Leiendecker, B; Näke, A; Scheffer, H; Voit, T; Willemsen, MA, 2005)
"Following KA-induced seizures, severe neuronal cell damage was observed in the CA1 and CA3 subfields of hippocampal 3 days after KA administration."( Matsumoto, K; Murakami, Y; Sumanont, Y; Tohda, M; Vajragupta, O; Watanabe, H, 2006)
"Fifteen of the sixteen patients had no seizures after the administration of carbamazepine."( Furukawa, S; Hayashi, T; Ichiyama, T; Matsufuji, H; Nishikawa, M; Suenaga, N, 2005)
"Total seizure duration of 720+/-50 s after single PTZ administration (80 mg/kg i."( Bahçekapili, N; Sarper Diler, A; Uzüm, G; Ziya Ziylan, Y, 2006)
"Therapeutic measures included seizure prophylaxis with phenytoin and total brain radiation therapy of brain metastases from bronchial carcinoma."( Loewe, R; Pickl, WF; Stingl, G; Wagner, SN; Wöhrl, S, 2005)
"A patient with a history of seizures controlled with long-term carbamazepine therapy developed seizures when he started treatment with oxycodone CR at recommended doses."( Brill, S; Gurevich, B; Klein, M; Lifshitz, M; Lottan, M; Rudich, Z; Weksler, N, 2005)
"Centrally mediated seizures are a common consequence of exposure to organophosphates (OP) despite conventional treatment with atropine and an oxime."( Chapman, S; Gilat, E; Kadar, T, 2006)
"Electroconvulsive seizure (ECS)-treatment, an animal model for the antidepressant treatment electroconvulsive therapy, can enhance proliferation of glial cells."( Ekstrand, J; Hellsten, J; Lindgren, H; Tingström, A; Wennström, M, 2006)
"Pentylenetetrazole-induced seizures in rats treated with L-NAME caused a significant increase in Evans blue dye extravasation into cerebral cortex, diencephalon and cerebellum, as compared with seizures evoked by pentylenetetrazole injection to L-NAME-untreated rats (P<0."( Ahishali, B; Arican, N; Elmas, I; Kalayci, R; Kaya, M; Kucuk, M, 2006)
"Pentylenetetrazole-induced seizure threshold was increased with the administration of 2 and 10 mg/kg zolpidem as well as with lorazepam."( Fahey, JM; Grassi, JM; Greenblatt, DJ; Reddi, JM, 2006)
"Without avizafone in the combination, seizures induced by 3 or 4 x LD(50) of soman could not be terminated unless an adjunct therapy consisting of procyclidine (6 mg/kg), diazepam (10 mg/kg), and pentobarbital (30 kg/kg) was given, and the mortality rate was comparatively high (78%)."( Aas, P; Enger, S; Myhrer, T, 2006)
"Moreover, the duration and severity of seizures developed by htTG transgenics in response to kainic acid administration were significantly more pronounced than those observed in WT mice."( Johnson, GV; Roth, KA; Tucholski, J, 2006)
"As far as seizure recurrence was concerned, a lower number (16% versus 33%) of intravenous methyl prednisolone treated patient had recurrence, the difference was insignificant."( Agarwal, A; Garg, RK; Kar, AM; Prakash, S; Shukla, R; Singh, MK; Verma, R, 2006)
"There was no relationship between seizures after etomidate administration and prior seizure history (p = 0."( Gaines, BA; Herr, SM; King, C; Pitetti, RD; Roth, KR; Zuckerbraun, NS, 2006)
"Pentylenetetrazol (PTZ)-induced seizure in rats, a relevant model of human absence and of generalized tonic-clonic epilepsy, was used to stimulate seizure activity within 30 s of administration while collecting continuous, high-resolution, multislice images at subsecond intervals."( Brevard, ME; Ferris, CF; King, JA; Kulkarni, P, 2006)
"Treatment with ESM blocked seizures, decreasing PTZ-induced activation in most forebrain areas."( Brevard, ME; Ferris, CF; King, JA; Kulkarni, P, 2006)
"Treatment to terminate the seizures necessitated intubation and ventilation, and cooling measures brought the temperature within normal limits."( Duffy, MR; Swart, M, 2006)
"Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy."( Castillo, CG; Freed, WJ; Giordano, M; Mendoza, S, 2006)
"In addition, convulsive seizure activity was induced by systemic administration of either 4-aminopyridine (4-AP; 10 mg/kg, i."( Henry, M; Hescheler, J; Kamp, M; Krieger, A; Radhakrishnan, K; Schneider, T; Weiergräber, M, 2006)
"Intranasal lorazepam stopped convulsions within 10 min in 60 (75%) episodes treated (absolute risk 0."( Ahmad, S; Ellis, JC; Kamwendo, H; Molyneux, E, 2006)
"Acute seizures following brain injury have been associated with a worsening of patient outcome, but they are often undiagnosed and untreated when they occur without motor convulsions."( Bautista, CC; Chen, RW; Dave, JR; Hartings, JA; Lu, XC; Tortella, FC; Williams, AJ, 2006)
"Magnetic seizure therapy (MST) was developed as an alternative therapy that could reduce postseizure side effects through the induction of more "focal" seizure activity."( Amos, Q; Downing, M; Husain, MM; Lisanby, SH; McClintock, S; Stool, L; Thornton, L; White, PF; Zhang, Y, 2006)
"Norfloxacin provoked clonic convulsions in rats treated concomitantly with biphenylacetic acid, a major metabolite of the nonsteroidal anti-inflammatory drug fenbufen."( Chen, BY; Cheng, NN; Li, XT; Tang, WL; Wang, YM; Zhang, LR, 2006)
"Although electroconvulsive seizures (ECS) are widely used as a treatment for severe depression, the working mechanism of ECS remains unclear."( Christensen, DZ; Kristiansen, H; Mikkelsen, JD; Olesen, MV; Woldbye, DP, 2006)
"Following a literature review, a seizure management training package was developed to enhance the implementation of a trial treatment protocol for the administration of intranasal midazolam (INM)."( Coulthard, K; Harbord, M; Kay, D; Kyrkou, M; Kyrkou, N, 2006)
"Furthermore, we investigated whether convulsions elicited by intrastriatal MMA administration are accompanied by striatal protein carbonyl content increase and changes in Na(+),K(+)-ATPase activity in rat striatum."( Coelho, RC; de Carvalho Myskiw, J; Ferreira, AP; Fighera, MR; Fiorenza, NG; Furian, AF; Mello, CF; Oliveira, MS; Petry, JC; Royes, LF, 2007)
"Limbic seizures were evoked in freely moving rats by intrahippocampal administration of pilocarpine via a microdialysis probe."( Clinckers, R; Ebinger, G; Meurs, A; Michotte, Y; Smolders, I, 2006)
"The rapid onset of seizure development following injection was most likely due to inadvertent intravascular administration."( Dorf, E; Holstege, CP; Kelsey, J; Kuntz, AF, 2006)
"SCH 23390 protected against seizures, increased the latency to first seizure and reduced the mortality of the animals treated with pilocarpine Theses results suggest that dopamine receptor system receptor subtypes exert opposite functions on the regulation of convulsive activity."( Fonteles, MM; Freitas, RM; Sousa, FC; Vasconcelos, SM; Viana, GS, 2006)
"Early treatment of prolonged seizures with rectal diazepam has been the method of choice in order to avoid this complication."( Batista, D; Bausà, T; Elias, C; Font, D; Hijano, A; Melendez, R; Rocha, A, 2006)
"We treated 52 prolonged seizures in 10 patients enrolled in the study."( Batista, D; Bausà, T; Elias, C; Font, D; Hijano, A; Melendez, R; Rocha, A, 2006)
"Following 6 stage-5 once daily convulsive seizures, guanfacine or idazoxan were re-administered."( McIntyre, DC; Shin, RS, 2007)
"We studied daily rhythms of chronic seizure activity and behavior in adult rats and mice treated with the cholesterol biosynthesis inhibitor AY-9944 (AY) during early postnatal development."( Bercovici, E; Cortez, MA; Mistry, N; Persad, V; Serbanescu, I; Shukla, R; Snead, OC; Stewart, LS, 2006)
"There was no difference in onset of seizure time between the pyridoxine-treated group of rats and the control rats."( Cameron, D; Chase, PB; Fernandez, MC; Roe, DJ; Walter, FG; Wolfson, M, 2006)
"The relationship between seizure duration and bispectral index (BIS) has not been studied well in modified electroconvulsive therapy (mECT)."( Minami, T; Miyazaki, S; Morimoto, K; Muratani, T; Shimizu, S; Tanaka, M, 2006)
"In addition, convulsions induced by lithium-methomyl treatment were associated with widespread neurodegeneration of limbic structures."( Blaszczak, P; Calderazzo, L; Cavalheiro, EA; Dekundy, A; Kaminski, RM; Parada-Turska, J; Turski, WA, 2007)
"In general, seizure length does not correlate with clinical outcome with electroconvulsive therapy (ECT), but whether markedly short seizures are still therapeutic is unknown."( Brady, BM; Hooten, WM; Laurila, DR; Lewis, CL; Marienau, ME; Niemeyer, KD; Rasmussen, KG; Schroeder, DR; Spackman, TM; Sun, NM, 2006)
"In this post hoc analysis, individual seizure counts from four double-blind trials of adjunctive treatment with levetiracetam were analyzed by non-linear mixed-effects modeling (NONMEM)."( Snoeck, E; Stockis, A, 2007)
"LEV was considered effective if seizure cessation or >75% seizure reduction occurred in the 24 h after starting LEV (compared with the previous 48 h), requiring no further antiepileptic drug (AED) treatment."( Amaro, S; Carreño, M; Delgado, R; Donaire, A; Falip, M; Maestro, I; Toledo, M, 2006)
"The onset of tonic seizures induced by strychnine was increased between 40-140% in the case of the coground system depending on dose and time of carbamazepine administration."( Adibkia, K; Anoush, M; Barzegar-Jalali, A; Barzegar-Jalali, M; Hanaee, J; Nayebi, AM; Sistanizad, M; Valizadeh, H, 2006)
"Review of the spontaneous reports on convulsions showed that patients with nephropathy, patients over 75 years and patients with a history of convulsive diseases were more likely to develop convulsions during LVX therapy."( Kawai, H; Komiya, M; Matsumoto, T; Nakayasu, T; Shimada, J; Yamaguchi, H; Yokoyama, H, 2007)
"We monitored the onset of seizures in patients undergoing osmotic disruption of BBB (BBBD) followed by intraarterial chemotherapy (IAC) to treat primary brain lymphomas."( Angelov, L; Diglaw, T; Fazio, V; Franic, L; Granata, T; Hallene, K; Hernandez, N; Janigro, D; Marchi, N; Masaryk, T; Najm, I, 2007)
"Treatment with PHT led to complete seizure control in two animals and a >50% reduction of seizure frequency in three other rats, which were considered PHT responders."( Bethmann, K; Brandt, C; Löscher, W, 2007)
"We investigated whether electroconvulsive seizure (ECS) in rats stimulates cellular proliferation in the PFC immediately and four weeks after the treatments."( Carlezon, WA; Cohen, BM; Dow, AL; Edwin, F; Eisch, AJ; Heckers, S; Ongür, D; Patel, TB; Pohlman, J, 2007)
"Theophylline-associated seizures (TAS) are considered a neurologic emergency, as they can sometimes be intractable and difficult to stop with standard treatments such as intravenous administration of diazepam."( Yoshikawa, H, 2007)
"The time-series records of seizures and processes of drug administrations were investigated."( Enoki, H; Matsubayashi, R; Matsubayashi, T; Nagasaki, R; Nakashima, Y; Ohro, Y; Takeda, S; Yokota, T, 2007)
"In two patients, seizures were resistant to single-dose CH therapy, and their doses of CH were 33."( Enoki, H; Matsubayashi, R; Matsubayashi, T; Nagasaki, R; Nakashima, Y; Ohro, Y; Takeda, S; Yokota, T, 2007)
"We report a case of neonatal seizures after lidocaine administration for circumcision."( Finkelstein, Y; Koren, G; Railton, C; Rezvani, M; Verjee, Z, 2007)
"Treatment of tumor-induced seizures is often inadequate with traditional antiepileptic drugs (AED) due to a variety of factors, including activation of glutamatergic NMDA receptors, alterations of neuronal input pathways, and tumor growth."( Dalton, J; Goldlust, S; Newton, HB; Pearl, D, 2007)
"Transient seizures were observed in the K/DET treated animals during induction."( Jago, M; Stegmann, GF, 2006)
"In 1929, yi jing (pestilent convulsion) was prevalent in Shanghai, Yan Cangshan, a noted modern physician, was active in treating and rescuing the patients."( Wu, WQ, 2006)
"Thus, the Li-pilocarpine seizure model may, despite its lack of face validity, be a biochemical marker for a model of mania treatment in animals."( Belmaker, RH; Bersudsky, Y, 2007)
"Each patient was without seizure on levetiracetam monotherapy, and there were no adverse effects."( Rotenberg, JS; Shoemaker, MT, 2007)
"Mortality rate and seizure score of p38alpha(+/-) mice administered with kainate were significantly reduced compared with the case of wild-type (WT) mice."( Furuya, M; Hama, H; Kasuya, Y; Kimura, S; Kuwaki, T; Matsuo, Y; Mizuhashi, S; Nakamura, A; Namiki, K; Sudo, T; Tokuhara, N; Yano, S, 2007)
"The relative risk of seizure remission in treatment versus control was 1."( Mazumdar, M; Pandharipande, P; Poduri, A, 2007)
"Sevoflurane-induced seizures are most often described during mask induction of anesthesia when high concentrations of the volatile agent are administered concomitant with alveolar hyperventilation."( Iqbal, Z; Kumar, V; Markan, S; Mohanram, A; Pagel, PS, 2007)
"Minor motor seizures from the 10th month onwards are successfully treated with Valproate."( Creemers, JW; Mullaart, RA; Reimer, A; Wortmann, SB, 2008)
"Theophylline-associated seizures (TAS) are considered a neurologic emergency, as they can sometimes be intractable and difficult to stop with standard treatments such as intravenous administration of diazepam."( Yoshikawa, H, 2007)
"The significant proportion of seizure-free cases (27%) on duotherapy is suggesting the usefulness of combination therapy in achieving seizure-freedom in epilepsies refractory to single drug treatment."( Auvinen, A; Keränen, T; Kharazmi, E; Peltola, J; Peltola, M; Raitanen, J, 2008)
"In patients presenting with seizures due to single viable parenchymal neurocysticercosis, albendazole hastens the resolution of SSECTL if treatment is given in the early phase of the illness."( Chattopadhyay, A; Khandelwal, N; Sawhney, IM; Thussu, A, 2008)
"The hypocalcaemia and seizure activity had resolved with medical therapy, with normal calcium levels and no seizures for a month."( Rewari, V; Sethi, D, 2007)
"Neonatal seizures appeared at 21 hours and empiric anticonvulsive and antimicrobial treatment was started."( Gardiner, J; Kaczala, GW; Messer, MA; Poskitt, KJ; Prendiville, JS; Senger, C, 2008)
"Acute "silent" seizures after brain injury are associated with a worsening of patient outcome and are often refractory to anti-epileptic drug (AED) therapy."( Gryder, D; Hartings, JA; Tortella, FC; Williams, AJ, 2008)
"They show, in two rodent seizure models, that leptin administered directly to the brain or nasal epithelium suppresses seizures via direct effects on glutamate neurotransmission in the hippocampus."( Diano, S; Horvath, TL, 2008)
"A subsample of 67 adult patients with partial seizures participating in a randomized, double-blind study comparing the cognitive effects of adjunctive lamotrigine (LTG) and adjunctive topiramate (TPM) was administered Performance On-Line (POL) in addition to a battery of neuropsychological tests at baseline, week 8 and week 16 of treatment."( Blum, DE; Caldwell, PT; Drazkowski, JF; Hammer, AE; Kustra, RP; Mills, KC, 2008)
"The role of PGE(2) in the convulsions induced by PTZ was further investigated by administering anti-PGE(2) antibodies (4 microg/2 microl, i."( Bohrer, D; Castelli, M; Cavalheiro, EA; Ferreira, J; Fighera, MR; Fiorenza, NG; Furian, AF; Machado, P; Mello, CF; Oliveira, MS; Royes, LF; Veiga, M, 2008)
"In infants with idiopathic low seizure threshold and fever, theophylline administration might possibly trigger a seizure."( Izumi, T; Korematsu, S; Miyahara, H; Nagakura, T; Suenobu, S, 2008)
"REM sleep rebound and reduced seizure threshold) upon treatment discontinuation is reported for GABA(A) receptor allosteric modulators acting via the benzodiazepine binding site, e."( Anderson, NJ; Cremers, TI; Ebert, B; Fahey, JM; Rasmussen, S; Sánchez, C; Vogel, V, 2008)
"Since seizure duration can influence the therapeutic effect of ect it is advisable to use bilateral electrode placement in patients with cardiovascular risk factors and to administer esmolol prior to seizure induction."( Birkenhäger, TK; Bruijn, JA; Groenland, TH; Kusuma, A; Mulder, PG; Pluijms, EM; van den Broek, WW, 2008)
"While propofol is known to shorten seizures during electroconvulsive therapy, in our previous study on patients with schizophrenia, there was no need for more frequent restimulations when using propofol compared with etomidate."( Gábor, G; Judit, T; Zsolt, I, 2007)
"After etomidate induction, seizure durations registered either by EEG or by EMG were longer than propofol treated cases (EEG: 49."( Gábor, G; Judit, T; Zsolt, I, 2007)
"This is a report of a jacksonian seizure in a non-psychotic manic patient who was treated with right prefrontal high frequency rTMS concomitant to pharmacotherapy."( Papadimitriou, GN; Psarros, C; Sakkas, P; Soldatos, CR; Theleritis, CG, 2008)
"Duration of seizure also significantly increased in propofol (5 mg/kg) treated group, but at 2 mg/kg of propofol treatment, no significant difference was observed."( Medhi, B; Prakash, A; Puri, A; Saikia, B, 2008)
"Both the patients developed seizures of various types that have been successfully treated with zonisamide."( Amamiya, S; Araki, A; Fujieda, K; Kajihama, A; Ohinata, J; Sugai, R; Suzuki, N; Takahashi, S; Tanaka, H, 2008)
"We determined if seizure induction and seizure-induced cell death are affected differentially in young adult, mature, and aged male C57BL/6J and FVB/NJ mice administered the excitotoxin, kainic acid."( Bloom, CS; Chancer, ZO; Lorenzana, A; McCord, MC; Schauwecker, PE, 2008)
"Occurrence of seizures following long-term oral administration of caffeine (0."( Costentin, J; El Yacoubi, M; Ledent, C; Parmentier, M; Vaugeois, JM, 2008)
"Decontamination and appropriate seizure or muscle fasciculation control were the basis of treatment."( Dymond, NL; Swift, IM, 2008)
"Notwithstanding the reduction in seizure severity, cell death (60-90% of cell loss in KA-treated animals) in limbic regions was unchanged by herbimycin A and K252a."( Mello, LE; Queiroz, CM, 2008)
"Tardive seizure is a serious adverse reaction of electroconvulsive therapy (ECT)."( Isse, K; Nakamura, M; Saito, T; Watari, M, 2008)
"Data collected included demographics, seizure type, etiology of seizures, age at onset of seizures and at initiation of LTG treatment, number of antiepileptic drugs (AEDs) prior to LTG, dose of LTG, length of follow-up, treatment response, and adverse events."( Hardison, HH; Khurana, DS; Kothare, SV; Legido, A; Marks, HG; Melvin, JJ; Piñol-Ripoll, G; Valencia, I, 2009)
"Because of myoclonic jerks and generalized seizures, benzodiazepines were administered."( Beyrau, R; Bodmer, M; Burkard, T; Haschke, M; Krähenbühl, S; Kummer, O, 2008)
"A single dose of MDZ terminated convulsions in all (100%), 9/12 (75%) and 5/8 (63%) children following IV, IM and buccal administration."( Edwards, G; Kokwaro, GO; Muchohi, SN; Newton, CR; Ogutu, BR; Ward, SA, 2008)
"To estimate the rate of new-onset seizure in ADHD patients in relation to ADHD pharmacotherapy."( Holdridge, KC; Hornbuckle, K; Johannes, CB; McAfee, AT; Walker, AM, 2008)
"Incidence of seizure was calculated for observation time during treatment with atomoxetine and stimulants/bupropion."( Holdridge, KC; Hornbuckle, K; Johannes, CB; McAfee, AT; Walker, AM, 2008)
"Sixteen were seizure-free during treatment and not included in the conditional analysis."( Briggs, DE; French, JA; Lee, CM; Spiegel, K, 2008)
"Three patients presented seizures during ertapenem therapy."( Abusada, NJ; Fica, AE, 2008)
"While 47 of the cases were seizure-free on pyridoxine monotherapy, over time, eight other cases also required the concomitant use of anticonvulsants for effective seizure control, while the remainder continued to have recurrent seizures, despite the use of pyridoxine and multiple anticonvulsants."( Basura, GJ; Gospe, SM; Hagland, SP; Wiltse, AM, 2009)
"Although it is controversial that seizure duration can influence the efficacy of electroconvulsive therapy (ECT), a missed or brief seizure is considered less effective ECT."( Inoue, A; Kano, A; Miyaoka, H; Nakajima, K; Okutomi, T; Sawayama, E; Sawayama, T; Takahashi, M, 2008)
"It is characterized by infantile seizures refractory to anticonvulsive treatments, microcephaly, delays in mental and motor development, spasticity, ataxia, dysarthria and other paroxysmal neurologic phenomena, often occurring prior to meals."( Cano, A; Chabrol, B; Ticus, I, 2008)
"VPC inhibits 4-AP-induced seizures and hearing loss, even after post-treatment, at a concentration about 10 times lower than CBZ."( Nekrassov, V; Sitges, M, 2008)
"We studied 23 patients with cancer and seizures treated with levetiracetam."( Fisher, PG; Partap, S, 2009)
"Pyridoxine-dependent seizures are a rare condition recognized when numerous seizures respond to pyridoxine treatment and recur on pyridoxine withdrawal."( Jakobs, C; Jozwiak, S; Kacinski, M; Kaczorowska, M; Kmiec, T; Kroczka, S; Salomons, GS; Struys, EA, 2008)
"Current treatments involve seizure suppression using antiepileptic drugs (AEDs); however, many patients remain refractory to current treatments or suffer serious side effects."( Batts, TW; Bertram, EH; Brown, ML; Hargus, NJ; Jones, PJ; Merrick, EC; Patel, MK; Stables, JP; Wang, Y, 2009)
"Because of poor seizure even at maximum electrical dosage, aminophylline was administered just before initiating electroconvulsive therapy."( Kaneko, S; Katagai, H; Kikuchi, A; Yasui-Furukori, N, 2009)
"Consecutive seizures in each animal were (1) treated with active rTMS, (2) treated with sham rTMS, or (3) were untreated."( Birnbaum, D; Harrington, M; Jensen, FE; Muller, P; Pascual-Leone, A; Riviello, JJ; Rotenberg, A, 2008)
"Patients with brain tumors and seizures should be treated with non-enzyme-inducing antiepileptic drugs (AED)."( Novy, J; Rossetti, AO; Stupp, R, 2009)
"Cocaine-induced paroxysmal activity and convulsions were evaluated in rats surgically implanted with radiotelemetry devices (N=6 per treatment group)."( Baladi, MG; Cooper, ZD; Jutkiewicz, EM; Narasimhan, D; Sunahara, RK; Woods, JH, 2009)
"In untreated controls, the percent of seizure induced by CC50 and percent of death among mice having convulsions were 50 and 20, respectively."( Küçükhüseyin, C; Yillar, DO, 2008)
"Experimental acute seizure in mice was induced by intraperitoneal injection of KA (30 mg/kg), and mice were provided for experiments after 48 h of KA treatment."( Honda, N; Nishimura, A; Shibata, N; Sugioka, N; Takada, K, 2008)
"Folinic acid-responsive seizures and pyridoxine-dependent epilepsy are two treatable causes of neonatal epileptic encephalopathy."( Gallagher, RC; Hyland, K; Jakobs, C; Mercimek-Mahmutoglu, S; Plecko, B; Rosenberg, EH; Salomons, GS; Scharer, G; Stockler-Ipsiroglu, S; Struys, EA; Van Hove, JL; Waters, PJ, 2009)
"There was a dramatic reduction in seizure frequency with rapamycin therapy."( Butler, IJ; Koenig, MK; Muncy, J, 2009)
"Daily repeated epileptic seizures were induced for 12 days by intraperitoneal administration of 4-aminopyridine (4-AP; 4."( Bakos, M; Borbély, S; Czégé, D; Dobó, E; Mihály, A; Molnár, E; Szucs, B; Világi, I; Vincze, A, 2009)
"Hippocampal EEG seizures were continuously monitored before, during and after treatment."( Aronica, E; Gorter, JA; Holtman, L; Queiroz, CM; van Schaik, R; van Vliet, EA, 2009)
"Talampanel treatment suppressed seizures in a dose-dependent manner, with maximal effect at 7."( Aujla, PK; Fetell, MR; Jensen, FE, 2009)
"Differential effects of postseizure treatment on functions of the thyroid, pancreas, and spleen were indicated."( Blomme, CG; Dupont, MJ; George, KR; Mazzuchin, A; Persinger, MA; Rico, T; St-Pierre, LS; Stewart, LS, 2009)
"Scopolamine treatment caused convulsions only in the animals given solid food in the first 30 min; no convulsions were observed in the animals given slurry food, liquid food ad libitum, gavage, or placebo."( Kara, I; Nurten, A; Ozen, I; Ozerman, B, 2009)
"After repeated treatment the PTZ seizure threshold was not different between the two drugs, while differences in sedation became larger than after the acute treatment."( Pericić, D; Vlainić, J, 2009)
"Finally, audiogenic seizures could be induced in wild-type mice by coadministering CGP 46381 and the mGluR5-positive allosteric modulator 3-cyano-N-(1,2 diphenyl-1H-pyrazol-5-yl) benzamide."( Hampson, DR; Heximer, SP; Pacey, LK, 2009)
"We describe an 11-year-old girl with a seizure disorder who developed fever, rash, rhabdomyolysis, and multiorgan failure 2 weeks after commencing a transition from sodium valproate to lamotrigine therapy."( Dargan, PI; Ferguson, LP; Hood, JL; Tibby, SM, 2009)
"Neonatal seizures have devastating consequences for brain development and are inadequately treated by available antiepileptics."( Barnett, SM; Kahle, KT; Sassower, KC; Staley, KJ, 2009)
"Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited."( Rijsman, RM; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2009)
"The duration of NMDA seizures was longer after acute MA administration relative to animals without acute MA pretreatment in both control groups."( Bernásková, K; Matejovská, I; Rokyta, R; Schutová, B; Slamberová, R, 2009)
"Ciprofloxacin-associated seizures (CAS) occur most commonly in patients with special risk factors that may cause accumulation of drug (high doses of the drug, old age, renal insufficiency, drug interactions) or that may decrease the threshold of epileptogenic activity (electrolyte abnormalities, history of seizures, electroconvulsive therapy)."( Agbaht, K; Bayraktar, M; Bitik, B; Piskinpasa, S; Topeli, A, 2009)
"This type of seizures never appeared in caffeine-treated 25-day-old animals."( Kubová, H; Mares, P; Tchekalarova, J, 2009)
"She developed generalized seizures shortly after the administration of flumazenil."( Pedersen, LM; Petersen, M; Søndergaard, I, 2009)
"We compared the seizure activity as well as seizure lethality in 2- and 6-month-old mice, transgenic for the above-mentioned point mutation, and their wildtype littermates and found that mice harboring the hN141I mutation showed a relative resistance to excitotoxic treatment."( Gunther, T; Hüll, M; Schüle, R; Schulte, EC; Slawik, H, 2009)
"The presence of multiple seizures prior to medical treatment has been suggested as a potential predictor of poor outcome."( Brandt, C; Löscher, W, 2010)
"Before treatment with PB, average seizure frequency in PB nonresponders was significantly higher than seizure frequency in responders, which, however, was due to six nonresponders that exhibited > 3 seizures per day."( Brandt, C; Löscher, W, 2010)
"The second child in family B developed seizures on the seventh day, because pyridoxine maintenance therapy had not been instituted after birth."( Been, JV; Bok, LA; Jakobs, C; Rijper, EA; Struys, EA; Willemsen, MA, 2010)
"The results suggest that seizure activity is necessary for the expression of depression-like behavioral symptoms and confirm that epileptogenesis can be prevented by early and chronic treatment."( Kulikov, MA; Kuznetsova, GD; Sarkisova, KY; van Luijtelaar, G, 2010)
"Neonatal seizures in which hypoxic-ischemic encephalopathy is the main triggering etiology have a challenging diagnosis and limited efficacy of treatment."( Dacosta, JC; de Oliveira, IM; Dolganov, A; Greggio, S; Henriques, JA; Menegat, FD; Rosa, RM, 2009)
"Clonic seizures were rare in NMDA-treated P25 rats, but valproate pretreatment increased their incidence significantly."( Kubová, H; Mares, P, 2010)
"On day 15, seizure susceptibility was tested by administration of pentylenetetrazole (40 mg/kg i."( Avti, PK; Chakrabarti, A; Khanduja, KL; Medhi, B; Prakash, A, 2009)
"Theophylline-associated seizures (TAS) often progress to prolonged or treatment-resistant convulsions."( Fukuda, M; Hino, H; Ishii, E; Kuzume, K; Morimoto, T; Suzuki, Y, 2010)
"Tonic flexion convulsion was occurred three fifth in the wild type mice group by administration of PTZ, but tonic flexion was not observed in NCX1 knockout mice groups."( Baba, A; Honda, K; Iwamoto, T; Kaneko, E; Kita, S; Komuro, I; Matsuda, T; Saito, R; Takano, Y; Tanaka, Y, 2009)
"Accordingly, the risk of occurrence of convulsion related to TBPM-PI administration was low compared to IPM/CS administration, and TBPM-PI was considered to be less potential to induce convulsions in clinical use."( Kurata, Y; Kurosawa, T; Nawa, T; Shibasaki, S; Suzuki, H; Yagi, Y, 2009)
"This study of LEV versus PHT for seizure prevention in the NSICU showed improved long-term outcomes of LEV-treated patients vis-à-vis PHT-treated patients."( Lindsell, CJ; Sangha, KS; Shutter, LA; Szaflarski, JP, 2010)
"Furthermore, a strong reduction of seizure activity and cytokine production was observed in animals treated with anti-c-Jun siRNAs."( Cardoso, AL; Costa, P; Culmsee, C; de Almeida, LP; de Lima, MC; Plesnila, N; Simões, S; Wagner, E, 2010)
"PTZ-induced seizure severity is decreased in FRAXAD mice pre-treated with the mGluR(5) antagonist MPEP."( Malter, JS; Westmark, CJ; Westmark, PR, 2009)
"After 5 days of admission, clonic convulsions that progressed to generalized seizures were noted following the intravenous administration of the tranexamic acid."( Chen, HC; Chen, SC; Huang, MS; Wang, CS; Yang, CJ, 2011)
"Food intake triggers convulsions in fasted mice and rats treated with antimuscarinic drugs, scopolamine or atropine."( Baran, E; Enginar, N; Karamürsel, Y; Nurten, A; Zengin, A, 2010)
"Results showed that seizures alter reference memory when compared to saline-treated animals."( de Freitas, RM; de Sales Santos, IM; Feitosa, CM, 2010)
"The average latency to onset of clonic seizure was prolonged by 1 time and the average PTZ threshold increased 1 time in the nifedipine, the levetiracetam and the flumazenil treatment groups."( Bian, FZ; Wang, L; Wang, YH; Wang, YX, 2010)
"Onset of convulsions and death were observed in rats with increased CYP2E1 activity, whereas convulsions and death did not appear in rats within 1 h after treatment with AN alone."( Aschner, M; Fangan, H; Guangwei, X; Rongzhu, L; Shizhong, W; Suhua, W; Wenrong, X; Xiaowu, Z; Ye, Z, 2010)
"Median percent reductions in seizure frequency per 28 days from baseline to maintenance (intention-to-treat, ITT) were 37."( Biton, V; Chung, S; Doty, P; Hebert, D; Krauss, G; Rudd, GD; Sperling, MR, 2010)
"At present, neonatal seizures are usually treated with Phenobarbital (PB) despite the limited efficacy and the potential risk this treatment holds for the developing brain."( Bast, T; Bussmann, C; Ebinger, F; Fürwentsches, A; Philippi, H; Pöschl, J; Ramantani, G; Rating, D; Schubert, S, 2010)
"Five patients remained seizure free after 3 months with ongoing LEV monotherapy."( Bast, T; Bussmann, C; Ebinger, F; Fürwentsches, A; Philippi, H; Pöschl, J; Ramantani, G; Rating, D; Schubert, S, 2010)
"asiatica; and PTZ-induced seizure rats pretreated with diazepam (2mg/kg body wt)."( Chetan, PS; Lokanatha, V; Prasad, KS; Rajendra, W; Visweswari, G, 2010)
"In Experiment 3, in the seizure-tested animals, subcutaneous administration of 400mg/kg of DHA significantly increased latency to PTZ seizure onset 1 hour postinjection relative to the saline- and OA-injected controls, which did not differ significantly from each other (P>0."( Bala, S; Burnham, WM; Jeffrey, MA; Taha, AY; Taha, NM, 2010)
"After PTZ administration, mice showed myoclonic seizure (MCL) and clonic seizure (CL) in order."( Fujiwara, A; Kamei, C; Takechi, K; Watanabe, Y, 2010)
"Based on their seizure scores during treatment and in a screening test performed 2 weeks post-treatment, the PTZ-treated animals were retrospectively divided into the kindled group and the unkindled group."( Fang, F; Lei, H, 2010)
"One to seven seizures were recognized before starting CBZ or Lidocaine therapy, followed by complete cessation in 57 episodes and one or two recurrent seizures in five."( Komatsu, M; Kubota, T; Nakajima, M; Okumura, A; Shimakawa, S; Tanabe, T, 2011)
"Five patients (83%) experienced generalized seizures during concurrent VPA-carbapenem treatment, including two with no prior history of seizures or epilepsy."( Golightly, LK; Jones, MA; Kick, SD; Tobin, JK, 2009)
"Rats had seizure epilepticus in 30 min after administrated of pilocarpine."( Jiang, W; Li, XW; Wang, Y; Wei, D; Zhang, SJ, 2010)
"Seizure behaviors or duration of seizure were not changed significantly by DBS treatment."( Hashizume, K; Hori, T; Kato, K; Maehara, M; Okada, Y; Tanaka, T; Urino, T, 2010)
"We report 3 cases of clinical seizure activity associated with nitrous oxide administration for pediatric procedural sedation."( Doescher, JS; Zier, JL, 2010)
"This noninferiority analysis compares seizure outcomes and side effects in patients with glioma treated with phenytoin and levetiracetam monotherapy."( Anderson, SK; Lachance, DH; Merrell, RT; Meyer, FB, 2010)
"The stimulus dose and the seizure duration of ECT treatments with concurrent LMT (≥200 mg/d) were compared with the stimulus dose and seizure duration of ECT treatments without concurrent LMT."( Demunter, H; Peuskens, J; Roelens, Y; Sienaert, P; Van Heeringen, C; Vansteelandt, K, 2011)
"Missed seizures, however, occurred more frequently during ECT treatments with concurrent LMT."( Demunter, H; Peuskens, J; Roelens, Y; Sienaert, P; Van Heeringen, C; Vansteelandt, K, 2011)
"Kainate-induced seizure behavior progressed further in OVX rats, but was attenuated in prolactin-treated rats, both intact and OVX, compared to vehicle-treated rats."( Cerbón, M; Morales, T; Tejadilla, D, 2010)
"There was neither improvement in seizure nor any significant changes in lipid peroxidation and antioxidant enzyme levels in etoricoxib-treated group."( Khanduja, KL; Medhi, B; Pandhi, P; Rao, RS, 2010)
"In the pentylenetetrazole-induced seizure model, the administration of 1 mg/kg and 2 mg/kg amlodipine protected 33 percent of the animals from mortality, and 67 percent were protected with the administration of 4 mg/kg."( Sathyanarayana Rao, KN; Subbalakshmi, NK, 2010)
"The time of seizure control averaged 40+/-32 minutes in the midazolam group compared with 69+/-24 minutes in the diazepam group after maintenance treatment (P<0."( Tang, RH; Zhou, JB, 2010)
"The median time to seizure was compared between observers told the animal received placebo and those told the animal received active treatment."( Cleveland, NR; Heard, KJ; Krier, S, 2010)
"The reported median time to seizure was similar for observers told that the animals were treated with placebo and those told they were treated with study medication."( Cleveland, NR; Heard, KJ; Krier, S, 2010)
"Eight infants with seizures were treated with phenytoin from 2 weeks to 3 months of age."( Banwell, B; Cheng, A; Freeman, D; Levin, S; Rieder, M; Seabrook, JA, 2010)
"A 5-month-old boy with migrating partial seizures in infancy acquired bromoderma 4 weeks after initiating potassium bromide (KBr) therapy (60mg/kg/day)."( Komaki, H; Kosaka, M; Nabatame, S; Nakagawa, E; Saito, Y; Sakuma, H; Sasaki, M; Sugai, K; Uchiyama, K, 2010)
"The greatest attenuation of convulsive seizures, to a level consisting only of motor excitation, was obtained in 60% of the rats between 1 and 2 h after administration."( Lukomskaya, NY; Magazanik, LG; Oganesyan, GA; Vataev, SI; Zhabko, EP, 2010)
"Thirty-three subjects with nonzero nonepileptic seizure rates at baseline were included in intent-to-treat analysis of the primary outcome."( Blum, AS; Keitner, GI; LaFrance, WC; Machan, JT; Miller, IW; Papandonatos, GD; Ryan, CE, 2010)
"Delay in onset of PTZ-induced seizures with CZMME compared with positive control and placebo-treated groups confirmed the improved brain uptake."( Ambikanandan, M; Ankur, K; Florence, K; Kumar, BA; Kumar, MA; Manisha, L, 2011)
"Sex, age, familial history, type of seizures and AED treatment were noted and EEG monitoring, MRI and CT scanning, and developmental and psychomotor evolution were investigated."( Caraballo, R; Cersósimo, R; Flesler, S; Sakr, D, 2010)
"A reduction in seizure frequency by 50% of the baseline was considered as 'response' (significant change), meriting further continuation of pyridoxine therapy."( Gulati, S; Kalra, V; Mishra, D; Saha, N; Seth, R, 2010)
"To determine the threshold for clonic seizures, PTZ was administered intravenously."( Asghari-Roodsari, A; Dehpour, AR; Javadi-Paydar, M; Khodadad, TK; Lesani, A; Norouzi, A; Shirkhodaei, M, 2010)
"In the remaining animals that exhibited seizures, KB-R7943 pretreatment delayed the onset of seizures and status epilepticus, and reduced seizure severity."( Martinez, Y; N'Gouemo, P, 2010)
"At the dose administered, non-seizure and sustained seizure responses were observed in both agent groups and in the tabun-exposed group some subjects experienced an unsustained seizure response."( Acon-Chen, C; McDonough, JH; O'Donnell, JC; Shih, TM, 2010)
"The trend to increased seizure frequency in the tranexamic acid group may be a direct consequence of this treatment, consistent with other recently published reports."( Berman, M; Cardone, D; Dunning, J; Gerrard, C; Jenkins, D; Klein, A; Sharples, L; Tsui, S; Vuylsteke, A, 2010)
"Behavioral and electroencephalographic seizures were monitored for 20 min following pentetrazol administration."( Fukuhara, S; Kaida, Y; Kamei, C; Takechi, K; Uehara, T; Watanabe, Y, 2011)
"In vivo, KA administration induced seizures and the same neurodegenerative events exhibited in vitro."( Alapafuja, SO; Bahr, BA; Butler, D; Hwang, J; Karanian, DA; Makriyannis, A; Naidoo, V; Nikas, SP; Vadivel, SK; Wood, JT; Zhao, J, 2011)
"The attenuation in the drop of NMDA seizure threshold (percentage of reversal) was 58 and 20 % upon acute intraperitoneal administrations of magnesium chloride hexahydrate (28 mg magnesium/kg) and the antioxidant ebselen (20 mg/kg), respectively."( Agnani, G; Bac, P; Delplanque, B; Durlach, J; German-Fattal, M; Maurois, P; Pages, N; Poupaert, J; Vamecq, J, 2009)
"Therapy is often unnecessary and seizures spontaneously end at puberty."( Fusco, L; Specchio, N; Trivisano, M; Vigevano, F, 2010)
"To examine seizure thresholds, increasing doses of pilocarpine were administered to adult mice and seizures were scored behaviorally."( Aaron, G; Asik, K; Briggs, SW; Lombroso, P; Naegele, J; Walker, J, 2011)
"Neonatal seizures are often refractory to treatment with initial antiseizure medications."( Abend, NS; Clancy, RR; Dlugos, DJ; Gutierrez-Colina, AM; Monk, HM, 2011)
"All patients had seizure disorders that were treated with anticonvulsants."( Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK, 2011)
"The data of the patients treated for seizures (convulsions, epileptic seizures, disturbance of consciousness and epileptic seizures in children with neurodevelopmental disability) in the Pediatrics Clinic of the University Clinical Center of Tuzla were retrospectively analyzed during 2008 in relation to seasonal distribution, admission time (month, week, admission moment, day in a week, time of the day) and the lunar cycle."( Hadzic, BC; Hadzic, D; Mladina, N; Numanovic, A, 2010)
"Clinical seizure remission within 10 min of drug administration was found in 80% of the intravenous group as compared to 83."( Arya, R; Gulati, S; Kabra, M; Kalra, V; Sahu, JK, 2011)
"We describe here how behavioural seizures can be triggered in adult zebrafish by the administration of kainate and are very similar to those observed in rodent models."( Alfaro, JM; Burgos, JS; Ripoll-Gómez, J, 2011)
"Acute seizures are readily recognizable episodes requiring urgent treatment."( Chen, YI; Chiang, LM; Chou, ML; Deng, ST; Hung, PC; Lin, KL; Shen, HH; Tseng, CH; Wang, HS, 2011)
"Seizures or seizure-like phenomena which are mostly convulsive have been observed during the induction, maintenance and withdrawal phases of propofol administration."( Abou-Khalil, B; Arain, A; Patton, T; Smithson, K; Sonmezturk, HH; Zubair, S, 2011)
"To assess clonic seizure threshold, pentylenetetrazole (PTZ) was administered intravenously."( Baradaran, N; Dehpour, AR; Dehpour, S; Kabiri, T; Moezi, L; Shafaroodi, H, 2011)
"An increase in seizure frequency subsequent to generic substitution was associated with polytherapy compared to monotherapy (3."( Chaluvadi, S; Chiang, S; Friedman, DE; Goldsmith, CE; Tran, L, 2011)
"In humans, melatonin may attenuate seizures, and it is most effective in the treatment of juvenile intractable epilepsy."( Banach, M; Borowicz, KK; Gurdziel, E; Jędrych, M, 2011)
"In 3 out of 13 rats, limbic convulsive seizures, which were not related to the time of drug administration, were observed after 5-8 days."( Perescis, MF; van Luijtelaar, G; van Rijn, CM; Vinogradova, L, 2011)
"Electrical stimulation to control seizures may be an additive therapy."( Besio, WG; Koka, K; Liu, X; Medvedev, AV; Wang, L, 2011)
"Neonatal stroke presents with seizures that are usually treated with phenobarbital."( Comi, AM; Johnston, MV; Kadam, SD; Markowitz, GJ; Smith, DR, 2011)
"He experienced convulsions from day 4 and was administered anticonvulsants."( Hagioka, S; Maeyama, H; Morimoto, N; Nagae, M; Naito, H; Okada, D; Okahara, S, 2011)
"Clinical data (including preoperative seizure history), radiological data, surgical treatment, antiepileptic treatment were retrospectively reviewed."( Ciccarino, P; d'Avella, D; Del Moro, G; Della Puppa, A; Denaro, L; Lombardi, G; Manara, R; Rossetto, M; Rotilio, A; Scienza, R, 2011)
"Here, we report three cases of seizures that developed after the administration of zoledronic acid."( Gruber, M; Hamann, C; Hofbauer, LC; Rachner, TD; Tsourdi, E; Ziemssen, T, 2011)
"After treatment with levetiracetam, seizures recurred and intravenous loading with valproic acid was administered, but resulted in a rapid increase in international normalized ratio (INR) to 7."( Giraldo, EA; Wijdicks, EF; Yoon, HW, 2011)
"Patients reported an increase in seizure activity to their neurologists after treatment was switched from Keppra to generic levetiracetam formulations."( Fitzgerald, CL; Jacobson, MP, 2011)
"The latency to the onset of the first seizure induced by PTZ was significantly increased by ICV administration of MgSO₄ at a dose of 100 µg compared to the control treatment."( Futuro Neto, Hde A; Nakamura-Palacios, EM; Oliveira, LD; Oliveira, RW, 2011)
"A by-treatment difference in incident seizures was not detected."( Boaz, M; Dabby, R; Gilad, R; Lampl, Y; Sadeh, M, 2011)
"LEV administrations in preseizure-manifesting SERs reduced the decrease of CA3 neurons and mossy fibers sprouting at 10-11 weeks of age in both group A and B."( Arita, K; Hanaya, R; Kumafuji, K; Kurisu, K; Sasa, M; Serikawa, T; Sugata, S; Tokudome, M, 2011)
"Three epileptic seizures occurred during anticonvulsive therapy in the LEV group, and two in the VPA group, including one non-convulsive status epilepticus (NCSE)."( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011)
"End of seizure episode (clinically) was defined as cessation of visible epileptic phenomenon or return of purposeful response to external stimuli within 15 min of drug administration."( Gathwala, G; Goel, M; Mittal, K; Singh, J, 2012)
"In the latter rats, audiogenic running seizures reappeared for at least two weeks after the end of treatment."( Shatskova, AB; van Rijn, CM; Vinogradova, LV, 2011)
"However, generalized seizures occurred in a significantly lesser proportion of subjects in the treatment group (n = 3, 15."( Khandelwal, N; Lal, V; Medhi, B; Modi, M; Prabhakar, S; Singla, M, 2011)
"Demographic and seizure characteristics were similar in treatment and control groups."( de Souza, A; Kovoor, JM; Nalini, A; Siddalingaiah, HS; Thennarasu, K; Yeshraj, G, 2011)
"The frequency of prior seizure in flumazenil-treated patients was 30 times higher (8."( Cooper, G; Dyas, J; Routledge, PA; Thompson, JP; Veiraiah, A, 2012)
"Finally, we showed that kainate induced seizures and glycemia were not modified by spadin treatments."( Borsotto, M; Coppola, T; Gandin, C; Heurteaux, C; Labbal, F; Mazella, J; Moha Ou Maati, H; Veyssiere, J; Widmann, C, 2012)
"However, in those mice that do develop seizures, the pathological changes (neuronal cell loss, inflammation [perivascular cuffing, gliosis, activated microglia/macrophages]), and the numbers of virus infected cells in minocycline-treated or IL-6-deficient chimeric mice are very similar."( Fujinami, RS; Kennett, NJ; Libbey, JE; White, HS; Wilcox, KS, 2011)
"The mainstay of treatment for seizures is medical therapy with antiepileptic drugs."( Grant, R; Kerrigan, S, 2011)
"This seizure-suppressant effect of combination gene therapy with Y5 receptors and neuropeptide Y was significantly stronger as compared to neuropeptide Y overexpression alone."( Ängehagen, M; Christiansen, SH; Gøtzsche, CR; Kokaia, M; Nikitidou, L; Olesen, MV; Sørensen, AT; Sørensen, G; Woldbye, DP, 2012)
"CHV considerably enhanced the seizure activity leading to changes in clinically determined parameters of the treatment course: the necessity for increasing the electric charge, for re-stimulations (trend) and for bilateral stimulations was lower in the CHV group as compared to the UHV group."( Gillmann, B; Grözinger, M; Haeck, M; Janouschek, H, 2011)
"Levetiracetam also provided seizure control relative to placebo as adjunctive therapy in patients with idiopathic generalized epilepsy with myoclonic seizures or GTC seizures."( Lyseng-Williamson, KA, 2011)
"Efficacy results are reported for all seizure types [intention-to-treat (ITT) population, N = 217] and subpopulations with tonic-clonic (n = 152), myoclonic (n = 121), and/or absence (n = 70) seizures at baseline."( Delanty, N; Jones, J; Tonner, F, 2012)
"(1) they had more severe KA-induced seizures than apoE2 and 3 mice, (2) they exhibited neuron loss in hippocampus that was higher than in apoE2, 3 and WT mice, (3) KA administration resulted in higher counts of their head drops in the cross-area of elevated plus-maze, (4) they showed lower KA-induced rearing activity than apoE2 mice in the open-field test, (5) their KA-induced microglial expression of MHC-II and CD86 was elevated compared to apoE3 mice, (6) the KA-induced increase of microglial iNOS was higher than that in the other groups of mice, and (7) the TNF-α and IL-6 expression was decreased 7 days after KA application compared to untreated mice and mice treated 1 day with KA."( Adem, A; Mao, XJ; Mix, E; Pham, T; Winblad, B; Zhang, HL; Zhang, XM; Zheng, XY; Zhu, J, 2012)
"Midazolam was administered with seizure resolution."( Cole, JB; Gross, EA; Smith, SW; Stellpflug, SJ, 2011)
"In pilocarpine-induced seizures, the EUG-treated rats showed no shorter seizure latency but a lower seizure severity and mortality than the control rats."( Chow, JC; Huang, CW; Tsai, JJ; Wu, SN, 2012)
"Secondly, the number of seizures induced by pentylenetetrazole (PTZ) was quantified in rats following chronic sodium selenate treatment via drinking water."( Chen, T; Corcoran, NM; Grundy, R; Hovens, CM; Jones, NC; Nguyen, T; O'Brien, TJ; Velakoulis, D, 2012)
"Oxygen toxicity seizures (OTS) are a known complication of hyperbaric oxygen therapy (HBOT)."( Banham, ND, 2011)
"The median percent reduction in weekly seizure frequency over the treatment period was 59."( Cho, YW; Heo, K; Kim, KS; Kim, OJ; Kim, SE; Kim, SH; Lee, BI; Lee, JH; Lee, SJ; Park, SP; Shin, DJ; Song, HK; Yi, SD, 2012)
"MDR1 T allele carriers in the seizure reoccurrence (SR) group of GS and FS were high compared with the well-controlled seizure group (with no seizures after treatment)."( Bhiladvala, D; Chaudhari, JR; Das, UN; Hasan, Q; Jaleel, MA; Kaipa, PR; Ponnala, S, 2012)
"Therapy of seizure activity following exposure to the nerve agent soman (GD) includes treatment with the anticonvulsant diazepam (DZP), an allosteric modulator of γ-aminobutyric acid A (GABA(A)) receptors."( Kelley, NR; Lee, RB; Lumley, LA; Moffett, MC; Schultz, MK; Schwartz, JE; Stone, MF; Wright, LK, 2012)
"The CD₅₀ values for clonic and tonic seizures after oral administration were 0."( Banks, CN; Bruun, DA; Dhir, A; Hammock, BD; Inceoglu, B; Lein, PJ; McCoy, MR; Rogawski, MA; Sanborn, JR; Zolkowska, D, 2012)
"The enhanced anti-seizure and neuroprotective effect achieved by disruption of the A1R/neurabin/RGS4 complex is elicited by the on-site and on-demand release of endogenous adenosine, and does not require administration of A1R ligands."( Chen, Y; Cottingham, C; Greengard, P; Jiao, K; Liu, Y; McMahon, L; Wang, Q, 2012)
"Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT."( Bajwa, RP; Gross, TG; Pai, V; Skeens, M; Soni, S; Termuhlen, AM, 2012)
"To determine the threshold for clonic seizures, PTZ was administered intravenously."( Adabi Mohazab, R; Dehpour, AR; Delfan, B; Javadi-Paydar, M, 2012)
"To investigate the frequency of seizures associated with acepromazine administration when used as a premedicant with methadone for dogs undergoing myelography."( Drynan, EA; Gray, P; Raisis, AL, 2012)
"She had an acute onset of a generalized seizure and coma on the fourth day after chemotherapy."( Chen, CH; Chen, JS; Cheng, CY; Deng, ST; Lin, YC, 2011)
"When tested at 3-9 weeks after seizure/control treatment, seizure as compared to control rats showed no difference in finding a hidden platform in the water maze, but were deficient in learning and maintaining consecutive criterion performance in the 8-arm radial arm maze."( Boon, F; Boyce, R; Cain, DP; Crutchley, M; Leung, LS; Ma, J; Tsai, ML, 2012)
"Adults with a history of seizure who used Dilantin Kapseals 100 mg extended phenytoin sodium, USP, capsules and whose therapy was interchanged to Taro Pharmaceuticals' AB-rated generic extended phenytoin sodium capsules, USP, 100 mg between July 2007 and May 2008 were included."( Bentley, WH; Delate, T; Kinikar, SA; Menaker-Wiener, CM, 2012)
"The individual time-course of the seizure threshold (ST) in electroconvulsive therapy is mostly unknown."( Hoyer, C; Janke, C; Kranaster, L; Lederbogen, F; Lewien, A; Sartorius, A, 2012)
"Innovative treatments of epileptic seizures are needed to improve the outcome of epilepsy."( Ikeda, H; Imai, K; Kubota, Y; Susa, F; Takahashi, Y; Yamazaki, E, 2013)
"Oxidative stress induced by seizures was also attenuated as indicated by significant increase in GSH and decrease in MDA levels in HEOM treated groups."( Kumar Gupta, Y; Mehla, J; Pahuja, M, 2012)
"In a kainic acid (KA)-induced seizure model in mice, hippocampal CA1 pyramidal cells undergo delayed neuronal death at day 3-4 following systemic KA administration."( Kinoshita, C; Kinoshita, Y; Morrison, RS; Schwartzkroin, PA; Wenzel, HJ, 2012)
"Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY)."( Ghauri, AA; Khan, AA; Shamim, MS; Zafar, SN, 2012)
"The results show enhancement of seizure severity with significant reduction in GABA levels upon PTX treatment that were reversed by its combination with sodium valproate."( Kamal, SM, 2012)
"We investigated the seizures induced by electroshock using increasing-current delivery in 3- or 4-week-old rats, and found that the threshold-current of tonic extensor seizures was elevated with age in weeks in the vehicle-treatment groups."( Kanda, T; Takizawa, F; Tamura, T; Yamada, K, 2012)
"The quantitative evaluation in the MES seizures after oral administration into rats showed that the most active were 1-[{4-(4-fluorophenyl)-piperazin-1-yl}-methyl]-3-(2-bromophenyl)-pyrrolidine-2,5-dione (14) with ED(50) of 7."( Kamiński, K; Obniska, J; Rzepka, S, 2012)
"In our patient, seizures immediately stopped upon initiation of vigabatrin treatment, and his development and neurological examination at one year are normal."( Fluss, J; Korff, CM; Picard, F; Vulliemoz, S, 2012)
"The frequency of seizures among acutely poisoned adults who are administered flumazenil has not been well established."( Cantrell, FL; Clark, RF; Kreshak, AA; Tomaszewski, CA, 2012)
"Total spike number and the generalized seizure duration were reduced in the carbenoxolone treated group compared to the PTZ group."( Acar, MD; Bagirici, F; Marangoz, C; Sefil, F, 2012)
"On the contrary, we observed seizures and mortality in fluoxetine-treated Ts65Dn mice, raising the possibility of a drug × genotype interaction with respect to these adverse treatment outcomes."( Ehninger, D; Heinen, M; Hettich, MM; Paesler, K; Ryan, DP; Schnell, S, 2012)
"In addition, the convulsion onset time was significantly delayed by apigenin administration."( Ahn, SY; Han, JY; Hong, JT; Kim, CS; Kim, HC; Kim, SK; Oh, KW; Yoo, SK, 2012)
"The only seizure test where short-term rapamycin treatment protected mice was against tonic hindlimb extension in the MES threshold test, though this protection waned with longer rapamycin treatment."( Dolce, A; Hardwick, JM; Hartman, AL; Santos, P, 2012)
"In the flurothyl seizure model only the 4-h pretreatment with RAP was anticonvulsant in the both age groups."( Chachua, T; DeSantis, K; Nesheiwat, L; Poon, KL; Velíšek, L; Velíšková, J; Yum, MS, 2012)
"Five minutes after initiation of convulsions, MGS, CRM, or MDZ were administered."( Bloch-Shilderman, E; Brandeis, R; Egoz, I; Grauer, E; Katalan, S; Lazar, S; Rabinovitz, I; Raveh, L, 2013)
"In order to analyze the dynamics of seizure-induced elemental changes, the samples taken from seizure-experiencing animals 3 h and 1, 4, and 7 days after proconvulsive agent administration were analyzed."( Appel, K; Chwiej, J; Gzielo-Jurek, K; Janeczko, K; Kutorasinska, J; Setkowicz, Z; Simon, R; Uram, L, 2012)
"The SE incidence, SE latency and seizure severity as well as mortality were significantly reduced after treatment with a-asarone at different doses."( Chen, QX; Li, C; Li, XW; Miao, JK; Wu, XM; Zhang, XP, 2013)
"A 54-year-old Asian man developed seizure activity requiring emergent intubation during his initial cetuximab infusion for the treatment of metastatic colorectal cancer."( Bell, WA; McClellan, NH, 2012)
"Drug-induced seizures are in view of a constantly ageing population and increasingly frequent polypharmacotherapy an increasing problem in daily routine praxis."( Block, F; Dafotakis, M, 2013)
"At P40, KA-induced seizures and neuronal loss were significantly diminished in rats previously treated with LEV."( Chang, M; Fitzgerald, E; Folkerth, RD; Jensen, FE; Kosaras, B; Murphy, A; Talos, DM, 2013)
"During convulsions, Zn treatment did not show any protective effect on BBB permeability."( Demir, G; Oztaş, B; Seker, FB; Yalçın, IE; Yorulmaz, H, 2013)
"Furthermore, the reduced seizure and excitotoxicity and normal spatial learning exhibited in TRPC5 KO mice suggest that TRPC5 is a promising novel molecular target for new therapy."( Abramowitz, J; Birnbaumer, L; Flockerzi, V; Freichel, M; Gottschall, PE; Howell, MD; Phelan, KD; Rhee, SW; Shwe, UT; Wu, H; Zheng, F, 2013)
"The reduction in seizure count was also evident following insulin induced hypoglycemia with the triheptanoin treated group having significantly less SWDs than control animals under similar low blood glucose conditions."( Borges, K; Kim, TH; Petrou, S; Reid, CA, 2013)
"We examined the seizure susceptibility of these mice to determine if the presence (BXD29-Trl4(lps-2J)/J) or absence (C57BL/10J) of p-ACC, in strains with MCD, confers a differential response to chemi-convulsive treatment."( Gabel, LA; Ibanez, N; Manglani, M; Ramos, RL; Roberts, J; Rosen, GD, 2013)
"Neonatal seizures can lead to later life epilepsy and neurobehavioral deficits, and there are no treatments to prevent these sequelae."( Fitzgerald, EF; Huganir, RL; Hunganir, RL; Jensen, FE; Klein, PM; Rakhade, SN; Sun, H; Zhou, C, 2012)
"The patients who had a single seizure at the time of consultation were, in principle, followed without any treatment, and those with repeated seizures were treated with intravenous injection of 10 mg/kg PB."( Ban, H; Takami, Y, 2012)
"PB was administered after a single seizure in one patient, and the remainder were treated after 2-7 seizures, no patient had repeated seizures."( Ban, H; Takami, Y, 2012)
"Further, E-64d-pretreated seizure rats (EXP2) showed a significant downregulation of mRNA expression of PRG-1, PRG-3 and PRG-5, cathepsin B and ApoE, as well as up-regulated nSMase and ANX7 in hippocampus when compared with EXP1 rats."( Feng, X; Ni, H; Ren, SY; Sun, Q; Tian, T; Zhang, LL, 2013)
"Pilocarpine-induced seizure increased p47 immunofluorescence in the plasma membrane of hippocampal neurons at 12h post-insult and apocynin treatment prevented this increase."( Choi, BY; Choi, HC; Chung, TN; Jang, BG; Kim, HS; Kim, JH; Sohn, M; Song, HK; Suh, SW, 2013)
"Aminoguanidine increased the initial seizure and latency until death, and administration of 1400W did not have an effect."( Cavalcante Melo, FH; de Carvalho Lima, CN; de França Fonteles, MM; Freire Vasconcelos, L; Leite Dias, M; Moura Rocha, NF; Rodrigues Carvalho, AM; Soares Lopes, K; Vasconcelos Rios, ER, 2013)
"When (sub)clinical seizures are treated, there is no consensus about the most appropriate treatment for neonatal seizures and how to assess the efficacy of treatment."( de Vries, LS; Hellström-Westas, L; van Rooij, LG, 2013)
"We pretreated mice with MG before seizure induction with picrotoxin or pilocarpine and then assessed seizures behaviorally or by electroencephalography (EEG)."( Distler, MG; Escayg, A; Gorfinkle, N; Palmer, AA; Papale, LA; Termini, J; Winawer, MR; Wuenschell, GE, 2013)
"This case documents a generalized tonic-clonic seizure in a 15-year-old girl after receiving 60 mg of methohexital and numerous prior episodes of bitemporal electroconvulsive therapy."( Rasmussen, KG; Swintak, CC; Vande Voort, JL; Wall, CA, 2013)
"Although antiseizure medication is the first-line treatment for epilepsy, currently available medications are ineffective in a significant percentage of patients and have not clearly been demonstrated to have disease-specific effects for epilepsy."( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013)
"ESX treatment significantly reduced seizures in GAERS during the treatment phase, and this effect was maintained during the 12-week posttreatment phase (p < 0."( Blumenfeld, H; Dezsi, G; Jones, NC; O'Brien, TJ; Ozturk, E; Powell, KL; Stanic, D, 2013)
"Thirteen of 14 children became seizure-free with treatment."( Agostinelli, S; Capovilla, G; Chiarelli, F; Coppola, G; Curatolo, P; Foiadelli, T; Grosso, S; Parisi, P; Prezioso, G; Romeo, A; Savasta, S; Spalice, A; Striano, P; Verrotti, A, 2013)
"Neonates whose seizures were not controlled by the assigned drug were then crossed over to be treated with other drug in same dose."( Chawla, D; Goel, SP; Pathak, G; Pathak, U; Upadhyay, A, 2013)
"During the follow-up study, the seizure severity increased in animals treated with 0."( Firoozabadi, SM; Javan, M; Mirnajafi-Zadeh, J; Mongabadi, S; Shojaei, A, 2013)
"We examined seizure activity on the real time and amplitude integrated EEG records of 14 full-term infants with perinatal asphyxial encephalopathy treated within 12 h of birth with 30% inhaled xenon for 24 h combined with 72 h of moderate systemic hypothermia."( Azzopardi, D; Edwards, AD; Griffiths, J; Kapetanakis, A; Mathieson, SR; Rennie, JM; Robertson, NJ, 2013)
"In addition, the seizures resulted in up-regulation of Drp1 expression and mdivi-1 treatment had no effect on the expression."( Lian, Y; Wang, C; Wu, C; Xie, N; Zhang, H; Zhang, Q, 2013)
"The treatment of neonatal seizures has not changed significantly over the last 50 years despite advances in antiepileptic drug (AED) development for older children and adults."( Mangum, B; Pressler, RM, 2013)
"We present a female with seizures one month after delivery who had borderline elevated liver enzymes prior to the initiation of OXC treatment."( Bielen, A; Bielen, I; Marusić, M; Planjar-Prvan, M; Sruk, A, 2013)
"Cefepime or meropenem-associated convulsions were defined according to the following criteria: (1) administration or dose escalation of diazepam, phenytoin, phenobarbital and thiamylal given via the intravenous route (2) convulsions recorded in medical records during administration of cefepime or meropenem."( Araki, H; Suemaru, K; Takechi, K; Tanaka, A; Tanaka, M; Watanabe, S, 2013)
"The prevalence of convulsions was significantly greater in the cefepime treated group than in the meropenem-treated group."( Araki, H; Suemaru, K; Takechi, K; Tanaka, A; Tanaka, M; Watanabe, S, 2013)
"Treatment of neonatal seizures still relies primarily on phenobarbital, despite an estimated efficacy of less than 50% and concern over neurodegenerative side effects."( Ågren, J; Flink, R; Hellström-Westas, L; Lundqvist, M; Wickström, R, 2013)
"Twenty-two patients developed convulsions, which was the most common complication during therapy."( Alaygut, D; Bolat, F; Cevit, Ö; Doğan, MT; Gültekin, A; Güven, AS; Içağasoğlu, FD; Oflaz, MB; Özdemir, G, 2013)
"To analyze seizure control, dose adjustments, and other changes of antiepileptic drug (AED) treatment during pregnancy in a large cohort of women with epilepsy entering pregnancy on monotherapy with carbamazepine, lamotrigine, phenobarbital, or valproate."( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Tomson, T; Vajda, F, 2013)
"Data collected included overall seizure frequency, frequency of prolonged seizures, and use of rescue medications and emergency room (ER)/hospital visits in the year preceding stiripentol initiation, and with stiripentol therapy."( Chancharme, L; Chugani, H; de Menezes, MS; Devinsky, O; Franz, DN; Hamiwka, L; Hernandez, A; Laux, L; Le Guern, ME; Mikati, MA; Morse, RP; Saneto, RP; Sullivan, J; Valencia, I; Wirrell, EC, 2013)
"AEA and WIN both reduced absence seizures independently from the brain focal site of infusion while, conversely, rimonabant increased absence seizures but only when focally administered to the ventroposteromedial thalamic nucleus (VPM)."( Calignano, A; Citraro, R; De Sarro, G; Ngomba, RT; Nicoletti, F; Russo, E; Scicchitano, F; Whalley, BJ, 2013)
"Sublingual lorazepam stopped seizures within 10 minutes of administration in 56% of children compared with intrarectal diazepam in 79% (P < ."( Dubru, JM; Kahamba, DM; Kokolomani, J; Malu, CK; Mayamba, RM; Misson, JP; Mukampunga, C; Musalu, EM; Walker, TD; Wilmshurst, JM, 2014)
"Hypothermia reduced seizure burden during and after treatment in all cases."( Buttram, S; Guilliams, K; Miller, B; Pineda, J; Rosen, M; Shoykhet, M; Zempel, J, 2013)
"Handling-evoked and spontaneous convulsive seizures were observed in many BoNT/B-treated animals but not in vehicle-treated controls."( Bröer, S; Gernert, M; Rogawski, MA; Zolkowska, D, 2013)
"Optimal treatment of seizures in AS remains undetermined."( Gurnett, CA; Kasasbeh, AS; Smyth, MD, 2014)
"The most favorable seizure outcome was seen in a patient with partial agenesis of the corpus callosum treated with CC."( Gurnett, CA; Kasasbeh, AS; Smyth, MD, 2014)
"Understanding how seizures spread throughout the brain is an important problem in the treatment of epilepsy, especially for implantable devices that aim to avert focal seizures before they spread to, and overwhelm, the rest of the brain."( Hall, D; Kuhlmann, L, 2013)
"To provide two-year seizure and neuropsychological outcomes in patients treated by stereotactic radiofrequency amygdalohippocampectomy (SAHE), an alternative, minimally invasive method for the treatment of mesial temporal lobe epilepsy (MTLE)."( Kramska, L; Liscak, R; Lukavsky, J; Malikova, H; Vojtech, Z, 2013)
"Valproate treatment suppressed seizures by 80% in GAERS (p<0."( Dedeurwaerdere, S; Elms, J; Morris, MJ; O'Brien, TJ; Powell, KL; van Raay, L, 2013)
"Recently, seizures in dogs have been proposed as a translational platform for human therapeutic trials on new epilepsy treatments."( Hoffmann, K; Löscher, W; Potschka, H; Töllner, K; Twele, F, 2013)
"FTA significantly increased the seizure latency and decreased the mortality in PTZ-treated mice."( Cui, R; Li, B; Li, Y; Liu, L; Song, Y; Tang, F; Wang, L; Wang, Y; Zhao, J; Zhou, Y, 2013)
"The precise metabolic cause of the seizures remains unknown and pyridoxine treatment apparently does not cure the epilepsy."( Abeling, NGGM; Bosch, AM; Cobben, JM; de Roo, MGA; Duran, M; Koelman, JHTM; Majoie, CB; Poll-The, BT, 2014)
"The treatment profile for epilepsy, seizure control, and maternal and neonatal outcomes in both groups were compared using Chi-square test or Fisher's exact test and Mann-Whitney U test."( Abe, K; Hamada, H; Minakami, H; Obata-Yasuoka, M; Yamada, T; Yoshikawa, H, 2014)
"Although seizures have been reported in interferon-treated patients with multiple sclerosis and in a variety of malignancies, the epileptogenic potential of interferon-α in the treatment of HCV infection is considered minimal."( Antinori, S; Cattaneo, D; Falvella, FS; Gervasoni, C; Magni, C; Milazzo, L; Peri, AM; Vidale, S, 2013)
"Hence, seizure prophylaxis is routinely utilized during BU administration for stem cell transplantation (SCT)."( Aricò, M; Caselli, D; Cesaro, S; Cicalese, MP; Faraci, M; Lo Nigro, L; Locatelli, F; Longoni, D; Maximova, N; Menconi, MC; Nesi, F; Paolicchi, O; Podda, M; Prete, A; Ripaldi, M; Rosati, A; Santarone, S; Ziino, O, 2014)
"Neonatal seizures are often refractory to treatment with initial antiseizure medications."( Ariguloglu, EA; Koklu, E; Koklu, S, 2014)
"There was a tendency towards lower seizure rate in the O2-treated group at one month after pilocarpine-induced SE."( Groeneweg, L; Kirschstein, T; Köhling, R; Müller, L; Müller, S; Sellmann, T; Tokay, T, 2014)
"Six patients had no prior history of seizures, and 1 patient with a prior history was not taking AED therapy at the time of presentation."( Beran, RG; Cordato, DJ; Malkan, A; Patel, V, 2014)
"Thirteen cats had no additional seizures after initiation of PB treatment."( Barnes Heller, HL; Finnerty, KE; Giovanella, CJ; Lau, VW; Mercier, MN; Rylander, H, 2014)
"However, the effects of the seizures, as well as possible treatment strategies, have yet to be elucidated, particularly in juvenile or insulin-dependent diabetes mellitus (IDDM)."( Carlen, PL; del Campo, M; El-Hayek, Y; Giacca, A; Hazrati, L; Maheandiran, M; Mylvaganam, S; Sugumar, S; Wu, C; Zhang, L, 2013)
"Metabolic encephalopathy in the form of seizures can result from many inborn errors of metabolism and considering the large number of disorders causing metabolic encephalopathy, enzyme assays or conventional molecular tests are expensive and take considerably long period of time which results in delayed treatment."( Adıyaman, G; Biberoğlu, G; Çiftci, B; Ezgu, F; Gökmenoğlu, H; Hasanoğlu, A; Kasapkara, Ç; Küçükçongar, A; Topçu, B; Tümer, L, 2014)
"Latency and probability of PTZ-induced seizures were shorter and higher respectively, in hyperthermia-treated animals compared to controls."( Abdeen, Z; Al Shawaaf, F; Al-Ansari, S; Alsaffar, Y; Hassan, Z; Kamal, A; Mandeel, M; Rajab, E, 2014)
"However, the treatment of some seizure types and novel drug formulations deserve further advances in epilepsy research."( Citraro, R; De Sarro, G; Franco, V; Grillo, E; Iudice, A; Russo, E, 2014)
"We therefore conclude that a seizure reduction of >50% following dietary treatment is not a suitable criterion for identifying patients with GLUT1-DS, as these patients generally achieve complete seizure freedom shortly after diet initiation."( Haavardsholm, KC; Nakken, KO; Ramm-Pettersen, A; Selmer, KK, 2014)
"It was found that seizures, tachycardia, nerve damage, clinical symptoms, brain injuries and mortality induced by such lethal toxin were effectively prevented by the prophylactic patch treatment up to certain LD50 level."( Banerjee, S; Chattopadhyay, P; Ghosh, A; Gogoi, J; Pathak, MP; Veer, V, 2014)
"Repeated treatment with electroconvulsive seizure (ECS) induces changes in histone acetylation, expression of various genes, and intrabrain cellular changes, including neurogenesis."( Ahn, YM; Kim, SH; Kim, YS; Park, HG; Park, S; Yu, HS, 2014)
"All the seizure parameters were significantly reduced when phenobarbital (3 mg/kg) was administered prior to the application of the non-effective pattern of LFS."( Asgari, A; Atapour, N; Mirnajafi-Zadeh, J; Moradi, H; Semnanian, S; Shojaei, A, 2014)
"The brain seizure, not the method of induction, is the essential element in the efficacy of convulsive therapy."( Fink, M, 2014)
"Mean seizure severity and cumulative seizure duration proved to be comparable between vehicle- and L-701,324-treated mice."( Aronica, E; Gorter, J; Potschka, H; Salvamoser, JD; Soerensen, J; van Vliet, EA; Zellinger, C, 2014)
"Current treatments for seizure emergencies, such as status epilepticus, include intravenous or rectal administration of benzodiazepines."( Georg, GI; Kapoor, M; Lis, L; Siegel, RA; Winter, T, 2014)
"Severe metabolic acidosis and seizure have been described, but the use of renal replacement therapy has not been studied in the context of overdose."( Al-Abri, SA; Anderson, IB; Colby, JM; Olson, KR; Pedram, F, 2015)
"Despite reports of seizures, coma, and death associated with its use as well as banning of its environmental use by the Environmental Protection Agency (EPA), the US Food and Drug Administration (FDA) still allows treatment with lindane as a second-line scabicide and pediculicide."( Kelley, M; Olson, KR; Russell, JL; Walson, PD; Wiles, DA, 2015)
"We have reported significantly higher convulsion prevalence in patients treated with cefepime than in those treated with meropenem."( Araki, H; Suemaru, K; Takechi, K; Tanaka, A; Tanaka, M; Watanabe, S, 2014)
"In addition to seizure suppression in vivo, GS967 treatment greatly improved the survival of Scn2a(Q54) mice, prevented hilar neuron loss, and suppressed the development of hippocampal mossy fiber sprouting."( Anderson, LL; Bush, WS; Frankel, WN; George, AL; Hawkins, NA; Kearney, JA; Nath, RD; Petersohn, AA; Rajamani, S; Thompson, CH; Vanoye, CG, 2014)
"On admission, he redeveloped convulsions and loading doses of phenytoin, phenobarbitone and midazolam were administered."( David, HS; Rajavelu, KK; Sampath, S; Sivathanu, S, 2014)
"In this KA-induced seizure model, the systemic administration of GL 30 min before KA administration significantly suppressed neuronal cell death and markedly suppressed gliosis and proinflammatory marker inductions."( Jin, Y; Kim, ID; Lee, JK; Luo, L, 2014)
"Pretreatment with stansin 6 inhibited convulsions in rats from kainic acid-induced seizures, reduced the degeneration pattern in the CA3 region, decreased astrocytic reactivity, and reduced the expression of IL-1β and TNF-α induced by kainic acid."( Aguilar-Guadarrama, B; Aguirre-Moreno, A; Campos-Peña, V; Castillo-España, P; Estrada-Soto, S; León-Rivera, I; Navarrete-Vázquez, G; Rios, MY; Rivera-Leyva, JC; Villeda-Hernández, J, 2014)
"Psychogenic nonepileptic seizures, the most common conversion disorder, are as disabling as epilepsy and are not adequately addressed or treated by mental health clinicians."( Baird, GL; Barry, JJ; Blum, AS; Frank Webb, A; Keitner, GI; LaFrance, WC; Machan, JT; Miller, I; Szaflarski, JP, 2014)
"Five patients became seizure-free on LCM monotherapy following withdrawal of their initial treatment."( Brodie, MJ; Kelly, K; Parker, P; Stephen, LJ, 2014)
"torvum leaves is used to treat epileptic seizures."( Bock, M; Buenafe, OE; Challal, S; Crawford, AD; Dayrit, FM; de Witte, PA; Esguerra, CV; Harvey, AL; Kloeti, W; Lerche, H; Maljevic, S; Marcourt, L; Queiroz, EF; Wolfender, JL, 2014)
"Here, we evaluated various behavioral seizure abnormalities in neonatal rats (Sprague-Dawley; postnatal day 9) after an intraperitoneal administration of NMDA."( Chopra, K; Dhir, A, 2015)
"In another experiment, seizure threshold with tramadol was investigated in rats intracerebroventricularly administered with either a serotonin receptor antagonist (methysergide) or saline (n = 6)."( Fujimoto, Y; Funao, T; Mori, T; Nishikawa, K; Suehiro, K; Takahashi, R, 2015)
"Pretreatment significantly affected seizure threshold and serotonin fluctuations."( Fujimoto, Y; Funao, T; Mori, T; Nishikawa, K; Suehiro, K; Takahashi, R, 2015)
"Although a rational time-frame of seizure prophylactic treatment with LEV for after TBI is not well established, clinical prophylaxis with LEV often includes treatment duration similar to clinical treatment guidelines with Phenytoin."( Fowler, L; Hurwitz, M; Wagner, AK; Zou, H, 2015)
"Animals with spontaneous recurrent seizures induced by pilocarpine administration were implanted with movable microelectrodes in the right anterior and posterior hippocampus to evaluate the effects of gap junction blockers administered in the entorhinal cortex."( Medina-Ceja, L; Ventura-Mejía, C, 2014)
"Thirty minutes of seizure activity is usually the time period used in longstanding definitions of CSE but it is not acceptable to wait for 30 minutes before treatment."( Chin, RF, 2014)
"Finally, using multiple in vivo seizure models, we identify potent lead candidates for the treatment of epilepsy."( Cano-Jaimez, M; Chang, P; Close, AJ; McEvoy, JP; Spencer, J; Walker, MC; Williams, RS; Williams, S; Zuckermann, AM, 2015)
"After adjustment for seizure burden, neonates managed during the Neonatal Neurocritical Care Service era, on average, received 30 mg/kg less cumulative phenobarbital (95% confidence interval 15-46 mg/kg) and were on maintenance 5 fewer days (95% confidence interval 3-8 days) than those who were treated prior to implementation of the service."( Bonifacio, SL; Glass, HC; Kuzniewicz, MW; McCulloch, CE; Wietstock, SO, 2015)
"A patient presented with convulsive seizures when sodium valproate (VPA) and tebipenem pivoxil (Orapenem) were co-administered accidentally."( Miki, A; Nakamoto, N; Satoh, H; Sawada, Y; Shihyakugari, A, 2015)
"He experienced convulsive seizures the day after beginning co-administration."( Miki, A; Nakamoto, N; Satoh, H; Sawada, Y; Shihyakugari, A, 2015)
"The ESES phenomenon and seizures were observed before and after treatment."( Bao, X; Chang, X; Chen, J; Fu, N; Ji, T; Jiang, Y; Liu, X; Qin, J; Wang, S; Wu, Y; Xiong, H; Yang, Z; Zhang, Y, 2014)
"Both medication were effective for seizure control and no significant difference was found between successful treatments after administering the medication (P = 0."( Azizi Malamiri, R; Fayezi, A; Jafari, M; Maraghi, E; Momen, AA; Nikkhah, A; Riahi, K, 2015)
"The 6 Hz model of focal seizures has been increasingly used to identify anticonvulsant compounds with potential activity against therapy-resistant epilepsy, but the protective response to anticonvulsants in this model could be dependent on experimental conditions and selection of mouse strains."( Kaminski, RM; Leclercq, K, 2015)
"Because seizures reappeared during tapering the dosage of PB, potassium bromide (KBr) at a daily dose of 80 mg/kg was additionally administrated."( Aiba, H; Okumura, Y; Watanabe, S, 2014)
"Although inactive in acute seizure tests, repeated administration of SAR127303 delays the acquisition and decreases kindled seizures in mice, indicating that the drug slows down epileptogenesis, a finding deserving further investigation to evaluate the potential of MAGL inhibitors as antiepileptics."( Arlt, H; Augé, F; Avenet, P; Beeské, S; Bergis, OE; Bert, L; Bertrand, T; Brittain, S; Didier, M; Escoubet, J; Even, L; Françon, D; George, P; Griebel, G; He, T; Houtmann, J; Jacquet, A; Leroy, T; Lopez-Grancha, M; Menet, V; Michot, N; Mikol, V; Pichat, P; Rak, A; Redon, N; Sun, F; Tolstykh, T; Vallée, F; Wiederschain, D; Yu, Q; Zhang, B, 2015)
"PTZ-kindled mice showed high seizure activity, hippocampal neuronal loss, and expression of growth-associated phosphoprotein (GAP-43) compared with saline-treated mice."( Alhaj, MW; Moustafa, YM; Zaitone, SA, 2015)
"PTZ administration induces absence-seizures at low dose, and generalised convulsive seizures at higher dose."( Anderson, P; Argyropoulos, A; Hannan, AJ; Hill-Yardin, EL; Hosie, S; O'Brien, TJ; Rind, G, 2015)
"The reported cases achieved control of seizures with adjunctive LCM treatment and were afterwards converted to monotherapy."( Papacostas, SS, 2015)
"Only 29% of LEV-treated animals had seizures compared to all controls following a latent period that was similar in duration."( Avoli, M; Behr, C; Lévesque, M, 2015)
"There was no apparent change of the seizure initiation pattern when kainic acid was coadministrated with AM404, URB597 or AM251."( Aliev, R; Kitchigina, V; Shubina, L, 2015)
"Post-traumatic seizures can exacerbate injurious outcomes of severe brain trauma, yet effective treatments are limited owing to the complexity of the pathology underlying the concomitant occurrence of both events."( Bridson, GW; Chen, Z; Graham, PB; Leung, LY; Lu, XC; Shear, DA; Tortella, FC; Uttamsingh, V, 2015)
"Treatment-resistant seizures affect about a third of patients suffering from epilepsy."( Afrikanova, T; Buenafe, OE; Crawford, AD; De Prins, A; de Witte, PA; Esguerra, CV; Kaminski, RM; Langlois, M; Leclercq, K; Rospo, CC; Smolders, I; Van Eeckhaut, A, 2015)
"Food intake triggers convulsions in fasted BALB/c mice and Wistar albino rats treated with antimuscarinic drugs, scopolamine or atropine."( Çağla, B; Enginar, N; Nurten, A; Türkmen, AZ, 2015)
"LF was administrated 7 d before seizure induction (pre-treatment) or 24 h after seizure induction (post-treatment) for 7 d."( Chen, DJ; Liu, FR; Liu, JX; Wang, YZ; Xie, QM; Yang, XJ; Zeng, LH, 2015)
"We report a case of isoniazid induced convulsions in 35 years old male alcoholic and smoker patient receiving intensive phase therapy for pulmonary tuberculosis."( Aiwale, AS; Barvaliya, MJ; Jha, PR; Patel, UA; Tripathi, C, 2015)
"Ethosuximide (250 mg/kg) reduced seizure severity in mice undergoing ethanol withdrawal with concurrent PTZ treatment (20 mg/kg)."( Godwin, DW; Masicampo, ML; Riegle, MA; Shan, HQ; Xu, V, 2015)
"However, the incidence of seizures induced by pentylenetetrazole significantly decreased in the groups administered systematically with 40 and 80 mg/kg of mefloquine."( Ballesteros-Zebadúa, P; Franco-Pérez, J; Manjarrez-Marmolejo, J, 2015)
"Furthermore, the melatonin-pretreated seizure rats (Mel + RS) exhibited a significantly upregulated expression of calcium/calmodulin-dependent protein kinase II α (CaMKIIα), acetyl-Coenzyme A acetyltransferase 1 (ACAT1), ZnT-1, metallothionein 1 (MT-1), nSMase and Cathepsin-E, compared with the RS rats."( Feng, X; Ni, H; Sun, BL; Sun, Q; Tian, T, 2015)
"Anti-seizure drugs are the most commonly employed treatment option for epilepsy and these generally provide effective management of seizures."( Pilitsis, JG; Shin, DS; Smith, AB; Yu, W, 2015)
"Most seizure emergencies occur outside of the hospital, and there is a need for treatment interventions that can be administered quickly and safely by nonclinical caregivers."( Kälviäinen, R, 2015)
"The threshold for seizure induction with progressive intravenous infusion of pentylenetrazole (PTZ) was evaluated in anesthetized Wistar rats two hours after a single 1 ml intragastric administration of BD-AcAc2 (i."( Arnold, P; Coppola, G; D'Agostino, D; Monda, M; Pilla, R; Viggiano, A, 2015)
"She experienced seizures on the third day of her hospitalization and was treated with anticonvulsant drugs."( Afroze, F; Ahmed, T; Chisti, MJ; Das, SK; Faruque, AS; Huq, S; Islam, MM; Matin, FB; Sarker, SA; Shahrin, L, 2015)
"In most cases, either the seizure or the medications used to treat the seizure may contribute to cognitive and psychosocial difficulties of various degrees of severity."( Blakeley, J; Piotrowski, AF, 2015)
"Evaluation for reversible causes of seizure activity along with anticonvulsant administration is generally the standard of care for breakthrough seizures."( Dewberry, RG; Pula, T; Vasagar, B; Verma, BR, 2015)
"How aggressively these seizures should be treated is unclear."( Husain, AM, 2015)
"The median time after EEG seizure onset before administration of in-MDZ was 2."( Bauer, S; Belke, M; Fründ, D; Kay, L; Knake, S; Reif, PS; Rosenow, F; Strzelczyk, A, 2015)
"Thirty mice that developed seizures were randomly divided into three groups and administered PHT as well as the following treatments: saline (negative control); verapamil (20 mg/kg, positive control); and G."( Chen, SL; Fan, Q; Ma, H; Zhang, C, 2015)
"Epilepsy is a highly prevalent seizure disorder which tends to progress in severity and become refractory to treatment."( Akula, KK; Boison, D; Coffman, SQ; Lusardi, TA; Masino, SA; Ruskin, DN, 2015)
"Importantly, chronic seizures in the mouse model of TLE were robustly suppressed by systemic administration of the GlyT1 inhibitor LY2365109."( Aronica, E; Boison, D; Bright, KA; Gorter, J; Hanthorn, M; Lytle, NK; Shen, HY; van Vliet, EA, 2015)
"In a kainate-induced murine seizure model, administration of a dose of an M-channel inhibitor that did not affect kainate-induced seizure transiently eliminated the anticonvulsant effects of VPA."( Greene, DL; Hoshi, N; Kang, S; Kay, HY; Kosenko, A, 2015)
"In a seizure model where mice received intracerebellar kainic acid injections, Houttuyniae Herba water extract treatment resulted in a lower seizure stage score, ameliorated cognitive impairment, protected neuronal cells against kainic acid-induced toxicity, and suppressed neuronal degeneration in the hippocampus."( Hong, SI; Jeong, HU; Kim, HG; Oh, MS, 2015)
"The results of seizure scoring and histopathological findings in the hippocampus revealed a more pronounced response to the same administered TMT dose in juvenile mice, compared with that in adult mice."( Im, HI; Kang, S; Kim, J; Kim, JC; Kim, SH; Lee, S; Moon, C; Park, K; Shin, T; Son, Y; Takayama, C; Yang, M, 2015)
"Evidence regarding symptomatic seizures from fluoroquinolones only relies on case reports and case series with most reports for ciprofloxacin in patients with renal dysfunction, mental disorders, prior seizures, or coadministered theophylline."( Rüegg, S; Sutter, R; Tschudin-Sutter, S, 2015)
"All of the patients remained seizure-free during levetiracetam treatment."( Chen, CL; Chen, NC; Chuang, YC; Lin, CH; Lin, TK; Tsai, MH, 2015)
"Acute seizures were treated with intranasal midazolam."( Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ, 2016)
"Maternal separation increased the seizure threshold, and administration of anticonvulsant/proconvulsant doses of morphine (1 and 30 mg/kg, respectively) reversed the impact of MS."( Alijanpour, S; Amini-Khoei, H; Amiri, S; Dehpour, AR; Haj-Mirzaian, A; Hassanipour, M; Mehr, SE; Mohammadi-Asl, A; Rahimi-Balaei, M; Shirzadian, A, 2015)
"Sleep architecture and seizures were assessed using continuous video-electroencephalography-electromyography recordings in Kcna1-null mice treated with vehicle or the dual orexin receptor antagonist, almorexant (100 mg/kg, intraperitoneally)."( Johnson, C; Matthews, SA; Roundtree, HM; Samson, KK; Simeone, KA; Simeone, TA, 2016)
"The risk of seizure recurrence with six months treatment compared with 12 to 24 months treatment was not statistically significant (odds ratio (OR) 1."( Mathew, A; Sharma, M; Singh, T, 2015)
"For those presenting with seizures, there is no reliable evidence regarding the duration of treatment required."( Mathew, A; Sharma, M; Singh, T, 2015)
"Using the maximal electroshock seizure (MES) as a model of tonic-clonic generalized seizures, we report that mice treated with TTA-A2 (0."( Chemin, J; Forichon, L; Françon, D; Gangarossa, G; Lerat, B; Lerner-Natoli, M; Lory, P; Sakkaki, S; Valjent, E, 2016)
"In the two animal models of seizures, the pretreatment of the IF (25, 50 and 75 mg/kg) with flumazenil blocked the anticonvulsant effect, suggesting that the mechanism of action of this ester derived of ferulic acid may be related to activity in the benzodiazepine-binding site of the GABAA receptor (γ-aminobutyric acid, type A)."( De Sousa, DP; Freitas, RM; Islam, MT; Junior, AL; Machado, KC; Oliveira, GL, 2015)
"The number of seizure events, severity of seizures, and seizure duration were then compared between the two treatment groups."( Bauquier, SH; Chen, Y; Cook, MJ; Halliday, AJ; Jiang, JL; Lai, A; McLean, KJ; Moulton, S; Sui, Y; Wallace, GG; Yue, Z, 2015)
"For nearly 30% of people with epilepsy, seizures are not controlled by current treatments."( Brigo, F; Igwe, SC; Storti, M, 2015)
"Treatment was judged effective when seizure frequencies fell by ⩾75%."( Abe, S; Igarashi, A; Ikeno, M; Nakahara, E; Nakazawa, M; Okumura, A; Shimizu, T; Takasu, M, 2016)
"We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy."( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2016)
"Efficacy of the KD (defined as 50% seizure reduction) was evaluated after three months of treatment and related to the AEDs used."( Catsman-Berrevoets, CE; Desadien, R; Neuteboom, RF; van der Louw, EJ; van der Sijs, H; Vehmeijer, FO, 2015)
"Patients with seizure and abnormal findings on electroencephalography after initial treatments had lower fractional anisotropy and higher radial diffusivity."( Ando, N; Azuma, Y; Fukasawa, T; Ishihara, N; Ito, Y; Kawai, H; Kidokoro, H; Kubota, T; Naganawa, S; Natsume, J; Ogawa, C; Sakaguchi, Y; Takeuchi, T; Tsuji, T; Yamamoto, H, 2016)
"Recurrent seizures had a significant effect on HRQoL, a subtle effect on cognitive performance, and no effect on psychological symptoms over one year in newly diagnosed or previously untreated adults with partial epilepsy."( Heo, K; Kim, MJ; Kim, OJ; Kim, SO; Lee, BI; Lee, HW; Lee, SA; Shin, DJ; Song, HK, 2015)
"The primary outcome was recurrent convulsions after completion of MgSO4 therapy."( Anjum, S; Garg, N; Goel, N; Mohsin, Z; Sharma, R, 2016)
"To report a case of refractory seizures following congenital portosystemic shunt (CPSS) ligation that regained normal neurologic and hepatic function with novel treatment."( Giordano, P; Heidenreich, DC; Kirby, BM, 2016)
"The proportion of different seizure classes, as well as the number of SRS/day were calculated for the vehicle and treatment period."( Ali, I; Amhaoul, H; Bhattacharya, A; Bielen, K; Ceusters, M; Dedeurwaerdere, S; Kumar-Singh, S; Lord, B; Missault, S; Mola, M; Rech, J; Szewczyk, K; Van Eetveldt, A, 2016)
"Phenytoin is a common medication for seizure treatment and prophylaxis in the intensive care unit (ICU)."( Barletta, JF; Bikin, DS; Buckley, MS; Reeves, BA, 2016)
"The threshold for seizure induction with progressive intravenous infusion of pentylenetrazole (PTZ) was evaluated in anesthetized Wistar rats after a ten-day oral administration of BD-AcAc2 (gavage)."( Arnold, P; Coppola, G; D'Agostino, D; Monda, M; Pilla, R; Viggiano, A; Zeppa, P, 2016)
"Felbamate was approved in 1993 to treat partial seizures with and without secondary generalization in adults and in Lennox-Gastaut Syndrome in children."( Devinsky, O; Friedman, D; Kothare, SV; Shah, YD; Singh, K, 2016)
"Electroconvulsive seizures (ECS), an animal model of electroconvulsive therapy, strongly stimulate hippocampal neurogenesis, but it is not known how this relates to the therapeutic effect or to the unwanted cognitive side effects."( Ekstrand, J; Grahm, M; Höglund, P; Johansson, M; Svensson, M; Tingström, A, 2016)
"LEV3D treatment attenuated seizure activity with significant reductions in NCS incidence (54%), frequency, duration, and delayed latency to seizure onset compared to vehicle treatment."( Caudle, KL; Lu, XC; Mountney, A; Shear, DA; Tortella, FC, 2016)
"Although spontaneous behavioral seizures have been reported previously in this mouse model, the observation of seizures and death consequential to fluoxetine treatment is new."( de Nijs, L; Hoogland, G; Prickaerts, J; Rutten, BP; Sierksma, AS; Steinbusch, HW; van den Hove, DL; van Leeuwen, FW; Vanmierlo, T, 2016)
"Antitumour therapy can contribute to seizure control, and antiepileptic drugs might have beneficial effects on tumours."( Huberfeld, G; Vecht, CJ, 2016)
"Pretreatment with LU suppressed seizure induction, duration, and severity following PTZ injection, reversed cognitive impairment, reduced neuronal and oxidative stress damage, and increased phosphoactivation of PKA and CREB as well as BDNF expression."( Chang, YN; Fu, T; Liu, JQ; Qu, ZZ; Wang, WP; Zhen, JL, 2016)
"Reflex epileptic seizures can often be prevented by avoidance or modification of triggers or by prophylactic benzodiazepine administration."( Guaranha, M; Lin, K; Wolf, P, 2016)
"The maximum seizure burden evaluated 1 h before each phenobarbitone dose (T-1) was compared to seizure burden in periods of increasing duration after each phenobarbitone dose had been administered (T+1, T+2 to seizure offset)."( Boylan, GB; Livingstone, V; Low, E; Mathieson, SR; Rennie, JM; Ryan, AC; Stevenson, NJ, 2016)
"Phenobarbitone significantly reduced seizures within 1 h of administration as assessed with continuous multi-channel EEG monitoring in neonates."( Boylan, GB; Livingstone, V; Low, E; Mathieson, SR; Rennie, JM; Ryan, AC; Stevenson, NJ, 2016)
"However, intermittent seizures were recorded on electroencephalogram from 6 h after diazepam treatment until 24 h, but had disappeared after 15 days."( Ardourel, MY; Calas, AG; Herzine, A; Lauga, F; Menuet, A; Montécot-Dubourg, C; Mortaud, S; Palomo, J; Pâris, A; Perche, A; Perche, O; Pichon, J; Richard, O, 2016)
"The pivotal trials demonstrated that seizure control following conversion from other AEDs was superior for eslicarbazepine acetate monotherapy (1200 or 1600 mg once daily) compared with a pseudo-placebo historical control."( Dhillon, S; Shirley, M, 2016)
"Patients with any type of seizure or epilepsy syndrome were recruited in 16 neurological and neuropediatric centers in Germany if the treating physician decided to administer LCM-iv for any reason."( Bös, M; Bösel, J; Burghaus, L; Dziewas, R; Evers, S; Kellinghaus, C; Kraft, A; Lammers, T; Lang, N; Lange, M; Ruf, S; Sabolek, M; Schmitt, FC; Schubert-Bast, S; Stephani, U; van Baalen, A; Weber, Y, 2016)
"Studies were included if they reported seizure frequency data pertaining to levetiracetam use in patients with brain tumors as either monotherapy or as an add on agent."( Nasr, ZG; Paravattil, B; Wilby, KJ, 2016)
"Effects on seizure threshold and locomotion were studied using C57BL/6N mice and compared with saline-treated controls."( Haider, M; Hering, S; Hintersteiner, J; Khom, S; Luger, D; Mihovilovic, MD; Pototschnig, G; Schwarzer, C, 2016)
"SAHA pretreatment increased seizure latency and decreased seizure scores."( Hu, QP; Mao, DA, 2016)
"The increased frequency of seizures may enable raised awareness of clinicians for potential complications and treatment adjustments perioperatively early at clinical admission."( Eicker, SO; Emami, P; Lamszus, K; Matschke, J; Mohme, M; Regelsberger, J; Westphal, M, 2016)
"Firstly, seizure latency induced by pentylenetetrazole was significantly prolonged 6 weeks after brain injury in group of SR141716A treatment."( Liu, C; Wang, X; Wang, Y; Wei, N; Zhang, C; Zhang, JG; Zhang, K; Zhao, B, 2016)
"After treatment, convulsions were suppressed and daily life continued, but intellectual impairment and high-level dysfunction remained."( Endo, W; Haginoya, K; Kitamura, T; Nishio, T; Numata, Y; Ohura, T; Takayanagi, M; Uchida, T, 2016)
"Chronotherapy tailored to the patients' seizure susceptibility patterns may improve care in epilepsy patients as differential dosing may allow for higher overall treatment doses at times of greatest seizure susceptibility without increased side effects at other times."( Fernández, IS; Jackson, M; Kadish, NE; Klehm, J; Loddenkemper, T; Manganaro, S; Thome-Souza, S, 2016)
"In the present study soman-induced seizures were also substantially prevented when the animals were intravenously treated with tariquidar post-poisoning, in addition to HI-6 and atropine."( Hamelink, J; Joosen, MJA; Klaassen, SD; van den Berg, RM; Vester, SM, 2016)
"After treatment, median seizure frequency reduction was 50% overall, 50% in children, and 33% in adults; 44% in primary generalized, 38% in secondarily generalized, and 33% in partial seizures."( Devinsky, O; Friedman, D; Kothare, SV; Luciano, D; Shah, YD; Singh, K, 2016)
"The effect of 5-HTP administration on seizure-induced mortality evoked by acoustic stimulation or by PTZ was investigated in DBA/1 mice."( Cotten, JF; Feng, HJ; Xue, Q; Yang, X; Zhang, H; Zhao, H, 2016)
"This toxicity, which manifested as seizures, bradycardia, hypotension, nausea, and emesis, was rapidly recognized and appropriately treated, with a good clinical outcome for the patient."( Nicholas, E; Thornton, MD, 2016)
"• For seizures with duration of more than 5 min, the administration of anticonvulsive rescue medication is recommended."( Bernhard, MK; Bertsche, A; Bertsche, T; Frontini, R; Hoppe, SC; Kaune, A; Kiess, W; Merkenschlager, A; Neininger, MP; Schumacher, PM; Syrbe, S, 2016)
"Remission of recurrent, unprovoked seizures can be achieved in two-thirds of cases by treatment with anticonvulsant medication, surgical resection, and/or nerve/brain electrode stimulation."( Beyer, BS; Ferland, RJ; Herron, BJ; Kadiyala, SB; Nalwalk, JW; Papandrea, D; Yannix, JQ, 2016)
"Here, we suggest that triggering limbic seizures with low doses of PTZ in pilocarpine-treated marmosets might provide a more effective basis for the development of AED."( Blanco, MM; Cinini, SM; Lima, TZ; Mello, LE; Pontes, JC; Queiroz, CM, 2016)
"The effect of chronic seizures and ASD administration on cognitive performance in NOPR was also determined with corneal-kindled mice."( Barker-Haliski, ML; Mau, MJ; Underwood, TK; Vanegas, F; White, HS, 2016)
"Understanding the seizure-inducing mechanisms of TBI is of the utmost importance, because these seizures are often resistant to traditional first- and second-line anti-seizure treatments."( Cotrina, ML; Gu, S; He, X; Huang, JH; Liu, W; Nedergaard, M; Shapiro, LA; Wang, EW; Wang, F; Wang, W; Wang, X, 2017)
"Higher ≥50% and ≥75% responder and seizure freedom rates were observed in lacosamide-treated patients vs placebo."( Du, X; Hong, Z; Inoue, Y; Liao, W; Meng, H; Tennigkeit, F; Wang, W; Wang, X; Zhang, L; Zhou, L, 2016)
"an acute anti-seizure effect after IV LCM was especially evident when it was first used - (SC) or second line (established SE) treatment."( Avolio, C; Carapelle, E; d'Orsi, G; Di Claudio, MT; Mancini, D; Martino, T; Pacillo, F; Pascarella, MG; Specchio, LM; Trivisano, M, 2016)
"Improved seizure control was maintained for 4 years in the majority of patients with TSC with medically refractory epilepsy treated with everolimus."( Agricola, K; Capal, J; Franz, DN; Holland-Bouley, K; Krueger, DA; Mays, M; Talley, CM; Tudor, C; Wilfong, AA, 2016)
"Neonatal seizures are a common problem in the neonatal intensive care unit and are frequently treated with antiepileptic drugs."( Ahmad, KA; Ahmad, SF; Bennett, MM; Clark, RH; Desai, SJ; Ng, YT; Tolia, VN, 2017)
"After 12 hours of seizure free period of the initial loading dose of phenobarbitone, one group received IV maintenance therapy and other 'no maintenance' (saline as placebo)."( Gupta, P; Saxena, P; Sharma, S; Singh, A; Upadhyay, A; Vishnubatla, S, 2016)
"Cysticidal therapy leads to better seizure control and increased resolution of lesions on short-term follow-up."( Deo, B; Khandelwal, NK; Malhi, P; Singhi, P; Suthar, R, 2017)
"Side effects and seizure frequency when phenobarbital was administered every 12 hours or 8 hours were compared."( Barnett, CR; De Risio, L; Stabile, F, 2017)
"Treatment-related seizures were associated with leukoencephalopathy and decreased neuropsychological performance."( Ashford, JM; Cheng, C; Conklin, HM; Glass, JO; Jeha, S; Laningham, FH; Nassar, SL; Pui, CH; Reddick, WE; Zhou, Y, 2017)
"In PTZ-induced acute seizures model, behavioral assay showed that chronic metformin treatment decreased the mortality, and LFPs recording showed that chronic metformin treatment shortened the duration of generalized tonic-clonic seizures and prolonged the duration of postictal depression."( Hu, Y; Li, Y; Wang, X; Yang, Y; Zhang, Y; Zheng, F; Zhu, B, 2017)
"Importantly, GR1 demonstrated anti-seizure properties and reduced post-seizure hyperexcitability in neonatal mice, highlighting its drug candidate potential for treating epilepsies and other neurological diseases involving network hyperexcitability."( Coughlin, DJ; Lutz, GJ; Lykens, NM; Reddi, JM; Tallent, MK, 2017)
"Obestatin treatment reduced the average seizure score, decreased the occurrence and duration of generalized tonic-clonic seizures, presenting with a shorter latency to their onset."( Akakın, D; Atal, SS; Kervancıoğlu Demirci, E; Koyuncuoğlu, T; Üren, D; Vızdıklar, C; Yeğen, BÇ; Yıldırım, Ç; Yılmaz, H; Yüksel, M, 2017)
"Understanding how the brain responds to seizures is important for development of new treatment strategies for epilepsy, a neurological condition characterized by recurrent and unprovoked seizures."( Beattie, CE; Berberoglu, MA; Duy, PQ; Hall, CW, 2017)
"Distinctive seizure-like events (SLEs) are induced in the olfactory regions by acute treatment of both tangential brain slices and the isolated guinea pig brain with the potassium channel blocker 4-aminopyridine."( Chikhladze, M; de Curtis, M; Gnatkovsky, V; Milesi, G; Morbin, M; Saccucci, S; Tassi, L; Uva, L, 2017)
"156,539 benzodiazepine-treated seizures were identified."( Meurer, WJ; Shtull-Leber, E; Silbergleit, R, 2017)
"The events leading to seizure generation and epileptogenesis remain largely unknown, hindering development of new treatments."( Binder, DK; Fiacco, TA; Murphy, TR, 2017)
"Motor seizure frequency, quality of life, and adverse events were recorded from the eighth week of the pretreatment period, eight weeks after starting maintenance dose (week 14), and the most recent visit."( Comi, AM; Kaplan, EH; Offermann, EA; Sievers, JW, 2017)
"The presence of subclinical seizures, monotherapy treatment failure, and distribution of seizure burden (including status epilepticus) was similar in preterm and term neonates."( Abend, NS; Bonifacio, SL; Chang, T; Chu, CJ; Cilio, MR; Glass, HC; Massey, SL; Shellhaas, RA; Soul, JS; Tsuchida, TN; Wusthoff, CJ, 2017)
"The present study examined seizure clusters as a primary outcome in patients receiving treatment for PNES."( Baird, GL; Harlow, LL; LaFrance, WC; Machan, JT, 2017)
"CORM-A1, administered before or during seizures, greatly improved the outcome of seizures on cerebrovascular functions in both male and female piglets."( Fedinec, AL; Leffler, CW; Liu, J; Parfenova, H; Pourcyrous, M, 2017)
"Decrease of both the frequency of seizures and the incidence of ADRs after TDM implementation suggests that TDM may have given clinicians the opportunity to achieve more optimal patient treatment."( Brozmanova, H; Grundmann, M; Kacirova, I; Koristkova, B, 2017)
"The search for new treatments for seizures and epilepsy relies upon studies in animal models of epilepsy."( Anbazhagan, A; Chen, M; Reutens, DC; Tieng, QM, 2017)
"Mean seizure stages or generalized seizure durations in the 10 and 20 mg/kg lamotrigine pretreated groups were significantly lower or shorter when received 3 times of pentylenetetrazole after the washout period."( Chen, Y; Fang, Z; He, X; Sun, Q; Zhou, L, 2017)
"Repetitive and continuous seizures that do not respond to benzodiazepines require second line therapy."( Alunday, RL; Bussmann, S; Lee, T; Sarangarm, P; Seifert, SA; Smolinske, SC; Warrick, BJ, 2018)
"Eleven GCSE patients (65%) remained seizure free after LEV therapy."( Alunday, RL; Bussmann, S; Lee, T; Sarangarm, P; Seifert, SA; Smolinske, SC; Warrick, BJ, 2018)
"Patients developing seizures during their ertapenem treatment course were identified as case patients."( Cho, HL; Hsiao, CY; Huang, YJ; Hung, MC; Hung, SC; Lai, LF; Lee, YC; Tong, SH; Wang, JT, 2017)
"The development of ertapenem-associated seizures may occur more frequently and much earlier due to its widespread use in treating drug-resistant pathogens, especially when these pathogens emerged worldwide."( Cho, HL; Hsiao, CY; Huang, YJ; Hung, MC; Hung, SC; Lai, LF; Lee, YC; Tong, SH; Wang, JT, 2017)
"We induced generalized tonic-clonic seizures with the administration of 60 mg/kg pentylenetetrazole (PTZ) in male Wistar Albino rats."( Ateş, N; Dede, F; Eraldemir, FC; Karadenizli, S; Özsoy, ÖD; Şahin, D, 2017)
"Caffeine pretreatment did not change seizure latency and seizure duration."( Ateş, N; Dede, F; Eraldemir, FC; Karadenizli, S; Özsoy, ÖD; Şahin, D, 2017)
"The intensity of seizures in pretreated mice varied significantly according to circadian stage."( Aouam, K; Ben-Attia, M; Boughattas, NA; Dridi, I; Khedhaier, WBC; Reinberg, A, 2017)
"For effective control of seizures, antiepileptic drugs (AEDs) are administered at higher dose which is associated with several adverse effects."( Gupta, YK; Joshi, D; Kaleekal, T; Kumar, R; Sarangi, SC, 2017)
"Treatment for refractory seizures included benzodiazepines and eventual intubation and sedation with propofol."( Ovakim, DH; Powell, JD; Thompson, J, 2018)
"Recurrent and prolonged seizures are harmful for the developing brain, emphasizing the importance of early seizure recognition and effective therapy."( Brilstra, E; Cilio, MR; de Vries, LS; Mendes Ribeiro, J; Striano, P; Vilan, A; Weckhuysen, S; Weeke, LC, 2017)
"Semiology, seizure frequency, and therapy were assessed for all patients."( Bisulli, F; Ferri, L; Gramegna, LL; Licchetta, L; Lodi, R; Naldi, I; Rizzo, G; Testa, C; Tinuper, P; Tonon, C, 2017)
"Tonic seizures with high-voltage discharges over the contralateral cerebral hemisphere and secondary generalization were successfully treated with phenobarbital."( Bohner, G; Bührer, C; Dame, C; Mühlbacher, T, 2018)
"The onset and frequency of the convulsions, as well as fatality, were dependent on the amount of Urografin® administered."( Ezaki, J; Kibayashi, K; Shimada, R, 2017)
"Pretreatment with genistein delayed seizure onset, reduced the seizure duration, improved oxidative stress profile, decreased estrogen receptor expression, reduced apoptosis, and improved the histopathological pattern."( Elsayed, AA; Ibrahim, BMM; Khalifa, AE; Menze, ET; Sabri, NA; Tadros, MG, 2018)
"A 77-year-old man developed a seizure after administration of enzalutamide."( Iwanishi, T; Kobayashi, M; Koida, Y; Komori, K; Ono, Y; Yumiba, S, 2017)
"We assessed the seizure vulnerability and anxiety responses following the chronic co-administration of, and withdrawal from, caffeine and ethanol in male rats."( Alele, PE; Matovu, D, 2018)
"A neonate with prolonged seizures was administered PB."( Graudins, A; Johnstone, LM; Le Page, AK; Roehr, CC; Stewart, AE, 2018)
"In the strychnine-induced seizure test, PSE treatment did not significantly affect the latency to convulsions and time until death when compared to controls."( Abotsi, WKM; Boakye-Gyasi, E; Daanaa, S; Woode, E, 2018)
"The cat remained seizure free with no recurrence of the aforementioned concerns after reinstitution of phenobarbital treatment."( Collinet, A; Sammut, V, 2017)
"Epileptic seizures are refractory to treatment in approximately one-third of patients despite the recent introduction of many newer antiepileptic drugs (AEDs)."( Dash, A; Desudchit, T; Leung, H; Lim, KS; Tiamkao, S; Tsai, JJ; Wu, T, 2018)
"Neonatal seizures are treated with phenobarbital and prolonged treatment does not prevent postneonatal epilepsy."( Beatty, CW; Gust, J; Hamiwka, L; Natarajan, N, 2018)
"She was treated with CsA and developed seizures, progressive loss of consciousness, and visual disturbance on the 7th day of treatment."( Gavrilovici, C; Miron, I; Munteanu, M; Stârcea, M, 2018)
"Despite the development of newer anti-seizure medications over the past 50 years, 30-40% of patients with epilepsy remain refractory to treatment."( de la Hoz, CL; Gavrilovici, C; Ibhazehiebo, K; Kaushik, G; Kim, DY; Kurrasch, DM; Ma, SC; Meza Santoscoy, PL; Nath, N; Rehak, R; Rho, JM; Scott, L, 2018)
"Caffeine can increase seizure susceptibility and protect from seizures, depending on the dose, administration type (chronic or acute), and the developmental stage at which caffeine exposure started."( Bauer, PR; Sander, JW; Schuitema, I; van Koert, RR; Visser, GH, 2018)
"Seven days postseizure, saline-treated animals were found to have reduced left ventricular function, increased fibrotic scarring, and an elevated risk of aconitine-induced arrhythmias."( Harrison, JC; Kerr, DS; McCann, DM; Millen, RN; Read, MI; Sammut, IA, 2018)
"Attenuation of seizure with diazepam offered no cardiac protection; however, coadministration of atenolol with diazepam prevented the development of seizure-induced cardiac dysfunction."( Harrison, JC; Kerr, DS; McCann, DM; Millen, RN; Read, MI; Sammut, IA, 2018)
"Some patients reported less vigorous seizures, shorter duration of seizures, shorter time to recovery, and other positive side effects of CBD treatment."( Neubauer, D; Osredkar, D; Perković Benedik, M, 2018)
"excellent seizure outcome group and not-excellent seizure outcome group after methylprednisolone treatment."( Bian, KG; Gong, P; Liu, XY; Qian, P; Xue, J; Yang, HP; Yang, ZX, 2018)
"Mean seizure frequency was compared between the 3-month baseline period and subsequent 3-month treatment period."( Andres, E; Hamer, H; Kerling, F; Winterholler, M, 2018)
"A total of 174 children with generalized seizures on VPA therapy were enrolled."( Fang, F; Feng, W; Gao, B; Mei, S; Wu, X; Yang, W; Yu, Y; Zhao, Z; Zhu, L, 2018)
"In children with generalized seizures on VPA therapy, polymorphisms of UGT2B7, CYP3A4, and SCN1A genes were associated with seizure reduction."( Fang, F; Feng, W; Gao, B; Mei, S; Wu, X; Yang, W; Yu, Y; Zhao, Z; Zhu, L, 2018)
"Clinical response (number of seizures per week) was evaluated on third and sixth month of the therapy."( Ali, N; Nazish, H; Shakir, S, 2018)
"FR180204 had no significant effect on seizure parameters when administered at the dose of 1 μg/μl in kindled group of animals."( Dehghan, S; Komaki, A; Mardani, P; Mirnajafi-Zadeh, J; Oryan, S; Sarihi, A; Shojaei, A, 2018)
"For nearly 30% of people with epilepsy, seizures are not controlled by current treatments."( Bragazzi, NL; Brigo, F; Igwe, SC, 2018)
"Serotonin syndrome and seizures can be effectively treated by administering benzodiazepines, providing supportive care, and discontinuing tramadol and other contributing agents."( Dale, W; Danovitch, I; Hassamal, S; Miotto, K, 2018)
"To assess seizure activity, we employed 2 in vivo mouse models of epilepsy, intravenous (iv) pentylenetetrazol (PTZ) and hippocampal electrical kindling, in the presence or absence of Sema4D treatment."( Acker, DWM; Kang, M; Paradis, S; Wong, I, 2018)
"midazolam as first-line treatment for seizures."( Dao, K; Diezi, M; Giannoni, E; Lebon, S; Roulet-Perez, E, 2018)
"There were a total of 38 seizures in 33 patients when all treatment pressures were examined."( Sherlock, S; Tabah, A; Way, M, 2018)
"Of the patients, total number of seizures and seizure control rates 6 months before and 3 and 6 months after the add-on treatment were compared."( Acar, T; Aras, YG, 2018)
"TTA-P2 (10 mg/kg) reduced seizure severity in mice undergoing alcohol WD with concurrent PTZ treatment (20 mg/kg)."( Godwin, DW; Masicampo, ML; Shan, HQ; Speagle, M; Xu, V, 2018)
"To predict the probability of a seizure-free (SF) state in patients with epilepsy (PWEs) after treatment with levetiracetam and to identify the clinical and electroencephalographic (EEG) factors that affect outcomes."( Han, JY; Han, X; He, GN; Huang, DL; Wang, N; Zhang, JH; Zhang, Y; Zhao, D; Zhao, HW; Zhao, T; Zhu, XR, 2018)
"Flurothyl-induced seizures (RS group) produced long-term abnormal neurobehavior, which was improved with leptin treatment."( Jin, MF; Li, LL; Li, YC; Ni, H; Zhao, DJ, 2018)
"Organophosphate (OP) induced seizures are commonly treated with anticholinergics, oximes and anticonvulsants."( Cornelissen, AS; Hesseling, P; Joosen, MJA; Klaassen, SD; Lucassen, PJ; Meerhoff, GF; Vester, SM, 2018)
"Responder rate (≥50% seizure frequency reduction) and seizure freedom rate (seizure freedom at least since prior visit) were assessed after 3, 6 and 12 months of ESL treatment and at last visit."( Delanty, N; Holtkamp, M; McMurray, R; Sales, F; Serratosa, J; Villanueva, V, 2019)
"When tested 3-4 days after five stage-5 seizures, 10 mg/kg naloxone-treated rats, as compared to saline-treated rats, showed a statistically significant loss of gating of hippocampal auditory evoked potentials, and significant reduction of startle response amplitude, but non-significant differences in prepulse inhibition and methamphetamine-induced locomotion."( Leung, LS; Ma, J, 2019)
"BACKGROUND Recurrent seizure in patients with magnesium sulfate-treated eclampsia is very rare and requires meticulous management due to poor prognosis."( Achmadi, A; Aldika Akbar, MI; Harsono, AAH; Joewono, HT, 2018)
"Side-effects such as hypersensitivity, convulsion and arrhythmia were also recorded in the patients and infants in group A within 24 h after aminophylline administration."( Chen, T; Ni, X; Wang, W; Yang, CJ; Yu, WY, 2019)
"Patient selection for seizure prophylaxis after traumatic brain injury (TBI) and duration of anti-epileptic drug treatment for patients with early post-traumatic seizures (PTS), remain plagued with uncertainty."( Anwar, F; Belli, A; Bulters, D; Chari, A; Coles, J; Duncan, JS; Ercole, A; Ham, T; Hutchinson, PJ; Kolias, AG; Lecky, F; Manford, M; Marson, AG; McMahon, C; Mee, H; Tudur-Smith, C; Turner, C; Uff, C; Wilson, MH, 2019)
"These data suggest that convulsive seizures can be obtained in FPI-treated rats when NSS is used as an inclusion criterion to select rats with severe injury."( Kelly, W; MacWilliams, Z; Patterson, D; Poulsen, A; Poulsen, D; Rau, T; Smith, D, 2018)
"After identification of seizures, infants were treated with PHB or LEV at the discretion of treating physicians."( Chanlaw, T; Cho, A; Garg, M; Hussain, SA; Rao, LM; Sankar, R; Zaki, T, 2018)
"Our lab has demonstrated that TBI or seizure-induced oxidative injury and neuronal death were reduced by apocynin treatment."( Choi, BY; Choi, HC; Hong, DK; Jeong, JH; Kang, BS; Kang, DH; Kho, AR; Lee, SH; Song, HK; Suh, SW, 2018)
"An increased frequency of seizures was observed in three cases after the second year of treatment."( Canpolat, M; Coskun, A; Gumus, H; Kumandas, S; Per, H, 2018)
"He had a history of neonatal seizures, had been stabilized with vigabatrin, and was seizure free without treatment for several months."( Amad, A; Corfiotti, C; Ferrafiat, V; Jardri, R; Leroy, A; Medjkane, F; Nguyen The Tich, S, 2018)
"The results showed reduction in the seizure score, percentage of kindled rats and neurological damage score in DMF treated rats."( Banerjee, D; Bhatia, A; Chakrabarti, A; Kumari, P; Saha, L; Singh, J; Singh, N, 2019)
"The 6-Hz psychomotor seizure induced ultra-structural changes in both cortex and hippocampus in mice treated with PCPA."( Jahan, K; Pillai, KK; Vohora, D, 2019)
"Eighty-nine children with focal seizures on VPA therapy were enrolled."( Fang, F; Feng, W; Gao, B; Han, J; Li, J; Mei, S; Wu, Y; Yu, Y; Zhao, Z; Zhu, L, 2019)
"We evaluated the acute antiseizure effect of CBD in the maximal electroshock seizure, 6-Hz psychomotor seizure, and pentylenetetrazol acute seizure tests, as well as the corneal kindling model of chronic seizures in mice following intraperitoneal administration."( Barker-Haliski, M; Bazelot, M; Glyn, S; Jones, N; McNeish, AJ; Patra, PH; Sandhu, H; Whalley, BJ; White, HS; Williams, CM, 2019)
"CBD was effective in a battery of acute seizure models in both mice and rats following intraperitoneal administration."( Barker-Haliski, M; Bazelot, M; Glyn, S; Jones, N; McNeish, AJ; Patra, PH; Sandhu, H; Whalley, BJ; White, HS; Williams, CM, 2019)
"Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary."( Bergner, C; Hörnschemeyer, J; Kirschstein, T; Köhling, R; Krause, BJ; Lange, F; Linnebacher, M; Mullins, CS; Porath, K; Weßlau, K, 2019)
"The treatment of choice for CAE with absence seizures only is ethosuximide."( Kessler, SK; McGinnis, E, 2019)
"The EEG-recorded seizure activity was also evaluated in two treatment protocols."( Atanasova, D; Galchev, T; Kortenska, L; Lazarov, N; Marinov, P; Shishmanova-Doseva, M; Tchekalarova, J, 2019)
"Treatment of seizures in the neonatal patient is urgent and time sensitive."( Anderson, J; Arboleda, N; Calleo, V, 2018)
"After an episode of clonic seizures on day 11, phenobarbitone was administered intravenously at a loading dose of 20 mg/kg followed by maintenance doses of 6 mg/kg per day in 2 divided doses for 5 days."( Dudeja, S; Dutta, S; Krishnamurthy, B; Pattanaik, S, 2019)
"Epilepsy is marked by seizures that are a manifestation of excessive brain activity and is symptomatically treatable by anti-epileptic drugs (AEDs)."( Choo, BKM; Johan Arief, MFB; Kumari, Y; Kundap, UP; Othman, I; Shaikh, MF; Wong, CP; Yap, JL, 2019)
"DFP triggered rapid and sustained seizure behavior irrespective of PB pretreatment, and there was no significant difference in average seizure behavior score during the first 4 h following injection between DFP animals pretreated with PB or not."( Bruun, DA; Guignet, M; Harvey, DJ; Lein, PJ, 2019)
"He had seizures since the newborn period and he had been treated with phenobarbital but there was no favorable response to therapy."( Alan, B; Ceylaner, S; Kasapkara, CS; Kurt, ANÇ; Nergız, ME; Özlü, SG; Yılmaz, S, 2019)
"In this study, mice in which epileptic seizures were induced by administering picrotoxin (PTX) were used as a case group, and mice injected with saline were employed as the control group."( He, Z; Li, D; Li, P; Li, Y; Liang, L; Luo, X; Ma, J; Qin, L; Sun, Y; Zhou, X, 2019)
"Five patients who had seizures after administration of normal saline were administered 10 mg/kg of PB, and no patients had a seizure thereafter."( Nakagawa, T; Takami, Y, 2019)
"Thereafter, PTZ seizure threshold was measured in control and treated rats, and different brain regions were analyzed for levels of oxidative stress biomarkers."( Al Yacoub, ON; Alomari, MA; Alrabadi, NN; Alzoubi, KH; Banihani, SA; Hasan, ZA; Khabour, OF; Mayyas, FA, 2019)
"against strychnine induced convulsions model, at 1, 7, 15 and 30th day of treatment."( Fatima, A; Maqbool, S; Sadaf, R; Younus, I, 2019)
"Rats with KA-induced seizures showed longer average escape latency and decreases in the number of platform crossings and average time spent in the target quadrant in the Morris water maze; ISL pretreatment reversed this decline in cognitive impairment and increased the protein levels of synaptophysin, postsynaptic density-95 and brain-derived neurotrophic factor while reducing the number of Fluoro Jade B-positive cells, microglia, and astrocytes; cleaved-Caspase-3 and -9 protein levels; and tumor necrosis factor-α, interleukin (IL)-1β, and IL-18 production."( Chen, O; Huang, S; Liu, J; Wang, Y; Xue, J; Zhu, W; Zhu, X, 2019)
"Furthermore, KN-93 is able to attenuate seizure behaviors by preventing its effects on neuron loss, so, it is valuable for the treatment of epileptic seizures."( Ebrahimi, F; Khamse, S; Mohammadian Haftcheshmeh, S; Mohseni-Moghaddam, P; Navid Hamidi, M; Roghani, M; Sadr, SS; Zamani, E, 2019)
"Unlike the seizure induced by PTZ, or pilocarpine, induction of seizure by PTZ + pilocarpine was resistant to phenytoin and sodium valproate treatment."( Jand, A; Mousavi-Hasanzadeh, M; Palizvan, MR; Rezaeian-Varmaziar, H; Shafaat, O, 2019)
"Neonatal seizures are different from adult seizures, and many antiepileptic drugs that are effective in adults often fail to treat neonates."( Bai, Y; Chen, G; Dong, F; Feng, M; Huo, Q; Li, ST; Long, C; Lüscher, B; Ren, L; Wang, GL; Wang, Y; Wu, G; Wu, Z, 2019)
"Rapid control of seizure activity is important to minimize neuronal injury and the resulting neurological and behavioral disorders; however, early treatment will not be possible after mass release of OPs or NAs."( Bealer, SL; Dudek, FE; Pouliot, W; Roach, B; Spampanato, J, 2019)
"MDZ-induced seizure suppression was equivalent in magnitude regardless of treatment delay (ie, seizure duration)."( Bealer, SL; Dudek, FE; Pouliot, W; Roach, B; Spampanato, J, 2019)
"The patient has remained seizure-free for 23 months and demonstrated an excellent response to pulsed dye laser treatment."( López-Gutiérrez, JC; Sánchez-Carpintero, I; Triana Junco, PE, 2019)
"We found reduced seizure worries over time among people with epilepsy allocated to either generic switch or continued treatment with brand LEV."( Källén, K; Olsson, P; Reimers, A, 2019)
"Patients with focal seizures taking ESL monotherapy had excellent retention, high seizure-free rates, and good tolerability up to 2 years."( Alvarez, BM; Baiges, JJ; Bermejo, P; Bertol, V; Bonet, M; Castro-Vilanova, MD; Esteve, P; Galiano, ML; Garcés, M; Giner, P; Hampel, K; López-González, FJ; Massot-Tarrús, A; Mauri, JÁ; Montoya, J; Ojeda, J; Poza, JJ; Quiroga-Subirana, P; Rodríguez-Osorio, X; Rodriguez-Uranga, JJ; Ruiz-Giménez, J; Toledo, M; Tortosa-Conesa, D; Villanueva, V, 2019)
"KA-induced seizure score and elevations of glutamate release in rat hippocampi were inhibited by pretreatment with dexmedetomidine."( Chiu, KM; Lee, MY; Lin, TY; Lu, CW; Wang, MJ; Wang, SJ, 2019)
"A higher incidence of convulsions and loss of the righting reflex, and decreased rates of survival, as well as elevated CYP2E1 activity, were observed in diabetic rats treated with AN when compared to those in non-diabetic rats, suggesting that diabetes confers susceptibility to the acute toxicity of AN."( Dong, Y; Jiang, Y; Li, F; Lu, R; Wang, S; Xing, G; Yang, B, 2021)
"Thirty term neonates with seizures were randomized to receive PB or LEV; the Hammersmith Neonatal Neurological Examination (HNNE) was used at baseline (T0) and again one month after the initial treatment (T1)."( Barbagallo, M; Corsello, G; Falsaperla, R; Mauceri, L; Pavone, P; Pisani, F; Ruggieri, M; Vitaliti, G, 2019)
"The intractable seizures showed complete but transient responsiveness to pyridoxal phosphate and finally controlled by valproate treatment."( Chu, VL; Fung, CW; Kwong, AK; Rodenburg, RJT; Smeitink, J, 2019)
"On day 15 of injury, seizures were induced by administration of a GABAA receptor antagonist, pentylenetetrazole (PTZ, 30 mg/kg)."( Ghadiri, T; Hajali, V; Khodagholi, F; Vakilzadeh, G, 2019)
"The effect of treatments on seizure severity was recorded using Racine scale."( Adeyemi, OO; Afolayan, OO; Ajayi, AM; Ben-Azu, B; Ishola, IO; James, AB; Ojo, ES; Umukoro, S, 2019)
"To evaluate safety- and seizure-related outcomes with repeated intermittent use of a novel formulation of midazolam administered as a single-dose nasal spray (MDZ-NS) in the outpatient treatment of patients experiencing seizure clusters (SCs)."( Detyniecki, K; Meng, TC; Pullman, WE; Sequeira, DJ; Van Ess, PJ; Wheless, JW, 2019)
"The association between seizure outcomes and treatment over time demonstrated lack of linearity and heterogeneity, requiring the inclusion of time-treatment interaction terms for valid modeling."( Carpio, A; Chang, M; Hauser, WA; Jaramillo, A; Kelvin, EA; Romo, ML; Zhang, H, 2019)
"RSE was defined as seizure continuing after the first- and second-line treatments."( Choi, JY; Hong, JM; Huh, K; Kim, BG; Kim, TJ, 2019)
"Early recognition and treatment of seizures is essential for optimal patient outcomes."( Abramson, TM; Kearl, YL; Loza-Gomez, A; Rose, E, 2019)
"Due to refractory tonic seizures with a frequency of 1 to 4 per day, we initiated cannabidiol (CBD) treatment, raising it to a daily dose of 200 mg."( Bast, T; Stiller, B; Wiemer-Kruel, A, 2019)
"LEV monotherapy stopped seizures in only a small portion of cases."( Courchia, B; Del-Moral, T; Kurtom, W; Pensirikul, A; Sosenko, I, 2019)
"Furthermore, PTZ evoked seizure severity was considerably decreased, while latency to clonic-like seizure was increased in adult zebrafish group treated with 100 nM of LY294002."( Kumari, S; Mazumder, AG; Singh, D, 2019)
"When spontaneous seizures were recorded by continuous (24/7) video-EEG recording starting 6 weeks after termination of treatment, no effects on incidence or frequency of seizures were observed."( Anjum, M; Brandt, C; Gericke, B; Hillmann, P; Kaczmarek, E; Löscher, W; Schidlitzki, A; Theilmann, W; Twele, F; Welzel, L, 2020)
"Lidocaine is used to treat neonatal seizures refractory to other anticonvulsants."( de Haan, TR; Egberts, TCG; Favié, LMA; Groenendaal, F; Huitema, ADR; Nuytemans, DHGM; Rademaker, CMA; Rijken, M; Simons, SHP; van den Broek, MPH; van Straaten, HLM, 2020)
"Though atonic seizures were observed during the treatment, it disappeared after isoniazid discontinuation and pyridoxal phosphate administration."( Hatoya, S; Hirai, K; Kanegi, R; Nabetani, T; Sugiura, K; Tanaka, T; Wada, Y; Yasugi, M, 2019)
"Thus, CXCR7 may regulate epileptic seizures and represents a novel target for antiepileptic treatments."( Chen, Y; Deng, J; Liu, X; Liu, Y; Ou, S; Tan, C; Wang, T; Xu, T; Yang, J; Yu, X; Yuan, J, 2019)
"In adults with focal seizures, adjunctive BRV treatment does not affect plasma concentrations of the evaluated AEDs but increases carbamazepine epoxide metabolite."( Moseley, BD; Otoul, C; Staelens, L; Stockis, A, 2019)
"Overall, a uniquely different seizure response profile was detected in the C57BL/6J strain with few observable instances of seizure response despite repeated convulsant administration by two mechanisms."( Adhikari, A; Copping, NA; Petkova, SP; Silverman, JL, 2019)
"Epileptic seizures are frequent in patients with glioma, and anticonvulsive treatment is often indicated."( Kirschstein, T; Köhling, R; Krause, BJ; Lange, F; Mayer, J; Porath, K; Resch, T, 2020)
"Audiogenic seizure-prone mice can be protected from seizure-associated death by exposure to an oxygen atmosphere or treatment with selective serotonergic reuptake inhibitors (SSRIs)."( Banerjee, A; Gurevich, R; Kollmar, R; Mooney, S; Silverman, JB; Stewart, M; Sundaram, K; Tromblee, J, 2020)
"Controlling seizures is essential during GBM treatment because they are often present and closely associated with the quality of life of GBM patients."( Chang, MJ; Min, KL; Ryu, JY, 2019)
"We examined 122 voluntary reports of seizures (n = 114) and neurological symptoms (syncope, n = 7; and tremor, n = 1) in 123 ENDS users (one report contained information on two users) received by the Food and Drug Administration between December 1, 2010, and June 30, 2019."( Faulcon, LM; Limpert, J; Murphy, I; Rudy, S; Wang, B, 2020)
"Incidence of olanzapine-induced seizures (OIS) is low with monotherapy."( Chachar, AS; Mansoor, M; Mesiya, MH, 2019)
"Mean reduction in weekly seizure frequency was greater at the best point of seizure control within the first year than at two months of treatment with CBD, regardless of concomitant CLB usage (all p > 0."( Anagnos, CJ; Bruno, PL; Savage, TE; Skirvin, LA; Sourbron, J; Thiele, EA; Wolper, ES, 2020)
"We found no significant differences in seizure frequency, duration, severity, or administered KA doses before SE between the groups."( Bayat, A; Jones, A; Joshi, S; Koubeissi, MZ; Xiao, X, 2020)
"For focal MRE, seizures originate in the epileptogenic zone (EZ), which is the minimum amount of cortex that must be treated to be seizure free."( Bulacio, J; Costacurta, J; Fitzgerald, Z; Hu, K; Li, A; Martinez-Gonzalez, J; Palepu, A; Sarma, SV, 2019)
"Neonatal seizures are difficult to diagnose and, when they are, tradition dictates first line treatment is phenobarbital."( Alix, JJP; Gossling, L; Hart, AR; Stavroulakis, T, 2020)
"EPO pretreatment decreased seizure severity and prolonged seizure latency."( Akgün-Dar, K; Kaptan, Z; Kapucu, A; Üzüm, G, 2020)
"Eliminating or reducing seizures is a main goal of epilepsy treatment, and clinicians rely mainly on patient self-report regarding seizure frequency."( Chen, H; Koubeissi, M, 2020)
"VGB was administered for 3 and 7 days."( Czuczwar, SJ; Krzyżanowski, M; Świąder, K; Świąder, MJ; Wróbel, A; Zakrocka, I; Łuszczki, JJ, 2020)
"NMDA-induced seizures consisted of wild running-like behavior (WRLB), flexion seizures (FSs), clonic seizures (CSs), GTCSs, and tonic seizures (TSs); these seizures were observed in both control-treated and PAE-treated, male and female, P7 and P15 rats."( Cho, SJ; Khandai, P; Li, T; Lovinger, DM; Luta, G; N'Gouemo, P; Newton, J, 2020)
"We examined whether post-seizure anti-inflammatory treatment with dexamethasone after early-life seizures could decrease future seizure susceptibility and ameliorate heightened microglia activation and cell injury in response to later-life seizures."( Fox, P; Koh, S; Mithal, DS; Sanchez, RM; Somogyi, JR; Vien, AC, 2020)
"Other patients benefit from seizure control by drug therapy at the expense of dose-related toxicity and side effects."( Alam, O; Nazar, S; Siddiqui, N, 2020)
"Cessation of seizure occurred in 61% of the intramuscular and 46% of the buccal treatment groups, (P = 0."( Al Jawala, SA; Alansari, K; Barkat, M; Mohamed, AH; Othman, SA, 2020)
"Secondary outcomes included seizure freedom and rescue medication use within 12 h of trial medication administration."( Greve, B; Moseley, BD; Sadek, A; Szaflarski, JP; Varner, JA; Williams, P, 2020)
"Eleven of 45 patients had a seizure within 12 h of trial medication administration (LZP 5/15 [median time to next seizure: 5."( Greve, B; Moseley, BD; Sadek, A; Szaflarski, JP; Varner, JA; Williams, P, 2020)
"Appropriate treatment of neonatal seizures with an effective therapy is important in reducing long-term neurologic disabilities."( Akisu, M; Aktan, G; Altun Köroğlu, Ö; Dokurel Cetin, İ; Gokben, S; Kanmaz, S; Kultursay, N; Serin, HM; Simsek, E; Tekgul, H; Terek, D; Yalaz, M; Yilmaz, S, 2021)
"The overall incidence of seizure during methylphenidate treatment was 4·4 per 10 000 patient-years."( Besag, FMC; Coghill, D; Cross, JH; Ip, P; Lau, WCY; Man, KKC; Wong, ICK, 2020)
"The incidence of seizures was higher in the period immediately after the start of methylphenidate treatment than in the non-exposed period."( Besag, FMC; Coghill, D; Cross, JH; Ip, P; Lau, WCY; Man, KKC; Wong, ICK, 2020)
"For nearly 30% of people with epilepsy, seizures are not controlled by current treatments."( Bragazzi, NL; Brigo, F; Igwe, SC, 2020)
"Despite appropriate antiseizure drug (ASD) treatment, around two-thirds of dogs with idiopathic epilepsy (IE) have seizures long-term and 20-30per cent of affected dogs remain poorly controlled."( Añor, S; Conboy, L; de la Fuente, C; Ferreira, A; Gandini, G; Jean-Philippe, C; Luchsinger, E; Menchetti, M; Molina, J; Montoliu, P; Ribeiro, JC; Spycher, A; Varejão, A; Volk, HA; Wenger-Riggenbach, B; Wrzosek, MA; Zanghi, B, 2020)
"Exposure, seizure outcomes, and treatment-emergent adverse events (TEAEs) were analyzed."( Inoue, Y; Kaneko, S; Krauss, GL; Laurenza, A; Malhotra, M; Patten, A; Rektor, I; Wechsler, RT; Williams, B, 2020)
"In the chronic model of seizure, 30 min after the treatment with gamma-decanolactone, mice received pentylenetetrazole once every third day."( Fontenla, JA; Gonçalves, DA; Krebs, C; Luft, JG; Pereira, P; Pflüger, P; Regner, GG, 2020)
"The few in-ED seizures occurred before medication administration."( Barbic, D; Chiu, I; Duley, S; Grafstein, E; Grunau, B; Innes, G; Kestler, A; Lane, DJ; Miles, I; Moe, J; Nolan, S; Scheuermeyer, FX; Slaunwhite, A; Sljivic, I; Ti, L; Yan, A, 2020)
"The diagnosis was delayed, coma and convulsions were severe manifestations continuous renal replacement therapy (CRRT) was effective in the treatment of severe cases, and all 6 cases were cured."( Chen, W; Chen, ZJ; Fan, XK; Xiang, TX; Yang, LL; Zhong, BT, 2020)
"A dose-dependent biphasic seizure modulation of morphine was demonstrated in the acute treatment with morphine; acute treatment at a dose of 0."( Aghaei, I; Bahremand, T; Dehpour, AR; Ejtemaei-Mehr, S; Rahimi, N; Shafaroodi, H; Shayan, M; Zamanian, G, 2020)
"Automatic seizure detection technology not only reduces workloads of neurologists for epilepsy diagnosis but also is of great significance for treatments of epileptic patients."( Hu, X; Leng, Y; Xu, F; Yuan, K; Yuan, Q; Yuan, S, 2020)
"All dogs experienced seizure activity in the initial 24 h following extubation and were treated with various anticonvulsant protocols; no patients experienced documented seizures after 48 h of discontinuation from MV."( Cortellini, S; Donaldson, RE; Humm, K, 2020)
"The relationships between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life (HRQoL) may be important for determining the overall impact of medication therapy on patients with epilepsy."( Anastassopoulos, KP; Colman, S; Cramer, JA; Grinnell, T; Mehta, D; Williams, GR, 2020)
"Inaccurate subjective seizure counting poses treatment and diagnostic challenges and thus suboptimal quality in epilepsy management."( Baud, M; Cook, M; Duun-Henriksen, J; Friedman, D; Heasman, JM; Kjaer, TW; Kouvas, G; Peltola, J; Richardson, MP; Zibrandtsen, IC, 2020)
"Phenytoin was administered, and seizures disappeared."( Hanaoka, R; Taniguchi, Y, 2021)
"Eliciting a generalized seizure is essential to electroconvulsive therapy (ECT), but there is still a need to understand how patient and session variables interact to generate a seizure of adequate quality."( Chiavaro da Fonseca, R; Magalhães, PVS; Martini, M; Patusco, LM; Tedeschi, EA; Zahler, S, 2021)
"This study examined childhood seizure treatment in a rural area in Japan."( Ando, H; Kido, S; Kidokoro, H; Natsume, J; Shiraki, A; Takahashi, Y; Yasui, M, 2021)
"We considered etiology, seizure duration, and treatment according to the specialties of the doctors providing initial care."( Ando, H; Kido, S; Kidokoro, H; Natsume, J; Shiraki, A; Takahashi, Y; Yasui, M, 2021)
"We extracted 236 seizure events: 40 initially treated by pediatricians, 16 by a mobile doctor team, and 180 by other doctors."( Ando, H; Kido, S; Kidokoro, H; Natsume, J; Shiraki, A; Takahashi, Y; Yasui, M, 2021)
"In rural Japan, many children with seizures are initially treated by doctors other than pediatricians or emergency physicians, and they require a longer time to achieve seizure cessation."( Ando, H; Kido, S; Kidokoro, H; Natsume, J; Shiraki, A; Takahashi, Y; Yasui, M, 2021)
"On a follow-up visit, six months later, seizure control and tolerance to the chosen treatment were recorded."( Baraldés-Rovira, M; Gallego, Y; Mauri-Capdevila, G; Purroy, F; Quílez, A; Sanahuja, J, 2020)
"Because theophylline-associated seizures are a major concern, we suggest an evaluation of low-dose theophylline for treating patients with severe pallid breath-holding spells without febrile convulsions or epilepsy before proceeding with permanent pacemaker insertion."( Asakai, H; Oda, Y; Sato, A, 2021)
"The distinction between acute convulsive seizure and status epilepticus can be misconstrued resulting in BZD administration prior to a patient meeting criteria of status epilepticus."( Gopal, M; Greene-Chandos, D; Hamed, M; Hussein, O; Kamdar, HA; Peters, E; Sawalha, K; Shanmugam, K; Smetana, KS; Thakur, G; Yasin, R, 2020)
"25 patients had TXA-related seizures postoperatively and were started on anticonvulsant therapy, giving an incidence of 2."( Barrow, L; Jenkins, D; Ng, CY; Tan, Z; Valchanov, K, 2020)
"Time of follow-up, seizure frequency during early treatment, compliance, annual cost for epilepsy treatment and annual income were related to the seizure outcome."( Chen, D; Deng, Y; He, J; He, YJ; Liu, L; Zhou, D; Zhu, LN, 2020)
"In addition to these epileptiform seizure-like events, DFP-exposed larvae showed increased neuronal apoptosis, which were both partially alleviated by diazepam treatment, suggesting a causal link between neuronal hyperexcitation and cell death."( Bar, O; Brenet, A; Dal-Bo, G; Dupuis, N; Hassan-Abdi, R; Igert, A; Nachon, F; Romain, C; Saurat, D; Somkhit, J; Soussi-Yanicostas, N; Taudon, N; Yanicostas, C, 2020)
"The time to the first clinical seizure was significantly longer with preventive than conventional treatment [RCT: 364 days (95% confidence interval [CI] = 223-535) vs 124 days (95% CI = 33-149); OLT: 426 days (95% CI = 258-628) vs 106 days (95% CI = 11-149)]."( Aronica, E; Benova, B; Borkowska, J; Curatolo, P; de Ridder, J; Domańska-Pakieła, D; Feucht, M; Głowacka-Walas, J; Hertzberg, C; Hulshof, H; Jansen, AC; Jansen, F; Jóźwiak, S; Kotulska, K; Krsek, P; Kwiatkowski, DJ; Lagae, L; Moavero, R; Nabbout, R; Riney, K; Sadowski, K; Scholl, T; Sijko, K; Weschke, B; Wojdan, K, 2021)
"These children had failed to achieve seizure freedom with available treatment options and were ineligible to participate in randomized controlled trials that only included patients with Lennox-Gastaut and Dravet syndromes."( Diamond, MP; Flamini, JR; Linder, DF; Long, SA; Moretz, K; Park, YD; Pope, J, 2020)
"Cannabidiol safety, changes in seizure type, frequency, and seizure-free days were evaluated for children aged 1-18 years (at time of consent) as an adjunctive treatment for 36 months."( Diamond, MP; Flamini, JR; Linder, DF; Long, SA; Moretz, K; Park, YD; Pope, J, 2020)
"Decreases in major seizure frequency and an increase in seizure-free days compared with baseline were reported during treatment."( Diamond, MP; Flamini, JR; Linder, DF; Long, SA; Moretz, K; Park, YD; Pope, J, 2020)
"Total seizure burden varied widely, with much higher seizure burden in treatment versus control groups (median = 3."( Bergin, AM; Dong, M; Fortuno, CR; Hayes, B; Jensen, FE; Krishnamoorthy, K; O'Reilly, D; Rofeberg, V; Singh, A; Soul, JS; Staley, KJ; Stopp, C; Vinks, AA; Wypij, D, 2021)
"The antiseizure drugs commonly used as first- and second-line treatments for neonatal seizures display poor efficacy."( Culjat, M; Forcelli, PA; Huizenga, MN, 2021)
"All untreated rat pups had seizures within 10 minutes after termination of asphyxia."( Ala-Kurikka, T; Gailus, B; Hampel, P; Johne, M; Kaila, K; Löscher, W; Römermann, K; Theilmann, W, 2021)
"Herein, we investigated the anti-seizure effect by administering KD and a lactic acid bacteria (LAB) in murine model of chemically induced seizures."( Eor, JY; Kim, SH; Kwak, MJ; Son, YJ; Tan, PL, 2021)
"PB therapy for the management of seizures in newborns and children might be associated with poisoning."( Balali-Mood, M; Darchini-Maragheh, E; Ghorani-Azam, A; Riahi-Zanjani, B; Sadeghi, M, 2021)
"Electrographic seizure prevalence was 14% (95% confidence interval, 10%-19%; 39/278) in the entire cohort and 13% (95% confidence interval, 7%-21%) in the subgroup of patients meeting the primary outcome of the Established Status Epilepticus Treatment Trial (clinical treatment success within 60 minutes of randomization)."( Bleck, TP; Chamberlain, JM; Elm, JJ; Kapur, J; Rosenthal, ES; Shinnar, S; Silbergleit, R; Underwood, E; Zehtabchi, S, 2022)
"Electrographic seizures may occur in patients who stop seizing clinically after treatment of convulsive status epilepticus."( Bleck, TP; Chamberlain, JM; Elm, JJ; Kapur, J; Rosenthal, ES; Shinnar, S; Silbergleit, R; Underwood, E; Zehtabchi, S, 2022)
"We also examined the degree of seizure severity and the modulation of pro-inflammatory cytokines in the treated animals."( Bremm Padilha, R; de Lima Rosa, G; Dias de Oliveira Amaral, V; Muliterno Domingues, A; Muller Guzzo, E; Simon Coitinho, A, 2021)
"The mean seizure-free time after the sulthiame treatment was 27."( Aydın, K; Kılıç, B; Tekin, HG; Topçu, Y; Turanlı, G, 2021)
"In the penicillin-induced seizure model, 1, 5, or 10 mg/kg vortioxetine administration significantly decreased mean spike frequency."( Aygun, H; Ayyildiz, M, 2021)
"Patients had focal-onset seizures despite treatment with one to three ASMs and were 18 years of age and older."( Coe, P; Elizebath, R; Gutierrez, EG; Krauss, GL; Yang, J; Zhang, E, 2021)
"When administered repeatedly, seizures were suppressed during the entire day."( Baekelandt, V; Boon, P; Carrette, E; Delbeke, J; Desloovere, J; Goossens, MG; Larsen, LE; Meurs, A; Raedt, R; Sprengers, M; Van den Haute, C; Vanhove, C; Verstraete, AG; Vonck, K; Wadman, W, 2021)
"Such capability can greatly increase seizure freedom rate in surgically treated drug resistant epilepsy cases."( Battaglia, DI; Bianchi, F; Chieffo, DPR; Fuggetta, F; Quintiliani, M; Ramaglia, A; Tamburrini, G, 2021)
"Rescue therapy for seizure clusters has focused on the use of benzodiazepines."( Carrazana, E; Cloyd, J; Haut, S; Rabinowicz, AL, 2021)
"In particular, tonic seizures (in a subset of 23 children) were reduced (24-hour tonic seizure count pre-treatment was 8 [4-13] and 3 [1-5] post-treatment EEG#1, p=0."( Gofshteyn, JS; Gourley, D; Grinspan, Z; J, JL; K, KG; Marquis, BO; Nangia, S, 2021)
"Adults with uncontrolled focal seizures despite treatment with 1-3 antiepileptic drugs/antiseizure medications (AEDs/ASMs) were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg once daily."( Ferrari, L; Nisman, A; Rosenfeld, WE, 2021)
"Steroid treatment may improve seizure outcomes, but the mechanism remains unknown."( Jackson, MR; Lee, K; Loring, KE; Mattiske, T; Noebels, JL; Shoubridge, C; Zysk, A, 2021)
"In male Wistar rats, seizures were induced with a single administration of pilocarpine (60 mg/kg; i."( El-Sahar, AE; El-Sayed, SS; El-Yamany, MF; Salem, HA, 2021)
"Patients achieving seizure-freedom during the treatment period were 14."( Wang, C; Wang, J; Zhang, L, 2021)
"Presentation of first seizure, diagnostic workup, treatment, and impact should be considered individually based on continuously updated knowledge of treating physicians."( Carrizosa-Moog, J; Jiménez-Villegas, MJ; Lozano-García, L, 2021)
"Minor and major seizures were induced after each MP administration."( Frías-Soria, CL; Orozco-Suárez, S; Pérez-Pérez, D; Rocha, L, 2021)
"The patients were grouped by seizure subgroups, antiepileptic treatment used, electroencephalography characteristics, and seizure treatment response."( Baklan, B; Mermi Dibek, D; Öztura, İ, 2022)
"Busulfan is associated with tonic-clonic seizures in ~10% of patients if administered without seizure prophylaxis."( Garrity, L; Hughes, K; Lane, A; Nelson, AS; Teusink-Cross, A, 2021)
"His blood pressure and seizures were successfully treated during hospital admission, with complete resolution of his neurological deficits."( Anne, M; Muralidharan, R; White, JD, 2021)
"The antiseizure drug, carbamazepine (CBZ), and the antiabsence drug, ethosuximide (ETX), were administered separately to determine if they selectively suppressed unilateral- versus bilateral-onset SWDs, respectively."( Barth, DS; Dudek, FE; Poulsen, DJ; Smith, ZZ; Tatum, S; Taylor, JA, 2021)
"Fenfluramine (FFA), an antiseizure medication (ASM) indicated for treating convulsive seizures in Dravet syndrome, was assessed in six patients (five female; 83%) with CDD whose seizures had failed 5-12 ASMs or therapies."( Conway, E; Devinsky, O; King, L; Price, D; Schwartz, D, 2021)
"For the double-blind studies, baseline seizure frequency, number of baseline AEDs, baseline seizure type, baseline concomitant enzyme-inducing AEDs (EIAEDs), baseline carbamazepine, lamotrigine, or valproic acid, age at diagnosis, time since diagnosis, etiology, and perampanel plasma concentration were included individually with study treatment."( Ben-Menachem, E; Krauss, GL; Laurenza, A; Malhotra, M; Patten, A; Wechsler, RT; Williams, B, 2021)
"Patients treated 3397 seizure episodes (moderate frequency, 14."( Biton, V; Carrazana, E; Cascino, GD; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Mauney, W; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021)
"We analyzed the effect of CBD on seizure frequencies and concomitant antiepileptic drug (AED) use at 1 year after starting treatment and the most recent study visit."( Bruno, PL; Fleming, B; Grinspoon, R; Patel, S; Skirvin, LA; Thiele, EA; Wade, C; Wolper, E, 2021)
"After re-administration of LCM, the seizures and epileptic discharges clearly disappeared."( Maruyama, H; Morino, H; Neshige, S; Ohshita, T; Shishido, T; Ueno, H; Yamada, H, 2021)
"Future trials on neonatal antiseizure medication therapy should include continuous electroencephalogram (EEG) monitoring as standard of care and enrol a homogenous population with similar seizure aetiology."( Bhulani, A; Hooper, RG; Ramaswamy, VV; Satodia, P; Wahid, RM, 2021)
"Data were pooled from patients with focal seizures on 1-2 concomitant antiseizure medications (ASMs) randomized to BRV 50, 100, 200 mg/day, or placebo in 3 phase 3 trials (N01252 [NCT00490035], N01253 [NCT00464269], and N01358 [NCT01261325]) with a 12-week treatment period."( Elmoufti, S; Heo, K; Hur, B; Kim, SE; Laloyaux, C; Lee, SA; Lee, SK, 2021)
"Oxygen toxicity seizures (OTS) are a well-recognised complication of hyperbaric oxygen treatment (HBOT)."( Banham, N; Bonnington, S; Foley, K; Gawthrope, I, 2021)
"The rate of oxygen toxicity seizures in a monoplace chamber is not significantly higher than for treatment in the multiplace chamber."( Banham, N; Bonnington, S; Foley, K; Gawthrope, I, 2021)
"Furthermore, Nestorone treatment caused seizure exacerbation in the WT epileptic animals, but not in the PRKO epileptic animals."( Batabyal, T; Joshi, S; Kapur, J; Labuz, A; Shiono, S; Sun, H; Williamson, J, 2021)
"Benzodiazepines are the mainstay of seizure rescue medication; for decades, rectally administered diazepam was the only approved rescue medication for seizure clusters outside the hospital setting."( Bougher, G; Brooks, L; Dean, P; O'Hara, K; Santilli, N; Shinnar, R, 2021)
"Better seizure control was found in children both in the whole cohort (without seizure 49% vs 37% adults), as well as in monotherapy (56% vs 44%), in children with PL 5-20 mg/L vs <5 mg/L (65% vs 44%) and in children with PL 5-10 mg/L vs <2 mg/L (63 vs 14%)."( Brozmanova, H; Grundmann, M; Kacirova, I; Koristkova, B, 2022)
"The potential antiseizure effects of fenfluramine were first identified in patients with photosensitive epilepsy in the 1980s but it was not rigorously explored as a treatment option until 30 years later."( Simmons, R; Sullivan, J, 2021)
"Sustained reductions in drop and total seizure frequency were observed for up to 156 weeks, demonstrating long-term benefits of CBD treatment for patients with LGS."( Checketts, D; Chin, RF; Devinsky, O; Dunayevich, E; Gil-Nagel, A; Gunning, B; Halford, JJ; Mazurkiewicz-Bełdzińska, M; Mitchell, W; Patel, AD; Scott Perry, M; Thiele, EA; Weinstock, A, 2021)
"Neither seizure nor mortality was observed in co-administration of probiotics with DZP."( Kangi, S; Najimi, S; Rahimi, HR; Sabouri, S, 2021)
"We treated frontal lobe onset seizures with a D2R agonist sumanirole, and it suppressed seizures."( Brodovskaya, A; Kapur, J, 2021)
"The anti-seizure and anti-depressive effects of 21 days of LCM administration were studied in this model."( Agarwal, S; Nirwan, N; Vohora, D; Vyas, P, 2021)
"In the acute PTZ convulsion test, treatment with rapamycin showed a significant increase in seizure latency and decreased seizure severity without any change in seizure incidence."( Rana, AK; Sharma, A; Sharma, S; Singh, D, 2022)
"Real-time continuous tracking of seizure state is necessary to develop feedback neuromodulation therapy that can prevent or terminate a seizure early."( Ahmadi, MB; Azgomi, HF; Contreras-Vidal, JL; Craik, A; Faghih, RT; Francis, JT; Parekh, S; Pati, S; Steele, AG, 2021)
"Treatment with finasteride increased seizure susceptibility and depression due to decreased progesterone and elevated estrogen levels coupled with decreased monoamine and elevated corticosterone levels."( Goel, RK; Pahwa, P; Singh, T, 2022)
"Patients with uncontrolled focal seizures taking stable doses of one to three ASMs were administered increasing doses of cenobamate (12."( Abou-Khalil, B; Aboumatar, S; Bhatia, P; Biton, V; Klein, P; Krauss, GL; Rosenfeld, WE; Sperling, MR; Vossler, DG; Wechsler, R, 2021)
"Patients with uncontrolled focal seizures taking stable doses of 1-3 antiseizure medications (ASMs) were administered increasing daily doses of cenobamate (12."( Abou-Khalil, B; Aboumatar, S; Bhatia, P; Biton, V; Ferrari, L; Grall, M; Klein, P; Krauss, GL; Rosenfeld, WE; Sperling, MR; Vossler, DG; Wechsler, R, 2021)
"The primary endpoint was seizure-freedom rate during Maintenance Period in the modified Intent-to-Treat (mITT) Analysis Set (patients who had ≥1 post-dose efficacy measurement during Maintenance Period); safety was monitored."( Hiramatsu, H; Husni, RE; Ngo, LY; Patten, A; Senokuchi, H; Watanabe, K; Yamamoto, T, 2022)
"Initial seizures observed in young rats during the 60 min after administration of pilocarpine (Pilo) were delayed and attenuated by pretreatment with a non-convulsive dose of methionine sulfoximine (MSO)."( Albrecht, J; Aldana, BI; Belfiori-Carrasco, LF; Czarnecka, AM; Obara-Michlewska, M; Pawlik, MJ; Popek, MP, 2021)
"Phenobarbital was the most common seizure treatment, but seizures were often refractory to initial antiseizure medication."( Abend, NS; Bonifacio, S; Chang, T; Chu, C; Cilio, MR; Glass, HC; Lemmon, ME; Massey, SL; McCulloch, CE; Shellhaas, RA; Soul, JS; Thomas, C; Wusthoff, CJ; Xiao, R, 2022)
"Regarding time to seizure cessation after midazolam (n = 326) or BDZ (n = 322) administration, there is no significant difference between the two groups {(mean difference = -0."( Chhabra, R; Gupta, LK; Gupta, R, 2021)
"In case of insufficient seizure control, subsequent treatment phases with other target serum levels followed."( Kadish, NE; Lehmann, I; May, TW; Stephani, U; Wiegand, G, 2021)
"Many individuals continue to have seizures despite medical and surgical treatments, suggesting new antiepileptic/anticonvulsant drugs are required."( Liu, D; Wang, Y, 2022)
"In the search for new antiseizure drugs (ASDs) to treat epilepsy, it is yet unclear which types of coumarins are particularly interesting as a systematic analysis has not been reported."( Budzyńska, B; Copmans, D; de Witte, PAM; Jóźwiak, K; Kozioł, E; Skalicka-Woźniak, K, 2021)
"In about 30% of patients, the seizures are resistant to current treatments; so more effective treatments are urgently needed."( Bankstahl, J; Bankstahl, M; Bloms-Funke, P; Kneip, C; Löscher, W; Schröder, W, 2022)
"The primary endpoint was a lower focal seizure frequency during the maintenance therapy period."( Akiyama, T; Fujita, A; Inoue, Y; Kada, A; Kakita, A; Kato, M; Miyake, N; Nakagawa, E; Saito, AM; Shiraishi, H; Takahashi, Y; Tohyama, J, 2022)
"The focal seizure frequency reduced by 25% in all patients during the maintenance therapy period and by a median value of 17%, 28%, and 23% during the 1-4-, 5-8-, and 9-12-week periods."( Akiyama, T; Fujita, A; Inoue, Y; Kada, A; Kakita, A; Kato, M; Miyake, N; Nakagawa, E; Saito, AM; Shiraishi, H; Takahashi, Y; Tohyama, J, 2022)
"Their demographic findings, seizure aetiology, pre-treatment and post-treatment electroencephalography findings, treatment responses and any side effects of the drugs given were assessed in these patients."( Aslan, M; Gungor, S, 2022)
"Rate of epileptic seizures after initiation of amantadine treatment was numerically higher in the amantadine group (amantadine: 10."( Balk, S; Gerner, ST; Giede-Jeppe, A; Huttner, HB; Jäger, J; Kallmünzer, B; Kuramatsu, JB; Madzar, D; Mueller, T; Rühl, L; Schwab, S; Sembill, JA; Sprügel, MI, 2022)
"Overall, median time to seizure cessation from drug administration varied from 2 to 15 min."( Aucott, L; Booth, C; Brazzelli, M; Counsell, C; Cruickshank, M; Imamura, M; Manson, P; Scotland, G, 2022)
"The proportion of seizure clusters treated with a second dose over time was consistently low across 24 h: 0-4 h, 152 (3."( Carrazana, E; Cascino, GD; Dlugos, D; Hogan, RE; Liow, K; Rabinowicz, AL; Sperling, MR; Wheless, JW, 2022)
"In addition, seizures were treatable in all patients with PS with a small dose of midazolam (0."( Ishiguro, A; Kawakami, S; Kubota, M; Nagata, C; Terashima, H, 2022)
"PS was characterized by 1) convulsive seizures shorter than 15 min, 2) seizures treatable with small doses of midazolam, and 3) autonomic symptoms."( Ishiguro, A; Kawakami, S; Kubota, M; Nagata, C; Terashima, H, 2022)
"The treatment of seizure disorders with currently available pharmacotherapeutic agents is not optimal due to the failure of some patients to respond, coupled with occurrences of side effects."( Al-Tannak, NF; Hemdan, A; Kamal, HJ; Phillips, OA, 2022)
"Regarding seizure control, it might be suggested that patients with epilepsy treated with PGB should avoid taking CAF."( Chwedorowicz, R; Czuczwar, SJ; Raszewski, G; Łukawski, K, 2022)
"This antiseizure action was recapitulated when JW-65 was administered after pilocarpine-induced behavioral seizures were well established and was confirmed by time-locked electroencephalographic monitoring and synchronized video."( Boda, VK; Hou, R; Jiang, J; Li, L; Li, W; Nagib, MM; Wu, Z; Yasmen, N; Yu, Y; Zhang, S, 2022)
"STP effects on absence seizures were quantified by electroencephalographic recording in two animal models: rats treated with a low dose of pentylenetetrazol (20 mg/kg ip) and rats from the WAG/Rij strain."( Heulard, I; Reversat, L; Riban, V; Si Hocine, H; Verleye, M, 2022)
"To evaluate the effect on seizure frequency of add-on telmisartan treatment in dogs with refractory idiopathic epilepsy."( Chai, O; Friedman, A; Gibeon, L; Hanael, E; Konstanitin, L; Rapaport, K; Ruggeri, M; Shamir, MH, 2022)
"Telmisartan has the potential to reduce seizure frequency when administered as an add-on antiepileptic drug in dogs with refractory idiopathic epilepsy."( Chai, O; Friedman, A; Gibeon, L; Hanael, E; Konstanitin, L; Rapaport, K; Ruggeri, M; Shamir, MH, 2022)
"We evaluated the seizure occurrences during 0-3, 4-6, and 7-12 months from the treatment initiation and the last 6 months of the follow-up."( Enoki, H; Fujii, Y; Fujimoto, A; Motoi, H; Okanishi, T; Sakuma, S; Shiraishi, H; Yazaki, K, 2022)
"Of the patients, 39%, 67% and 72% were seizure-free during 0-3, 4-6, and 7-12 months from treatment initiation, respectively."( Enoki, H; Fujii, Y; Fujimoto, A; Motoi, H; Okanishi, T; Sakuma, S; Shiraishi, H; Yazaki, K, 2022)
"More than thirty antiseizure medications (ASMs) are available for treating epilepsy."( Elmer, S; Reddy, DS, 2022)
"The primary outcome was change in convulsive seizure frequency from the pre-treatment baseline to the stable optimal dose phase."( Anderson, C; Devinsky, O; Friedman, D; Hamlin, T; Marmanillo, A; Ryan, D; Todd, G; Wilken, P, 2022)
"Brivaracetam (BRV) is an anti-seizure drug for the treatment of focal and generalized epileptic seizures shown to augment short-term synaptic fatigue by slowing down synaptic vesicle recycling rates in control animals."( Han, X; Sun, Z; Xing, H; Xu, S; Yang, S, 2022)
"Secondary outcomes were: seizure freedom, treatment withdrawal for any reason, treatment withdrawal due to adverse events, the proportion of participants who experienced any adverse events, and drug interactions."( Bresnahan, R; Marson, AG; Panebianco, M, 2022)
"The coil method detected 19-21 Hz seizure activity after PTZ administration."( Chang, WJ; Lu, HC; Shyu, BC; Wei Huang, AC, 2022)
"We measured seizure reduction, median reduction in seizure frequency, median dose, responder rate, and treatment-emergent adverse events."( Karkare, S; Kothare, SV; Shah, YD; Varughese, RT, 2022)
"The use of resveratrol in treating seizures has been reported in recent studies."( Aggarwal, NB; Akhter, J; Arora, I; Asad, M; Hoda, U; Rastogi, S; Samim, M; Siddiqui, MA, 2022)
"We optimized a locomotor-based seizure assay in zebrafish with pentylenetetrazol (PTZ) as the pharmacological proconvulsant to generate a therapeutic window in which proconvulsant-treated zebrafish larvae could be discriminated from a non-treated control."( Luyten, W; Panda, SK; Shaw, PAG; Stanca, A, 2022)
"PB treatment significantly reduced seizures."( Akin, AT; Aygun, H; Karabulut, D; Kızılaslan, N; Sumbul, O, 2023)
"Clinical data, frequency of seizure types and treatments were collected from caregivers and medical records in 42 children."( Bjurulf, B; Hallböök, T; Kolbjer, S; Reilly, C; Sigurdsson, GV; Thunström, S, 2022)
"We review common toxins that cause seizure, their mechanisms, associated toxidromes, and treatments."( Phillips, HN; Tormoehlen, L, 2022)
"≥50% reduction in drop seizure frequency from baseline and occurrence of treatment-emergent adverse events (TEAEs) were the primary efficacy and safety outcomes."( Ameen, R; Bansal, D; Devi, N; Madaan, P; Sahu, JK, 2022)
"Efficacy was assessed by comparing seizure frequency before and after initiating STM therapy."( Bautista, C; Cachia, P; Caraballo, RH; Espeche, A; Fortini, S; Galicchio, S; Gallo, A; Gamboni, B; Reyes Valenzuela, G; Semprino, M, 2022)
"An inadequate seizure occasionally occurs during a course of acute electroconvulsive therapy (ECT) under the maximum approved electrical stimulation in Japan of 504 mC."( Gon, J; Iwamoto, T; Kurata, A; Shimizu, H; Wada, K, 2022)
"We induced seizure using intravenous administration of PTZ."( Amini-Khoei, H; Boroujeni, SN; Lorigooini, Z; Rahimi-Madiseh, M; Taji, M, 2022)
"Cenobamate is an antiseizure medication (ASM) approved in Europe as adjunctive therapy for adults with inadequately controlled focal seizures."( Ben-Menachem, E; Brandt, C; García Morales, I; Rosenfeld, WE; Santamarina, E; Serratosa, JM; Steinhoff, BJ, 2022)
"The primary outcome was the absence of seizures and improvement in the level of consciousness 1 hour after study drug administration."( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022)
"AEDs were administered 30 min before seizure induction once intragastrically at conditionally effective (ED50) and sub-effective (½ ED50) doses: sodium valproate and topiramate - at doses of 300 and 150 mg/kg; levetiracetam - at doses of 100 and 50 mg/kg."( Mishchenko, M; Shtrygol, D; Shtrygol, S; Tsyvunin, V, 2022)
"Intrathecal administration of antiseizure drugs (ASDs) e."( Buschhoff, AS; de Mooij-van Malsen, JG; Scherließ, R; Schiffelholz, T; Stephani, U; Wulff, P, 2022)
"The effect of ASDs on seizures measured by the Racine scale is less pronounced in both investigated AD models and suggests that seizures of young AD mice are more difficult to treat."( Aourz, N; Barker-Haliski, M; Bjerke, M; De Bundel, D; Engelborghs, S; Nagels, G; Smolders, I; Vande Vyver, M, 2022)
"PER was associated with reduction in myoclonic seizure frequency in patients with myoclonic seizures treated in everyday clinical practice."( Alsaadi, T; Carreño, M; D'Souza, W; Di Bonaventura, C; McMurray, R; Mohanraj, R; Montoya, J; Shastri, O; Villanueva, V; Yamamoto, T, 2022)
"The impact of seizure clusters and the use of intermittent rescue therapy for clusters on the quality of life (QoL) of patients with epilepsy has not been widely studied."( Carrazana, E; Cramer, JA; Davis, C; Faught, E; Misra, SN; Rabinowicz, AL, 2022)
"In this case, the patient had an epileptic seizure while on enzalutamide treatment."( Demir, O; Demirag, G, 2023)
"AED prophylaxis in seizure-naïve BTRE patients is not recommended, but AED treatment should be initiated after a first seizure has occurred."( Koekkoek, JAF; Taphoorn, MJB; van der Meer, PB, 2022)
"The most commonly reported seizure-related benefits (> 50 % of participants) of FFA treatment included a reduction in seizure activity, fewer seizure triggers, and shorter post-ictal recovery."( Amtmann, D; Galer, BS; Gammaitoni, AR; Jensen, MP; Salem, R; Wilkie, D, 2022)
"Despite introduction of several antiseizure medications over the past two decades, treatment options for childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE) remain limited."( Bast, T; Cleveland, JM; Elshoff, JP; Floricel, F; Morita, D; Schulz, AL, 2022)
"Use of EEG capture in addition to seizure diaries offers a robust mechanism of detecting seizure activity and measuring treatment effect."( Bast, T; Cleveland, JM; Elshoff, JP; Floricel, F; Morita, D; Schulz, AL, 2022)
"The acute seizure in childhood is a medical emergency which is usually managed by benzodiazepines used as a first line of therapy."( Ghosh, T; Roy, UK; Rudra, N, 2021)
"We evaluated long-term seizure control, for VPA, LEV, LTG mono and combination therapy."( Castro, LHM; Pipek, HZ; Pipek, LZ, 2022)
"Evidence for treating seizures in AS mainly derives from low-quality studies."( Samanta, D, 2022)
"There is still no consensus on seizure therapy, owing to poor scientific evidence."( Bedetti, L; Berardi, A; Casa Muttini, ED; Cavalleri, F; Ferrari, F; Guidotti, I; Lugli, L; Ori, L; Pugliese, M; Roversi, MF; Stefanelli, F, 2022)
"Therapy for neonatal seizures should be prompt and tailored, based on semeiology, mirror of the underlying cause, and cEEG features."( Bedetti, L; Berardi, A; Casa Muttini, ED; Cavalleri, F; Ferrari, F; Guidotti, I; Lugli, L; Ori, L; Pugliese, M; Roversi, MF; Stefanelli, F, 2022)
"Up to 30% of people with epilepsy have seizures that are resistant to currently available antiepileptic drugs and require treatment with multiple antiepileptic drugs in combination."( Bresnahan, R; Dong, J; Geng, J; Martin-McGill, KJ; Ni, H; Shi, LL, 2022)
"These seizures result from cyclic changes in circulating progesterone and estradiol levels and there is no effective treatment for this form of intractable epilepsy."( Dhillon, HK; Goel, RK; Singh, T, 2022)
"Inadequate control of seizures by VPA monotherapy and post-operative status epilepticus are closely related to a significant excitatory rebound after VPA injection (rebound electrodes≧5/64, p = 0."( Chen, L; Cui, Z; Guo, Y; Jiang, S; Ke, Z; Liu, Y; Mao, Y; Tong, Y; Wang, D; Wu, Z; Zhang, H; Zhu, Z; Zou, X, 2022)
"Progression of seizure severity and duration were compared between treatment groups and wildtype mice (WT)."( Chan, J; Jones, NC; Kwan, P; Shen, Y; Silva, JC, 2022)
"Beyond effectiveness for aborting seizure clusters, no data exist on how intermittent rescue therapy may impact the long-term natural course of seizure clusters."( Carrazana, E; Davis, C; Misra, SN; Peters, JM; Rabinowicz, AL; Rao, VR; Sperling, MR, 2022)
"Increased time between seizure clusters may reflect a previously unrecognized beneficial effect of intermittent rescue therapy."( Carrazana, E; Davis, C; Misra, SN; Peters, JM; Rabinowicz, AL; Rao, VR; Sperling, MR, 2022)
"These electrographic seizures and the ensuing hyperoxic episodes are associated with deficits in working memory and motor coordination that were reversible through attenuation of the posttraumatic and postictal (postseizure) hyperoxia, via administration of a vasoconstricting agent, the calcium channel agonist Bay K8644."( Malik, H; Mychasiuk, R; Teskey, GC; Wolff, MD, 2022)
"The primary goal of treatment for seizure clusters is cessation of the cluster to avoid progression to more severe conditions, such as prolonged seizures and status epilepticus."( Detyniecki, K; Gidal, B, 2022)
"Only 67-78% of PWE received anti-seizure medication (ASM) treatment in the community-based studies, mostly monotherapy with phenobarbital, phenytoin or carbamazepine."( Amos, A; Escheu, G; Harrison, W; Hauke, P; Kaducu, J; Keller, L; Matuja, W; Ngowi, BJ; Ovuga, E; Pfausler, B; Richter, V; Schmidt, V; Schmutzhard, E; Stelzle, D; Welte, TM; Winkler, AS, 2022)
"PWE suffer from high seizure rates and subsequent injuries, as well as from socio-economic consequences due to insufficient ASM treatment."( Amos, A; Escheu, G; Harrison, W; Hauke, P; Kaducu, J; Keller, L; Matuja, W; Ngowi, BJ; Ovuga, E; Pfausler, B; Richter, V; Schmidt, V; Schmutzhard, E; Stelzle, D; Welte, TM; Winkler, AS, 2022)
"PGES following generalized seizures induced by electroconvulsive therapy (ECT) has been previously linked to antidepressant response."( Avidan, MS; Brian Hickman, L; Ching, S; Farber, NB; Guay, CS; Hogan, RE; Huels, ER; Kafashan, M; Kelz, MB; Labonte, AK; Mashour, GA; Maybrier, H; Palanca, BJA; Subramanian, S, 2022)
"The total seizure duration in the asphyxia+ganaxolone group was less than the untreated asphyxia group."( Allison, BJ; Bennet, L; Boyd, BJ; Castillo-Melendez, M; Fahey, MC; Hirst, JJ; Hunt, RW; Jenkin, G; Malhotra, A; McDonald, C; Mihelakis, J; Miller, SL; Nitsos, I; Pham, Y; Sutherland, AE; Walker, DW; Wong, F; Yawno, T, 2022)
"Ganaxolone provided better seizure control than phenobarbital in this perinatal asphyxia model and was neuroprotective for the newborn brain, affording a new therapeutic opportunity for treatment of neonatal seizures."( Allison, BJ; Bennet, L; Boyd, BJ; Castillo-Melendez, M; Fahey, MC; Hirst, JJ; Hunt, RW; Jenkin, G; Malhotra, A; McDonald, C; Mihelakis, J; Miller, SL; Nitsos, I; Pham, Y; Sutherland, AE; Walker, DW; Wong, F; Yawno, T, 2022)
"Patients with uncontrolled focal seizures taking stable doses of 1-3 antiseizure medications were administered increasing doses of cenobamate (12."( Aboumatar, S; Biton, V; Ferrari, L; Rosenfeld, WE; Wechsler, R, 2022)
"Quercetin pretreatment alleviates seizure-like behaviors and cognitive impairment in KA-induced epileptic mice."( Bentley, R; Hu, G; Jiang, X; Lowe, S; Mei, H; Sun, C; Wu, Y; Xie, R; Zhao, W, 2022)
"The maximal seizure stage (SS), stage 2 and 4 latency (S2L, S4L), stage 4 and 5 duration (S4D, S5D), and seizure duration (SD) were all assessed 20 min after PTZ administration by observation."( Giahi, M; Hosseinmardi, N; Janahmadi, M; Tavassoli, Z, 2022)
"About 7/18 (39%) of patients showed seizure-free with pyridoxine (PN) or pyridoxal-5'-phosphate treatment."( Gong, P; Jiao, X; Niu, Y; Xu, Z; Yang, Z; Zhang, Y, 2023)
"Exposure, retention, seizure outcomes, and treatment-emergent adverse events (TEAEs) were analyzed."( Malhotra, M; Patten, A; Piña-Garza, JE; Rosenfeld, W; Villanueva, V; Yoshinaga, H, 2022)
"The median number of seizures per month before CBD treatment was 11, and after CBD treatment was 2."( Navarro, CE, 2023)
"The incidence of seizure after craniotomy for tumor resection is low regardless of duration of therapy."( Cibula, J; Eisenschenk, S; Ghiaseddin, A; Heaton, S; Hodik, M; McGrew, N; Melnick, K; Murad, G; Rahman, M; Roper, S; Smith, J; Wang, Y, 2023)
"Perampanel a third-generation antiseizure medication, belongs to a new promising class of drugs called AMPA receptor antagonists, approved to treat focal-onset seizures with or without focal to bilateral tonic clonic seizures and primary generalized tonic-clonic seizures."( Abou-Setta, AM; Aboulatta, L; Aloud, B; Askin, N; Eltonsy, S; Lavu, A; Rabbani, R; Shouman, W; Zarychanski, R, 2022)
"The key outcomes were reduction in seizure frequency, differences in 50% responder rates, adverse events, and interactions with clobazam as co-therapy."( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023)
"Novel and effective antiseizure medications are needed to treat refractory and rare forms of epilepsy."( Reddy, DS, 2023)
"The primary outcome was assigned as the seizure cessation rate within 30 min of the administration of the study drug."( Asami, M; Egawa, S; Fukuda, Y; Hoshiyama, E; Inoue, Y; Ishikawa, E; Kaneko, J; Kimura, A; Kondo, Y; Maruo, K; Marushima, A; Matsumaru, Y; Mochizuki, M; Nakamoto, H; Nakamura, K; Takahashi, Y; Uchida, M; Unemoto, K; Yamada, T; Yonekawa, C, 2023)
"Differentiating epileptic seizures from other causes of Transient Loss of Consciousness (TLOC) remains a challenge in the Emergency Department (ED), where it may lead to erroneous administration of anti-epileptic drugs."( Martinez, S; Patel, J; Pourmand, A; Tran, QK; Wright, H, 2022)
"Electroencephalography, seizure diary, patient caregivers' global impression, serum inflammatory markers and neuropsychological evaluation were performed at baseline and after each treatment phase."( Ayash, TA; Berrahmoune, S; Corriveau, I; Dassi, C; Myers, KA; Osterman, B; Poulin, C; Schiller, K; Sébire, G; Shevell, MI; Simard-Tremblay, E, 2023)
"Treatment of seizure clusters endeavors to prevent additional seizures and avoid progression to conditions such as prolonged seizures and status epilepticus."( Gidal, BE; Kotloski, RJ, 2022)
"Only rats that presented tonic-clonic seizures during the first 1-5 min after PTZ treatment were included in the study."( González-Burgos, I; Guevara, MÁ; Hernández-González, M; Romero-Guerrero, C, 2022)
"A total of 1108 seizures were recorded in 130 subjects, of which 110 (65 seizures in 23 subjects in IN group; 45 seizures in 18 subjects in IM group) seizures required midazolam administration and were included in final analysis."( Appukuttan, R; Mehta, S; Ramanujan, B; Shaikh, RG; Singh, RK; Tripathi, M; Vibha, D, 2022)
"Primary outcome was antiseizure medication (ASM) treatment failure for any reason, and secondary outcomes were treatment failure due to uncontrolled seizures and due to adverse effects."( Dirven, L; Koekkoek, JAF; Maschio, M; Taphoorn, MJB; van der Meer, PB, 2023)
"Treatment failure due to uncontrolled seizures did not differ significantly between EIASMs and LEV (aHR = 1."( Dirven, L; Koekkoek, JAF; Maschio, M; Taphoorn, MJB; van der Meer, PB, 2023)
"Primary outcome was antiseizure medication (ASM) treatment failure for any reason, and secondary outcomes were treatment failure due to uncontrolled seizures and due to adverse effects."( Dirven, L; Koekkoek, JAF; Maschio, M; Taphoorn, MJB; van der Meer, PB, 2023)
"Treatment failure due to uncontrolled seizures did not differ significantly between EIASMs and LEV (aHR = 1."( Dirven, L; Koekkoek, JAF; Maschio, M; Taphoorn, MJB; van der Meer, PB, 2023)
"Primary outcome was antiseizure medication (ASM) treatment failure for any reason, and secondary outcomes were treatment failure due to uncontrolled seizures and due to adverse effects."( Dirven, L; Koekkoek, JAF; Maschio, M; Taphoorn, MJB; van der Meer, PB, 2023)
"Treatment failure due to uncontrolled seizures did not differ significantly between EIASMs and LEV (aHR = 1."( Dirven, L; Koekkoek, JAF; Maschio, M; Taphoorn, MJB; van der Meer, PB, 2023)
"It was shown that the latency of generalized seizures increased after administration of both lamotrigine and LY341495."( Bashkatova, VG; Bogdanova, NG; Nazarova, GA; Sudakov, SK, 2022)
"It was shown that the latency of generalized seizures increased after administration of both lamotrigine and LY341495."( Bashkatova, VG; Bogdanova, NG; Nazarova, GA; Sudakov, SK, 2022)
"It was shown that the latency of generalized seizures increased after administration of both lamotrigine and LY341495."( Bashkatova, VG; Bogdanova, NG; Nazarova, GA; Sudakov, SK, 2022)
"Efficacy variables were derived from seizure-related changes, and tolerability and safety variables from reported treatment-emergent adverse events (TEAEs), BRV withdrawal, and changes to questionnaire scores."( Cavill, R; Manuel, M; Naddell, S; Sieradzan, K; White, P, 2023)
"Efficacy variables were derived from seizure-related changes, and tolerability and safety variables from reported treatment-emergent adverse events (TEAEs), BRV withdrawal, and changes to questionnaire scores."( Cavill, R; Manuel, M; Naddell, S; Sieradzan, K; White, P, 2023)
"Recurrence of seizures was observed 30 min after ILE, and the seizures disappeared after re-administration of ILE."( Imai, T; Iwabuchi, S; Kinoshita, K; Matsuoka, M, 2023)
"Recurrence of seizures was observed 30 min after ILE, and the seizures disappeared after re-administration of ILE."( Imai, T; Iwabuchi, S; Kinoshita, K; Matsuoka, M, 2023)
"Among neonates with seizures, differences across treatment groups in median maximal hourly seizure burden were assessed using adjusted quantile regression models."( Ahmad, KA; Bonifacio, SL; Comstock, BA; Glass, HC; Gonzalez, FF; Heagerty, PJ; Juul, SE; Maitre, N; Massey, SL; Mayock, DE; Mietzsch, U; Natarajan, N; Numis, AL; Sokol, GM; Thomas, C; Van Meurs, KP; Wu, YW; Wusthoff, CJ, 2023)
"Among neonates with seizures, differences across treatment groups in median maximal hourly seizure burden were assessed using adjusted quantile regression models."( Ahmad, KA; Bonifacio, SL; Comstock, BA; Glass, HC; Gonzalez, FF; Heagerty, PJ; Juul, SE; Maitre, N; Massey, SL; Mayock, DE; Mietzsch, U; Natarajan, N; Numis, AL; Sokol, GM; Thomas, C; Van Meurs, KP; Wu, YW; Wusthoff, CJ, 2023)
"Treatment-emergent AEs included seizures (33%), headache (37%), and focal neurologic symptoms (28%)."( Abedi, M; Aiken, RD; Bota, DA; Bota, PG; Carrillo, JA; Dillman, RO; Duma, CM; Hsieh, C; Hsu, FPK; Keirstead, HS; Kesari, S; Kong, XT; LaRocca, RV; Nistor, GI; Piccioni, DE; Taylor, TH, 2022)
"Treatment-emergent AEs included seizures (33%), headache (37%), and focal neurologic symptoms (28%)."( Abedi, M; Aiken, RD; Bota, DA; Bota, PG; Carrillo, JA; Dillman, RO; Duma, CM; Hsieh, C; Hsu, FPK; Keirstead, HS; Kesari, S; Kong, XT; LaRocca, RV; Nistor, GI; Piccioni, DE; Taylor, TH, 2022)
"Since arrhythmia often accompanies seizures, patients suffering from epilepsy are frequently co-treated with antiepileptic and antiarrhythmic drugs."( Banach, M; Borowicz-Reutt, K, 2022)
"The role of stiripentol (STP) in seizure treatment in this population is not well understood."( Aungaroon, G; Franz, DN; Horn, PS; Mehta, A, 2023)
"Early onset of PTZ-induced seizure-like behavioural scores, the heightened intensity of seizure and reduced latency in different scores were found in PG and CPFX-administered groups."( Ramachandran, B; Sivarajan, D, 2023)
"The time to reach individual baseline seizure count was longer in patients with focal seizures receiving ESL as a first (Arm 1) versus later (Arm 2) adjunctive therapy (p = 0."( Aboumatar, S; Cantu, D; Grinnell, T; Krishnaiengar, SR; Zhang, Y, 2023)
"Cenobamate is an antiseizure medication (ASM) approved for the treatment of partial-onset seizures in adults."( Bien, CG; Brandt, C; Elakkary, S; Hagemann, A; Klimpel, D, 2023)
"In order to induce seizures, PTZ was administered intravenously."( Amini-Khoei, H; Korani, MS; Lorigooini, Z; Rahimi-Madiseh, M; Tahmasebi Dehkordi, H; Tavakoli, Z, 2023)
"During the motor seizure associated with electroconvulsive therapy (ECT), the muscles of the trunk and limbs contract forcefully and repetitively, predisposing to injuries to muscles, joints, teeth, and bones."( Andrade, C, 2023)
"In this study, we investigated the antiseizure effects of 5 and 10 mg/kg doses of tacrolimus treatment priorly to pentylenetetrazol (PTZ) induction of seizures in rats."( Egilmez, CB; Erbas, O; Erdogan, MA; Pazarlar, BA, 2023)
"2-deoxy-D-glucose has acute antiseizure actions in multiple in vivo and in vitro seizure models, including models of SE induced by the chemo convulsants pilocarpine and kainic acid, suggesting that focal enhanced delivery of 2DG to ictal brain circuits is a potential novel anticonvulsant intervention for the treatment of SE."( Fountain, NB; Sutula, TP, 2023)
"We aimed to explore the possible antiseizure effects of APN pretreatment and underlying molecular mechanisms in a rat model of TLE induced by KA."( Ahmadi, S; Hashemi, P, 2023)
"These patients received ACTH with antiseizure medication therapy for the first time and were regularly followed up for more than six months at our hospital."( Gao, Z; Geng, G; Liu, Y; Meng, Y; Ren, Y; Shi, J; Zhang, H, 2023)
"The mean seizure frequency significantly decreased five hours after BRV administration (a 79."( Chavarría, B; Principe, A; Rocamora, R; Sanabria, A; Zucca, R, 2023)
"From 225 patients, 169 (75%) had good seizure control, with most (60%) receiving monotherapy."( Bittar Guaranha, MS; Duarte, JTC; Guilhoto, LM; Hackbart, BA; Marques, VD; Peixoto-Santos, JE; Yacubian, EMT, 2023)
"Five individuals had daily seizures at baseline and experienced at least 50% seizure reduction with treatment, sustained in four."( Kelly, M; Knight, D; Mahida, S; Olson, HE; Poduri, A, 2023)
"The administration of TMP reduced the seizure score and percentage of kindled animals dose-dependently."( Danduga, RCSR; Kanakaraju, VK; Kandaswamy, S; Kola, PK; Polopalli, S; Shaik, HB, 2023)
"30 min before the seizure-induced procedure, NAC was administered at doses of 300 and 600 mg/kg as pretreatment to investigate anti-seizure and anti-oxidative effects."( Azak Pazarlar, B; Bilister Egilmez, C; Erbas, O; Erdogan, MA, 2023)
"Efficacy was measured by comparing seizure frequency before and after initiating STM therapy."( Adi, J; Cachia, P; Caraballo, R; Chacón, S; Espeche, A; Fortini, S; Galichio, S; Gallo, A; Gamboni, B; Reyes, G; Semprino, M, 2023)
"Efficacy was assessed by comparing seizure frequency before and after initiating CBD therapy."( Cachia, P; Caraballo, RH; Chacón, S; Espeche, A; Fasulo, L; Fortini, S; Galicchio, S; Gallo, A; Gamboni, B; Reyes Valenzuela, G; Semprino, M; Silva, W, 2023)
"Post-traumatic seizure (PTS) prophylaxis is recommended in patients with traumatic brain injury (TBI) at high risk for PTSs, but consensus on the optimal pharmacologic therapy has not yet been established."( Atwood, R; Bradley, M; Elster, E; Walker, P; Walper, D, 2023)
"Patients with a first unprovoked GTC seizure and evidence of GSWDs on EEG have a high risk of recurrence if left untreated."( Beaini, S; Beydoun, A; Hmeimess, G; Hotait, M; Jomaa, N; Nasreddine, W; Wazne, J, 2023)
"Spontaneous recurrent seizures appeared only in midazolam-treated rats, at three and six months postexposure in males and only at six months in females."( Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Rossetti, K, 2023)
"However, the seizure onset age, positive WES results, and number of ASMs before PER administration were not significantly."( Feng, J; Jin, W; Li, Y; Miao, P; Su, Q; Wang, S; Wang, Y; Xu, S; Yu, L; Zhu, X, 2023)
"Mean seizure frequency/28 days in the Full Analysis Set (n = 61) was comparable for adjunctive and monotherapy (0."( Kim, DW; Kim, KK; Lee, WG; Lee, Y; Lim, SC; Park, J; Seo, DW; Shon, YM, 2023)
"Drug treatment aims to stop eclampsia seizures and prevent reoccurrence of convulsions and complications."( Laskowska, M, 2023)
"Concomitant antiseizure medications (ASMs) with a statistically significant effect on the apparent systemic clearance (CL/F) of cenobamate in the PopPK model were used to compare simulated patient plasma exposures (area under the plasma concentration vs time curve [AUC]) following monotherapy versus adjunctive therapy."( Ferrari, L; Kamin, M; Rosenfeld, WE; Vashi, V, 2023)
"At the same points, seizure-free rates of PER monotherapy were 69%, 63% and 52%, and responder rates were 69%, 66% and 61%, respectively."( Feng, J; Guo, Y; Miao, P; Xu, S; Xu, ZY; Zheng, Y, 2023)
"Patients had good retention, seizure-free and responder rates, and relatively low AEs rate at a low dose of PER treatment."( Feng, J; Guo, Y; Miao, P; Xu, S; Xu, ZY; Zheng, Y, 2023)
"Severity of seizures were quantified for an hour and treated with midazolam (3 mg/kg, i."( Almanza, A; Bryant, E; Carlo, AM; Corson, BE; Gage, M; Kharate, M; Mafuta, C; Massey, N; Meyer, C; Ostrander, M; Rao, NS; Samidurai, M; Showman, L; Thippeswamy, T; Trevino, L; Vasanthi, SS; Wachter, L; Wang, C; Wohlgemuth, M, 2023)
"Both seizures and movement disorders can be highly treatment-refractory."( Appavu, B; Fahey, MC; Gamble, S; Heim, J; Kim, S; Kruer, MC; Lewis, SA; Mangum, T; Marku, I; Myers, SJ; Pankratz, M; Rosenberg, RB; Shetty, S; Stitt, G; Wilfong, AA; Zhao, N, 2023)
"Mean seizure class did not differ between the treatment groups."( Ali, I; Brady, RD; Braine, E; Casillas-Espinosa, PM; Cheng, JY; Fukushima, K; Haskali, MB; Hudson, MR; Jones, NC; Jupp, B; Kwan, P; Major, B; Mychasiuk, R; O'Brien, TJ; Sachdev, P; Shultz, SR; Silva, J; Thergarajan, P; Vivash, L; Wright, DK; Yamakawa, GR, 2023)
"Finally, convulsions in Toledo voles were reduced or prevented by treatment with the anti-epileptic drug levetiracetam."( Burkett, JP; Kile, KB; Lloyd, EAR; Neifer, AE; Neifer, KL; Swain, CC; Wischmeier, JN, 2023)
"The average number of seizures per month during the previous 3 months before CNB treatment was 19."( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023)
"The median time from urgent seizure onset to IV treatment administration was 60."( Asensio, M; Campos, D; Castillo, A; Chavarria, B; Escalza, I; Falip, M; Fernández-Cabrera, A; Garcés, M; García-Morales, I; Gifreu, A; Giménez, J; Guillén, V; Hampel, K; Hernández Pérez, G; Juiz-Fernández, Á; Martínez, AB; Massot, M; Montoya, J; Parejo-Carbonell, B; Rocamora, R; Rodriguez-Osorio, X; Rubio-Nazábal, E; Ruiz-Giménez, J; Santamarina, E; Sayas, D; Villanueva, V, 2023)
"Seizure frequency (seizures/month; sz/m), blood tests including concentrations of ZNS and β-hydroxybutyric acid, and owner's visual analogue scale score were collected from all dogs for both treatment periods."( Hasegawa, D; Nakatsuka, K; Zanghi, B, 2023)
"Besides antiseizure medications, other treatments such as vagal nerve stimulation, responsive neurostimulation, and deep brain stimulation are likely safe."( Harris, KM; Hope, OA, 2023)
"Tonic-clonic seizures were evoked experimentally in mice after systemic (ip) administration of the respective doses of ISOP, BOR, and classic ASMs."( Bojar, H; Chmielewski, J; Florek-Łuszczki, M; Jankiewicz, K; Skalicka-Woźniak, K; Łuszczki, JJ, 2023)
"However, with chronic treatment, antiseizure effects are lost as tolerance develops."( Deking, L; Feja, M; Felmy, F; Gernert, M; Javadova, A; MacKeigan, D; Meller, S; Veenhuis, A, 2023)
"The primary outcome was postoperative seizures occurring within 7 days after surgery, analyzed in both the intention-to-treat and per-protocol populations."( Li, S; Liu, M; Peng, Y; Sessler, DI; Wu, Y; Yan, X; Yang, J; Zeng, M; Zhang, L; Zhou, D, 2024)
"In neonates who achieve seizure control after the first loading dose of phenobarbital, maintenance therapy compared to no maintenance ASM may have little or no effect on all-cause mortality before discharge, mortality by 18 to 24 months, neurodevelopmental disability by 18 to 24 months and epilepsy post-discharge (low-certainty evidence)."( Abiramalatha, T; Brigo, F; Hartmann, H; Pressler, R; Ramaswamy, VV; Thanigainathan, S, 2023)
"However, the severity of seizures was significantly reduced after treatment."( Diespirov, GP; Griflyuk, AV; Kalita, AD; Postnikova, TY; Sinyak, DS; Zaitsev, AV; Zubareva, OE, 2023)

Research

Studies (27,186)

TimeframeStudies, This Condition (%)All Conditions %
pre-19909617 (35.37)23.3326
1990's4314 (15.87)12.5806
2000's4771 (17.55)18.1394
2010's5923 (21.79)28.8240
2020's2561 (9.42)9.53
DrugIndicatedRelationship StrengthStudiesTrials
acetylcarnitine0low50
ethylene dichloride0low10
2,3-dihydroxybenzoic acid0low20
alpha-hydroxyglutarate0low40
2-oxo-3-methylvalerate0low10
alpha-ketoisovalerate0low10
2-keto-4-methylvalerate0low20
3-hydroxyanthranilic acid0medium31
3-hydroxykynurenine0medium51
acetoacetic acid0low40
phosphoserine0low70
cysteine sulfinic acid0low10
gamma-aminobutyric acid0medium1,27222
4-hydroxybenzaldehyde0low10
aminolevulinic acid0low100
5-aminovaleric acid0low40
5-hydroxytryptophan0low760
ethylene glycol0low50
acetic acid0low130
acetaldehyde0low170
acetamide0low50
acetone0low260
adenine0low140
adipic acid0low10
agmatine0low120
ammonium hydroxide0low1550
anthranilic acid0medium31
quinacrine0low130
beta-alanine0low100
benzaldehyde0low10
benzene0low60
benzoic acid0low50
benzyl alcohol0low20
betaine0low80
bromide0medium462
1-butanol0low50
butyric acid0low30
carbamates0medium11111
carbamic acid0low10
ureidosuccinic acid0low10
carbon monoxide0low140
aminooxyacetic acid0low630
carnitine0low410
catechol0low10
chlordecone0low30
chloroacetic acid0low10
choline0low500
citric acid, anhydrous0low80
chlorine0low1580
hydrochloric acid0low50
coumarin0low20
salicylic acid0medium1703
octane0low10
phloroglucinol0low20
gallic acid0low10
4-nitrophenylphosphate0low10
octanoic acid0low50
hydrogen sulfide0low70
dihydrolipoic acid0low10
3-hydroxybutyric acid0medium501
bupropion0medium1038
bw 306u0low10
caprylic aldehyde0low10
guaiacol0low10
2-aminoadipic acid0low130
2,4-diaminobutyric acid0low50
methylmalonic acid0low160
n(g),n(g')-dimethyl-l-arginine0medium11
malic acid0low30
1-aminocyclopropane-1-carboxylic acid0low30
phosphonoacetic acid0low20
3,4-dihydroxyphenylacetic acid0low160
3-methylthiopropionate0low10
aminocaproic acid0low80
creatine0medium581
cytosine0low30
lactic acid0low880
dihydrouracil0low20
diacetyl0low30
dihydroxyacetone0low10
dimethylglycine0low10
dimethylamine0low10
dimethyl sulfoxide0low260
ethanolamine0low30
formaldehyde0low110
gamma-butyrobetaine0low10
glutaric acid0low90
glycine0low2480
glyceraldehyde0low20
glyceric acid0low10
glycerol0low290
glycocyamine0low30
carbonic acid0low10
hydrogen cyanide0low30
hydrogen carbonate0low570
dalteparin0low40
histamine0low710
toxopyrimidine0low20
hydrogen0low110
hydroquinone0low30
hydroxylamine0low10
imidazole0low60
indole0low30
indoleacetic acid0low10
iodine0low170
dihydroxyphenylalanine0low520
kynurenine0medium492
pipecolic acid0low140
thioctic acid0low170
malonic acid0low20
pyruvaldehyde0low40
methanol0low420
inositol0low260
melatonin0medium895
croton oil0low40
nickel0low70
niacinamide0low270
niacin0low300
nitrates0low160
nitroxyl0low20
nitrites0low260
nitrous oxide0low520
hydroxide ion0low10
orotic acid0low130
oxaloacetic acid0low30
oxalic acid0low20
oxamic acid0low10
4-aminobenzoic acid0low70
triphosphoric acid0low20
palmitic acid0low40
parathion0low120
phenylacetic acid0low10
phenethylamine0low50
5-phenylhydantoin, (+-)-isomer0low10
phosphorylcholine0low30
phosphorylethanolamine0low40
phthalic acid0low10
picolinic acid0low50
porphobilinogen0low100
diphosphoric acid0low20
pqq cofactor0low10
propylene glycol0low60
1-propanol0low20
propionic acid0low30
pteridines0low160
purine0low50
putrescine0low160
pyrazinamide0medium51
pyrazinoic acid0low10
pyrazole0low60
pyridine0low10
pyridoxal0low60
pyridoxal phosphate0low970
pyridoxamine0low30
pyridoxine0medium3106
pyridoxine 5-phosphate0low20
pyrogallol0low60
pyruvic acid0low260
quinolinic acid0low610
thiosulfates0low110
sarcosine0low30
selenic acid0medium31
sulfites0low80
spermidine0low140
spermine0low140
succinic acid0low50
succinic semialdehyde0low10
sulfur dioxide0low30
taurine0low1010
thiamine0medium413
thymine0low50
toluene0low220
trimethylamine0low30
tryptamine0low80
tungstic(vi) acid0low40
uracil0low80
uric acid0medium481
urea0medium1173
xanthine0low50
isocitric acid0low10
normetazocine0low10
2-amino-5-phosphonovalerate0low1520
sk&f 812970low10
8-hydroxy-2-(di-n-propylamino)tetralin0low170
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid0low650
2,3-piperidinedicarboxylic acid0low50
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid0low370
4-iodo-2,5-dimethoxyphenylisopropylamine0low60
1-hydroxy-3-amino-2-pyrrolidone0low90
ibotenic acid0low290
gallopamil0low30
normetanephrine0low10
sk&f-383930low140
1h-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-0low10
huperzine a0low110
menthol0low30
(alpha-carboxycyclopropyl)glycine0low20
4-carboxy-3-hydroxyphenylglycine0low30
1,10-diaminodecane0low10
1,10-phenanthroline0low10
1,2-dimethylhydrazine0low20
1,3-diethyl-8-phenylxanthine0low10
1,3-dipropyl-8-cyclopentylxanthine0low250
1,3-dipropyl-8-(4-sulfophenyl)xanthine0low10
pk 111950low190
1-(3-chlorophenyl)biguanide0low50
1-(3-chlorophenyl)piperazine0low40
1-(2-trifluoromethylphenyl)imidazole0low20
1-aminocyclohexanecarboxylic acid0low10
1-anilino-8-naphthalenesulfonate0low20
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine0low30
n-(3-(aminomethyl)benzyl)acetamidine0low10
2,4-dichlorophenoxyacetic acid0low10
2,4-dinitrophenol0low30
2-hydroxysaclofen0low10
mercaptoethanol0low30
monomethylpropion0low10
2-aminoethoxydiphenyl borate0low10
3,4-methylenedioxyamphetamine0low80
n-methyl-3,4-methylenedioxyamphetamine0low420
amitrole0low10
phaclofen0low70
tramiprosate0low40
aminopropionitrile0low10
3-bromo-7-nitroindazole0low10
meglutol0low10
3-hydroxybenzylhydrazine0low10
3-methoxytyramine0low10
3-methoxytyrosine0low10
3-methoxymorphinan0low10
enprofylline0low40
3-nitropropionic acid0low50
ro 5-48640low240
4,5,6,7-tetrahydroisoxazolo(4,5-c)pyridin-3-ol0low40
4-aminobenzamidine0low10
4-aminopyridine0low1830
p-chloromercuribenzoic acid0low10
4-diphenylacetoxy-1,1-dimethylpiperidinium0low10
homovanillic acid0medium342
phenytoin0medium1,57983
5,7-dichlorokynurenic acid0low40
5,8,11,14-eicosatetraynoic acid0low10
ethylisopropylamiloride0low10
5-carboxamidotryptamine0low10
5-hydroxydecanoate0low10
hydroxyindoleacetic acid0medium742
5-methoxytryptamine0low40
6-methoxytryptoline0low20
7-chlorokynurenic acid0low170
7-nitroindazole0low480
8-(4-sulfophenyl)theophylline0low40
8-cyclopentyl-1,3-dimethylxanthine0low130
8-phenyltheophylline0low20
tacrine0low90
acebutolol0low10
acetaminophen0medium312
acetazolamide0medium681
acetohexamide0low10
acridone0low20
afloqualone0low20
1-aminoindan-1,5-dicarboxylic acid0low40
alachlor0low10
alaproclate0low10
albendazole0medium7820
albuterol0low90
alendronate0low20
alpha-methyltyrosine methyl ester0low20
alprazolam0medium243
alprenolol0low10
am 2510low200
amantadine0low200
diatrizoic acid0low130
aminoglutethimide0low50
pimagedine0low170
p-aminohippuric acid0low10
4-amino-3-hydroxybutyric acid0low50
ampyrone0low10
theophylline0low2130
amiodarone0low100
dan 21630low20
amitriptyline0medium671
amlodipine0low130
amobarbital0medium372
amoxapine0medium251
amsacrine0low20
anethole trithione0low20
aniracetam0low50
antazoline0low20
antipyrine0low200
2-amino-4-phosphonobutyric acid0low50
acetovanillone0low30
aprindine0low10
arcaine0low40
arecoline0low80
aspirin0medium551
astemizole0low30
atenolol0low60
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate0low60
azathioprine0low190
azobenzene0low10
azosemide0low20
aztreonam0low30
baclofen0medium1031
barbital0low510
bay-k-86440low210
bemegride0medium802
benserazide0low90
benzamide0low20
benzamidine0low10
benzo(a)pyrene0low10
benzocaine0low30
berberine0low40
betahistine0low20
betaxolol0low10
bethanechol0low20
bifemelane0low10
biperiden0low100
bisbenzimidazole0low10
bisindolylmaleimide i0low10
bretylium0low10
bromazepam0low20
bromisovalum0low10
seratrodast0low10
brotizolam0low10
bu 2240low10
buflomedil0low70
bumetanide0medium505
bupivacaine0medium1232
buspirone0medium91
busulfan0medium415
caffeine0medium1631
verapamil0medium413
pantogab0low30
metrizoate0low10
camphor, (+-)-isomer0low420
candesartan cilexetil0low10
candesartan0low10
cannabinol0low50
carbamazepine0medium78648
carbamazepine epoxide0medium82
carbetapentane0low30
carbofuran0low20
carcinine0low20
carisoprodol0low20
carmustine0medium93
carvedilol0low20
cefuroxime0low10
celecoxib0medium111
cetirizine0low10
chloral hydrate0medium382
chlorambucil0low170
chlordiazepoxide0medium1157
chlormezanone0medium21
chloroquine0medium362
chlorothiazide0low30
chlorpheniramine0low70
chlorpromazine0medium1894
chlorpropamide0low10
chlorpyrifos0low60
chlorthalidone0low20
chlorzoxazone0low10
cimetidine0low130
eucalyptol0low10
cinoxacin0low10
ciprofloxacin0medium331
cirazoline0low10
cisapride0low20
citalopram0medium492
clemizole0low40
clenbuterol0low20
clidinium0low10
clioquinol0low50
clobazam0medium847
clobenpropit0low80
clofibrate0low10
clomipramine0low200
clonazepam0medium1652
clonidine0medium782
clotrimazole0low10
phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide0low10
cyclobenzaprine0low20
cyclocreatine0low30
cycloleucine0low140
cyclopentolate0low10
cyclothiazide0low90
cypermethrin0low30
cyproheptadine0low120
cystamine0low10
dantrolene0medium162
dapi0low60
dapsone0low100
debrisoquin0low10
decamethonium0low30
decanoic acid0low50
deferiprone0low10
deferoxamine0low60
atenolol0low10
desipramine0low420
nordazepam0low140
amphetamine0low1560
eflornithine0medium92
diazepam0medium1,19649
diazinon0low20
diazoxide0low240
methylene bromide0low10
dibucaine0low20
diclofenac0low150
dichlorodiphenyl dichloroethylene0low20
ddt0low300
dichlorphenamide0low20
dichlorvos0low60
diethylcarbamazine0low70
pentetic acid0low30
dilazep0low10
dimaprit0low20
dimefline0low20
dimercaprol0low110
dimethadione0low10
diphenhydramine0low450
dipyridamole0low90
disopyramide0low60
disulfiram0low340
diuron0low10
valproic acid0medium1,05350
2-amino-7-phosphonoheptanoic acid0low640
racemetirosine0low120
p-chloroamphetamine0low60
thiorphan0low10
donepezil0medium111
doxapram0low40
doxazosin0low30
doxepin0low40
droperidol0medium102
dsp 40low80
dyphylline0low10
ebselen0low40
eburnamonine0low10
9-(2-hydroxy-3-nonyl)adenine0low40
embelin0low10
endosulfan0low140
enflurane0low400
enoxacin0low180
eperisone0low10
epinastine0low20
eprazinone0low10
erythrosine0low450
estazolam0low10
ethacrynic acid0low90
ether0low390
ethosuximide0medium1964
ethotoin0low10
ethyl loflazepate0low10
ethylenediamine0low20
etidronate0medium21
etizolam0low10
etodolac0low10
famotidine0low30
felbamate0medium461
fenbufen0low100
fenfluramine0medium4611
fenofibrate0low20
fenoldopam0low10
berotek0low10
fentanyl0medium542
fenvalerate0low20
fexofenadine0low20
flecainide0low20
fleroxacin0low40
fluconazole0medium92
fluphenazine0low100
flumazenil0low2010
flumequine0low10
flunitrazepam0low900
fluorouracil0low200
fluoxetine0medium844
flurazepam0low250
flurbiprofen0low20
flutamide0low50
fomepizole0low20
foscarnet0medium62
furazolidone0low20
furosemide0low320
fusaric acid0low20
gabapentin0medium9811
gaboxadol0low200
4-amino-5-hexynoic acid0medium71
vanoxerine0low40
gbr 129350low30
gentamicin0medium211
2,5-dihydroxybenzoic acid0low20
gliclazide0low10
glipizide0low20
glutethimide0low170
glyburide0low160
glyphosate0low30
guaifenesin0low20
guanethidine0low110
guanfacine0low60
guanidine0low30
guvacine0low30
gyki 524660low480
1-(5-isoquinolinesulfonyl)-2-methylpiperazine0low70
fasudil0low60
haloperidol0medium1291
halothane0low420
harmaline0low130
hexadecanesulfonyl fluoride0low10
heptachlor0low10
hexachlorophene0medium41
hexahydrosiladifenidol0low10
4-fluorohexahydrosiladifenidol0low10
hexamethonium0low40
hexobarbital0low680
tele-methylhistamine0low10
alpha-methylhistamine0low20
ethidium0low20
hydralazine0low170
hydrochlorothiazide0low40
hydroxychloroquine0low70
hydroxyurea0low50
hydroxyzine0medium83
ibuprofen0medium131
phenelzine0low120
lidocaine0medium3528
mephentermine0low10
idebenone0low20
ifenprodil0low200
ifosfamide0medium41
imipramine0low950
indapamide0low10
indomethacin0low360
iodixanol0low40
iodoquinol0low10
iofetamine0low50
iohexol0medium131
iomeprol0low30
iothalamic acid0low360
iotrolan0low30
iodipamide0low20
ioversol0low20
ioxaglate0low10
iproniazid0low290
1-methyl-3-isobutylxanthine0low20
isocarboxazid0low40
isoflurane0medium391
isoguvacine0low40
isoniazid0medium2393
4-piperidinecarboxylic acid0low10
2-propanol0low70
isoproterenol0low320
isradipine0low60
staurosporine aglycone0low10
ketamine0medium1517
ketanserin0low140
ketoconazole0low70
ketoprofen0low20
ketorolac0low20
ketotifen0low60
khellin0low10
kojic acid0low30
kynurenic acid0low630
2-amino-3-phosphonopropionic acid0low10
pyrrolidine-2,4-dicarboxylic acid0low10
labetalol0medium113
lamotrigine0medium24723
lansoprazole0low20
lauric acid0low10
leflunomide0low30
letrozole0low40
tetramisole0low10
qx-3140low10
linopirdine0low40
lomefloxacin0low20
lomustine0low70
loperamide0low30
loratadine0low20
lorazepam0medium13911
lorglumide0low10
losartan0low110
loxapine0low10
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one0low20
malathion0low40
maprotiline0medium332
edaravone0low90
mebendazole0low20
mecamylamine0low190
mechlorethamine0low40
meclizine0low20
meclofenamic acid0low20
meclofenoxate0low90
medazepam0low20
mefenamic acid0low110
memantine0medium342
meperidine0low600
mephenesin0low230
mephenytoin0low110
mepivacaine0low280
meprobamate0low500
mescaline0low220
mesoridazine0low10
metformin0low70
methadone0medium271
methamidophos0low10
methantheline0low10
methapyrilene0low10
methazolamide0low30
methenamine0low10
methiothepin0low20
methocarbamol0low50
methomyl0low40
methoxsalen0low20
methoxyflurane0low30
methyl parathion0low10
methyl salicylate0low10
n-methylcarbamylcholine0low20
methylphenidate0medium423
metoclopramide0low70
metolazone0low10
metoprolol0low50
metronidazole0low190
metyrapone0low110
mexiletine0medium131
mianserin0low200
miconazole0low40
midazolam0medium25335
midodrine0low10
minaprine0low10
mirtazapine0low60
moclobemide0low40
modafinil0low50
molsidomine0low10
muscimol0low1800
myristicin0low20
deet0low100
1-(3-trifluoromethylphenyl)piperazine0low20
n-methylephedrine0low10
fg 71420low340
n-methyl-dl-aspartic acid0low40
clorgyline0low40
apnea0medium2382
nafronyl0low30
nalidixic acid0low160
activins0low40
naphazoline0low50
nefazodone0low20
nefopam0low40
neostigmine0low210
nevirapine0low20
nialamide0low180
nicardipine0medium152
niclosamide0low10
nifedipine0medium331
nimesulide0low40
nimetazepam0low10
nimodipine0medium421
nipecotic acid0low120
nisoxetine0low20
nitrazepam0low240
nitrendipine0low160
nitroglycerin0low60
nomifensine0medium112
norfloxacin0low170
cm 71160low10
norfluoxetine0low10
nortriptyline0low80
npc 154370low10
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide0low60
octopamine0low20
ofloxacin0low220
omeprazole0low70
ondansetron0low110
orphenadrine0low70
oxamniquine0low40
oxaprozin0low20
oxazepam0medium251
oxidopamine0low470
oxolinic acid0low20
oxotremorine m0low10
oxotremorine0low280
oxprenolol0low20
benoxinate0low10
oxybutynin0low40
oxymetazoline0low20
oxyphenbutazone0low70
aminosalicylic acid0low30
quinone0low20
fenclonine0low530
palmidrol0low30
pamidronate0low30
pantoprazole0low30
papaverine0low150
1,7-dimethylxanthine0low10
pargyline0low200
patulin0low10
pd 980590low30
pemoline0low30
pentamidine0low10
pentobarbital0medium2732
pentoxifylline0low50
perphenazine0low120
phenacemide0low140
phenacetin0low40
phenindione0low20
pheniramine0low40
phenmetrazine0low30
phenobarbital0medium1,21369
phenoxybenzamine0low120
phentermine0low20
4-phenylbutyric acid0low40
phenylbutazone0low90
phenylmethylsulfonyl fluoride0low30
moxonidine0low10
pifithrin0low40
pilsicainide0low10
pinacidil0low20
pindolol0medium81
pioglitazone0low90
piperazine0low90
piperidine-4-sulfonic acid0low10
piracetam0medium39635
pirenzepine0low150
piretanide0low10
piribedil0low30
potassium chloride0low390
4-aminobenzoic acid0low10
practolol0low40
ono 10780low20
prazepam0low10
praziquantel0medium253
prazosin0low290
prilocaine0low140
primidone0medium1019
proadifen0low110
probenecid0low160
procainamide0low60
procaine0low820
procarbazine0low20
prochlorperazine0low90
procyclidine0low170
proglumide0low40
promazine0medium124
promethazine0low220
pronethalol0low10
propafenone0low100
propantheline0low10
proxymetacaine0low10
propentofylline0low10
propidium0low10
propofol0medium20128
propranolol0medium911
propyliodone0low10
protriptyline0low10
pyrilamine0low70
pyrimethamine0low190
pyrithyldione0low10
sch 161340low10
quipazine0low50
7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol0low10
1,6-bis(cyclohexyloximinocarbonyl)hexane0low10
riluzole0low130
rimantadine0low10
risperidone0medium171
ritanserin0low40
ro 15-45130low210
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone0low10
rofecoxib0low80
rolipram0low30
roxarsone0low10
3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol0low10
2-aminopropanol0low10
saccharin0low40
safrole0low20
sb 2065530low10
sb 2021900low10
sebacic acid0low10
secobarbital0low30
carbamylhydrazine0low10
sevoflurane0medium547
sibutramine0low10
sulfadiazine0low60
sk&f 975410low10
sodium fluoride0low20
fluoroacetic acid0low70
sotalol0low80
spiperone0low90
spiroxatrine0low10
stearic acid0low30
vorinostat0low30
succinylacetone0low10
succinylcholine0medium639
sulfamerazine0low10
sulfamethoxazole0low50
sulfanilamide0low40
sulfaphenazole0low10
sulfasalazine0low90
sulfinpyrazone0low10
sulfisoxazole0low10
sulfobromophthalein0low20
sulpiride0low110
sulthiame0low80
sumatriptan0medium111
talipexole0low10
gatifloxacin0low40
telenzepine0low10
temazepam0low50
temozolomide0medium245
terbutaline0low30
terfenadine0low40
tetracaine0low120
tetraethylammonium0low30
krypton0low10
tetraisopropylpyrophosphamide0low20
3-hydroxyaspartic acid0low10
thalidomide0low120
theobromine0low50
thiethylperazine0low10
thioridazine0low60
thiotepa0low20
thiram0low10
ticlopidine0low20
tinidazole0low10
tipepidine0low20
tizanidine0low50
nikethamide0low180
tofisopam0low30
tolazoline0low20
tolbutamide0low130
tolmetin0low20
tolnaftate0low10
tosufloxacin0low20
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine0low30
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid0low10
tranexamic acid0medium747
trapidil0low10
trazodone0medium161
tremorine0low170
triamterene0low20
triazolam0low120
trientine0low20
trifluoperazine0low90
triflupromazine0low40
trihexyphenidyl0low100
trimeprazine0low10
trimethadione0medium821
trimethoprim0low40
trimipramine0low40
tripelennamine0low20
tropicamide0low10
tyramine0medium71
urethane0low210
vigabatrin0medium1397
viloxazine0low70
w 70low20
wb 41010low10
pirinixic acid0low10
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine0low20
xanthurenic acid0low20
xylazine0low70
zaleplon0low20
zinc chloride0low60
zolpidem0low330
zomepirac0low10
zonisamide0medium655
zopiclone0low70
zotepine0low30
hydrocortisone acetate0low10
mitomycin0low10
corticosterone0low740
prednisolone0medium695
estriol0low40
lysergic acid diethylamide0low320
reserpine0low2080
cephaloridine0medium51
phentolamine0low230
sorbitol0low80
alloxan0low40
thymidine0low50
piperonyl butoxide0low20
benzimidazole0low20
triethylenemelamine0low10
bromouracil0low10
hydroxyproline0low70
thyroxine0low390
dibenzylchlorethamine0low40
dextroamphetamine0low570
carbachol0low660
spironolactone0low140
aldosterone0low150
penicillamine0low240
trichlorfon0low10
lynestrenol0low20
prednisone0medium763
estrone0low40
methylprednisolone acetate0low20
oxandrolone0low20
androsterone0low20
etiocholanolone0low10
dehydroepiandrosterone0low60
adrenochrome0low10
penicillin g0medium1811
idoxuridine0low30
metaraminol0low50
pilocarpine0medium7761
dimethylphenylpiperazinium iodide0low20
pentylenetetrazole0medium3,4515
amifampridine0low20
triiodothyronine0low160
pheniprazine0low10
isoflurophate0low430
biguanides0low90
carbon tetrachloride0low30
alanine0low680
serine0low640
desoxycorticosterone acetate0low10
4-nitroquinoline-1-oxide0low10
chloramphenicol0medium282
aspartic acid0medium1961
glutamine0medium991
lysine0low500
cyanides0low290
dimazine0low30
physostigmine0low1130
sulfamic acid0low10
sucrose0low160
ethinyl estradiol0low50
chlordan0low80
testosterone propionate0low20
tubocurarine0low340
apomorphine0medium871
aminopyrine0low240
tetrabenazine0low280
puromycin aminonucleoside0low10
adenosine diphosphate0low210
cephalothin0medium41
2,3,4,6-tetrachlorophenol0medium308
uridine0low130
uridine monophosphate0low20
kanamycin a0low100
bromodeoxyuridine0low620
galactose0low100
carbostyril0low340
piperoxan0low20
phenylephrine0low140
benzoxazolone0low10
levodopa0low630
edetic acid0low260
phenylethyl alcohol0low40
tyrosine0low570
cysteamine0low100
monomethylhydrazine0low120
veratramine0low10
phlorhizin0low10
acepromazine0low150
methoxamine0low20
adenosine monophosphate0low100
methicillin0low90
n,n-dimethyltryptamine0low30
niridazole0medium21
cloxacillin0low60
methylene blue0low200
zoxazolamine0low40
leucine0low620
methacholine chloride0low10
aniline0low10
androstenedione0low10
carbaryl0low20
cytidine diphosphate0low10
uridine triphosphate0low10
lactose0low20
methionine0low680
phenylalanine0low460
3-tolylcarbamide0low30
n-phenylurea0low10
desoxycorticosterone0low320
colchicine0low170
gallamine triethiodide0low210
cytidine0low30
oxacillin0low20
cycloheximide0low360
egtazic acid0low100
barbituric acid0low200
chloroform0low70
fluocinolone acetonide0low10
sodium citrate, anhydrous0low10
dimethylformamide0low10
norethindrone0low10
norethynodrel0low20
cycloserine0medium161
17-alpha-hydroxyprogesterone0low10
caffeine citrate0low10
chlorisondamine0low50
tubercidin0low90
ampicillin0medium292
mannitol0medium511
cytarabine0medium162
dithionitrobenzoic acid0low30
ornithine0low130
asparagine0low150
histidine0medium231
n-pentanol0low30
1,1,1-trichloroethane0low10
medroxyprogesterone acetate0low20
valine0low500
threonine0low110
mestranol0low30
methaqualone0low190
dichlorodiphenyldichloroethane0low10
tryptophan0medium821
isoleucine0low150
arginine0medium1611
methyl bromide0low50
acetylene0low20
methyl chloride0low10
boranes0low50
propane0low20
ethyl chloride0low60
acetonitrile0low10
methylene chloride0low10
carbon disulfide0low30
cyclopropane0low10
tetramethylammonium0low10
tert-butyl alcohol0low10
tribromoethanol0low20
pivalic acid0low10
trichloroacetic acid0low50
perflutren0low10
bromcresol green0low10
phencyclidine0low760
caramiphen0low90
methsuximide0low100
carbromal0low10
methylpentynol0low10
tabun0low80
tromethamine0low80
quinic acid0low20
tetraethyl lead0low10
3-mercaptopropionic acid0low670
linalool0low40
isoprene0low10
methylethyl ketone0low10
trichloroethylene0low40
propionamide0low10
acrylamide0low10
acrylic acid0low10
n-methylacetamide0low10
isobutyric acid0low10
dichloroacetic acid0low40
pempidine0low10
pantothenic acid0low90
phenaglycodol0low20
alpha-pinene0low30
dehydrocholic acid0low20
rhodamine b0low10
pyridoxic acid0low20
cyclizine0low20
methylprednisolone0medium1172
rotenone0low20
diquat0low20
acetrizoic acid0low10
brompheniramine0low10
phensuximide0low50
propoxycaine0low30
penicillin v0low20
isosorbide dinitrate0low10
penicillanic acid0low40
xylitol0low30
n-vinyl-2-pyrrolidinone0low50
2-isopropylphenol0low10
dinoseb0low10
4-nitrophthalimide0low10
thymol0low40
2-phenylbutyric acid0low10
xanthone0low30
pseudoephedrine0low30
diethylpropion0low20
quinoxalines0low1120
1,2,3,4-tetrahydroisoquinoline0low20
quinoline0low10
isatin0low100
tolonium chloride0low10
diphenyl0low50
phenylpiperazine0low30
acridan0low10
xanthenes0medium101
phenothiazine0low180
2-acetylnaphthalene0low10
propylparaben0low40
benzotriazole0low10
benzothiazole0low60
diethyl ketone0low10
4-butyrolactone0low260
soman0low1860
1,3-ditolylguanidine0low20
arsanilic acid0low20
pyrrolidonecarboxylic acid0low60
acetophenone0low10
nitrobenzene0low10
trehalose0low20
carveol0low10
carvone0low20
methylparaben0low10
4-cymene0low10
4-nitroaniline0low10
benzylamine0low10
benzonitrile0low10
phenylhydrazine0low10
quinuclidines0low60
cyclamic acid0low20
pyridostigmine bromide0low220
4,4'-diphenylmethane diisocyanate0low10
4,4'-diaminodiphenylmethane0low10
di-(4-aminophenyl)ether0low10
phenylurethane0low10
boric acid0low20
benzonatate0low20
caprolactam0low40
4-vinyl-1-cyclohexene dioxide0low20
butane0low10
allylamine0low20
propionitrile0low10
acrylonitrile0low50
sarin0low360
tetraethyl pyrophosphate0low10
2-methylpentane0low60
1,3-butylene glycol0low30
deanol0low10
biuret0low10
maleic anhydride0low10
3-xylene0low20
methyl malonate0low20
cyclohexanol0medium312
cyclohexanone0low10
n-pentanoic acid0low10
pentane0low10
pyrroles0low390
tetrahydrofuran0low10
thiophenes0low390
n-hexane0low40
1,4-butanediol0low80
piperidine0low40
1,5-pentanediol0low10
diethylenetriamine0low10
pelargonic acid0low10
behenic acid0low10
ergotamine0low40
methylergonovine0low20
phenformin0low50
obidoxime chloride0low20
dimethyl ether0low10
isobutylene0low10
mephobarbital0low180
pentaerythritol0low10
linalyl acetate0low10
tris(chloroethyl)phosphate0low10
acetol0low30
2-methylbutanoic acid0low10
etryptamine0low10
trinitrotoluene0low10
framycetin0low30
isoquinoline0low20
scoparone0low20
dimethoxyphenylethylamine0low50
2,4-dinitrotoluene0low10
vanillic acid0low10
cyclonite0low120
iodoantipyrine0low80
diatrizoate meglumine0low70
meglumine0low40
chloroprocaine0low80
1-naphthylamine0low20
2-naphthol0low20
2-aminobenzothiazole0low10
diamthazole0low50
shikimic acid0low10
4,4'-thiodianiline0low10
benzathine0low10
citronellol0low10
ethyl acetate0low60
n-heptane0low10
sodium cyanide0low10
pregnenolone0low120
20-alpha-dihydroprogesterone0low10
yohimbine0low390
3-o-methylglucose0low30
2-chloroadenosine0low200
diphenhydramine hydrochloride0low280
ditiocarb0low180
1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt0low20
potassium cyanide0low100
methohexital0medium5012
catechin0low60
thiamine pyrophosphate0low10
quinazolines0low430
acridines0low80
indazoles0low650
benzoxazoles0low110
indolizine0low10
adamantane0low150
cyclopentane0low220
isoxazoles0medium1014
oxazoles0medium661
thiazoles0low750
1,2,4-triazole0low80
pyrimidine0low30
pyrazines0low180
nitroblue tetrazolium0low20
calcium gluconate0medium201
ephedrine0low230
allylisopropylacetamide0low20
muscarine0low10
hydrazine0low880
benactyzine0low100
2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-0low70
perfluorodecalin0low10
paraoxon0low190
perfluorotributylamine0low10
hemicholinium 30low70
evans blue0low180
testosterone enanthate0low10
opipramol0medium21
thioproperazine0low10
aminophylline0medium692
azacitidine0low10
6-aminonicotinamide0low10
n-phenethylpiperidine0low10
flurothyl0medium1921
perfluorooctanoic acid0low10
carbutamide0low10
3-acetylpyridine0low20
perflexane0low20
1,2-dichloro-1,2,3,3,4,4-hexafluorocyclobutane0low10
galantamine0low60
nandrolone decanoate0low10
aminoimidazole carboxamide0low20
methysergide0low200
trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride0low20
cuprizone0low30
citrulline0low160
betamethasone0low110
4-hydroxyphenobarbital0low20
prenylamine0low30
nandrolone0low10
thiazolidine-4-carboxylic acid0low30
coniine0low10
4-fluoroamphetamine0low10
hydantoins0medium1052
chlorphentermine0low20
fluorobenzenes0low60
3-aminopyridine0low50
homocystine0low20
n-pentyl nitrite0low30
dextropropoxyphene0low250
chlorfenvinphos0low10
methylguanidine0low30
limestone0low100
oxamide0low10
chenodeoxycholic acid0low10
nuciferine0low10
fusarium0low20
boldine0low20
imperatorin0low30
osthol0low20
dihydralazine0low30
cytisine0low40
ninhydrin0low10
bicuculline0low5580
kainic acid0low1,5750
bufotenin0low10
thymoquinone0medium61
phenylpropanolamine0low140
melarsoprol0low20
butenolide0low10
arecaidine0low10
carvacrol0low30
indophenol0low10
phloroglucinol dimethyl ether0low20
beclamide0low10
4-hydroxybutyric acid0low110
isovaleric acid0low10
alpha-aminopyridine0low280
1,3-propanediol0low40
thiazolidines0low170
mustard gas0low30
hexacosanoic acid0low10
oleanolic acid0low30
tetranitromethane0low10
dihydroergotamine0low20
echothiophate iodide0low20
hematoxylin0low30
podophyllotoxin0low10
psilocybin0low40
medroxyprogesterone0low30
dihydrotestosterone0low30
luminol0low10
dimenhydrinate0low20
8-chlorotheophylline0low10
ricinine0low20
tryptophol0low30
gluconic acid0low10
copper gluconate0medium81
azomycin0medium41
chlormethiazole0low200
pyrithiamine0low40
methoxyhydroxyphenylglycol0low50
crimidine0low10
perillyl alcohol0low10
methamphetamine0medium761
oxophenarsine0low20
tricaprylin0low10
trilaurin0low10
1,2-dichloroethylene0low10
aminoacetonitrile0low40
senecioic acid0low10
3-aminobutyric acid0low10
malondialdehyde0medium741
myristic acid0low10
trinitrobenzenesulfonic acid0low20
eosine yellowish-(ys)0low30
lucanthone hydrochloride0low20
1-naphthylisothiocyanate0low10
paeonol0low10
lithium carbonate0low110
tristearin0low10
brocresine0low20
glycylglycine0low10
phenoperidine0low10
4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol0low10
glycerylphosphorylcholine0low30
formestane0low10
congo red0low10
3-hydroxyflavone0low20
succinimide0low10
n-methylphenethylamine0low10
levulinic acid0low10
butylurea0low20
allyl sulfide0low10
glycopyrrolate0medium43
methyl carbamate0low20
ethylmalonic acid0low10
2,6-dinitrotoluene0low10
toyocamycin0low10
2-pyrrolidone0low20
trimecaine0low30
acetylcysteine0low130
3-isopropylphenol0low10
dimethyl disulfide0low10
propylurea0low10
amyl acetate0low10
c.i. 425100low30
clopenthixol0low20
2-pyrrolecarboxylic acid0low10
fluoroacetamide0low10
benzydamine0low10
erythromycin0low140
dehydroepiandrosterone sulfate0low30
2-piperidone0medium61
perfluoropentane0low10
1,3-diisopropylcarbodiimide0low10
decan-4-olide0low30
2,3-dimethylmaleic anhydride0low10
ameltolide0low90
levonorgestrel0low20
calcium citrate0low10
calcium lactate0low10
4-methylimidazole0low20
trimethylolpropane phosphite0low20
adamantanecarboxylic acid0low10
boldenone0low10
lormetazepam0low10
alpha-fluoro-beta-alanine0low10
1,4-androstadiene-3,17-dione0low10
lithium citrate0low10
2-cyclohexen-1-one0low10
2-hydroxybenzothiazole0low10
methylparaoxon0low10
methidathion0low10
deoxycytidine0low50
ethylestrenol0low20
cytidine diphosphate choline0medium51
2,4,6-triaminopyrimidine0low10
4-ethyl-1-phospha-2,6,7 trioxabicyclo(2.2.2)octane-1-oxide0low30
acetylhydrazine0low10
allylglycine0low210
ethambutol0medium61
pyrithioxin0low20
dimethyl glutarate0low10
tetramethylpyrazine0low20
n-benzyloxycarbonylglycine0low20
pyrovalerone0low10
phenazocine0low60
zinc oxide0low20
beta-pinene0low10
hydrofluoric acid0low10
vancomycin0low120
nsc 653460low10
glycyrrhizic acid0low30
d-alpha tocopherol0low370
tocopherols0low10
propanidid0low40
pregnenolone carbonitrile0low10
selenomethionine0low10
fluanisone0low10
vincamine0low10
malaoxon0low40
azaperone0low10
diphenyldiselenide0low90
digoxigenin0low20
spectinomycin0low10
laudanosine0low90
decane0low10
2-amino-6-methoxybenzothiazole0low10
1,2-diaminoanthraquinone0low10
cyclopropanecarboxylic acid0low10
azacyclonol0low10
norfenfluramine0low10
paraquat0low50
2'-deoxyadenosine triphosphate0low20
s,n,n'-tripropylthiocarbamate0low210
2-tert-butylhydroquinone0low10
5-hydroxyindole0low10
dronabinol0low660
methionine sulfoximine0low750
amiloride0low100
diallyl trisulfide0low10
pimozide0low190
benperidol0low20
fenitrooxone0low10
phenethyl isothiocyanate0low20
fluorescein0low100
methylprednisolone hemisuccinate0low10
flupenthixol0low10
alpha-terpineol0low10
fucose0low20
sulfadoxine0low10
uridine diphosphate glucuronic acid0low10
ddms0low20
octogen0low10
sulfuryl fluoride0low10
chlordesmethyldiazepam0low10
stavudine0low20
n-(3-aminopropyl)cyclohexylamine0low10
fluorescein-5-isothiocyanate0low10
tetramethylsuccinonitrile0low10
sabinene0low50
mannose0low50
dithiothreitol0low10
palmatine0low10
megestrol0low10
cyclazocine0medium81
dimethyl trisulfide0low10
5-methylchrysene0low10
tranylcypromine0low270
fenethylline0low10
streptomycin0low150
carbonates0medium71
Brilliant Blue0low10
2-octanol0low10
valnoctamide0low60
9-benzyladenine0low10
tybamate0low10
cladribine0medium21
acetylthiocholine0low10
carbenicillin0low60
metanephrine0low10
trimetazidine0low10
buthionine sulfoximine0low50
5,6-dihydroxytryptamine0low40
metocurine0low10
floxacillin0low10
dihydrostreptomycin sulfate0low10
vidarabine0medium31
iodinated glycerol0low40
dimethindene0low20
limonene0low20
pipazethate0low10
chlorphenamidine0low20
n-methylaspartate0low3410
enbucrilate0low30
bipiperidyl mustard0low10
trimethaphan0low30
cyheptamide0low10
phenylethylmalonamide0low50
hepes0low10
molindone0low30
manganese0low180
mercury0low90
molybdenum0low40
neon0low40
palladium0low20
platinum0medium71
rhodium0low30
ruthenium0low20
silver0low40
technetium0low90
titanium0low20
tungsten0low190
argon0medium41
cadmium0low40
gadolinium0medium191
gold0low100
helium0low260
uranium0low20
vanadium0low10
xenon0medium111
lead sulfate0low10
aluminum chloride0low20
magnesium sulfate0medium19231
mercuric chloride0low10
acetylglucosamine0low10
galactosamine0low10
6-nitroindazole0low10
phosphoric acid, trisodium salt0low90
sodium nitrate0low10
cesium chloride0low10
camptothecin0low40
ferric chloride0low140
ferrous sulfate0low10
bromine0low40
barium sulfate0low30
monoethylglycinexylidide0low40
zinc sulfate0low20
tricalcium phosphate0medium21
ferrous chloride0low60
chromates0low10
metoprine0low60
sodium thiosulfate0low50
deuterium0low20
fluorine0medium381
chlorine0low110
thallium chloride0low30
methyl demeton0low20
galactose0low50
poloxalene0low10
vasotocin0low40
barium nitrate0low10
ozone0low30
aluminum sulfate0low10
sodium selenite0low30
cadmium chloride0low10
barium chloride0low10
trolamine salicylate0low150
tetrazepam0low10
ethyldiphacil0low10
clodronic acid0low10
chrysotile0low10
ammonium chloride0low130
ethionine0low40
cysteic acid0low30
misonidazole0medium21
menthone0low10
4-chlorophenylalanine methyl ester0low10
tiletamine0low20
tiletamine hydrochloride0low90
etorphine0low50
selegiline0low80
phytanic acid0low10
levamisole0low60
thiamphenicol0low20
cephalexin0low20
2,3-dihydroxyquinoxaline0low10
cromolyn sodium0low40
tetradecanoylphorbol acetate0low30
sodium bisulfide0low10
fluorides0low130
metergoline0low60
lisuride0low40
verbenone0low10
cresyl violet0low70
4-amino-2,6-dinitrotoluene0low10
daba0low20
oxadiazon0low10
phenyl valerate0low10
iodine0low10
cannabichromene0low10
daunorubicin0low30
lofexidine0low10
phosphotyrosine0low40
dexetimide0low10
bromocriptine0low250
fenitrothion0low10
phenyl acetate0medium1519
cetylpyridinium chloride anhydrous0low50
2,5-dimethylpyrazine0low10
myrcene0low10
acetylacetone0low10
paraldehyde0medium483
pyrrolidine0low20
butyl acetate0low10
isoamyl acetate0low10
picrotoxin0low10
triamcinolone0low40
methiodal0low10
sulfolane0low10
tetrachloroethylene0low10
dimethylacetamide0low10
fludrocortisone0low20
ursodeoxycholic acid0low20
pregnanolone0medium815
isothiuronium0low20
benzonidazole0low10
4-methoxyamphetamine0low340
dihydro-beta-erythroidine0low30
1-phenylcyclohexylamine0low40
8-bromo cyclic adenosine monophosphate0low10
dh 5240low10
dihydroxyethyldithiocarbamate0low30
carticaine0low30
1-(2-(2,4-dichlorophenyl)-2-hydroxyethyl)-1h-imidazole0low10
transferrin0low80
normeperidine0low70
androstane-3,17-diol0low80
alkenes0low20
calcium oxalate0low10
glutamic acid0medium4691
cefazolin0medium241
allura red ac dye0low10
bis(4-methyl-1-homopiperazinylthiocarbonyl)disulfide0low110
sodium azide0low20
azides0low260
adenosine diphosphate ribose0low20
amoxicillin0low70
timolol0low30
tramadol0low640
eterobarb0low10
nicergoline0low20
safrazine0low10
oxcarbazepine0medium1018
4-ethynylbiphenyl0low10
s-adenosylmethionine0low50
vidarabine phosphate0low10
zidovudine0low30
zolazepam0low10
5,7-dihydroxytryptamine0low150
3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6h-dibenzo(b,d)pyran-1-ol0low10
tobramycin0low20
paclitaxel0low90
etoposide0low150
substance p0low250
acetosulfame0low10
isoproturon0low10
dobutamine0low50
oxetorone0low10
gamma-aminobutyric acid cetyl ester0low20
zipeprol0low40
ticarcillin0low10
norsalsolinol0low10
penbutolol0low10
etidocaine0low110
ribavirin0medium21
amikacin0low40
phorbol 12,13-dibutyrate0low10
fluorescamine0low10
hydroxymaprotilin0medium21
methyldopa0medium171
tocainide0low40
spirogermanium0low20
sq-117250low10
diltiazem0medium151
vecuronium bromide0medium61
vx0low140
2-methyl-4-isothiazolin-3-one0low10
ng-nitroarginine methyl ester0low1130
4-isopropylbicyclophosphate0low20
phenazepam0low60
permethrin0low60
quisqualic acid0low250
decamethrin0low40
1-carboxyglutamic acid0low10
vindesine0low10
rp 312640low20
meptazinol0low10
6-benzoyl benzoxazolinone0low10
sufentanil0low70
torsemide0low40
epirubicin0low30
desflurane0low20
enkephalin, methionine0low410
dihydroalprenolol0low90
propiconazole0low120
cefonicid0low20
piperacillin0low80
cefotiam0low20
paroxetine0medium122
captopril0low60
progabide acid0low10
progabide0medium352
cefoperazone0low10
ethylcholine aziridinium0low10
atracurium0low100
moxalactam0low20
nicorandil0low30
bw-755c0low10
pergolide0low10
colforsin0low110
pimonidazole0low10
avobenzone0low10
pefloxacin0low50
daurisoline0low10
nafimidone0low60
alfentanil0medium103
fomesafen0low2730
fenoxycarb0low10
1-(3,4-dihydroxyphenyl)-2-(1-imidazolyl)ethanone0low10
lovastatin0low30
flupirtine0low60
rimcazole0low10
dazmegrel0low10
milacemide0low60
n-(4-nitrophenacyl)imidazole0low10
denzimol0medium101
enoximone0low10
castanospermine0low10
simvastatin0medium81
idazoxan0low190
fengabine0low10
remoxipride0low10
quinpirole0low120
cabergoline0low10
atomoxetine hydrochloride0low150
alpidem0low20
raloxifene hydrochloride0low40
gepirone0low30
mifepristone0low60
itraconazole0low60
antineoplaston a100medium11
fosphenytoin0medium607
salmeterol xinafoate0low10
ranolazine0low40
ipsapirone0low20
fura-20low10
finasteride0low200
cy 208-2430low20
pazinaclone0low10
esmolol0low20
sabeluzole0low10
temafloxacin0low20
sertindole0low20
adapalene0low10
sparfloxacin0low40
remacemide0low80
clopidogrel0low10
tiagabine0medium453
topotecan0low10
eliprodil0low10
gemcitabine0low30
enadoline0low20
aripiprazole0low90
sipatrigine0low20
remifentanil0medium235
atorvastatin0low150
lamivudine0low20
duloxetine hydrochloride0low80
irinotecan0low10
ziprasidone0low60
3-iodobenzylguanidine0low10
simendan0low10
relcovaptan0low10
capecitabine0low50
adenosine0low1830
metaldehyde0low110
safranal0low10
3-n-butylphthalide0low10
nitrogen chloride0low50
cymantrene0low10
vanadates0low10
dimethylhydrazines0low50
4-methyloctanoic acid0low10
carfentanil0low10
cathinone0low60
isothiocyanic acid0low10
rubidium chloride0low10
carbogen0low10
tenocyclidine0low100
cyamemazine0low10
cisatracurium0low20
venlafaxine hydrochloride0medium343
trazodone hydrochloride0low10
hydrochlorothiazide-triamterene0low10
trovafloxacin0medium21
caffeine, sodium benzoate drug combination0low30
efavirenz0low70
nelfinavir0low30
tetramethylenedisulfotetramine0medium191
cyclohexyl methylphosphonofluoridate0low60
glucose, (beta-d)-isomer0low150
3,4-dihydro-2(1h)-quinolinone0low10
beta-hydroxy-beta-ethyl-phenylpropionamide0low30
chloroquine diphosphate0low20
2',7'-dichlorofluorescein0low10
ursolic acid0low20
norharman0low10
thiazolyl blue0low20
betulinic acid0low10
baicalin0low20
plerixafor0low20
oseltamivir0low80
5-methylcytosine0low10
thionine0low10
epigallocatechin gallate0low50
n-acetylaspartic acid0medium241
homocitrulline0low10
fluorexon0low10
distearoyl phosphatidylglycerol0low10
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose0low10
fluorophosphate0low30
2-deoxy-2,3-dehydro-n-acetylneuraminic acid0low10
dopamine hydrochloride0low10
peroxynitric acid0low10
glutathione disulfide0low50
hypusine0low10
fanasil, pyrimethamine drug combination0low10
4-nitrobenzylthioinosine0low40
iopamidol0low150
metamizil0low10
cephalosporin c0medium341
erdosteine0low10
ritipenem0low10
isbufylline0low10
3-bromophenylsuccinimide0low30
tretoquinol0low10
divaplon0low10
milnacipran0low10
cm 409070low20
azetirelin0low10
nerisopam0low10
abecarnil0low130
prulifloxacin0low10
pazufloxacin0low40
andolast0low10
lubeluzole0low20
telmisartan0low30
dioxadrol0low10
dexamisole0low10
xenon radioisotopes0low40
parabanic acid0low10
bromosuccinimide0low10
1,7-phenanthroline0low20
triazoles0medium1153
1h-tetrazole0low40
1,2,4-triazine0low10
g 295050low10
guanidinopropionic acid0low10
tangeretin0low10
isopimpinellin0low10
delphinidin0low10
n,n-carbonyldiimidazole0low10
guanidinoethane sulfonate0low60
toltrazuril0low10
medetomidine0low90
setoperone0low10
fluorodeoxyglucose f180medium1083
sertraline0medium233
picosulfate sodium0low10
selfotel0low140
zoledronic acid0low40
p2970low10
budipine0low20
pirlindole0low10
delta sleep-inducing peptide0low80
mesulergine0low20
tianeptine0low30
ryodipine0low10
artemether0low20
acetylurea0low30
4-aminopyrimidine0low10
glycine amide0low10
4,4'-diaminobenzophenone0low10
3-amino-3-phenylpropionic acid0low10
5-methylhydantoin0low20
4-methoxypyridine0low10
triheptanoin0medium91
tricaprin0low10
beta-hydroxyisovaleric acid0low10
fructose-6-phosphate0low10
1-methyluric acid0low10
cyclopropylamine0low10
4-phenylpiperidine0low20
4,4'-diaminobenzanilide0low10
1,3-dimethyluric acid0low20
3-methylxanthine0low20
glutarimide0low20
dipropylacetamide0medium61
nefiracetam0low70
acamprosate0low10
n-methylscopolamine0low80
enrofloxacin0low20
cromakalim0low90
barbexaclone0low40
pipequaline0low40
posatirelin0low10
sarmazenil0low10
taltrimide0low10
girisopam0low10
atipamezole0low50
lifarizine0low20
ljc 106270low20
masoprocol0low10
voriconazole0low70
prethcamide0low10
enocitabine0low10
aceclofenac0low10
niaprazine0low10
indenolol0low10
pro-diazepam0low40
indorenate0low10
panipenem0low20
terlipressin0low20
sydnophen0low10
octylonium0low10
losoxantrone0low10
tolycaine0low10
zetidoline0low10
timefurone0low10
methotrimeprazine0low20
magnolol0low30
honokiol0low10
betulin0low10
picropodophyllin0low10
centazolone0low10
indole-2-carboxylic acid0low20
vexibinol0low10
serpentine (alkaloid)0low10
beta-amyrin0low10
doripenem0low50
5-(n-methyl-n-isobutyl)amiloride0low10
2,6-dimethylphenylphthalimide0low20
calpeptin0low10
5-benzylhydantoin0low10
corilagin0low10
sakuranetin0low10
bilobalide0low30
maslinic acid0low10
carbohydrazide0low10
oxazolidin-2-one0low40
glutamic acid diethyl ester0low180
perfluorooctane sulfonic acid0low10
pentafluorobenzyl bromide0low10
2-(methylamino)isobutyric acid0low10
tutin0low20
n-desmethylflunitrazepam0low10
1-benzylpiperazine0low40
4-aminobenzamide0low10
7-bromo-5-phenyl-1,2-dihydro-2h-1,4-benzodiazepin-2-one0low10
2-chlorodiazepam0low10
4-methoxymethylpyridoxine0low100
g 16160low10
1-benzylimidazole0low10
rivastigmine0low20
rosiglitazone0low60
boc-glycine0low10
4-nitrophenethyl bromide0low10
3-chloropropionamide0low10
1-nitro-2-phenylethane0low10
1-methylxanthine0low10
carvacryl acetate0low10
s200980low60
1-ethyl-2-benzimidazolinone0low20
4-phenylbutylamine0low10
biocytin0low80
cocaine methiodide0low10
d-aspartic acid0low10
clarithromycin0low20
asperuloside0low10
bromates0low10
1,2-dibenzoyl-tert-butylhydrazine0low10
coenzyme a0low80
2-(2-aminoethyl)thiazole0low10
7,8-dihydromethysticin0low10
5-thio-d-glucose0low20
nicotine0low1630
nsc-1727550low20
1-aminocyclobutanecarboxylic acid0low10
n-desmethylclobazam0medium31
fibrinogen0low100
4-methoxymethamphetamine0low10
tiagabine hydrochloride0low30
beta-thujone0low30
beta-eudesmol0low10
aucubin0low10
equol0low10
indium arsenide0low10
3,4-dihydroxyphenylglycol0low30
homocysteine0low710
alpha,beta-methyleneadenosine 5'-triphosphate0low10
5-(3-hydroxyphenyl)-5-phenylhydantoin0low10
2-methylhistamine0low10
acetylsalicylic acid lysinate0low20
sk&f 952820low20
sclareol glycol0low40
4-methylaminorex0low10
adenosine 5'-methylenediphosphate0low40
1-methyl-1,2,3,4-tetrahydroisoquinoline0low40
tetrakis-mu-acetylsalicylato-dicopper(ii)0low10
levobupivacaine0low50
zofenopril0low10
n-(4,4-diphenyl-3-butenyl)nipecotic acid0low20
mci 90380low20
lopinavir0medium31
brexanolone0low30
5-alpha-dihydroprogesterone0low40
arginine methyl ester0low10
droxidopa0low60
glutamic acid dimethyl ester0low10
alpha-benzyl-n-methylphenethylamine0low10
4-methylumbelliferyl-galactopyranoside0low10
methyl beta-galactoside0low10
dehydroabietic acid0low10
glucuronic acid0low10
palmitone0low30
isovaline0low30
2-chloroadenine0low10
n-hydroxymethylsuccinimide0low10
desethylchloroquine0medium11
imidazoleacetic acid0low20
oxymethacil0low10
pimprinine0low10
bromotubercidin0low10
5-iodotubercidin0low80
1,3,4-oxadiazole0low10
5-chlorotubercidin0low10
3-aminopropylphosphonic acid0low10
nicotinic acid benzylamide0low10
2-(4-bromo-2,5-dimethoxyphenyl)ethylamine0low10
nipecotic acid ethyl ester0low10
3-hydroxy-3-phenacyloxindole0low10
3,7-dimethyl-1-propargylxanthine0low20
pyrimidin-2-one beta-ribofuranoside0low10
gamma-glutamylglycine0low30
enkephalinamide-met, ala(2)-0low90
diphenylditelluride0low10
2,5-dihydro-2-(4-methoxyphenyl)-3h-pyrazolo(4,3-c)quinolin-3-one0low10
tetrahydrodeoxycorticosterone0low100
pregnanetriol0low10
2,3-bis(4-hydroxyphenyl)-propionitrile0low10
cobalt0low1540
p-methoxy-n-methylphenethylamine0low30
fulvestrant0low10
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid0low50
yttrium radioisotopes0low10
1-amino-1,3-dicarboxycyclopentane0low140
carbidopa, levodopa drug combination0low20
tert-butylbicyclophosphorothionate0low300
enkephalin, d-penicillamine (2,5)-0low60
vitamin b 60low500
1,4-dihydropyridine0low20
imipenem, anhydrous0medium535
cremophor el0low10
alphaxalone0low70
sr1417160low110
bicuculline methiodide0low350
cp-55,9400low10
2-propyl-4-pentenoic acid0low10
u 74006f0medium11
diacetyldichlorofluorescein0low10
2-phenylpyrazolo(4,3-c)quinolin-3(5h)-one0low170
u 74389f0low20
2-(2-cresyl)-4h-1-3-2-benzodioxaphosphorin-2-oxide0low20
methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate0low450
paxilline0low40
fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether0low10
artesunic acid0low10
cyanates0low40
3,4-methylenedioxyethamphetamine0low10
(3h)2-carbomethoxy-3-(4-fluorophenyl)tropane0low10
pregnenolone sulfate0low60
beta-carboline-3-carboxylic acid ethyl ester0low210
epibatidine0low30
beta-n-methylamino-l-alanine0low10
u 695930low40
fumitremorgin b0low10
methyllycaconitine0low20
fluorocitrate0low80
n,n-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine0low30
bremazocine0low20
cgp 353480low100
beta-carboline-3-carboxylic acid methyl ester0low280
fumitremorgin a0low30
indoxacarb0low10
inositol 1-phosphate0low50
propionylcarnitine0low10
1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol0low30
saikosaponin d0low10
hypotaurine0low10
enkephalin, ser(2), leu(5), thr(6)-0low50
geniposide0low10
procyanidin0low30
dihydrokainate0low20
sr 955310low110
epicatechin gallate0low10
phosphites0low20
1-hydroxymethylmidazolam0low10
2'-5'-oligoadenylate trimer0low10
asulacrine0low10
bretazenil0low50
5-hydroxypropafenone0low10
solenopsin a0low10
cl 2188720low70
s-methylthiocitrulline0low10
fingolimod hydrochloride0low60
daidzin0low10
propylisopropylacetamide0low30
6-chloro-2-(1-piperazinyl)pyrazine0low20
3,5-dihydroxyphenylglycine0low70
cobaltiprotoporphyrin0low10
5-methoxy 3-(1,2,3,6-tetrahydro-4-pyridinyl)1h indole0low20
2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3h)-one0low40
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol0low10
st 14350low10
parthenolide0low10
acromelic acid a0low20
npc 126260low30
2-deoxyglucose-6-phosphate0low10
schizandrin b0low10
dynorphin (1-8)0low20
1-hexadecyl-2-acetyl-glycero-3-phosphocholine0low120
zacopride0low10
ci 9880low10
deoxyglucose0medium981
tadalafil0low60
anserine0low10
s 1350low20
6-methyl-2-ethyl-3-hydroxypyridine0low10
10-hydroxycarbamazepine0medium72
metaphit0low110
valerates0low230
thromboxanes0low30
n-n-propyl-n-phenylethyl-4(3-hydroxyphenyl)ethylamine hydrochloride0low10
landiolol0medium22
tanshinone0low10
tert-butylbicyclo-2-benzoate0low70
sc 419300low10
s-sulphocysteine0low10
gastrodin0low60
quadazocine0low10
tyrosyl-prolyl-leucyl-glycinamide0low20
way 1001350low10
2-(2,3-dicarboxycyclopropyl)glycine0low70
megestrol acetate0low30
isofloxythepin0low30
3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate0low10
tifluadom0low10
zk 934260low10
ginkgolide a0low10
panipenem-betamipron0low20
2',6'-pipecoloxylidide0low10
phenobarbital-n-glucoside0low10
morphiceptin, n-me-phe(3)-0low30
bw 373u860low30
prunasin0low10
asiatic acid0low10
7-methoxytacrine0low10
2-n-propyl-4-pentynoic acid0low10
imidazenil0low120
1-methyl-5-phenyl-5-propylbarbituric acid0low10
morphiceptin0low20
arg-3-hyp-7-phe-bradykinin0low10
5-fluoromethylornithine0low10
afdx 3840low10
3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole0low40
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride0low20
caprylates0low80
1,3,4-thiadiazole0low30
tris(2-carboxyethyl)phosphine0low20
ah 68090low10
gamma-glutamylaminomethylsulfonic acid0low40
alphaprodine0low10
carglumic acid0low10
ezogabine0medium393
egta acetoxymethyl ester0low10
4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline0low10
zk 934230low20
methylthio-adp0low10
dihydropicrotoxinin0low20
pd 1173020low20
dopamine 3-o-sulfate0low10
pyroglutamyl-glutamyl-proline amide0low10
gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate0low10
1-(4-methoxyphenyl)pyridinium0low10
l 6599890low10
luzindole0low40
neo-kyotorphin0low10
sulforhodamine 1010low10
uh 3010low10
mebikar0low10
san 2027910low10
a 689300low20
peroxynitrous acid0low30
fullerene c600low10
imatinib mesylate0low30
almotriptan0low10
mk 06630low40
tazobactam0low20
des-enkephalin-gamma-endorphin0low10
propyl beta-carboline-3-carboxylate0low20
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine0low20
1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine0low10
zk 912960low30
cdp ethanolamine0low10
nnc 7110low20
argipressin (4-9)0low10
deltorphin ii, ala(2)-0low10
phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide0low10
kyotorphin0low20
2-chloro-n(6)cyclopentyladenosine0low70
ro 8-05760low10
angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-0low20
n,n-dimethylarginine0medium11
cyclic adp-ribose0low10
3-(2,2,2-trimethylhydrazine)propionate0low10
interleukin-1beta (163-171)0low10
hydroxycitric acid0low10
glycylglutamine0low10
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide0low130
pristanic acid0low10
dopamine 4-o-sulfate0low10
sk&f 864660low10
zd 72880low50
acth (4-9)0medium11
4-amino-n-(2,6-dimethylphenyl)phthalimide0low20
desloratadine0low20
garenoxacin0low20
iguratimod0low10
ly 2061300low10
3-ethoxy-beta-carboline0low20
1-amino-5-bromouracil0low10
tert-butyl beta-carboline-3-carboxylate0low10
1-(4-chlorobenzoyl)piperazine-2,3-dicarboxylic acid0low10
1-(4-bromobenzoyl)piperazine-2,3-dicarboxylic acid0low10
3-(methoxycarbonyl)amino-beta-carboline0low30
glycerophosphoinositol 4,5-bisphosphate0low10
blonanserin0low10
valproylcarnitine0low10
ethoxyidazoxan0low10
ly 1885440low30
sk&f 1048560low10
(tetrazol-5-yl)glycine0low20
bd 10080low60
pre 0840low20
vv-hemorphin-70low10
lestaurtinib0low20
1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid0low10
amthamine0low10
gyki 536550low20
sb 2006460low10
methotrexate0medium712
pyrrolidine-2,3-dicarboxylic acid0low10
reboxetine0low40
idph-7910low10
paeonimetabolin i0low10
ro 19-46030low30
ar 124560low10
bw-a 78u0low30
3-(2-carboxypiperazine-4-yl)propyl-1-phosphate0low30
(3-nitrobenzoyl)alanine0low10
acea 10110low20
ly 2935580low120
1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine0low10
5'-deoxytoyocamycin0low10
4-hydroxytriazolam0low10
alpha-ethyl, alpha-methyl-thiobutyrolactone0low20
beta-ethyl, beta-methyl-thiobutyrolactone0low10
hemorphin 40low10
salvinorin a0low10
dihydroethidium0low10
ici 1062700low10
gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide0low30
s 3120low10
rufinamide0medium223
1-naphthylacetylspermine0low20
l 6635810low10
antiprimod0low10
cgp 367420low20
cgp 463810low10
5-aminocarbonyl-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5,10-imine0low40
alpha-acetamido-n-benzyl-alpha-(furan-2-yl)acetamide0low40
sulbactam0low20
5'-o-(4,4'-dimethoxytrityl)thymidine-3'-o-(2,4-dinitrophenyl) succinate0low10
nafimidone alcohol0low10
glutapyrone0low10
n-(6-methoxy-8-quinolyl)-4-toluenesulfonamide0low10
5,7-dinitroquinoxaline-2,3-dione0low10
1-methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline0low10
alpha-isopropyl-alpha-methyl-gamma-butyrolactone0low20
safinamide0low50
4-amino-1-(6-chloro-2-pyridyl)piperidine hydrochloride0low20
ly 2746140low20
cgp 524320low10
u 920320low10
l 6903300low10
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide0low10
5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate0low10
af-cx 921xx0low10
omega-n-methylarginine0low40
ivabradine0low40
sonepiprazole0low10
sk&f 839590low20
n-aminomethylpiperazine 3,3-diethyl-2,4-pyridinedione0low20
beta-casomorphin, des-tyr-0low10
carbapenems0low220
di-beta-(morpholinoethyl)selenide0low10
ganglerone0low20
triiodothyronine0low120
aspartame0low170
sk&f 100330-a0low20
ethylketocyclazocine0low20
xylose0low20
valerylsalicylate0low10
alpha-guanidinoglutaric acid0low30
2-acetamido-n-benzyl-2-methylacetamide0low30
beta-lactams0low160
methylenecyclopropylglycine0low10
phytol0low10
proline0low310
cucurbitaceae0low20
ro 17-18120low10
escitalopram0medium11
docetaxel anhydrous0medium21
bdp 120low10
tariquidar0low70
rs 42358-1970low10
levofloxacin0medium181
ezetimibe0low10
ertapenem0low130
allophanic acid0low10
cariporide0low10
5-methoxy-n,n-diisopropyltryptamine0low10
1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline0low10
glycine tert-butyl ester0low10
1-thioglucose0low10
moxifloxacin0low30
pralnacasan0low10
mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin0low20
naproxen0low40
alpha-methylhistamine0low10
dn 14170low70
pk 90840low40
hydroxyl radical0low30
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid0low10
atazanavir sulfate0low30
jte 5220low10
rhodioloside0low10
baldrinal0low10
acetyltaurine0low10
ukrain0low10
ketobemidone, n,n-dimethyl-3,3-diphenyl-1-methylallylamine drug combination0low20
dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination0low10
carbodiimides0low10
delta-guanidinovaleric acid0low10
harmalan0low10
ar-turmerone0low10
cannabidiolic acid0low20
allysine0low40
prostaglandins b0low10
gamma-glu-asp0low10
methindione0low10
homocysteinesulfinic acid0low10
ag 3-50low10
4-phenyl-4-piperidinocyclohexanol0low10
substance p (5-11)0low10
n-desmethylzopiclone0low10
asenapine0low10
normorphine-3-glucuronide0low10
neurokinin a (4-10), nle(10)-0low10
substance p, sar(9)-met(o2)(11)-0low10
5-(3-hydroxybenzoyl)-2-thiophenesulfonamide0low10
bmy 400620low10
4-methyl-3-methylsulfonyl-5-phenyl-4h-1,2,4-triazole0low20
4-(2'-pyridyldithio)benzyldiazoacetate0low10
ly 3001640low150
methylinositol0low10
delta-1-piperidine-6-carboxylic acid0low10
n-phthaloyl-4-aminobutyric acid0low20
technetium tc 99m pentetate0low30
clorazepate dipotassium0low130
n-n-propylnorapomorphine0low10
2-ethyl-2-methyl-4-butyrolactone0low20
3-(2-carboxyindol-3-yl)propionic acid0low10
chloropent0low10
varenicline0low60
1-benzylimidazole-4,5-dicarboxylic acid0low10
isopulegol0low10
feracryl0low10
biotin0low260
angiotensin ii0low210
dipiperidinoethane-di-n-oxide0low20
3-fluoronorepinephrine0low10
4-hydroxynipecotic acid0low10
beta-methyleneaspartate0low10
carboline-3-carboxylic acid0low10
n(6)-(2-(4-chlorophenyl)bicyclo(2.2.2.)-octyl)(3)-adenosine0low10
gangliotetraose0low10
4-chlorokynurenine0low10
enkephalin, alanh2(5)-0low10
2,10,11-trihydroxy-n-n-propylnoraporphine0low10
gabaculine0low50
1-nitrohydroxyphenyl-n-benzoylalanine0low10
atropine0medium2411
trimix0low10
ropivacaine0medium351
sb 2035800low20
nbi 279140low10
sb 2167630low10
gacyclidine0low40
zm 2413850low60
erlotinib hydrochloride0low30
homocysteic acid0low150
organophosphonates0low60
dexketoprofen trometamol0low20
antalarmin0low20
eslicarbazepine acetate0medium6727
dizocilpine0low40
2,2,3,3-tetramethylcyclopropane carboxamide0low40
3-hydroxyglutaric acid0low30
esketamine0low10
pilocarpic acid0low10
schaftoside0low10
u 54494a0low40
ah 79210low10
alpha-fluoromethylhistidine0low50
isospaglumic acid0low110
bd 10470low20
deflazacort0low10
3-isoxazolidone0low10
cassine0low10
2'-deoxyadenosine 5'-o-(1-thiotriphosphate)0low10
nantenine0low10
1-phenylcyclohexylamine hydrochloride0low10
dronedarone0low20
ramelteon0low10
zk 2007750low10
eglumetad0low30
cp 4243910low10
dabigatran0low10
tolvaptan0low10
sorafenib0low10
regadenoson0low20
lacosamide0medium16320
cp 101,6060low30
3-hydroxy-quinazoline-2,4-dione0low10
sandaracopimaric acid0low10
l-glutamic acid-gamma-hydrazide0low10
estradiol 3-benzoate0low50
cortisone0low330
eudesmin0low10
3-nitrotyrosine0low60
lanosterol0low10
anisomycin0low50
benzofurans0low220
potassium bromide0medium212
sodium bromide0low20
estramustine0low10
lupeol0low10
gardenin a0low10
withaferin a0low10
acivicin0low10
wortmannin0low30
ibogaine0low40
6-Fluoro-1,3-benzothiazol-2-amine0low10
a-130a0low10
withanolides0low10
trimethoprim, sulfamethoxazole drug combination0low110
bortezomib0low10
ritonavir0medium91
mrs 11910low10
dihydropyridines0low190
protoverin0low10
methylmercuric chloride0low20
povidone-iodine0low40
4-aminopiperidine0low10
carboplatin0medium71
anatoxin a0low20
lithium chloride0low630
leptomycin b0low10
s-adenosylhomocysteine0low30
glycogen0low820
ribulose 5-phosphate0low10
arabinose0low10
n-acetylneuraminic acid0low20
fibrin0low20
bradykinin0medium131
glucosamine0low20
elastin0low20
carnosine0medium101
mevalonic acid0low30
raffinose0low10
naringenin0low10
diaminopimelic acid0low10
oxytocin0low450
theanine0low30
inositol 1,4,5-trisphosphate0low40
ouabain0low530
agaritine0low10
amastatin0low10
puromycin0low80
desmosterol0low30
tartaric acid0low20
pentostatin0low20
nitroarginine0low350
inositol 3-phosphate0low60
elymoclavine0low20
arbutin0low10
strychnine0low4790
quinidine0medium221
meropenem0medium351
digitoxin0low120
pentazocine0low160
pancuronium0low130
rocuronium0medium41
abacavir0low10
netilmicin0low10
linezolid0low20
canaline0low20
norpseudoephedrine0low10
ryanodine0low10
ginsenoside re0low10
ginsenoside rg10low10
brucine0low20
decursin0low10
picrotoxinin0low20
genipin0low10
naringin0low20
swertiamarin0low20
securinine0low20
cyclopamine0low20
lignans0low30
bq 1230low20
n-formylmethionine leucyl-phenylalanine0low10
devazepide0low20
diprenorphine0low30
ergonovine0low100
metrizamide0medium381
vinpocetine0medium61
sultamicillin0low10
betadex0low20
acetyl coenzyme a0low20
tretinoin0low50
arachidonic acid0low160
fumaric acid0low10
farnesol0low10
phosphoramidon0low30
3-hydroxy-3-methylglutaryl-coenzyme a0low10
resveratrol0low140
retinol0medium151
rwj 379470low10
latrunculin a0low50
oleic acid0low30
tacrolimus0medium401
ferulic acid0low60
cerivastatin0medium11
cocaine0medium3102
eicosapentaenoic acid0low40
alpha-methyl-4-carboxyphenylglycine0low70
thapsigargin0low10
mycophenolic acid0low60
clindamycin0medium91
gw 64710low20
mdl29,9510low20
lycopene0low30
fosfomycin0low10
zithromax0low10
adenylosuccinate0low10
hts 4662840low10
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea0low10
y 276320low20
adenosine-5'-(n-ethylcarboxamide)0low120
benzoylecgonine0low20
prostaglandin d20low80
h 890low50
imidazolidines0low50
acid fuchsin0low10
iridoids0low40
cefamandole0low20
dactinomycin0low110
arsphenamine0low10
azaserine0low10
melphalan0low50
enkephalin, leucine0low940
tenofovir0low10
6-bromoflavone0low10
l 743,8720low10
riboflavin0low40
potassium permanganate0low20
sodium bicarbonate0low230
sodium benzoate0low20
sodium cyanate0low10
ammonium acetate0low80
norlevorphanol0low20
dipyrone0low70
oxazolidine0low40
4-chloro-2,5-dimethoxyamphetamine0low10
bromochloroacetic acid0low30
6-propan-2-yl-1,3-benzothiazol-2-amine0low10
7-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one0low10
desmethylclomipramine0low10
carbenoxolone sodium0low130
meglumine iodipamide0low10
tenatoprazole0low10
alpha-asarone0low50
anethole0low10
geraniol0low10
dimethyl fumarate0low20
glycosides0low150
isomethyleugenol0low170
isosafrole0low20
piplartine0low10
citral0low20
piperine0low90
stilbenes0low150
isoliquiritigenin0low10
phenyl-n-tert-butylnitrone0low50
picibanil0low10
ilepcimide0low20
flavin-adenine dinucleotide0low10
pseudococaine0low10
cocaethylene0low10
norcocaine0low20
cannabidiol0medium19824
buprenorphine0low60
lypressin0low40
arginine vasopressin0low280
sea 04000low10
pyrophosphate0low70
gw96620low50
amygdalin0low10
trilostane0low10
methylatropine0low50
canrenoic acid0low10
iothalamate meglumine0low210
tropisetron0low20
sodium metabisulfite0low10
ly3828840low10
xe 991, anthracenone0low20
leuprolide0low30
fludarabine0low10
dithizone0low20
propylthiouracil0low100
nsc 43470low20
n(6)-cyclopentyladenosine0low150
sesquiterpenes0low310
chlorprothixene0low70
etomidate0medium447
mercaptopurine0medium81
methylthiouracil0low10
sb 3667910low10
3,3',4,5'-tetrahydroxystilbene0low10
bemesetron0low20
alpha-methyltryptophan, (l)-isomer0low30
thioinosine0low40
phenylthiourea0low10
(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide0low10
cinromide0low40
caffeic acid0low10
rg1080low20
n-benzoylalanine0low10
3,4,5-trimethoxycinnamic acid0low10
purine-nucleoside phosphorylase0low10
cotinine0low20
vu 01550410low10
flunarizine0low290
tetrahydropalmatine0low10
dieldrin0low310
curcumin0low220
hc 0300310low40
benztropine0low50
thiouracil0low20
thiohydantoins0low10
methimazole0low60
urb 5970low80
cinnarizine0low50
capsaicin0low70
enclomiphene0low30
metiamide0low10
terbinafine0low20
aurapten0low10
idrocilamide0low10
4-hydroxyphenylmethylene hydantoin0low10
3-methylglutaconic acid0low10
1-(1h-indol-3-ylcarbonyl)-n-(4-methoxybenzyl)formamide0low10
chlorogenic acid0low40
nipecotic acid0low10
thiobarbituric acid0low20
ethylenethiourea0low10
thiosemicarbazide0low290
thiourea0low270
D-fructopyranose0medium16624
unithiol0medium21
succimer0low50
digoxin0low90
N1-[4-(aminosulfonyl)phenyl]-2,2-dimethylpropanamide0low10
capsazepine0low20
fumonisin b10low10
tamoxifen0low150
nadp0low140
1,1-diphenyl-2-picrylhydrazyl0low30
ethionamide0low20
t 00709070low10
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole0low10
methyl-thiohydantoin-tryptophan0low10
fusidic acid0low10
at 610low10
lincomycin0low10
rhyncophylline0low10
thiopental0medium15512
estrone sulfate0low10
ranitidine0medium111
fursultiamin0low10
maraviroc0low20
u 01260low20
zinc oxide0low10
telaprevir0low10
nelarabine0low10
pica0medium91
4-diphenylacetoxy-n-methylpiperidine methiodide0low10
6-methyl-2-(phenylethynyl)pyridine0low130
lithium0medium1782
thiamylal0medium81
zineb0low20
cobaltous chloride0low30
nitrogen dioxide0low20
maneb0low20
phosphamidon0low10
dimethyl-heptyl tetrahydrocannabinol0low10
dermatan sulfate0low10
adrafinil0low10
nizatidine0low10
raclopride0low20
panadiplon0low30
ranitidine n-oxide0low10
bn 507300low10
loreclezole0low60
quinine0medium251
mitragynine0low10
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester0low10
androstane-3,17-diol glucuronide0low20
mr 22660low40
methylglucamine orotate0low20
mdl 725270low10
ici 1541290low60
ro 19-80220low40
gamma-endorphin, des-tyr(1)-0low10
triptorelin0low20
4-(1h-imidazol-4-ylmethyl)piperidine0low10
thioperamide0low80
cystine0low40
u-504880low170
ro 31-69300low10
hirsutine0low10
dimemorfan0low20
freedom0medium342
ketazocine0low10
9,10-dihydroergosine0low20
valmane0low10
oxalylglycine0low10
barakol0low10
glycyl-prolyl-glutamic acid0low10
methyl prednisolonate0low10
2-(2-benzofuranyl)-2-imidazoline0low10
sr 1445280low10
glutaryl-coenzyme a0low10
pca 509410low10
awd 131-1380medium91
ginsenosides0low50
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine0low90
alatrofloxacin0low10
N-(2,4,6-trimethylphenyl)-3-bicyclo[2.2.1]heptanecarboxamide0low10
napelline0low10
n-(indol-3-ylglyoxylyl)benzylamine0low10
phosphothreonine0low10
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline0low690
ovalbumin0low60
3,4-dicarboxyphenylglycine0low20
4-aminopyrrolidine-2,4-dicarboxylic acid0low50
crocin0low20
ncs 3820low10
2-chloro-5-hydroxyphenylglycine0low20
l 6635360low10
rs 1022210low10
6-bromo-3'-nitroflavone0low20
6-cyano-7-nitroquinoxaline-2,3-dione0low380
zinc protoporphyrin ix0low20
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3h)-quinazolinone0low30
sb 2250020low10
fg 90410low210
4-phenyl-2-propionamidotetraline0low10
cp 942530low10
6-nitro-1,4-dihydroquinoxaline-2,3-dione0low10
alpha-chymotrypsin0low20
ferrostatin-10low10
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione0low20
17-ketosteroids0low70
naphthoquinones0low10
am 2810low10
am 6300low50
digitoxigenin0low70
cfm 20low90
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol0low30
icodextrin0low10
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide0low10
rhodamine 1230low10
9-(2-morpholinoethyl)-2-(4-fluorophenyl)imidazo(1,2-alpha)benzimidazole0low10
myelin basic protein0low60
sm 210low10
3-propoxy-beta-carboline0low10
diclofenac sodium0low10
cgp 79300low10
2-mercaptoacetate0low20
1,2-diamino-4-nitrobenzene0low10
ro 60-01750low10
tetrathiomolybdate0low10
cinnamamide0low30
sphingosine0low30
quercetin0low150
bilirubin0medium202
dinoprostone0low300
dinoprost0low180
biochanin a0low10
leukotriene a40low10
vitexin0low10
apigenin0low30
luteolin0low50
linoleic acid0low20
calcitriol0low140
scopoletin0low10
vitamin k semiquinone radical0low150
beta carotene0low30
11-cis-retinal0low20
leukotriene b40low30
hymecromone0low10
alprostadil0low40
5-hydroxy-6,8,11,14-eicosatetraenoic acid0low10
vitamin d 20low180
stigmasterol0low30
cholecalciferol0low100
rutin0low90
leukotriene d40low30
leukotriene e40low20
6-ketoprostaglandin f1 alpha0low20
6-ketoprostaglandin e10low10
arachidonic acid omega-9 hydroperoxide0low10
gamma-linolenic acid0low10
alpha-linolenic acid0low60
harmine0low110
genistein0low50
amphotericin b0medium121
clavulanic acid0low50
montelukast0low70
mivacurium0medium31
kava0low10
carboprost0low10
ethchlorvynol0low40
paricalcitol0low20
astaxanthine0low20
spinasterol0low10
harman0low60
toxiferine0low10
esculetin0low10
pteryxin0low10
7-hydroxycoumarin0low30
humulene0medium861
oleuropein0low10
baicalein0low30
chrysin0low10
fisetin0low10
hispidulin0low20
hyperoside0low20
morin0low20
pterostilbene0low20
echinacoside0low10
caffeic acid phenethyl ester0low20
rosmarinic acid0low30
rottlerin0low20
ellagic acid0low30
coenzyme q100low60
anandamide0low150
geranylgeranylacetone0low10
iobenguane (131i)0low20
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid0low10
domoic acid0low260
glyceryl 2-arachidonate0low80
ro 61-80480low10
isotretinoin0low20
misoprostol0low20
olopatadine hydrochloride0low10
dothiepin hydrochloride0low40
triprolidine0low20
pitavastatin0low20
thromboxane b20low70
4-hydroxy-2-nonenal0low30
oleylamide0low30
ubiquinone 80low20
fucosterol0low10
codeine0low240
phenylephrine hydrochloride0low70
3-amino-1,4-dimethyl-5h-pyrido(4,3-b)indole0low20
3-amino-1-methyl-5h-pyrido(4,3-b)indole0low20
cyproterone0low10
dihydrocodeine0low30
granisetron0low20
hydrocodone0low10
hydromorphone0low60
levetiracetam0medium63462
nabilone0low10
nalorphine0low180
naloxone0medium1854
oxycodone0low50
vitamin k 10low10
proscillaridin0low10
sirolimus0medium733
topiramate0medium19626
lobeline0low30
morphine0low2490
as 6052400low10
cgp 623490low20
a 853800low10
2r,4r-4-aminopyrrolidine-2,4-dicarboxylate0low10
7-benzylidenenaltrexone0low10
alpha-neoendorphin0low20
arachidonyl-2-chloroethylamide0low100
arachidonylcyclopropylamide0low10
atosiban0low10
bay u97730low10
beta-funaltrexamine0low70
bibp 32260low50
bw 723c860low10
istradefylline0low20
deamino arginine vasopressin0low390
dexmedetomidine0medium294
olvanil0low10
fluticasone0low10
herbimycin0low10
gp 6830low10
goserelin0low10
iloprost0low30
preclamol0low20
j 1133970low10
l 3652600low10
al 88100low10
ly 3201350low10
lysophosphatidic acid0low10
lysophosphatidylcholines0low30
mdl 1009070low50
cytochalasin b0low10
nalbuphine0low30
neurokinin a0low20
neurokinin b0low30
ciguatoxins0low10
pd 1233190low40
l7967780low10
l8030870low10
sib 18930low10
stiripentol0medium351
kn 930low10
kn 620low10
sb 2710460low10
sulprostone0low30
cannabigerol0low10
collinin0low10
linarin0low10
andrographolide0low10
icariin0low10
licochalcone a0low10
nerolidol0low10
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one0low10
caryophyllene0low50
thebaine0low60
fluvoxamine0low90
lacinartin0low10
casein kinase ii0low20
ag-4900low10
su 112480low20
ergothioneine0low20
lead0medium411
tin0low10
3-hydroxymethyl-beta-carboline0low10
6,7-dihydroxyflavone0low10
8-(3-chlorostyryl)caffeine0low10
brevetoxin t170low10
mdl 1055190low10
n-(aminocarbonyl)-2-ethyl-2-butenamide0low10
antimony0low10
cesium0low50
barium0low110
mevinphos0low20
rubidium0low40
trimethyltin0low140
aluminum0low650
levorphanol0low80
strontium0low10
bismuth0low50
thallium0low80
arsenic0low70
naltrexone0low700
morphine-6-glucuronide0low20
dextromethorphan0low440
dextrorphan0low140
lasalocid0low10
butorphanol0low10
methylnaltrexone0low10
lisinopril0low10
indinavir sulfate0low20
sulfur0low130
methylazoxymethanol acetate0low80
zimeldine0medium42
veratrine0low20
puerarin0low10
enalapril0low80
1-methyl-beta-carboline-3-carboxylic acid0low80
nitrofurazone0low10
thevetine0low10
sinomenine0low10
6-codeinone0low10
fumarates0low60
cysteine0medium412
thyronines0low20
silicon0low10
phosphorus0low530
boron0low60
bialaphos0low20
heroin0medium192
enkephalin, ala(2)-mephe(4)-gly(5)-0low10
normorphine0low20
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid0low10
metkephamid0low10
cefepime0low120
norbinaltorphimine0low70
ceftazidime0low20
ici 1185510low40
morphine-3-glucuronide0low20
enkephalin, ala(2)-mephe(4)-gly(5)-0low110
licostinel0low30
lespenefril0low10
6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione0low70
lofepramine hydrochloride0low50
sinigrin0low10
acetylcodeine0low10
enkephalin-met, ala(2)-0low30
naltrindole benzofuran0low10
pregabalin0medium529
quercetin 3-sambubioside0low10
hibifolin0low10
aliskiren0low20
triolein0low10
naltrindole0low110
25-hydroxyvitamin d 20low10
salubrinal0low20
3,4-dichlorophenyl propenylisobutylamide0low10
cefotaxime0medium93
aztreonam0low10
syntide-20low10
cyprodime0low10
4-hydroxycordoin0low10
tg4-1550low10
1,2-dielaidoylphosphatidylethanolamine0low10
roquefortine0low20
cgp 378490low240
derricidin0low10
piriqualone0low10
bisabolol0low10
magnesium citrate0low30
ajmaline0low60
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid0low20
coomassie brilliant blue0low20
saralasin0low20
tetrodotoxin0low410
germanium0low20
selenium0low170
selenocysteine0low20
cyhexatin0low10
radium0low60
trimethyltin hydroxide0low20
oxalates0low80
clovoxamine0low10
3-aminopropylphosphinic acid0low10
palonosetron0low10
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid0low20
cgp 395510low130
diacetylmonoxime0low20
dihydroergotoxine0low60
dizocilpine maleate0low2950
ubp 3100low10
neramexane0low10
methylazoxymethanol0low50
glycine linoleamide0low10
taxine0low20
pumiliotoxin a0low10
cilastatin0medium304
ralitoline0low20
sarcophine0low10
trans-2-en-valproate0low50
3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid0low100
manoalide0low10
1,2-dioleoyloxy-3-(trimethylammonium)propane0low10
2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid0low10
cgp 396530low50
sphingosine phosphorylcholine0low10
gabalid0low10
valerenic acid0low40
liga 200low10
diacetylcurcumin0low20
everolimus0medium276
skf 99101h0low10
bifenthrin0low10
arvanil0low10
brompheniramine, pseudoephedrine drug combination0low10
cannabigerolic acid0low20
gavestinel0low20
axitinib0low10
salvianolic acid B0low10
i(3)so3-galactosylceramide0low30
belotecan0low10
methyl chlorogenate0low10
azlocillin0low10
tanespimycin0low10
fm1 430low10
verlukast0low10
carumonam0low20
paclobutrazol0low10
beta-escin0low140
nipecotic acid, (s)-isomer0low10
n-(4-amino-2-chlorophenyl)phthalimide0low10
(8R)-7-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol0low10
s-nitroso-n-acetylpenicillamine0low10
sb 2222000low10
nitrofurantoin0low50
suloctidil0low10
l 6895600low10
am 4040low30
ro 25-69810low60
sb 2699700low20
sb 334867-a0low40
n,n'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine0low20
iem 14600low20
nifurtimox0medium11
peplomycin0low10
6 beta-hydroxycortisol0medium11
butylscopolammonium bromide0low10
gadolinium dtpa0low70
morphinans0low220
ergoline0low230
adenosine-3',5'-cyclic phosphorothioate0low10
songorine0low10
enkephalin, leucine-2-alanine0low150
tiapamil hydrochloride0low10
montirelin0low20
sk&f 89976-a0low20
cv 18080low10
beraprost0low10
dexniguldipine0low30
u 628400low10
ciclesonide0low10
sitafloxacin0low10
rmp 70medium11
n-valproyl glycinamide0low10
hexarelin0low10
adrogolide hydrochloride0low10
ganaxolone0medium233
vilazodone hydrochloride0low40
tonabersat0low10
vofopitant0low10
rwj-3333690low30
jwh-1330low20
n-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide0low10
6,6-dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5h)-one0low10
sb 3998850low10
rebaudioside a0low10
isoborneol0low40
staurosporine0low30
chloralose0low180
n-(4-methylthiazol-2-yl)-2-(6-phenylpyridazin-3-ylthio)acetamide0low10
hypericum0low70
phosphocreatine0low630
grayanotoxin i0low10
sl 3270low40
chlorhexidine0low30
sri 2240low10
mannich bases0low190
s 17430low10
ropizine0low20
aldicarb0low30
gemifloxacin0low10
naloxonazine0low20
1-methyl-1,6-dihydropyridine-2-carbaldoxime0low10
cefoselis0low30
oxamyl0low10
nepicastat0low10
alphadolone0low10
desvenlafaxine succinate0low20
cgp 56999a0low40
tebipenem0low20
macimorelin0low10
amoxicillin-potassium clavulanate combination0low20
dp-b990low10
acth (4-7), pro-gly-pro-0low20
biie 02460low10
5'-amino-5'-deoxyadenosine0low20
4-(4-fluorophenoxy)benzaldehyde semicarbazone0low10
benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-0low10
ly 3414950low10
(2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine0low10
kb r79430low30
jasplakinolide0low20
davunetide0low10
sincalide0low120
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(o- methyl-l-tyrosine)-8-l-arginine-0low10
ucb 347140medium7228
tapentadol0low40
reparixin0low10
dysiherbaine0low30
n(6)-cyclohexyladenosine0low220
2-propyl-4,5,5a,6,7,11b-hexahydro-3-thia-5-azacyclopent-1-ena(c)phenanthrene-9,10-diol0low10
egis-83320low20
ro 64-61980low10
cp 465,0220low20
ursodoxicoltaurine0low20
ly 3067400low10
paliperidone palmitate0low30
sun n80750low10
4,5-dihydro-7,8-dimethoxy-1-phenyl-3h-2,3-benzodiazepin-4-one0low40
mocetinostat0low60
sc 2360low30
cgp 745880low10
l 7799760low10
incarvillateine0low10
lipid a0low20
eslicarbazepine0low50
4-iodo-2,6-diisopropylphenol0low10
biii 890 cl0low10
iem 17540low30
nnc 05-20900low10
6-(6-(4-hydroxypiperidinyl)hexyloxy)-3-methylflavone hydrochloride0low10
clomethiazole edisylate0low20
mart-1 antigen0low10
g(m2) ganglioside0low10
ica 272430low20
bay36-76200low10
ncr 6310low10
piperacillin0low10
ic 871140low10
psd 5020low30
6'-guanidinonaltrindole0low10
thiocolchicoside0low30
pd 1732120low10
sorbitan monooleate0low10
perampanel0medium14032
hydroxycodeinone0low10
gyki 472610low10
ly 3920980low10
ly 4041870low10
bpc 1570low20
seletracetam0low20
pitolisant0low20
u 18666a0low30
cgp 55845a0low30
g(m1) ganglioside0low70
vortioxetine0low20
aluminum oxide0low210
hypaconitine0low10
arachidonoylserotonin0low10
bicuculline methochloride0low20
ly 3897950low10
troparil0low10
linagliptin0low10
fmrfamide0low10
cystathionine0low30
phenobarbital sodium0low20
losigame0medium41
am 12410low10
2,2,3,3-tetramethylcyclopropanecarbonylurea0low30
apixaban0low20
indantadol0low10
vitamin u0low10
ly 3792680low20
2-amino-5-hydroxy-4-oxopentanoic acid0low10
dihydrokavain0low10
ar c1558580low10
homocarnosine0medium31
ro 16-01540low60
2-(4-iodo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)ethanamine0low20
4-iodo-2,5-dimethoxy-beta-phenethylamine0low30
sb-6499150low10
alpha-synuclein0low10
jwh 0180low80
snap 51140low20
jwh-0730low10
PB280low10
oxadiazoles0low330
sch 4424160low10
ly 3414950low20
ucn 1028 c0low10
ribose0low30
urb6020low10
sm-2166010low10
8-oxo-2'-deoxyadenosine0low10
lactulose0low40
grayanotoxin iii0low10
acesulfame potassium0low10
palytoxin0low10
cembra-2,7,11-triene-4,6-diol0low10
regorafenib0low10
tetrodotoxin0low10
calpain inhibitor iii0low10
wp10660low10
(+)-erythravine0low10
brimonidine tartrate0low10
pnu-2829870low10
nystatin a10low10
nnz 25660low10
vx 7650low10
neodysiherbaine a0low10
rh 7950low10
cp 1545260low10
fr 1802040low10
ly21832400low10
hu 3080low10
carfilzomib0low20
sitagliptin phosphate0low20
lisdexamfetamine dimesylate0low10
cannabidivarin0medium51
col-1440low10
veratridine0low100
lorcaserin0low30
n,n'-dibenzhydrylethane-1,2-diamine dihydrochloride0low10
trametinib0low10
losartan potassium0medium457
n-acetylmannosamine0low10
octanoylcarnitine0low10
doramectin0low10
technetium tc 99m exametazime0medium331
calcimycin0low40
dextrothyroxine0low200
2-amino-5-ureidopentanamide0low30
veliparib0medium11
delta-1-pyrroline-5-carboxylate0low10
indocyanine green0low10
scopolamine hydrobromide0low900
dactolisib0low10
pituitrin0low460
hirsuteine0low10
enerbol0low10
dihydrotachysterol0low50
rifamycins0low20
clove0low30
1,4-dihydroquinoline0low10
decahydroquinoline-5-carboxylic acid0low10
acid phosphatase0low130
mefloquine0low180
norhydrocodone0low10
ants0low20
m-trifluoromethyl-diphenyl diselenide0low10
2-deoxyinosose0low10
etoxadrol0low10
id0low20
angiotensin ii, sar(1)-me-tyr(4)-0low10
jaw0low20
carbon-11 methionine0low20
pentaborane0low20
ly 2330530low40
nad0low500
mdv 31000medium62
vonoprazan0low10
protectin d10low10
cytochrome c-t0low70
calcitonin0low30
cosyntropin0medium31
melitten0low10
cholecystokinin0low250
ceruletide0low80
dynorphins0low220
somatostatin0low10
atrial natriuretic factor0low30
cgp 239960low10
adrenocorticotropin zinc0low20
preprotachykinin b (50-79)0low10
histogranin0low10
nociceptin0low50
galantide0low10
fibrinopeptide b0low10
acetylcholine receptor alpha-subunit (125-148)0low10
gastrins0low10
gramicidin a0low20
glucagon0low350
mast cell degranulating peptide0low60
beta-endorphin0low180
sauvagine0low10
neuropeptide y0low1020
iberiotoxin0low40
astressin0low20
cortistatin 140low40
m400low10
cyn 1548060low10
tannins0low40
oligonucleotides0low30
liraglutide0low20
ziconotide0low10
glucagon-like peptide 10low50
conantokin-t0low10
msh, 4-nle-7-phe-alpha-0low10
c-peptide0low30
natriuretic peptide, c-type0low10
exendin (9-39)0low10
bombesin0low10
cellulose0low30
sodium borate0low10
ceftiofur0low10
endothelin-10low90
phosphatidylcholines0low140
3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3h)-one0low10
atractyloside0low10
buparlisib0low20
carbetocin0low10
phentin acetate0low10
thimerosal0low10
dihydroceramide0low10
nsc 237660low10
adenosine kinase0low230
hoe 333420low10
sodium salicylate0medium61
valproate sodium0low330
ubiquinone0low150
gdc 09410low10
cilastatin, imipenem drug combination0medium193
calpain0low120
hydromorphone-3-glucuronide0low10
succinyladenosine0low20
dihydroagarofuran0low10
lacosamide0low30
chitosan0low40
4-amino-8-(2-fluoro-6-methoxy-phenyl)-n-propylcinnoline-3-carboxamide0low10
butaclamol0low10
iocarmate meglumine0low10
mesna0medium41
sodium oxybate0low390
bucladesine0low140
sodium lactate0low10
urografin 760low20
sodium nitrite0low30
potassium bromate0low10
sodium acetylsalicylate, sodium bicarbonate, sodium citrate drug combination0low10
phenobarbital sodium0low10
sodium glutamate0low130
ro13-99040medium271
phenytoin sodium0low60
sodium pertechnetate tc 99m0low10
sodium ethylxanthate0low90
piperacillin, tazobactam drug combination0low30
chiniofon0low20
almorexant0low10
picrotoxinin0low40
methyl jasmonate0low10
s-adenosylmethionine0low60
picrotoxin0low4770
st28250low10
insulin, isophane0low10
garcinielliptone fc0low10
quetiapine fumarate0medium281
cardiovascular agents0medium251
trelstar0low20
rimorphin0low10
dynorphins0low20
nafarelin0low10
neurotensin0low70
histrelin0low10
fibrinopeptide a0low10
apelin-13 peptide0low20
substance p, prolyl(2)-tryptophan(7,9)-0low10
guanidinosuccinic acid0low50
phosphinothricin0low120
azd20140low10
cicutoxin0low50
4'-geranyloxyferulic acid0low10
lysophosphatidylserine0low10
triiodothyronine, reverse0medium11
enanthotoxin0low10
gw 10000low30
glycolipids0low90
idx 8990medium11
piperidines0medium2327
interleukin-80low40
antibiotic cv-10low10
pf-47785740low10
ulixacaltamide0low30
sec-butyl-propylacetamide0low60
pituitary adenylate cyclase activating polypeptide 380low10
gardiquimod0low10
ur-1440low10
mephedrone0low10
colistin0low50
hydroxocobalamin0low60
fosinopril0low10
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine0low10
selurampanel0low10
exenatide0low10
methylone0low20
endrin0low120
tak-0630low10
fructose-1,6-diphosphate0low20
methylcellulose0low30
pf-47086710low10
isoquercitrin0low20
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone0low30
fr 2642050low10
bal 300720low10
vasoactive intestinal peptide0low70
natriuretic peptide, brain0low70
heme0low170
vu04244650low10
sr 82780low10
AM22010low20
leukotoxin0low10
chondroitin0low10
heparitin sulfate0low20
ascorbic acid0low390
novobiocin0low10
tetracycline0low140
chlortetracycline0low10
oxytetracycline, anhydrous0low30
minocycline0low240
salicylates0low190
dicumarol0low10
piroxicam0low20
acenocoumarol0low20
mobic0low10
warfarin0low340
demeclocycline0low10
l 7013240low80
teriflunomide0low10
tigecycline0low10
mdl 1046530low20
6-deoxy-6-bromoascorbic acid0low10
dolutegravir0low20
sar1273030low10
byl7190low10
2'-hydroxy-5,9-dimethyl-2-allyl-6,7-benzomorphan0low60
omega-agatoxin iva0low10
snx 2300low10
toxin ii (anemonia sulcata)0low10
epidermal growth factor0low20
microcystin0low10
gastrin-releasing peptide0low10
calca protein, human0low10
kaolinite0low10
clay0low10
charybdotoxin0low20
transforming growth factor beta0low130
phytoestrogens0low50
semaglutide0low10
saxitoxin0low20
okadaic acid0low40
AKB480low10
wnt-c590low10
gs-4589670low30
cc-2230low10
pyrethrins0low140
jnj-479655670low10
tan 670low10
gsk-28161260low10
8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine0low10
nordidemnin b0low10
Adb-fubinaca0low30
coriaria lactone0low40
kiss1 protein, human0low10
rome0low20
tg6-10-10low10
agar0low20
1-pentyl-1h-indole-3-carboxylic acid 8-quinolinyl ester0low10
n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide0low20
hirudin0low10
glutaminase0low100
cyclin d10low20
incensole acetate0low10
caseins0low40
limbrel0low10
mancozeb0low10
acefyllin piperazinate0low10
n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1h-indazole-3-carboxamide0low20
n-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1h-indazole-3-carboxamide0low20
g(m3) ganglioside0low20
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone0low10
nitrophenols0low30
methysticin0low10
1 alpha,24-dihydroxyvitamin d30low10
neuropeptide y, leu(31)-pro(34)-0low10
conantokin r0low10
kaliotoxin0low10
3-iodothyroacetic acid0low10
cobamamide0low10
hyaluronoglucosaminidase0low10
adrenomedullin0low10
bacoside a0low10
epoetin alfa0low10
angiotensin iii0low20
diospyros0low10
carboxyatractyloside0low10
d-ala(2),mephe(4),met(0)-ol-enkephalin0low30
neferine0low20
tridihexethyl0low10
ganoderic acid a0low10
n-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide0low20
t-2 toxin0low10
aldrin0low70
peoniflorin0low20
vitamin b 120medium221
aconitine0low50
refludan0low10
insulin glargine0low20
s 89320low10
oxyntomodulin0low10
transforming growth factor alpha0low10
moxidectin0low40
cyclosporine0medium732
flavin mononucleotide0low10
silybin0low10
peptide yy0low10
lactoferrin0low10
diethyltoluamide, ethanol, glycerin, terpineol, water drug combination0low30
oxysophocarpine0low10
edetic acid0low10
2-hydroxyputrescine0low10
rs1006420low10
technetium tc 99m medronate0low20
apyrase0low30
thromboplastin0low20
muramidase0low20
chondroitin sulfates0low20
exudates0low140
technetium tc 99m dimercaptosuccinic acid0low10
neuropeptide y (13-36)0low20
acyclovir0medium451
levoleucovorin0medium212
cyclic gmp0medium751
deoxyguanosine0medium51
guanosine diphosphate0low10
guanosine diphosphate mannose0low10
guanosine monophosphate0low20
guanosine triphosphate0low40
guanine0low40
guanosine0low110
hypoxanthine0low50
inosine0low210
inosine triphosphate0low10
sapropterin0low30
folic acid0medium865
3-methyladenine0low20
guanosine 5'-o-(3-thiotriphosphate)0low130
neopterin0low30
rifampin0medium121
clozapine0medium1026
dacarbazine0medium192
didanosine0low10
ganciclovir0medium101
valacyclovir0low30
olanzapine0low260
pralidoxime0low180
hlo 70low10
zaprinast0low10
allopurinol0medium201
guanylyl imidodiphosphate0low30
5-nitro-1,2,4-triazol-3-one0low10
5,11-methenyltetrahydrohomofolate0medium11
4-hydroxyquinazoline0low20
norclozapine0low10
4-((3-(1,6-dihyro-6-oxo-9h-purin-9-yl)-1-oxopropyl)amino)benzoic acid0low10
cytarabine0low10
sildenafil citrate0low190
valganciclovir0low10
spd 5020low10
ceftobiprole0low10
etifoxine0low60
vardenafil dihydrochloride0low10
8-bromocyclic gmp0low20
trypan blue0low60
pyridine-2-aldoxime0low10
ro 5-36630low90
methylnitronitrosoguanidine0low10
8-hydroxy-2'-deoxyguanosine0medium71
asoxime chloride0low160
clozapine n-oxide0low30
coelenterazine0low10
pyridine-4-aldoxime0low10
n,n'-monomethylenebis(pyridiniumaldoxime)0low10
5-methyltetrahydrofolate0low60
imidacloprid0low10
heme arginate0low30
trimedoxime bromide0low40
pp2420low10
dibutyryl cyclic gmp0low50
3'-o-methylguanosine0low10
molybdenum cofactor0low150
alcian blue0low10
lon 9540low10
batrachotoxinin a 20-alpha-benzoate0low10
avermectin0low20
cholestyramine resin0low10
eye0medium401
maltodextrin0low10
carbidopa0low70
pd 1351580low10
argyrophilic acid0low10
ego0low30
concanavalin a0low20
technetium tc 99m bicisate0medium212
nirmatrelvir0low10
metallothionein0low90
dinitrobenzenes0low10
biphenylylacetic acid0low120
phosphorus radioisotopes0low50
preproenkephalin0low200
leptin0low180
pyrimidinones0medium121
filipin0low10
phenanthrenes0medium31

Protein Targets (4,977)

ProteinPotency MeasurementsInhibition MeasurementsActivation MeasurementsDrugs
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE34700347
Gamma-aminobutyric acid type B receptor subunit 207512
Gamma-aminobutyric acid receptor subunit alpha-107541117
Gamma-aminobutyric acid receptor subunit beta-1050859
Gamma-aminobutyric acid receptor subunit gamma-207329103
Gamma-aminobutyric acid receptor subunit rho-103821
Gamma-aminobutyric acid receptor subunit beta-30701889
Gamma-aminobutyric acid receptor subunit rho-201515
Gamma-aminobutyric acid receptor subunit alpha-50682796
Gamma-aminobutyric acid receptor subunit alpha-30701687
Gamma-aminobutyric acid receptor subunit alpha-20691888
Gamma-aminobutyric acid receptor subunit beta-20572583
Gamma-aminobutyric acid receptor subunit alpha-4054964
Gamma-aminobutyric acid receptor subunit alpha-6064974
Gamma-aminobutyric acid type B receptor subunit 107512
RAR-related orphan receptor gamma45500455
SMAD family member 215800158
SMAD family member 315800158
GLI family zinc finger 348600486
AR protein62100621
caspase 7, apoptosis-related cysteine protease860086
estrogen receptor 2 (ER beta)27800278
nuclear receptor subfamily 1, group I, member 341800418
progesterone receptor31700317
glucocorticoid receptor [Homo sapiens]46400464
retinoic acid nuclear receptor alpha variant 148600486
retinoid X nuclear receptor alpha39800398
estrogen-related nuclear receptor alpha57000570
farnesoid X nuclear receptor28300283
pregnane X nuclear receptor44000440
estrogen nuclear receptor alpha74900749
peroxisome proliferator-activated receptor delta28700287
vitamin D (1,25- dihydroxyvitamin D3) receptor29300293
caspase-3860086
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a31800318
thyroid stimulating hormone receptor20100201
activating transcription factor 619600196
thyrotropin-releasing hormone receptor420042
v-jun sarcoma virus 17 oncogene homolog (avian)25100251
Histone H2A.x18900189
thyroid hormone receptor beta isoform 247100471
nuclear factor erythroid 2-related factor 2 isoform 145100451
Voltage-dependent calcium channel gamma-2 subunit24200242
ATP-dependent translocase ABCB1010217153
Cytochrome P450 2D601214132
Glutamate receptor 22533912323
Substance-P receptor021122
Potassium voltage-gated channel subfamily H member 201911196
Kynurenine 3-monooxygenase0303
Kynurenine 3-monooxygenase0303
Kynureninase 0101
Kynurenine 3-monooxygenase0202
Sodium-dependent serotonin transporter016516183
Sodium-dependent dopamine transporter 014510155
Cytochrome P450 2C9 01327143
Chain A, HADH2 protein21200212
Chain B, HADH2 protein21200212
dopamine D1 receptor610061
thioredoxin reductase37800378
RGS129009
ClpP160016
NFKB1 protein, partial12400124
GLS protein28000280
TDP1 protein69700697
Thrombopoietin940094
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)13200132
regulator of G-protein signaling 425600256
arylsulfatase A25500255
euchromatic histone-lysine N-methyltransferase 263000630
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)620062
cytochrome P450 2D6 isoform 121200212
cellular tumor antigen p53 isoform a14900149
cytochrome P450 2C9 precursor16400164
D(1A) dopamine receptor16000160
vitamin D3 receptor isoform VDRA21400214
chromobox protein homolog 142000420
guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 19009
mitogen-activated protein kinase 120600206
flap endonuclease 114300143
serine/threonine-protein kinase mTOR isoform 111000110
DNA polymerase iota isoform a (long)21400214
M-phase phosphoprotein 812800128
muscarinic acetylcholine receptor M121400214
lethal factor (plasmid)20000200
D063268
D(3) dopamine receptor044149
D(2) dopamine receptor019019
D(1B) dopamine receptor031031
D(4) dopamine receptor034135
Histamine H2 receptor259104289
D(1A) dopamine receptor643067
D(2) dopamine receptor011618141
D013013
Ataxin-225600256
2,3-bisphosphoglycerate-independent phosphoglycerate mutase130013
ATP-dependent phosphofructokinase28100281
Chain A, Ferritin light chain17900179
ATAD5 protein, partial25700257
USP1 protein, partial32300323
Microtubule-associated protein tau30100301
thyroid stimulating hormone receptor33500335
glucocerebrosidase10000100
atrial natriuretic peptide receptor 1 precursor490049
atrial natriuretic peptide receptor 2 precursor540054
ras-related protein Rab-9A950095
nuclear receptor ROR-gamma isoform 122300223
DNA polymerase kappa isoform 116400164
survival motor neuron protein isoform d22300223
Transient receptor potential cation channel subfamily V member 1011516
Alpha-synuclein5822181
Transient receptor potential cation channel subfamily V member 10181944
Chain A, JmjC domain-containing histone demethylation protein 3A14500145
Glutamate receptor ionotropic, NMDA 1 29915139
Glutamate receptor ionotropic, NMDA 2A 19512128
Glutamate receptor ionotropic, NMDA 2B19713131
Glutamate receptor ionotropic, NMDA 2C19612131
Glutamate receptor ionotropic, NMDA 2D19112124
Glutamate receptor ionotropic, NMDA 3B19112124
Glutamate receptor ionotropic, NMDA 3A19112124
cytochrome P450 2C19 precursor18700187
cytochrome P450 3A4 isoform 137300373
Gamma-aminobutyric acid receptor subunit pi37310217493
Polyunsaturated fatty acid lipoxygenase ALOX15B14360149
Gamma-aminobutyric acid receptor subunit beta-137310217493
Gamma-aminobutyric acid receptor subunit delta37310217493
Gamma-aminobutyric acid receptor subunit gamma-237310419497
Gamma-aminobutyric acid receptor subunit alpha-537310217493
Gamma-aminobutyric acid receptor subunit alpha-337310217493
Gamma-aminobutyric acid receptor subunit gamma-137310317494
Gamma-aminobutyric acid receptor subunit alpha-237310318495
Sodium-dependent dopamine transporter060969
Gamma-aminobutyric acid receptor subunit alpha-437310217493
Gamma-aminobutyric acid receptor subunit gamma-337310217493
Gamma-aminobutyric acid receptor subunit alpha-637310217493
Lysosomal Pro-X carboxypeptidase0606
Gamma-aminobutyric acid receptor subunit alpha-137310719500
Gamma-aminobutyric acid receptor subunit beta-337310217493
Gamma-aminobutyric acid receptor subunit beta-237310419497
GABA theta subunit37310217493
Gamma-aminobutyric acid receptor subunit epsilon37310217493
Gamma-aminobutyric acid receptor subunit pi048048
Gamma-aminobutyric acid receptor subunit delta048149
Gamma-aminobutyric acid receptor subunit alpha-1014020
Gamma-aminobutyric acid receptor subunit beta-1014020
Gamma-aminobutyric acid receptor subunit alpha-2014020
Gamma-aminobutyric acid receptor subunit alpha-3014020
Gamma-aminobutyric acid receptor subunit alpha-4014020
Gamma-aminobutyric acid receptor subunit gamma-2014020
Gamma-aminobutyric acid receptor subunit epsilon048048
Gamma-aminobutyric acid receptor subunit gamma-1048048
Sphingosine-1-phosphate lyase 10303
Gamma-aminobutyric acid receptor subunit gamma-3048149
Gamma-aminobutyric acid receptor subunit theta048048
nonstructural protein 110500105
Indoleamine 2,3-dioxygenase 1016118
Alpha-2C adrenergic receptor014015162
Chain A, TYROSYL-DNA PHOSPHODIESTERASE22900229
Chain A, Beta-lactamase17700177
Chain A, Cruzipain10000100
endonuclease IV10100101
hypoxia-inducible factor 1 alpha subunit16300163
aldehyde dehydrogenase 1 family, member A143200432
cytochrome P450 family 3 subfamily A polypeptide 442100421
G28100281
cytochrome P450 2D633400334
67.9K protein15300153
peripheral myelin protein 22 isoform 113900139
geminin56400564
lamin isoform A-delta1048700487
Interferon beta37100371
HLA class I histocompatibility antigen, B alpha chain 28100281
Nitric oxide synthase, brain 014016
Inositol hexakisphosphate kinase 128100281
cytochrome P450 2C9, partial28100281
5-hydroxytryptamine receptor 3E022529
5-hydroxytryptamine receptor 3B023732
Integrin beta-310271110
Integrin alpha-V 0202
D(1A) dopamine receptor011312132
5-hydroxytryptamine receptor 3A09110
Delta-type opioid receptor0631089
5-hydroxytryptamine receptor 3A032944
Inositol monophosphatase 111400114
Trace amine-associated receptor 50033
5-hydroxytryptamine receptor 3D022529
5-hydroxytryptamine receptor 3C022529
acetylcholinesterase22200222
thyroid hormone receptor beta isoform a16600166
huntingtin isoform 2690069
peripheral myelin protein 2225900259
ATP-binding cassette sub-family C member 303140314
Multidrug resistance-associated protein 403190326
Bile salt export pump05070508
Beta-1 adrenergic receptor0572077
5-hydroxytryptamine receptor 1A07739120
5-hydroxytryptamine receptor 2C09317112
D(2) dopamine receptor015218182
5-hydroxytryptamine receptor 2A011722142
Alpha-1B adrenergic receptor015018170
5-hydroxytryptamine receptor 1A018627221
Alpha-1D adrenergic receptor010218125
5-hydroxytryptamine receptor 2A019616221
5-hydroxytryptamine receptor 2C020111215
5-hydroxytryptamine receptor 1B013415151
5-hydroxytryptamine receptor 1D0401659
5-hydroxytryptamine receptor 1F0391556
5-hydroxytryptamine receptor 5A0202
5-hydroxytryptamine receptor 2B08318101
5-hydroxytryptamine receptor 7 0391352
5-hydroxytryptamine receptor 7055464
Alpha-1B adrenergic receptor0461372
5-hydroxytryptamine receptor 2B01998210
Alpha-1A adrenergic receptor016420186
5-hydroxytryptamine receptor 601321141
Beta-2 adrenergic receptor0617
Canalicular multispecific organic anion transporter 103040306
Sigma non-opioid intracellular receptor 111353141
Sigma non-opioid intracellular receptor 1034540
histone acetyltransferase KAT2A isoform 121700217
5-hydroxytryptamine receptor 1D021129
bromodomain adjacent to zinc finger domain 2B12900129
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein0314
lethal(3)malignant brain tumor-like protein 1 isoform I300030
alkaline phosphatase, germ cell type preproprotein0224
Alkaline phosphatase, tissue-nonspecific isozyme0809
Intestinal-type alkaline phosphatase0606
Alkaline phosphatase, germ cell type0303
Muscarinic acetylcholine receptor M2051867
Guanine nucleotide-binding protein G690069
Phospholipase A-2-activating protein0606
Parkin650065
IDH116200162
nuclear factor erythroid 2-related factor 2 isoform 213400135
urokinase-type plasminogen activator precursor10100101
plasminogen precursor10100101
urokinase plasminogen activator surface receptor precursor10100101
Bloom syndrome protein isoform 120100201
Metabotropic glutamate receptor 8012217
Metabotropic glutamate receptor 6011924
Glutamate receptor 115431188
Glutamate receptor 315391184
Glutamate receptor 415391184
Glutamate receptor ionotropic, kainate 1029439
Metabotropic glutamate receptor 109514
Metabotropic glutamate receptor 205611
Metabotropic glutamate receptor 305611
Metabotropic glutamate receptor 404711
Metabotropic glutamate receptor 509716
Metabotropic glutamate receptor 60347
Metabotropic glutamate receptor 70336
Metabotropic glutamate receptor 5016929
Glutamate receptor ionotropic, kainate 2029338
Glutamate receptor ionotropic, kainate 3036143
Metabotropic glutamate receptor 80033
Glutamate receptor ionotropic, kainate 4025031
Metabotropic glutamate receptor 1021833
Metabotropic glutamate receptor 2018931
Metabotropic glutamate receptor 7010519
Metabotropic glutamate receptor 3011520
Metabotropic glutamate receptor 40161030
Glutamate receptor ionotropic, kainate 5025132
Chain A, Glutamate [NMDA] receptor subunit zeta 10303
Chain A, Glutamate [NMDA] receptor subunit zeta 10303
Chain A, Glutamate [NMDA] receptor subunit zeta 10303
phosphopantetheinyl transferase23800238
Chain A, 2-oxoglutarate Oxygenase24800248
DNA polymerase beta750075
peptidyl-prolyl cis-trans isomerase NIMA-interacting 110300103
DNA polymerase eta isoform 1490049
Chain B, pheromone binding protein0011
Chain A, pheromone binding protein0011
Chain A, RNA-directed RNA polymerase NS50404
acid sphingomyelinase290029
importin subunit beta-1 isoform 1830083
serine/threonine-protein kinase PLK1430043
snurportin-1830083
GTP-binding nuclear protein Ran isoform 1420042
fibroblast growth factor 22 isoform 1 precursor0001
Mitogen-activated protein kinase 1306814
Beta-lactamase018018
Transthyretin051121
Fatty acid-binding protein, intestinal09312
Fatty acid-binding protein, adipocyte08412
Cyclin-A20606
Cannabinoid receptor 10311041
Cyclin-dependent kinase 20172138
Choline O-acetyltransferase0404
Mitogen-activated protein kinase 12061016
Fatty acid-binding protein 50527
Fatty acid-binding protein 50033
Mitogen-activated protein kinase 11061925
Mitogen-activated protein kinase 140332053
Chain A, Glutaminyl-peptide cyclotransferase0101
Chain A, Glutaminyl-peptide cyclotransferase0101
Chain X, Glutaminyl-peptide cyclotransferase-like protein0101
Chain X, Glutaminyl-peptide cyclotransferase-like protein0101
Chain X, Glutaminyl-peptide cyclotransferase-like protein0101
Chain A, Glutaminyl-peptide cyclotransferase0101
transcriptional regulator ERG isoform 3470047
Camphor 5-monooxygenase0102
Cytochrome P450 1A2071481
Epoxide hydrolase 10005
Aromatase048060
Steroid 17-alpha-hydroxylase/17,20 lyase 0404
Cytochrome P450 11B1, mitochondrial0606
Translocator protein027735
Cytochrome P450 11B2, mitochondrial0606
Thromboxane-A synthase 025025
Glutaminyl-peptide cyclotransferase010010
Cytochrome P450 4Z10101
Glutaminyl-peptide cyclotransferase0707
Chain A, Putative fructose-1,6-bisphosphate aldolase10900109
aryl hydrocarbon receptor nuclear translocator0005
apical membrane antigen 1, AMA1660066
lysosomal alpha-glucosidase preproprotein610061
pyruvate kinase PKM isoform a100010
transforming acidic coiled-coil-containing protein 30005
Neuronal acetylcholine receptor subunit alpha-42535971
Neuronal acetylcholine receptor subunit beta-22533969
Caspase-30819
Cellular tumor antigen p5340010401
Choline O-acetyltransferase 08010
Small conductance calcium-activated potassium channel protein 3011112
Platelet-activating factor receptor1608
Cytochrome P450 3A4015812185
Phenylethanolamine N-methyltransferase013015
Chain A, High-affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D0101
Chain A, Phosphodiesterase 9A0101
Chain A, Class I phosphodiesterase PDEB10101
Chain A, High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A0101
Chain A, cGMP-dependent 3',5'-cyclic phosphodiesterase0101
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase catalytic domain, Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha chimera0101
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase catalytic domain, Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha chimera0101
Chain A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A0101
Chain A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A0101
glp-1 receptor, partial16500165
Phosphodiesterase 0707
cGMP-dependent 3',5'-cyclic phosphodiesterase016016
Monocarboxylate transporter 40106
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A0707
cGMP-specific 3',5'-cyclic phosphodiesterase021123
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A0404
Renin013114
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A 0909
cAMP-specific 3',5'-cyclic phosphodiesterase 4D 0607
cAMP-specific 3',5'-cyclic phosphodiesterase 4C0607
cAMP-specific 3',5'-cyclic phosphodiesterase 4B0608
Adenosine receptor A1273998
Adenosine receptor A3031032
Adenosine receptor A2a0562696
Adenosine receptor A2b0281153
Adenosine receptor A2b038360
Adenosine receptor A10471576
Adenosine receptor A2a06610104
Sodium-dependent serotonin transporter060669
Adenosine receptor A2a0718
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'0404
cAMP-specific 3',5'-cyclic phosphodiesterase 4A0607
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A012013
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B0909
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B012013
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B0606
cAMP-specific 3',5'-cyclic phosphodiesterase 4B020123
cAMP-specific 3',5'-cyclic phosphodiesterase 4D024126
cGMP-inhibited 3',5'-cyclic phosphodiesterase B017018
Voltage-dependent L-type calcium channel subunit alpha-1C059161
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A0707
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C015016
cGMP-inhibited 3',5'-cyclic phosphodiesterase A019020
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C0606
Phosphodiesterase 0101
Phosphodiesterase 0606
cAMP-specific 3',5'-cyclic phosphodiesterase 7B0404
Dihydropteridine reductase0101
Amine oxidase [flavin-containing] A075180
Amine oxidase [flavin-containing] B067574
Amine oxidase [flavin-containing] B014017
Thyroid hormone receptor beta0707
Xanthine dehydrogenase/oxidase024024
Carbonic anhydrase 12062286
Carbonic anhydrase 101332172
Carbonic anhydrase 2014812197
Carbonic anhydrase 3039254
Carbonic anhydrase 40802102
Carbonic anhydrase 6053274
Carbonic anhydrase 5A, mitochondrial061487
Carbonic anhydrase 7056278
Carbonic anhydrase 90853112
Carbonic anhydrase 15037044
Carbonic anhydrase 13036056
Carbonic anhydrase 14044266
Carbonic anhydrase 5B, mitochondrial049273
aryl hydrocarbon receptor25100251
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a18900189
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 118700187
Kelch-like ECH-associated protein 10022
Histone acetyltransferase KAT80202
15-lipoxygenase, partial16200162
peroxisome proliferator activated receptor gamma30300303
heat shock protein beta-118000180
Glucocorticoid receptor147769
Glycine receptor subunit alpha-1043043
Alpha-2A adrenergic receptor017514197
Adenosine receptor A30908101
Androgen receptor084187
Glycine receptor subunit beta042042
Glycine receptor subunit alpha-2043043
Glycine receptor subunit alpha-3042042
C-C chemokine receptor type 2011011
Flavodoxin0003
Smad313600136
Cannabinoid receptor 10471573
Cannabinoid receptor 2 0401868
Cannabinoid receptor 206511
Luciferase22200222
pregnane X receptor690069
Fumarate hydratase13900139
nonstructural protein 10303
polyprotein13900139
heat shock protein 900055
TPA: protein transporter TIM100606
TPA: protein transporter TIM230202
Caspase-7510051
tumor necrosis factor8008
runt-related transcription factor 1 isoform AML1b120012
caspase-3510051
histone deacetylase 9 isoform 3610061
core-binding factor subunit beta isoform 2120012
heat shock protein HSP 90-alpha isoform 205020
muscleblind-like protein 1 isoform 1840084
exodeoxyribonuclease V subunit RecD0404
exodeoxyribonuclease V subunit RecB0404
exodeoxyribonuclease V subunit RecC0404
Galanin receptor type 20314
Carboxypeptidase A10101
Thermolysin0505
Amyloid-beta precursor protein835449
Integrin alpha-IIb10251108
C-C chemokine receptor type 10112
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha0303
Protein farnesyltransferase subunit beta0303
Nuclear receptor ROR-gamma10443111
C-C chemokine receptor type 506310
C-C chemokine receptor type 80011
TAR DNA-binding protein 4312900129
Metallo-beta-lactamase VIM-1302011
ATPase family AAA domain-containing protein 515000150
Snake venom metalloproteinase neuwiedase0101
Collagenase ColG0101
Beta-lactamase VIM-1 02011
heat shock protein 90, putative00015
20-hydroxy-ecdysone receptor 0011
Protein ultraspiracle0011
Ecdysone receptor0011
Ecdysone receptor0011
Phenylethanolamine N-methyltransferase0315
CD44 antigen0011
CD44 antigen0112
Alpha-2B adrenergic receptor0691485
Alpha-2C adrenergic receptor0681484
Alpha-2A adrenergic receptor0691485
Nicotinamide N-methyltransferase0606
Genome polyprotein 0538
Prothrombin 0808
Coagulation factor X011011
Genome polyprotein0202
Replicase polyprotein 1ab0402666
Replicase polyprotein 1ab0673299
Alpha-amylase 1A 0606
5'-nucleotidase08110
Squalene monooxygenase 0606
Ectonucleoside triphosphate diphosphohydrolase 10404
Beta-secretase 1031133
Anthrax toxin receptor 20505
Xanthine dehydrogenase/oxidase016121
Neuraminidase 0101
5'-nucleotidase0505
potassium voltage-gated channel subfamily H member 2 isoform d23100231
Adenosine receptor A1015015
putative alpha-glucosidase5005
alpha-galactosidase560056
parathyroid hormone/parathyroid hormone-related peptide receptor precursor910091
Neuronal acetylcholine receptor subunit alpha-70181028
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha201416
Vasopressin V2 receptor0104
Mu-type opioid receptor010836161
Adenosine receptor A108616
Adenylate cyclase type 5010011
Adenylate cyclase type 10115
Sigma non-opioid intracellular receptor 1036440
polyadenylate-binding protein 10303
Rev0101
Female germline-specific tumor suppressor gld-10101
Cocaine esterase012013
Integrin beta-10404
Muscarinic acetylcholine receptor M1050967
Polyunsaturated fatty acid 5-lipoxygenase041144
Integrin alpha-40404
C-8 sterol isomerase010010
Delta-type opioid receptor0571179
Mu-type opioid receptor0731290
Kappa-type opioid receptor0271039
Kappa-type opioid receptor047977
Mu-type opioid receptor0581586
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase011112
Sigma intracellular receptor 2012012
Sigma intracellular receptor 2020020
Vesicular acetylcholine transporter0505
Chain A, Pentaerythritol Tetranitrate Reductase0011
Chain A, Pentaerythritol Tetranitrate Reductase0011
Chain A, PENTAERYTHRITOL TETRANITRATE REDUCTASE0011
Rap guanine nucleotide exchange factor 3450045
Cholinesterase051053
LIP1, secretory lipase 0101
Fatty-acid amide hydrolase 1018019
Phosphatidylserine lipase ABHD16A0101
Fatty-acid amide hydrolase 1126028
Platelet-activating factor acetylhydrolase0404
Neutral cholesterol ester hydrolase 10101
Lysophosphatidylserine lipase ABHD120202
Diacylglycerol lipase-beta0101
Diacylglycerol lipase-alpha0909
P2X purinoceptor 40617
Chain A, Retinaldehyde-binding protein 10011
Chain A, Retinaldehyde-binding protein 10011
nuclear receptor subfamily 1, group I, member 2650065
Sex hormone-binding globulin012021
Corticosteroid-binding globulin016016
Mitogen-activated protein kinase 3 091929
D(1B) dopamine receptor018123
Histamine H4 receptor0261142
Chain A, Amine oxidase [flavin-containing] B0011
Alpha-2B adrenergic receptor01619177
Nischarin015015
Trace amine-associated receptor 1011011
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-10101
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-10101
Chain A, Methyltransferase Wbdd0101
EWS/FLI fusion protein28400285
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform0141328
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha0303
Serine/threonine-protein kinase PLK4071926
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta03811
Bromodomain-containing protein 40336
5-hydroxytryptamine receptor 401473150
Serine/threonine-protein kinase pim-10112134
Casein kinase II subunit alpha'0181937
Proteinase-activated receptor 10326
Bromodomain-containing protein 20303
Phosphatidylinositol 3-kinase regulatory subunit alpha011113
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform0101
Type-1 angiotensin II receptor0617
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform0211638
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 0101
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform0121327
Serine/threonine-protein kinase mTOR0221436
Serine/threonine-protein kinase mTOR0101
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 0161330
Glycogen synthase kinase-3 beta0262147
Serine/threonine-protein kinase PLK10151530
Casein kinase II subunit beta018018
Casein kinase II subunit alpha020929
DNA-dependent protein kinase catalytic subunit013215
Serine-protein kinase ATM0606
Serine/threonine-protein kinase ATR05611
Bromodomain-containing protein 30101
Serine/threonine-protein kinase pim-302911
Phosphoinositide 3-kinase regulatory subunit 50505
Serine/threonine-protein kinase PLK3010919
Serine/threonine-protein kinase PLK208715
Proton-coupled amino acid transporter 1026027
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase0404
Cytochrome P450 2C19076282
neuropeptide S receptor isoform A920092
Membrane primary amine oxidase 0404
DNA repair and recombination protein RadA0044
Neutrophil cytosol factor 10617
Pteridine reductase 10909
Membrane primary amine oxidase0306
polyunsaturated fatty acid lipoxygenase ALOX12420042
Transient receptor potential cation channel subfamily M member 20415
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1013114
Transient receptor potential cation channel subfamily V member 305410
Transient receptor potential cation channel subfamily V member 20438
interferon gamma precursor00011
Adenosine receptor A10213
Adenosine receptor A10516
Adenosine receptor A2a0303
Adenosine receptor A30415
Cyclin-dependent kinase 10151530
NPYLR7B001212
vasopressin V1b receptor5005
glycogen synthase kinase-3 beta isoform 1001515
eukaryotic translation initiation factor 2-alpha kinase 3 isoform 1 precursor0022
relaxin receptor 1 isoform 1100010
high affinity choline transporter 1 isoform a0606
relaxin receptor 2 isoform 15005
Heat shock protein HSP 90-alpha0101223
Endoplasmin0449
Adenosine deaminase 0306
Ghrelin O-acyltransferase0303
Chain A, Neuraminidase0101
Chain A, Neuraminidase0101
Chain A, Neuraminidase0101
Chain A, Neuraminidase0101
Chain A, Sialidase0101
Chain A, Sialidase0101
Chain A, NEURAMINIDASE0101
Chain A, Neuraminidase0101
Chain A, Neuraminidase0101
Chain A, Neuraminidase0101
Chain A, NEURAMINIDASE0101
Chain A, Neuraminidase0101
Chain A, Sialidase0101
Sialidase 0101
Neuraminidase 019019
Sialidase-10202
Neuraminidase0606
Neuraminidase0101
Neuraminidase0303
Sialidase0101
Sialidase0707
Sialidase A0303
Hemagglutinin-neuraminidase 0101
Trans-sialidase0202
Trans-sialidase0202
Sialidase B0101
Neuraminidase 0101
Sialidase-40404
Sialidase-10404
Sialidase-30404
Sialidase-2011011
sentrin-specific protease 80101
Chain A, Ferritin light chain0022
Chain A, Ferritin light chain0022
Chain A, Ferritin light chain0022
Chain A, Ferritin light chain0022
Chain A, Ferritin light chain0022
Chain A, Ferritin light chain0022
Chain A, Ferritin light chain0022
Monocarboxylate transporter 10106
Monocarboxylate transporter 20606
Solute carrier family 22 member 20020020
Solute carrier family 22 member 6020021
Histamine H1 receptor011311130
Cytochrome P450 2A6023529
Sulfotransferase 1A1 0003
Cytochrome P450 2A50607
Sulfotransferase 1E10002
Sulfotransferase 1A10418
Sulfotransferase 2A10203
Alcohol dehydrogenase E chain09211
Alcohol dehydrogenase S chain09211
Peptidyl-prolyl cis-trans isomerase FKBP50235
D(1) dopamine receptor0011
D-amino-acid oxidase0415
D-amino-acid oxidase0819
Olfactory receptor 51E20178
interleukin 8770077
Nuclear receptor subfamily 1 group I member 2012223
Tyrosinase018019
Nuclear factor erythroid 2-related factor 200510
histone-lysine N-methyltransferase 2A isoform 2 precursor580058
Estrogen receptor1401156
Estrogen receptor beta121932
Chain A, Neutrophil gelatinase-associated lipocalin0011
72 kDa type IV collagenase014014
Matrilysin0707
Prolyl 4-hydroxylase subunit alpha-1010010
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT60505
Alpha-(1,3)-fucosyltransferase 70505
CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 10505
Glutamate receptor ionotropic, NMDA 2D025228
Glutamate receptor ionotropic, NMDA 3B023125
Glutamate receptor ionotropic, NMDA 1035137
Glutamate receptor ionotropic, NMDA 2A033236
Glutamate receptor ionotropic, NMDA 2B033338
Glutamate receptor ionotropic, NMDA 2C025228
Glutamate receptor ionotropic, NMDA 3A023125
Chain A, ATP-DEPENDENT DNA HELICASE Q1820082
Glutamate receptor ionotropic, kainate 1012216
Glutamate receptor 1019627
Glutamate receptor 2021629
Glutamate receptor 3016522
Glutamate receptor 4018626
Glutamate receptor ionotropic, kainate 2013215
Glutamate receptor ionotropic, kainate 30808
Peroxisome proliferator-activated receptor alpha1291334
Sodium- and chloride-dependent GABA transporter 1019019
Sodium- and chloride-dependent GABA transporter 2021021
Sodium- and chloride-dependent GABA transporter 3015015
Sodium- and chloride-dependent betaine transporter015015
Pyruvate dehydrogenase E1 component subunit alpha, mitochondrial0101
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial0101
BRCA1160016
Aminopeptidase N0707
Tyrosine-protein phosphatase non-receptor type 1033238
ORF730066
Prostaglandin G/H synthase 1046249
Dipeptidyl peptidase 4020225
Prostaglandin G/H synthase 2028029
Chain A, ANAEROBIC RIBONUCLEOTIDE-TRIPHOSPHATE REDUCTASE LARGE CHAIN0011
Chain A, ANAEROBIC RIBONUCLEOTIDE-TRIPHOSPHATE REDUCTASE LARGE CHAIN0011
S-adenosylmethionine synthase isoform type-10204
S-adenosylmethionine synthase isoform type-20103
P2Y purinoceptor 10055
Reverse transcriptase/RNaseH 0191147
P2Y purinoceptor 110044
Skn7p0003
HSP40, subfamily A [Plasmodium falciparum 3D7]0009
Synaptic vesicular amine transporter0718
Synaptic vesicular amine transporter0718
Uracil nucleotide/cysteinyl leukotriene receptor0729
Gamma-butyrobetaine dioxygenase0639
Nicotinamidase0202
Bifunctional dihydrofolate reductase-thymidylate synthase0606
Sodium- and chloride-dependent GABA transporter 1020020
Sodium- and chloride-dependent GABA transporter 2016016
Sodium- and chloride-dependent GABA transporter 3016016
Sodium- and chloride-dependent betaine transporter012012
Gamma-aminobutyric acid type B receptor subunit 2013013
Gamma-aminobutyric acid type B receptor subunit 1010010
Gamma-aminobutyric acid receptor subunit rho-300210
1-deoxy-D-xylulose 5-phosphate reductoisomerase0505
Botulinum neurotoxin type A 0707
D-aspartate oxidase0606
Amine oxidase [flavin-containing] A 026330
Nitric oxide synthase, endothelial0709
Nitric oxide synthase, brain020123
Nitric oxide synthase, inducible017018
Nitric oxide synthase, inducible012117
Beta-1 adrenergic receptor 051017
Beta-2 adrenergic receptor011217
Beta-1 adrenergic receptor016627
Beta-3 adrenergic receptor08210
Alpha-1A adrenergic receptor0471579
Ribonuclease H10101
DNA excision repair protein ERCC-10101
Deoxyribonuclease-10101
DNA repair protein complementing XP-G cells0101
Flap endonuclease 10101
DNA repair endonuclease XPF0101
Chain A, Phenazine biosynthesis protein phzF0011
Caspase 6, apoptosis-related cysteine peptidase0005
isocitrate dehydrogenase 1, partial170017
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase0707
glucose-6-phosphate 1-dehydrogenase isoform b0707
replicative DNA helicase0004
recombinase A0044
Caspase-7240025
Caspase-90506
large T antigen020121
pyruvate kinase260026
pyruvate kinase PKM isoform b260026
Ornithine decarboxylase262029
4-aminobutyrate aminotransferase, mitochondrial0326
Protein skinhead-10101
Calmodulin-109211
Androgen receptor124943
Pyruvate kinase PKM0819
Polyunsaturated fatty acid lipoxygenase ALOX15010011
Polyunsaturated fatty acid lipoxygenase ALOX120506
Fatty acid synthase011011
Cytochrome P450 1B1032134
Aurora kinase B0142034
Dipeptidyl peptidase 30808
Solute carrier family 22 member 6029039
Kynureninase0001
POU domain, class 2, transcription factor 101010
Spike glycoprotein233724264
Secreted chorismate mutase0606
Stromelysin-107310
Beta-lactamase 0407
Acetylcholine receptor subunit alpha0729
Acetylcholine receptor subunit beta0628
Acetylcholine receptor subunit gamma0628
Acetylcholine receptor subunit delta0639
Neuronal acetylcholine receptor subunit alpha-3018727
Muscarinic acetylcholine receptor M30471164
Muscarinic acetylcholine receptor M4044757
Muscarinic acetylcholine receptor M5043756
Neuronal acetylcholine receptor subunit alpha-209616
Neuronal acetylcholine receptor subunit beta-308716
Neuronal acetylcholine receptor subunit beta-4018727
Neuronal acetylcholine receptor subunit beta-2022530
Neuronal acetylcholine receptor subunit alpha-508615
Neuronal acetylcholine receptor subunit beta-4011518
Neuronal acetylcholine receptor subunit alpha-3012518
Neuronal acetylcholine receptor subunit alpha-6010718
Neuronal acetylcholine receptor subunit alpha-908615
Neuronal acetylcholine receptor subunit alpha-4021528
Neuronal acetylcholine receptor subunit alpha-7022932
Neuronal acetylcholine receptor subunit alpha-1008615
Chain A, DNA-3-methyladenine glycosylase I0011
Chain A, DNA-3-METHYLADENINE GLYCOSYLASE I0011
Chain A, Dna-3-methyladenine Glycosylase I0011
hemoglobin subunit beta170017
Delta-aminolevulinic acid dehydratase0303
Isocitrate lyase 10101
Isocitrate lyase0303
Isocitrate lyase0101
Glycoprotein hormones alpha chain100010
Tubulin--tyrosine ligase0202
Endolysin0044
Acetylcholinesterase0989111
Calcium dependent protein kinase0101
Nrf2250025
thioredoxin glutathione reductase760076
hypothetical protein, conserved280028
luciferase8008
P53150015
Replicase polyprotein 1ab0202545
NPC intracellular cholesterol transporter 1 precursor660066
FAD-linked sulfhydryl oxidase ALR0009
dual specificity tyrosine-phosphorylation-regulated kinase 1A0007
glycogen synthase kinase-3 alpha0007
DNA dC->dU-editing enzyme APOBEC-3G isoform 1228030
serine/threonine-protein kinase 33 isoform a0023
endoribonuclease toxin MazF0033
Arginase-10101
Tyrosine-protein kinase Lck0182241
Dipeptidyl peptidase 40707
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 10505
Tyrosine-protein kinase SYK092534
Lactoylglutathione lyase015015
Myosin light chain kinase, smooth muscle071926
Arginase-10404
Rap guanine nucleotide exchange factor 4420042
phosphoglycerate kinase160016
Chain A, Penicillin Amidohydrolase0101
Chain B, Penicillin Amidohydrolase0101
Chain A, Penicillin Amidohydrolase0101
Chain B, Penicillin Amidohydrolase0101
Chain A, Penicillin Amidohydrolase0101
Chain B, Penicillin Amidohydrolase0101
Chain A, Penicillin Amidohydrolase0101
Chain B, Penicillin Amidohydrolase0101
Chain A, Penicillin Amidohydrolase0101
Chain B, Penicillin Amidohydrolase0101
Chain A, Penicillin Amidohydrolase0101
Chain B, Penicillin Amidohydrolase0101
Chain A, Penicillin Amidohydrolase0101
Chain B, Penicillin Amidohydrolase0101
Chain A, Protocatechuate 3,4-dioxygenase0011
Chain M, Protocatechuate 3,4-dioxygenase0011
Olfactory receptor class A-like protein 10022
alkaline phosphatase, intestinal0123
intestinal alkaline phosphatase precursor0213
POsterior Segregation001011
Sodium-dependent noradrenaline transporter 017519195
Zinc finger protein mex-500910
5-hydroxytryptamine receptor 60141226
5-hydroxytryptamine receptor 5A0131225
5-hydroxytryptamine receptor 5B0131225
5-hydroxytryptamine receptor 3A0341549
5-hydroxytryptamine receptor 4 0171332
5-hydroxytryptamine receptor 3B0341549
Ectonucleotide pyrophosphatase/phosphodiesterase family member 10404
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 0303
Histamine H2 receptor071375
Histamine H3 receptor06123
Histamine H3 receptor029942
Tumor necrosis factor0314
cAMP-specific 3',5'-cyclic phosphodiesterase 4A020223
cGMP-dependent 3',5'-cyclic phosphodiesterase0404
cAMP-specific 3',5'-cyclic phosphodiesterase 4C013013
cGMP-specific 3',5'-cyclic phosphodiesterase0707
Sodium channel protein type 4 subunit alpha019023
Sodium channel protein type 9 subunit alpha025025
Chain A, TGF-beta receptor type-10101
tyrosine-protein kinase Yes200020
Serine/threonine-protein kinase 250099
Citron Rho-interacting kinase011920
Serine/threonine-protein kinase RIO30099
Serine/threonine-protein kinase Chk1012021
Aurora kinase A061925
Cyclin-G-associated kinase011920
Serine/threonine-protein kinase DCLK10099
Muscle, skeletal receptor tyrosine-protein kinase0099
3-phosphoinositide-dependent protein kinase 104913
Death-associated protein kinase 30099
Receptor-interacting serine/threonine-protein kinase 2021921
NUAK family SNF1-like kinase 103912
Tyrosine-protein kinase JAK2051318
Ribosomal protein S6 kinase alpha-5031922
Ribosomal protein S6 kinase alpha-4001919
Serine/threonine-protein kinase 16001919
Serine/threonine-protein kinase PAK 30099
Serine/threonine-protein kinase 17B0099
Serine/threonine-protein kinase 10001919
Serine/threonine-protein kinase D3072027
Cyclin-dependent kinase 140099
Mitogen-activated protein kinase kinase kinase kinase 4001919
Serine/threonine-protein kinase LATS1001919
Serine/threonine-protein kinase PAK 4021921
Tyrosine-protein kinase ABL10182242
Epidermal growth factor receptor0461965
RAF proto-oncogene serine/threonine-protein kinase07916
Receptor tyrosine-protein kinase erbB-2021930
High affinity nerve growth factor receptor021820
Insulin receptor031923
Tyrosine-protein kinase Fyn0332053
Tyrosine-protein kinase Fes/Fps001919
Macrophage colony-stimulating factor 1 receptor04913
Tyrosine-protein kinase Yes041923
Tyrosine-protein kinase Lyn021921
Proto-oncogene tyrosine-protein kinase receptor Ret061925
Insulin-like growth factor 1 receptor031922
Hepatocyte growth factor receptor091827
Tyrosine-protein kinase HCK031922
Proto-oncogene tyrosine-protein kinase ROS0099
Platelet-derived growth factor receptor beta091929
Tyrosine-protein kinase Fgr001515
Mast/stem cell growth factor receptor Kit091019
Fibroblast growth factor receptor 1061926
Myosin light chain kinase, smooth muscle0358
Proto-oncogene tyrosine-protein kinase Src0181938
Insulin receptor-related protein0099
Serine/threonine-protein kinase B-raf092029
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform001919
Platelet-derived growth factor receptor alpha051015
Tyrosine-protein kinase Fer001919
cAMP-dependent protein kinase catalytic subunit alpha0121931
Vascular endothelial growth factor receptor 1 07916
Interferon-induced, double-stranded RNA-activated protein kinase0099
Cyclin-dependent kinase 11B0099
Ephrin type-A receptor 1001919
Fibroblast growth factor receptor 200910
Fibroblast growth factor receptor 401911
Fibroblast growth factor receptor 300910
cAMP-dependent protein kinase catalytic subunit beta0101929
Tyrosine-protein kinase JAK1021921
Protein kinase C eta type091120
Activin receptor type-2A0099
MAP/microtubule affinity-regulating kinase 3001919
Mitogen-activated protein kinase 10162137
Ephrin type-A receptor 2001919
Ephrin type-A receptor 30099
Ephrin type-A receptor 80099
Ephrin type-B receptor 2011920
Leukocyte tyrosine kinase receptor0099
Non-receptor tyrosine-protein kinase TYK2001919
Wee1-like protein kinase001919
Tyrosine-protein kinase receptor UFO03912
Mitogen-activated protein kinase 40099
RAC-alpha serine/threonine-protein kinase0101929
RAC-beta serine/threonine-protein kinase011920
Dual specificity protein kinase TTK001818
Tyrosine-protein kinase receptor Tie-10099
Vascular endothelial growth factor receptor 309918
Vascular endothelial growth factor receptor 20191030
Dual specificity mitogen-activated protein kinase kinase 2041923
Receptor-type tyrosine-protein kinase FLT30161936
Bone morphogenetic protein receptor type-1A001919
Activin receptor type-1B001919
TGF-beta receptor type-1052126
Serine/threonine-protein kinase receptor R3001212
TGF-beta receptor type-2021719
Tyrosine-protein kinase CSK011920
Tyrosine-protein kinase Tec001919
Tyrosine-protein kinase TXK0099
Tyrosine-protein kinase ABL2022022
Tyrosine-protein kinase FRK001919
Tyrosine-protein kinase ZAP-700099
Mitogen-activated protein kinase 8012223
Mitogen-activated protein kinase 9012223
Dual specificity mitogen-activated protein kinase kinase 4021113
Dual specificity mitogen-activated protein kinase kinase 3001919
Casein kinase I isoform delta051924
MAP kinase-activated protein kinase 2011920
Cyclin-dependent kinase 801910
Casein kinase I isoform epsilon051924
Dual specificity protein kinase CLK1021719
Dual specificity protein kinase CLK2001818
Dual specificity protein kinase CLK3001515
Glycogen synthase kinase-3 alpha0131932
Cyclin-dependent kinase 7011920
Cyclin-dependent kinase 9011920
Tyrosine-protein kinase Blk0099
Ribosomal protein S6 kinase alpha-3011920
Cytoplasmic tyrosine-protein kinase BMX01910
cAMP-dependent protein kinase catalytic subunit PRKX0099
Serine/threonine-protein kinase Nek2021921
Tyrosine-protein kinase JAK306915
Dual specificity mitogen-activated protein kinase kinase 6011920
Death-associated protein kinase 109918
LIM domain kinase 1001919
LIM domain kinase 2001919
Mitogen-activated protein kinase 100112132
5'-AMP-activated protein kinase catalytic subunit alpha-2011012
Ephrin type-B receptor 3001919
Ephrin type-A receptor 5001919
Ephrin type-B receptor 4041923
Ephrin type-B receptor 10099
Ephrin type-A receptor 4001919
Serine/threonine-protein kinase SIK10099
Tubulin alpha-1A chain0055
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta0099
SRSF protein kinase 20099
Casein kinase I isoform gamma-2011617
Mitogen-activated protein kinase kinase kinase 901910
Cyclin-dependent kinase 3001818
Cyclin-dependent-like kinase 5 091928
Cyclin-dependent kinase 16001919
Cyclin-dependent kinase 17001717
Protein kinase C epsilon type0141125
Dual specificity mitogen-activated protein kinase kinase 1071926
Angiopoietin-1 receptor061218
Mitogen-activated protein kinase kinase kinase 1001910
Protein kinase C theta type092130
Activin receptor type-1001919
Focal adhesion kinase 1031922
Protein kinase C delta type0112132
Tyrosine-protein kinase BTK001919
Tyrosine-protein kinase receptor TYRO30099
Cyclin-dependent kinase 18001111
Activated CDC42 kinase 1001919
Epithelial discoidin domain-containing receptor 1001919
Tyrosine-protein kinase ITK/TSK0099
Myotonin-protein kinase02911
Tyrosine-protein kinase Mer021113
Serine/threonine-protein kinase 4001919
5'-AMP-activated protein kinase catalytic subunit alpha-1012123
Serine/threonine-protein kinase PAK 103912
Mitogen-activated protein kinase 7001818
Serine/threonine-protein kinase PAK 2001919
Serine/threonine-protein kinase 3001919
cGMP-dependent protein kinase 20099
Non-receptor tyrosine-protein kinase TNK1001919
Receptor-interacting serine/threonine-protein kinase 1021012
Calcium/calmodulin-dependent protein kinase type II subunit beta04914
Calcium/calmodulin-dependent protein kinase type II subunit gamma021922
Calcium/calmodulin-dependent protein kinase type II subunit delta031923
Activin receptor type-2B001818
Bone morphogenetic protein receptor type-2001919
Protein-tyrosine kinase 6001919
cGMP-dependent protein kinase 1 011920
Calcium/calmodulin-dependent protein kinase type 10099
Inhibitor of nuclear factor kappa-B kinase subunit epsilon001919
Protein-tyrosine kinase 2-beta001919
Maternal embryonic leucine zipper kinase001919
Serine/threonine-protein kinase D1071017
Ribosomal protein S6 kinase alpha-20099
Ephrin type-A receptor 7001717
Ribosomal protein S6 kinase alpha-1021921
Dual specificity testis-specific protein kinase 1001818
Serine/threonine-protein kinase STK11001919
NT-3 growth factor receptor0099
Serine/threonine-protein kinase N1021921
Serine/threonine-protein kinase N2021921
Calcium/calmodulin-dependent protein kinase type IV001818
Mitogen-activated protein kinase kinase kinase 11011920
BDNF/NT-3 growth factors receptor0099
Mitogen-activated protein kinase 6001010
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform0099
Discoidin domain-containing receptor 2021921
AP2-associated protein kinase 1011920
Serine/threonine-protein kinase TNNI3K01910
Serine/threonine-protein kinase MRCK alpha001919
Serine/threonine-protein kinase MRCK gamma001818
Serine/threonine-protein kinase Nek50099
Serine/threonine-protein kinase MARK2001919
Serine/threonine-protein kinase tousled-like 20099
Serine/threonine-protein kinase 32C0099
Myosin light chain kinase family member 40099
Calcium/calmodulin-dependent protein kinase type 1D0099
Mitogen-activated protein kinase kinase kinase kinase 3001919
MAP kinase-activated protein kinase 5031821
Serine/threonine-protein kinase BRSK20099
Serine/threonine-protein kinase DCLK20099
Calcium/calmodulin-dependent protein kinase kinase 10099
Casein kinase I isoform alpha-like0099
Myosin-IIIa0099
Ankyrin repeat and protein kinase domain-containing protein 10099
Atypical kinase COQ8A, mitochondrial001919
Mitogen-activated protein kinase 15001919
Serine/threonine-protein kinase Nek9001919
Serine/threonine-protein kinase BRSK10099
Serine/threonine-protein kinase Nek7001212
Myosin-IIIb0099
Mitogen-activated protein kinase kinase kinase kinase 1001818
Atypical kinase COQ8B, mitochondrial0099
MAP/microtubule affinity-regulating kinase 4001717
Calcium/calmodulin-dependent protein kinase type 1G001010
Serine/threonine-protein kinase Nek1001919
Calcium/calmodulin-dependent protein kinase kinase 2011920
SRSF protein kinase 10099
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase001919
Mitogen-activated protein kinase kinase kinase 5001919
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha0099
Serine/threonine-protein kinase RIO10099
MAP kinase-interacting serine/threonine-protein kinase 102911
Cyclin-dependent kinase 1901910
Testis-specific serine/threonine-protein kinase 10099
Serine/threonine-protein kinase 330099
Serine/threonine-protein kinase D2001919
Serine/threonine-protein kinase DCLK30099
NUAK family SNF1-like kinase 2001818
Serine/threonine-protein kinase SIK2001919
Myosin light chain kinase 2, skeletal/cardiac muscle0099
STE20-like serine/threonine-protein kinase 001919
Tyrosine-protein kinase Srms0099
Dual specificity protein kinase CLK4001717
MAP kinase-interacting serine/threonine-protein kinase 204913
Serine/threonine-protein kinase Nek601910
Casein kinase I isoform gamma-1011920
Serine/threonine-protein kinase PAK 6011213
Serine/threonine-protein kinase LATS20099
Serine/threonine-protein kinase 3601910
BMP-2-inducible protein kinase001919
Serine/threonine-protein kinase 32B0099
Mitogen-activated protein kinase kinase kinase 20011920
Serine/threonine-protein kinase MARK10099
Serine/threonine-protein kinase pim-2001212
Serine/threonine-protein kinase PAK 501910
Serine/threonine-protein kinase 26001919
eIF-2-alpha kinase GCN20099
Serine/threonine-protein kinase NLK011819
Serine/threonine-protein kinase 17A0099
Ephrin type-A receptor 60099
Death-associated protein kinase 20099
Ribosomal protein S6 kinase alpha-6001919
TRAF2 and NCK-interacting protein kinase011920
Serine/threonine-protein kinase tousled-like 10099
ALK tyrosine kinase receptor04913
Cyclin-dependent kinase 11A0099
Aurora kinase C0099
Calcium/calmodulin-dependent protein kinase type II subunit alpha04914
RAC-gamma serine/threonine-protein kinase011920
Serine/threonine-protein kinase 38-like001212
Dual specificity tyrosine-phosphorylation-regulated kinase 1B031215
Mitogen-activated protein kinase kinase kinase kinase 5001919
Serine/threonine-protein kinase MRCK beta001919
Interleukin-1 receptor-associated kinase 3001919
Serine/threonine-protein kinase 24001515
Casein kinase I isoform gamma-3001919
Mitogen-activated protein kinase kinase kinase 4001919
Kappa-type opioid receptor021835
Delta-type opioid receptor08729136
Kappa-type opioid receptor08929137
Mu-type opioid receptor025639
Aminopeptidase N0505
Poly [ADP-ribose] polymerase 108210
Urokinase-type plasminogen activator011011
Polyphenol oxidase 2039149
Thiopurine S-methyltransferase0202
Succinate-semialdehyde dehydrogenase, mitochondrial0303
4-aminobutyrate aminotransferase, mitochondrial0607
Dihydropteroate synthase 0011
Chain A, Toluene-4-monooxygenase system protein A0101
Potassium channel subfamily K member 20141428
Potassium voltage-gated channel subfamily A member 30415
Acetylcholinesterase014019
Potassium voltage-gated channel subfamily A member 10628
Acetylcholinesterase053459
[tau protein] kinase 0303
G2/mitotic-specific cyclin-B20909
cAMP-dependent protein kinase catalytic subunit alpha0909
Beta-casein0101
Protein kinase C alpha type0606
Protein kinase C delta type0606
Protein kinase C epsilon type0606
Protein kinase C zeta type0606
G2/mitotic-specific cyclin-B1013013
Protein kinase C gamma type0606
Protein kinase C beta type0606
Protein kinase C eta type0606
G2/mitotic-specific cyclin-B30909
Protein kinase C theta type0606
DNA topoisomerase 1 0101
short transient receptor potential channel 6 isoform 10044
voltage-dependent T-type calcium channel subunit alpha-1H isoform a0011
Muscarinic acetylcholine receptor M2012312144
Muscarinic acetylcholine receptor M401178131
Muscarinic acetylcholine receptor M501157126
Muscarinic acetylcholine receptor M1012813151
Muscarinic acetylcholine receptor DM10505
Muscarinic acetylcholine receptor M301139127
UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit0202
Cytochrome P450 1A10204
Cytochrome P450 1A2 0406
Transient receptor potential cation channel subfamily A member 1091322
Chain A, Nadph Dehydrogenase 10011
Acetylcholinesterase010111
Calcium/calmodulin-dependent protein kinase type II subunit alpha0303
Tetraspanin0101
Poly [ADP-ribose] polymerase 20202
Purine nucleoside phosphorylase0055
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A0708
5-hydroxytryptamine receptor 2C 09010
5-hydroxytryptamine receptor 2A0607
5-hydroxytryptamine receptor 5A017018
Chain A, Pyridoxal kinase0202
Chain A, Pyridoxal Kinase0202
Pyridoxal kinase001519
Equilibrative nucleoside transporter 1013013
Solute carrier family 28 member 30606
Adenosine kinase0103
Protein-tyrosine-phosphatase 0001
Receptor-type tyrosine-protein phosphatase beta0003
Serum paraoxonase/arylesterase 1011011
Tyrosine-protein phosphatase non-receptor type 50001
Melatonin receptor type 1A010313
Melatonin receptor type 1B07310
Muscarinic acetylcholine receptor M105513
Muscarinic acetylcholine receptor M40518
Muscarinic acetylcholine receptor M50215
Muscarinic acetylcholine receptor M302310
Muscarinic acetylcholine receptor M202110
Chain A, TRYPSIN0202
Chain A, TRYPSIN0202
Chain A, TRYPSIN0202
Chain A, TRYPSIN0202
Chain A, TRYPSIN0202
Chain A, TRYPSIN0202
Membrane primary amine oxidase0003
Cationic trypsin0909
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE0011
Histone deacetylase 3025129
Histone deacetylase 4023127
Histone deacetylase 1030235
Histone deacetylase 7023228
Histone deacetylase 2028233
Polyamine deacetylase HDAC10020124
Histone deacetylase 11 021125
Histone deacetylase 8026231
NAD-dependent protein deacylase sirtuin-5, mitochondrial0707
Histone deacetylase 6030336
Histone deacetylase 9023127
Histone deacetylase 5024128
Vesicular acetylcholine transporter0202
nuclear factor NF-kappa-B p105 subunit isoform 1280230
GALC protein550055
rac GTPase-activating protein 1 isoform a0202
Estrogen receptor beta0229
Estrogen receptor0229
Glutamate receptor 10216
Glutamate receptor 20205
Glutamate receptor 40205
Glutamate receptor 30205
PPM1D protein10000100
Rapamycin-insensitive companion of mTOR0202
Regulatory-associated protein of mTOR0707
Phosphatidylinositol 3-kinase catalytic subunit type 30448
Target of rapamycin complex 2 subunit MAPKAP10202
Target of rapamycin complex subunit LST80707
transient receptor potential cation channel subfamily V member 1100010
G-protein coupled bile acid receptor 1041418
Solute carrier family 15 member 1028130
5-hydroxytryptamine receptor 1B022327
5-hydroxytryptamine receptor 7040041
5-hydroxytryptamine receptor 1D0303
Adenosine kinase0101628
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
Chain A, Leukotriene A-4 hydrolase0202
90-kda heat shock protein beta HSP90 beta, partial0505
ubiquitin carboxyl-terminal hydrolase 2 isoform a610061
Leukotriene A-4 hydrolase08110
Tyrosinase012012
Disintegrin and metalloproteinase domain-containing protein 17465051
DNA repair protein RAD51 homolog 10011
Chain A, Mitogen-activated protein kinase 30101
Adenosine kinase0101
Adenosine kinase0303
Dual specificity tyrosine-phosphorylation-regulated kinase 1A091726
Adenosine kinase0202
Histone-lysine N-methyltransferase, H3 lysine-79 specific0617
Chain A, Breast cancer type 1 susceptibility protein6006
Cytochrome P450 1A1025329
Potassium voltage-gated channel subfamily A member 20011
Potassium voltage-gated channel subfamily A member 30011
Potassium voltage-gated channel subfamily A member 60011
Potassium voltage-gated channel subfamily A member 50516
Potassium voltage-gated channel subfamily C member 10011
Cholecystokinin receptor type A011314
Gastrin/cholecystokinin type B receptor011516
5-hydroxytryptamine receptor 408211
Transient receptor potential cation channel subfamily M member 808415
Transporter040546
Macrophage metalloelastase0404
Dihydrofolate reductase019023
Thymidylate synthase0606
Trifunctional purine biosynthetic protein adenosine-30202
Bifunctional purine biosynthesis protein ATIC0404
Folylpolyglutamate synthase, mitochondrial0105
Bifunctional purine biosynthesis protein ATIC0101
Catechol O-methyltransferase0416
Chain A, N-methyl-D-aspartate Receptor Subunit 10202
Chain A, N-methyl-D-aspartate Receptor Subunit 10202
Chain A, N-methyl-D-aspartate Receptor Subunit 10202
Trypsin-1011011
Trypsin-20808
Cyclic AMP-responsive element-binding protein 10002
Trypsin-30808
Mcl-10909
Myeloid cell leukemia sequence 1 (BCL2-related)0101
envelope glycoprotein0202
core protein, partial0202
glyceraldehyde-3-phosphate dehydrogenase isoform 13104
eukaryotic translation initiation factor 4 gamma 1 isoform 40606
eukaryotic translation initiation factor 4E isoform 10606
Vif0607
Tat0505
dual specificity protein phosphatase 60202
tyrosine-protein phosphatase non-receptor type 7 isoform 20202
bcl-2-like protein 1 isoform Bcl-X(L)0101
Caspase-1115118
S-adenosylmethionine decarboxylase proenzyme0203
Adenosylhomocysteinase0308
Solute carrier organic anion transporter family member 2A104011
Dihydroorotase0011
beta-2 adrenergic receptor110314
Luciferin 4-monooxygenase0617
Amine oxidase [flavin-containing] A0405
Leucine-rich repeat serine/threonine-protein kinase 205712
caspase-1 isoform alpha precursor270027
Aldo-keto reductase family 1 member B10909
D(3) dopamine receptor01507165
Vesicular glutamate transporter 30404
ERAP1 protein0003
Glyceraldehyde-3-phosphate dehydrogenase010010
Seed linoleate 13S-lipoxygenase-1016024
Aldo-keto reductase family 1 member B1036038
Glyceraldehyde-3-phosphate dehydrogenase, glycosomal0303
Genome polyprotein0202
Substance-P receptor017020
Quinone oxidoreductase0005
Cholinesterase037140
Sorbitol dehydrogenase0606
Induced myeloid leukemia cell differentiation protein Mcl-1014014
Zn finger protein 0202
Dihydroorotate dehydrogenase 0606
Nitric oxide synthase, endothelial010011
Nitric oxide synthase, endothelial 0101
aryl hydrocarbon receptor0011
nuclear receptor subfamily 1 group I member 2 isoform 10011
Amine oxidase [flavin-containing] B034136
Amine oxidase [flavin-containing] B0607
Tyrosyl-DNA phosphodiesterase 10707
Chain A, Endochitinase0202
Chain A, Endochitinase0202
Chain A, Endochitinase0202
Endochitinase0202
Endochitinase A10202
Acidic mammalian chitinase0202
mu-type opioid receptor isoform MOR-1001010
5-hydroxytryptamine receptor 2A0099
Alpha-1D adrenergic receptor012812153
D0606
5-hydroxytryptamine receptor 2A0505
Lysosomal alpha-glucosidase0303
Chain A, Avidin0022
Chain A, Avidin0022
Chain B, Avidin0022
Adenosine receptor A10404
Adenosine deaminase0304
Phosphatidylinositol 4-kinase alpha09010
Phosphatidylinositol 4-kinase type 2-beta0708
Phosphatidylinositol 4-kinase type 2-alpha0809
Phosphatidylinositol 4-kinase beta0111022
Acetylcholine receptor subunit alpha09413
Acetylcholine receptor subunit gamma09413
Acetylcholine receptor subunit beta09413
Acetylcholine receptor subunit delta09413
Albumin0193059
Broad substrate specificity ATP-binding cassette transporter ABCG2053562
Solute carrier family 22 member 1 0860105
Beta-2 adrenergic receptor0482271
Beta-3 adrenergic receptor0381654
Major prion protein0099
Trypanothione reductase022022
Taste receptor type 2 member 310146
Solute carrier family 22 member 6035038
UDP-glucuronosyltransferase 1A903113
Bile salt export pump065066
Cytochrome P450 2B10507
Myoglobin0101
Polyunsaturated fatty acid lipoxygenase ALOX15030030
UDP-glucuronosyltransferase 1-6014119
Arachidonate 5-lipoxygenase-activating protein0505
UDP-glucuronosyltransferase 1A1 025137
Prostaglandin G/H synthase 1061062
Prostaglandin G/H synthase 20691086
Cytochrome P450 2J2061063
toxin B0001
Chain A, CARBONIC ANHYDRASE II0011
Chain A, CARBONIC ANHYDRASE II0011
Chain A, CARBONIC ANHYDRASE II0011
Chain A, Carbonic Anhydrase Ii0011
Chain A, Carbonic Anhydrase Ii0011
Chain A, Class Iii Chitinase Chia10101
Chain A, Carbonic anhydrase 130101
Chain A, Carbonic anhydrase II0101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase0101
Chain B, Carbonic anhydrase0101
Chain A, Carbonic anhydrase 20101
Carbonic anhydrase 0008
Carbonic anhydrase 020020
Carbonic anhydrase 011011
Carbonic anhydrase 016016
Carbonic anhydrase016016
Carbonic anhydrase0707
Prolyl endopeptidase0505
Carbonic anhydrase-related protein 110103
Glycogen phosphorylase, muscle form013013
Carbonic anhydrase 20415
Cathepsin B0202
Steryl-sulfatase0608
Cytochrome P450 2C8026128
Cytochrome P450 2B6024229
Carbonic anhydrase 5A, mitochondrial0606
Carbonic anhydrase033039
Carbonic anhydrase0202
Corticosteroid 11-beta-dehydrogenase isozyme 10314
Carbonic anhydrase011018
Carbonic anhydrase 0606
Beta-carbonic anhydrase 1014014
Carbonic anhydrase 2013013
Squalene synthase0505
Carbonic anhydrase0606
Carbonic anhydrase, alpha family 013013
Carbonic anhydrase 08015
Carbonic anhydrase 3010010
Carbonic anhydrase012020
Carbonic anhydrase013021
Carbonic anhydrase 011011
Delta carbonic anhydrase011011
Renin0202
Carbonic anhydrase 08015
Multidrug resistance-associated protein 10101
Carbonic anhydrase 13019225
Carbonic anhydrase 4014019
Carbonic anhydrase 70101
Carbonic anhydrase 011011
Carbonic anhydrase 0101
Carbonic anhydrase 2, isoform A 0101
Free fatty acid receptor 30033
Free fatty acid receptor 20224
Fibrinogen C domain-containing protein 10101
3-alpha-hydroxysteroid dehydrogenase 0001
N-alpha-acetyltransferase 500022
Coagulation factor XII0606
Liver carboxylesterase 10404
Liver carboxylesterase 1013022
Mas-related G-protein coupled receptor member X2001616
Putative glycosyltransferase WbgO0001
Killer cell lectin-like receptor subfamily B member 1A0101
Early activation antigen CD690101
Chain A, Acetylcholinesterase0033
Chain A, Acetylcholinesterase0033
Chain A, Acetylcholinesterase0033
Chain A, Acetylcholinesterase0033
Chain A, Acetylcholinesterase0033
Chain A, Acetylcholinesterase0033
Chain A, Acetylcholinesterase0033
Polyunsaturated fatty acid 5-lipoxygenase014021
Prostaglandin G/H synthase 2 014017
Prostaglandin G/H synthase 1 015018
DNA topoisomerase 2-alpha0131545
karyopherin alpha 2 (RAG cohort 1, importin alpha 1), isoform CRA_b0022
serine-protein kinase ATM isoform a260026
Chain E, Purine nucleoside phosphorylase0101
Thymidine kinase 0405
Purine nucleoside phosphorylase0507
Thymidine kinase, cytosolic09016
POU domain, class 2, transcription factor 20103
Thymidine kinase 0101
Solute carrier family 22 member 8023034
Thymidine kinase0203
60 kDa chaperonin017017
Retinoic acid receptor alpha0339
60 kDa heat shock protein, mitochondrial023023
Retinoic acid receptor beta0339
Retinoic acid receptor gamma 0339
Aspartate aminotransferase, cytoplasmic0404
Glycine receptor subunit alpha-102911
10 kDa heat shock protein, mitochondrial023023
Thiosulfate sulfurtransferase020020
60 kDa chaperonin 024024
10 kDa chaperonin 024024
Chain A, MTA/SAH nucleosidase0101
Chain A, Ribosome-inactivating protein alpha-trichosanthin0011
Chain A, Ricin A chain0011
Chain A, Ribosome-inactivating protein 30011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
Chain A, Phenylethanolamine N-methyltransferase0011
tumor susceptibility gene 101 protein120012
Heat shock protein HSP 90-beta06515
Protein mono-ADP-ribosyltransferase PARP150303
Chain A, Membrane lipoprotein tmpC0033
Chain A, Membrane lipoprotein tmpC0033
Chain A, Membrane lipoprotein tmpC0033
Chain A, Structure of PAE2307 in complex with adenosine0011
Chain B, Structure of PAE2307 in complex with adenosine0011
Chain A, ADENOSINE RECEPTOR A2A0202
Chain A, ADENOSINE RECEPTOR A2A0202
Chain A, tRNA (guanine-N(1)-)-methyltransferase0011
Chain A, Uncharacterized protein MJ08830011
signal transducer and activator of transcription 6, interleukin-4 induced5005
Sodium/nucleoside cotransporter 10505
Calcium dependent protein kinase0101
Mitogen-activated protein kinase kinase kinase 7001010
Sodium/nucleoside cotransporter 20505
Phosphoglycerate kinase 1 0202
Avidin0011
Adenosine deaminase0102
Phosphoglycerate kinase 20202
Heat shock 70 kDa protein 1A 0213
Heat shock cognate 71 kDa protein0055
Inosine-5'-monophosphate dehydrogenase 2031518
Inosine-5'-monophosphate dehydrogenase 1 0303
Streptavidin0022
Adenylate kinase 2, mitochondrial0203
Adenylate kinase isoenzyme 1 0203
Equilibrative nucleoside transporter 20404
5-methylthioadenosine/S-adenosylhomocysteine deaminase0002
Adenosine transporter 10102
Phospholipase C, gamma 10101
Phospholipase C, beta 3 (phosphatidylinositol-specific)0101
5'-nucleotidase0606
Glycine--tRNA ligase0202
Chain A, Heat Shock Protein 900011
Chain A, GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE0011
Chain B, GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE0011
Chain A, EOSINOPHIL-DERIVED NEUROTOXIN0101
Chain A, EOSINOPHIL-DERIVED NEUROTOXIN0101
Chain A, EOSINOPHIL-DERIVED NEUROTOXIN0101
Chain A, Myosin Ie Heavy Chain0011
Chain A, Preprotein translocase secA0011
Chain A, Ribonuclease pancreatic0101
Chain A, Ribonuclease pancreatic0101
Chain A, Ribonuclease pancreatic0101
Chain A, Ribonuclease pancreatic0101
Chain A, Ribonuclease pancreatic0101
Chain A, Phosphoribosylformylglycinamidine synthase0101
Chain A, nucleoside diphosphate kinase A0011
Chain B, nucleoside diphosphate kinase A0011
Chain D, DNA polymerase III subunit gamma0011
Chain D, DNA polymerase III subunit gamma0011
Chain A [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 30011
Chain A [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 30011
Chain A, Kinesin-like protein KIF110101
HPr kinase/phosphorylase0011
ATP-dependent molecular chaperone HSP820102
2-dehydropantoate 2-reductase0347
Endoplasmic reticulum chaperone BiP0112
Pyruvate kinase PKM 0002
Pyruvate kinase PKLR 0002
Heat shock cognate 71 kDa protein0011
Endoplasmin0235
P2Y purinoceptor 20044
P2X purinoceptor 10033
P2Y purinoceptor 10145
P2X purinoceptor 10123
P2X purinoceptor 40134
P2X purinoceptor 50022
P2X purinoceptor 60022
P2X purinoceptor 30022
Heat shock protein 75 kDa, mitochondrial0202
P2Y purinoceptor 60044
P2Y purinoceptor 120426
Sensor protein kinase WalK0101
P2X purinoceptor 20022
Chain A, Glycogen Phosphorylase B0011
Chain B, Glycogen Phosphorylase B0011
Chain A, ADP-dependent glucokinase0101
Chain A, Ribonuclease pancreatic0101
Chain A, Ribonuclease pancreatic0101
Chain A, phosphodiesterase-nucleotide pyrophosphatase0101
Chain A, GLYCOGEN PHOSPHORYLASE B0011
Chain B, GLYCOGEN PHOSPHORYLASE B0011
Chain A, GLYCOGEN PHOSPHORYLASE B0011
2'-deoxynucleoside 5'-phosphate N-hydrolase 10101
2'-deoxynucleoside 5'-phosphate N-hydrolase 10101
5'-AMP-activated protein kinase subunit beta-20012
L-lactate dehydrogenase A chain0729
Adenylate kinase isoenzyme 10002
Fructose-1,6-bisphosphatase 10101
Fructose-1,6-bisphosphatase 10505
Inosine-5'-monophosphate dehydrogenase0101
GTP:AMP phosphotransferase AK3, mitochondrial0001
5'-AMP-activated protein kinase subunit gamma-1001718
Adenylate kinase 2, mitochondrial001517
Adenosine deaminase-like protein0001
Protease 015729
Histamine H3 receptor010314
5'-AMP-activated protein kinase subunit gamma-30012
5'-AMP-activated protein kinase subunit gamma-2001617
5'-AMP-activated protein kinase subunit beta-10023
Chain A, Endoplasmin0011
thyrotropin-releasing hormone receptor1001
Transmembrane domain-containing protein TMIGD30101
Aflatoxin B1 aldehyde reductase member 30101
Endoplasmin0011
2-oxoglutarate receptor 10101
Transient receptor potential cation channel subfamily A member 1062129
Transient receptor potential cation channel subfamily M member 808311
WRN110011
chaperonin-containing TCP-1 beta subunit homolog9009
Solute carrier family 22 member 2039049
Polyamine oxidase 10101
Solute carrier family 22 member 3021025
Solute carrier family 22 member 30507
Nischarin0707
Solute carrier family 22 member 1032040
Deoxyhypusine synthase0202
Solute carrier family 22 member 2027032
Prostaglandin E2 receptor EP1 subtype04410
Prostaglandin E2 receptor EP4 subtype0418
Prostaglandin E2 receptor EP3 subtype05210
Prostaglandin E2 receptor EP2 subtype0439
Prostacyclin receptor07413
Prostaglandin D2 receptor0226
Alanine racemase, biosynthetic0001
Adenosine deaminase0001
Methionine aminopeptidase0202
Beta-2 adrenergic receptor 02917
Beta-2 adrenergic receptor0101325
Mineralocorticoid receptor 19517
Mineralocorticoid receptor0213
Solute carrier organic anion transporter family member 1A1010018
Chain A, farnesyl pyrophosphate synthase0101
Geranylgeranyl pyrophosphate synthase0405
Farnesyl pyrophosphate synthase0808
Hypoxanthine-guanine phosphoribosyltransferase0202
Farnesyl pyrophosphate synthase 0404
Farnesyl pyrophosphate synthase 0202
Pepsin A0101
Renin-1 0101
Renin 0202
Cathepsin D 0202
Renin 0101
Protease 013519
Hypoxanthine-guanine phosphoribosyltransferase0105
Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase 0101
Nuclear receptor ROR-gamma0101
Shiga toxin subunit A0202
Chain A, Xcogt0011
Chain A, Xcogt0011
Chain A, Xcogt0011
Tyrosine-protein phosphatase 10202
Orexin receptor type 10406
Orexin receptor type 20405
Sigma non-opioid intracellular receptor 10404
Tryptophan 5-hydroxylase 10808
Histamine H1 receptor015625
D(2) dopamine receptor0808
5-hydroxytryptamine receptor 2B0606
Chain A, Glutamate Receptor Subunit 20011
Chain A, Glutamate receptor 20033
Chain A, Glutamate receptor 20033
Chain C, Glutamate receptor 20033
Cytochrome P450 3A509111
Cytochrome P450 3A70404
Glutamate carboxypeptidase 20528
Glutamate receptor ionotropic, kainate 50606
Cytochrome P450 3A43 0303
Excitatory amino acid transporter 10607
Excitatory amino acid transporter 20506
Excitatory amino acid transporter 30506
Glutamate receptor ionotropic, kainate 40303
Tyrosine-protein kinase 0011
3-hydroxy-3-methylglutaryl-coenzyme A reductase011011
3-hydroxy-3-methylglutaryl-coenzyme A reductase0202
Methylcytosine dioxygenase TET20314
phospholipase A2 precursor0101
cysteine protease ATG4B isoform a0101
DNA dC->dU-editing enzyme APOBEC-3F isoform a130013
Free fatty acid receptor 10066
Prostaglandin G/H synthase 1 020022
Trypsin0607
Coagulation factor VII011011
Tissue factor014014
Peroxisome proliferator-activated receptor gamma0112437
Free fatty acid receptor 40033
Chain A, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase0011
Chain A, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase0011
Chain A, Calmodulin-sensitive adenylate cyclase0101
Chain A, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase0011
P2X purinoceptor 20011
P2X purinoceptor 70426
Translocator protein017322
Cholecystokinin receptor type A120021
Cholecystokinin receptor type A012012
Prostaglandin E2 receptor EP3 subtype0303
Prostaglandin E2 receptor EP4 subtype0314
Prostaglandin E2 receptor EP1 subtype0303
Nuclear receptor subfamily 4 group A member 20178
Nuclear receptor subfamily 4 group A member 20011
Nuclear receptor subfamily 4 group A member 20011
Prostaglandin E2 receptor EP2 subtype0314
Solute carrier organic anion transporter family member 2A10308
Solute carrier organic anion transporter family member 2B10203
Solute carrier organic anion transporter family member 3A10001
Proteasome subunit beta type-110214
eyes absent homolog 2 isoform a140014
streptokinase A precursor003131
Proteasome subunit alpha type-70214
Estrogen receptor021720
Fatty acid-binding protein, liver0808
Proteasome subunit beta type-10215
Cruzipain013013
Proteasome subunit alpha type-10214
Proteasome subunit alpha type-20214
Proteasome subunit alpha type-30214
Proteasome subunit alpha type-40214
Proteasome subunit beta type-80214
Proteasome subunit beta type-90214
Proteasome subunit alpha type-50214
Proteasome subunit beta type-40214
Proteasome subunit beta type-60214
Proteasome subunit beta type-5015118
Proteasome subunit beta type-100214
Proteasome subunit beta type-30214
Proteasome subunit beta type-20215
Proteasome subunit alpha type-60258
Estrogen receptor beta011719
Proteasome subunit alpha-type 80214
Proteasome subunit beta type-70214
Cannabinoid receptor 205611
Matrix protein 20123
Matrix protein 20235
Multidrug and toxin extrusion protein 1050050
Cytosol aminopeptidase0101
Angiotensin-converting enzyme011112
Leucyl-cystinyl aminopeptidase0101
Glutamyl aminopeptidase0101
Leukotriene B4 receptor 10618
Aminoglycoside 3'-phosphotransferase 0002
Chain U, UROKINASE-TYPE PLASMINOGEN ACTIVATOR0202
Chain A, UROKINASE-TYPE PLASMINOGEN ACTIVATOR0202
Chain A, UROKINASE-TYPE PLASMINOGEN ACTIVATOR0202
Prothrombin013622
Plasminogen09212
Tissue-type plasminogen activator0808
Coagulation factor XI0101
Plasma kallikrein0209
Vitamin K-dependent protein C0202
Urokinase-type plasminogen activator0505
Sodium/hydrogen exchanger 10404
Sodium/hydrogen exchanger 10707
Sodium/hydrogen exchanger 30404
Amiloride-sensitive sodium channel subunit alpha0101
Sodium/hydrogen exchanger 20505
Acid-sensing ion channel 10303
Sodium channel protein type 5 subunit alpha043043
Sodium/hydrogen exchanger 50505
Acid-sensing ion channel 30101
Sodium/hydrogen exchanger0202
Chain A, PLASMINOGEN0022
Chain A, PLASMINOGEN0022
Chain A, Apolipoprotein0011
Sterol O-acyltransferase 10505
Cholesterol side-chain cleavage enzyme, mitochondrial 0112
Triosephosphate isomerase0404
Steroid 17-alpha-hydroxylase/17,20 lyase0808
Cholesterol side-chain cleavage enzyme, mitochondrial0101
Ribosyldihydronicotinamide dehydrogenase [quinone]0111728
Aromatase0224
Cytochrome P450 11B2, mitochondrial0101
Guanine deaminase0405
Solute carrier family 15 member 1010010
Solute carrier family 15 member 2019020
Cystathionine gamma-lyase0404
Cystathionine beta-synthase0101
Lysyl oxidase homolog 20101
Protein-lysine 6-oxidase0404
Protein-lysine 6-oxidase0101
Lysyl oxidase homolog 20101
Lysyl oxidase homolog 30303
Lysyl oxidase homolog 40303
Lysyl oxidase homolog 20505
Nicotinate phosphoribosyltransferase013013
microphthalmia-associated transcription factor isoform 90404
Voltage-dependent L-type calcium channel subunit alpha-1C017017
Solute carrier organic anion transporter family member 1A408017
Voltage-dependent L-type calcium channel subunit alpha-1F045146
Lysine-specific demethylase PHF20101
Thyroid hormone receptor alpha0101
ATP-dependent translocase ABCB1029029
Aldo-keto reductase family 1 member B101450145
Thyroid hormone receptor alpha0437
Thyroid hormone receptor beta0437
Lethal factor0404
ATP-dependent translocase ABCB1030233
Substance-K receptor047048
D(4) dopamine receptor063576
Carnitine O-palmitoyltransferase 2, mitochondrial0404
Endothelin-1 receptor08110
Lysine-specific demethylase 5A0404
B2 bradykinin receptor08111
Melanocortin receptor 4012113
Melanocortin receptor 5018119
Sodium channel protein type 1 subunit alpha016016
Squalene synthase0101
Melanocortin receptor 3012113
Carnitine O-palmitoyltransferase 1, liver isoform0404
C-C chemokine receptor type 40606
Sodium channel protein type 7 subunit alpha014014
Voltage-dependent L-type calcium channel subunit alpha-1D 045146
Voltage-dependent L-type calcium channel subunit alpha-1S045146
Squalene monooxygenase0303
Lysine-specific demethylase 7A0202
Carnitine O-palmitoyltransferase 1, muscle isoform0202
Sodium channel protein type 2 subunit alpha018018
NAD-dependent protein deacetylase sirtuin-3, mitochondrial0246
Sodium channel protein type 3 subunit alpha018018
Sodium channel protein type 11 subunit alpha013013
Histone lysine demethylase PHF80303
Sodium channel protein type 8 subunit alpha014014
Sodium channel protein type 10 subunit alpha014014
Albumin001515
Angiotensin-converting enzyme068069
UDP-glucuronosyltransferase 1A4012127
Histamine H1 receptor021122
UDP-glucuronosyltransferase 1A300112
Voltage-dependent N-type calcium channel subunit alpha-1B017017
Nuclear receptor subfamily 3 group C member 3 057057
Integrase 024125
NEDD8-activating enzyme E1 regulatory subunit isoform a0202
NEDD8-conjugating enzyme Ubc120202
Voltage-dependent L-type calcium channel subunit alpha-1C016017
Potassium channel subfamily K member 2 0404
Beta-lactamase 0207
Beta-lactamase 02012
Beta-lactamase 0009
Beta-lactamase 03013
Beta-lactamase 0007
Beta-lactamase SHV-10209
Beta-lactamase SHV-105018
Beta-lactamase03015
B2 metallo-beta-lactamase 00011
Solute carrier family 15 member 2014014
Beta-lactamase 02010
Beta-lactamase 01010
Beta-lactamase 02010
Beta-lactamase 0008
Substance-P receptor0606
Chain A, Mutant Al2 6e7p9g0011
Beta-lactamase 04011
Beta-lactamase 03011
Beta-lactamase 01012
Metallo-beta-lactamase type 201212
Metallo-beta-lactamase VIM-11 0008
Metallo-beta-lactamase VIM-20008
Beta-lactamase 01013
Metallo-beta-lactamase0009
Beta-lactamase 03011
Beta-lactamase OXA-70006
Beta-lactamase 0208
Beta-lactamase 0208
Beta-lactamase 0208
Efflux transporter 0206
Beta-lactamase 0109
Beta-lactamase Toho-10006
Beta-lactamase 0206
Class D beta-lactamase0308
Metallo-beta-lactamase0007
Beta-lactamase 03011
Beta-lactamase 02310
Metallo-b-lactamase 00019
Carbapenem-hydrolyzing beta-lactamase KPC05016
Beta-lactamase class B VIM-2 01225
DNA polymerase III, partial190019
Aldehyde oxidase 10303
DNA topoisomerase 2-beta031729
Aldehyde oxidase013017
Aldehyde oxidase 1 0606
Fatty-acid amide hydrolase 10405
Potassium channel subfamily K member 30909
Cannabinoid receptor 1010314
Corticotropin-releasing factor receptor 20303
Lanosterol 14-alpha demethylase021224
Transient receptor potential cation channel subfamily V member 2012618
Nuclear factor NF-kappa-B p105 subunit0708
Signal transducer and activator of transcription 30617
Hexokinase-20202
Bile acid receptor08311
Beta-glucuronidase0303
Gastrin/cholecystokinin type B receptor113116
Testosterone 17-beta-dehydrogenase 30909
Chain A, retinol dehydratase0101
Glucose-6-phosphate 1-dehydrogenase015015
Triosephosphate isomerase, glycosomal0101
Atrial natriuretic peptide receptor 30202
Type-1A angiotensin II receptor 07512
Type-1 angiotensin II receptor0011
Type-1B angiotensin II receptor0819
Type-1 angiotensin II receptor014624
Type-2 angiotensin II receptor012113
Type-2 angiotensin II receptor010111
Interleukin-1 receptor antagonist protein0101
Endoplasmic reticulum aminopeptidase 20101
Endoplasmic reticulum aminopeptidase 10101
Leucyl-cystinyl aminopeptidase0101
M17 leucyl aminopeptidase0202
Steroid C26-monooxygenase0077
Cytochrome P450 1300033
Cytochrome P450 1300033
Chain A, BCL-2-RELATED PROTEIN A100910
PAX800013
Hsf1 protein001520
hepatitis C virus polyprotein1001
caspase recruitment domain family, member 150404
Spike glycoprotein072431
receptor-interacting serine/threonine-protein kinase 2 isoform 10404
bcl-2-like protein 11 isoform 10099
Transmembrane protease serine 2072431
Bcl-2-like protein 110001
Glucose transporter0303
Hexose transporter 1 0303
Procathepsin L0142438
Replicase polyprotein 1a0132639
Replicase polyprotein 1ab0112435
Solute carrier family 2, facilitated glucose transporter member 10516
Angiotensin-converting enzyme 2 092534
Beta lactamase (plasmid)0606
Corticotropin-releasing factor receptor 10404
Corticotropin-releasing factor receptor 10214
Corticotropin-releasing factor receptor 20213
Apelin receptor0112
Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase0303
Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase0303
Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase0303
Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase0303
Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase0303
Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase0303
Chain A, Transthyretin0044
Chain A, Transthyretin0044
Chain A, Transthyretin0044
Chain A, Transthyretin0044
Chain B, Transthyretin0044
Chain A, Transthyretin0044
Chain B, Transthyretin0044
Chain A, Casein kinase II subunit alpha0202
Chain A, Casein kinase II subunit alpha0202
Chain A, Casein Kinase Ii Subunit Alpha0202
Aldo-keto reductase family 1 member B10017019
Poly [ADP-ribose] polymerase tankyrase-10314
Lysozyme C-10202
Myeloperoxidase014014
Beta-glucuronidase0303
Neutrophil elastase018019
Cystic fibrosis transmembrane conductance regulator0268
17-beta-hydroxysteroid dehydrogenase type 10708
Urease subunit alpha012012
G2/mitotic-specific cyclin-B0505
Mucin-10101
Glycogen synthase kinase-3 beta0707
Multidrug resistance-associated protein 1 013122
17-beta-hydroxysteroid dehydrogenase type 20808
Peroxisome proliferator-activated receptor gamma011011
Homeobox protein Nkx-2.5 0202
Estrogen receptor0022
Urease subunit beta012012
Lactoperoxidase0408
MO15-related protein kinase Pfmrk 0707
Cyclin-dependent kinase 6061521
Cyclin homolog0505
Transcription factor GATA-4 0202
Cyclin-dependent kinase 5 activator 10909
Substance-K receptor011011
Casein kinase II subunit alpha 3011011
Inositol polyphosphate multikinase0404
Enoyl-acyl-carrier protein reductase 012012
NACHT, LRR and PYD domains-containing protein 3 0404
Myocilin0011
Cyclin-dependent kinase 10505
Prenyltransferase homolog0004
Poly [ADP-ribose] polymerase tankyrase-20448
Carboxylic ester hydrolase 0608
NADPH oxidase 40303
Estrogen receptor beta0022
Inositol hexakisphosphate kinase 20404
Short transient receptor potential channel 50303
Chain A, Coagulation factor X (EC 3.4.21.6) (Stuart factor) (Stuart-Prower factor)0101
Coagulation factor X0101
E3 ubiquitin-protein ligase Mdm20505
Monocarboxylate transporter 10101
Chain A, ADIPOCYTE LIPID-BINDING PROTEIN0011
Chain A, SERUM ALBUMIN0022
Chain A, SERUM ALBUMIN0022
Calmodulin 03913
Solute carrier organic anion transporter family member 1B3037044
Cytosolic phospholipase A2 gamma0202
Solute carrier organic anion transporter family member 1B1043051
Polyphenol oxidase 10303
Taste receptor type 2 member 160023
Muscarinic acetylcholine receptor010213
Chain E, LYSINE, ARGININE, ORNITHINE-BINDING PROTEIN0033
Chain E, LYSINE, ARGININE, ORNITHINE-BINDING PROTEIN0033
Chain E, LYSINE, ARGININE, ORNITHINE-BINDING PROTEIN0033
Cationic amino acid transporter 30202
Vasopressin V2 receptor010415
Oxytocin receptor06511
Vasopressin V1a receptor0237
Vasopressin V1a receptor017522
Vasopressin V1b receptor0448
Vasopressin V2 receptor0011
Vasopressin V1b receptor0216
Translocator protein0406
Oxytocin receptor0426
Vasopressin V2 receptor 0428
5-hydroxytryptamine receptor 3A0325
3-hydroxy-3-methylglutaryl-coenzyme A reductase 010010
Multidrug and toxin extrusion protein 2027027
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform0101
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform0101
Dual specificity tyrosine-phosphorylation-regulated kinase 20279
CDGSH iron-sulfur domain-containing protein 1015015
Chain A, Hyaluronidase, phage associated0101
Pancreatic alpha-amylase0202
Albumin0315
Urease0506
Prolyl 4-hydroxylase subunit alpha-10001
Hyaluronate lyase0101
Prolyl hydroxylase EGLN20146
Egl nine homolog 106714
Prolyl hydroxylase EGLN30045
Hypoxia-inducible factor 1-alpha inhibitor0405
Solute carrier family 23 member 10101
Pancreatic alpha-amylase0608
Tyrosine-protein phosphatase non-receptor type 20808
DNA repair protein RAD52 homolog0505
Neuronal acetylcholine receptor subunit alpha-40314
Acetylcholinesterase 011011
Neuronal acetylcholine receptor subunit alpha-70505
Neuronal acetylcholine receptor subunit alpha-50303
Neuronal acetylcholine receptor subunit beta-30303
Neuronal acetylcholine receptor subunit beta-40505
Neuronal acetylcholine receptor subunit alpha-30303
Neuronal acetylcholine receptor subunit alpha-20303
Neuronal acetylcholine receptor subunit beta-20516
Neuronal acetylcholine receptor subunit alpha-60303
Neutral amino acid transporter A0505
Neutral amino acid transporter B(0)0505
Carbonic anhydrase-like protein, putative00010
Amino acid transporter0505
Excitatory amino acid transporter 40202
Glutamate transporter homolog0022
Chain A, Phospholipase A2 isoform 30011
GTP-binding protein (rab7)0033
ras protein, partial0033
Rac1 protein0033
cell division cycle 42 (GTP binding protein, 25kDa), partial0033
Prostaglandin-H2 D-isomerase0202
Prostaglandin G/H synthase 2 09010
Fatty acid-binding protein, liver015217
Glutathione hydrolase 1 proenzyme0101
Urotensin-2 receptor0202
4-aminobutyrate aminotransferase, mitochondrial0303
Ras-related protein Rab-2A0033
Rho-associated protein kinase 20505
ubiquitin-conjugating enzyme E2 N0909
Polycomb protein EED0415
HLA class I histocompatibility antigen, A alpha chain 0156
Somatostatin receptor type 20617
Somatostatin receptor type 40606
Somatostatin receptor type 30516
Somatostatin receptor type 50516
Heparanase0066
Solute carrier organic anion transporter family member 2B1 08011
Insulin receptor 0606
Dipeptidyl peptidase 40202
Atrial natriuretic peptide receptor 10112
Atrial natriuretic peptide receptor 1 0011
cystic fibrosis transmembrane conductance regulator0404
PINK1120012
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial0101
Cytochrome c oxidase subunit NDUFA40101
Acyl carrier protein, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10101
NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 30101
NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 0101
NADH dehydrogenase [ubiquinone] iron-sulfur protein 50101
NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial0101
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial0101
NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10101
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 60101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 30101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 0101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 70101
NADH dehydrogenase [ubiquinone] 1 subunit C20101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 100101
NADH-ubiquinone oxidoreductase chain 10101
NADH-ubiquinone oxidoreductase chain 20101
NADH-ubiquinone oxidoreductase chain 30101
NADH-ubiquinone oxidoreductase chain 4L0101
NADH-ubiquinone oxidoreductase chain 40102
NADH-ubiquinone oxidoreductase chain 50101
NADH-ubiquinone oxidoreductase chain 60101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 70101
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial0101
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial0101
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 80101
NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 60101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 50101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 110101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 20101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 30101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 20101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 40101
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13011314
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 120101
Complex I intermediate-associated protein 30, mitochondrial0101
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 90101
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 20202
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 20202
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 20202
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 20202
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 20202
Leukotriene C4 synthase0077
Bone morphogenetic protein receptor type-1B001717
Cell division cycle 7-related protein kinase001212
ATP-dependent RNA helicase DDX3X001515
Dual specificity mitogen-activated protein kinase kinase 70077
Inhibitor of nuclear factor kappa-B kinase subunit beta0179
Peripheral plasma membrane protein CASK0077
Inhibitor of nuclear factor kappa-B kinase subunit alpha0178
Ephrin type-B receptor 6001616
Peroxisomal acyl-coenzyme A oxidase 3001515
Mitogen-activated protein kinase kinase kinase 130077
Mitotic checkpoint serine/threonine-protein kinase BUB1001414
Dynamin-like 120 kDa protein, mitochondrial001515
Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma0077
Eukaryotic translation initiation factor 5B001212
Rho-associated protein kinase 2051823
Serine/threonine-protein kinase ULK1001616
Serine/threonine-protein kinase/endoribonuclease IRE1001717
U5 small nuclear ribonucleoprotein 200 kDa helicase001515
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma0077
Cyclin-dependent kinase-like 5001111
Structural maintenance of chromosomes protein 2001515
Mitogen-activated protein kinase kinase kinase 6001717
Serine/threonine-protein kinase OSR10077
Serine/threonine-protein kinase Chk20178
Guanine nucleotide-binding protein G(i) subunit alpha-2001212
ADP/ATP translocase 2001515
Protein kinase C beta type0131730
Glycogen phosphorylase, liver form021517
Adenine phosphoribosyltransferase001414
Signal recognition particle receptor subunit alpha001414
Cytochrome c1, heme protein, mitochondrial001515
Wee1-like protein kinase 20077
Uncharacterized serine/threonine-protein kinase SBK30077
Serine/threonine-protein kinase A-Raf011415
Glycogen phosphorylase, brain form021517
Breakpoint cluster region protein051724
Cyclin-dependent kinase 4081725
ADP/ATP translocase 3001515
cAMP-dependent protein kinase type II-alpha regulatory subunit001515
Protein kinase C alpha type0141834
General transcription and DNA repair factor IIH helicase subunit XPD001515
Ras-related protein Rab-6A001515
Serine/threonine-protein kinase MAK0077
Receptor tyrosine-protein kinase erbB-30077
Multifunctional protein ADE2001515
cAMP-dependent protein kinase catalytic subunit gamma0101222
Ferrochelatase, mitochondrial001515
Ribosomal protein S6 kinase beta-1031619
Beta-adrenergic receptor kinase 1021820
Probable ATP-dependent RNA helicase DDX6001515
Deoxycytidine kinase001521
UMP-CMP kinase 001213
Phosphatidylethanolamine-binding protein 1001414
Heme oxygenase 2001515
S-adenosylmethionine synthase isoform type-2011415
DnaJ homolog subfamily A member 1001515
G protein-coupled receptor kinase 40077
DNA replication licensing factor MCM4001515
Myosin-10001414
Electron transfer flavoprotein subunit beta001414
Glycine--tRNA ligase001515
Protein kinase C iota type081826
Exosome RNA helicase MTR4001515
Megakaryocyte-associated tyrosine-protein kinase0077
G protein-coupled receptor kinase 6021113
26S proteasome regulatory subunit 6B021517
Casein kinase I isoform alpha041721
Elongation factor Tu, mitochondrial001515
Choline-phosphate cytidylyltransferase A001010
Cysteine--tRNA ligase, cytoplasmic001414
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial001515
Ras-related protein Rab-27A001414
Interleukin-1 receptor-associated kinase 1001717
Serine/threonine-protein kinase Nek3001717
Serine/threonine-protein kinase Nek40077
Tyrosine--tRNA ligase, cytoplasmic001515
Hormonally up-regulated neu tumor-associated kinase0077
Receptor-interacting serine/threonine-protein kinase 40077
Ras-related protein Rab-10001515
Cell division control protein 2 homolog0077
Actin-related protein 3001515
Actin-related protein 2001515
Calcium-dependent protein kinase 10178
GTP-binding nuclear protein Ran001515
Serine/threonine-protein kinase PknB0077
Cyclin-dependent kinase-like 10077
ATP-dependent 6-phosphofructokinase, platelet type001515
Macrophage-stimulating protein receptor001717
Protein kinase C zeta type081119
Mitogen-activated protein kinase kinase kinase kinase 2001717
Mitogen-activated protein kinase kinase kinase 120077
Dual specificity mitogen-activated protein kinase kinase 5001717
Mitogen-activated protein kinase kinase kinase 1001717
Integrin-linked protein kinase001313
Rho-associated protein kinase 1041721
Serine/threonine-protein kinase PRP4 homolog0077
Cyclin-dependent kinase 13001616
Structural maintenance of chromosomes protein 1A001515
Chromodomain-helicase-DNA-binding protein 4001515
Peroxisomal acyl-coenzyme A oxidase 1001414
Serine/threonine-protein kinase 38001111
Receptor tyrosine-protein kinase erbB-40077
Delta(24)-sterol reductase001515
Rhodopsin kinase GRK10279
Myosin light chain kinase 3011617
Serine/threonine-protein kinase SBK10077
Mitogen-activated protein kinase kinase kinase 190077
Putative heat shock protein HSP 90-beta 2001313
Acyl-CoA dehydrogenase family member 10001313
Serine/threonine-protein kinase N3001212
Serine/threonine-protein kinase ULK3001717
Dual serine/threonine and tyrosine protein kinase0077
Mitogen-activated protein kinase kinase kinase 150077
Uncharacterized protein FLJ45252001515
Acyl-CoA dehydrogenase family member 11001414
Serine/threonine-protein kinase/endoribonuclease IRE2001414
ATP-dependent RNA helicase DHX30001010
Serine/threonine-protein kinase TAO1001717
STE20-related kinase adapter protein alpha001515
Myosin-14001515
AarF domain-containing protein kinase 1001515
ATP-dependent RNA helicase DDX42001212
Serine/threonine-protein kinase VRK20077
Homeodomain-interacting protein kinase 10178
Cyclin-dependent kinase-like 30077
Serine/threonine-protein kinase NIM10077
Eukaryotic peptide chain release factor GTP-binding subunit ERF3B0055
Serine/threonine-protein kinase ULK20077
Misshapen-like kinase 1001111
Homeodomain-interacting protein kinase 40178
Serine/threonine-protein kinase Nek110077
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma001616
Serine/threonine-protein kinase 350077
Rhodopsin kinase GRK70077
Serine/threonine-protein kinase 32A0077
ATP-dependent RNA helicase DDX1001515
Cyclin-dependent kinase-like 20077
Serine/threonine-protein kinase Sgk30077
Cyclin-dependent kinase 150077
PAS domain-containing serine/threonine-protein kinase001212
EKC/KEOPS complex subunit TP53RK001515
Mitogen-activated protein kinase kinase kinase 3001717
Eukaryotic translation initiation factor 2-alpha kinase 1001717
Serine/threonine-protein kinase RIO20077
Transient receptor potential cation channel subfamily M member 60077
Nucleolar GTP-binding protein 1001515
RNA cytidine acetyltransferase001515
Serine/threonine-protein kinase TAO3001717
Homeodomain-interacting protein kinase 20178
Homeodomain-interacting protein kinase 30178
dCTP pyrophosphatase 1001515
SNF-related serine/threonine-protein kinase0077
Phenylalanine--tRNA ligase beta subunit001515
Obg-like ATPase 1001515
Midasin001515
Interleukin-1 receptor-associated kinase 4001717
Cyclin-dependent kinase 12001515
Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial001414
STE20/SPS1-related proline-alanine-rich protein kinase0077
Serine/threonine-protein kinase TBK1021719
Septin-9001515
Serine/threonine-protein kinase TAO2001717
Long-chain-fatty-acid--CoA ligase 5001010
SRSF protein kinase 30077
Serine/threonine-protein kinase ICK001515
Microtubule-associated serine/threonine-protein kinase 10077
Serine/threonine-protein kinase SIK3001717
Mitogen-activated protein kinase kinase kinase 2001717
Thyroid hormone receptor-associated protein 3001212
Receptor-interacting serine/threonine-protein kinase 3011516
DNA (cytosine-5)-methyltransferase 10707
Histone-lysine N-methyltransferase EHMT2011011
D(3) dopamine receptor isoform e3003
Calcitonin gene-related peptide type 1 receptor0202
Protein-arginine deiminase type-4014014
Janus kinase 2 (a protein tyrosine kinase)0303
Orotidine 5'-phosphate decarboxylase0202
Orotidine 5'-phosphate decarboxylase0101
Membrane-associated progesterone receptor component 10099
MAP kinase-activated protein kinase 30055
Uncharacterized aarF domain-containing protein kinase 50088
Rab-like protein 30099
Dual specificity testis-specific protein kinase 2001010
Isoleucine--tRNA ligase, mitochondrial001111
Beta-lactamase 05011
Beta-lactamase 0409
Beta-lactamase 03011
Penicillin-binding protein 1A0101
Beta-lactamase 03011
AmpC 0204
Beta-lactamase 0001
BlaVIM-1 0008
Beta-lactamase 0001
Lysine-specific demethylase 4E010010
Lysine-specific histone demethylase 1A020021
Progesterone receptor014724
Lysosomal alpha-glucosidase0202
Sucrase-isomaltase, intestinal0202
Cytochrome P450 11B1, mitochondrial0404
Sucrase-isomaltase, intestinal0606
Linoleate 9S-lipoxygenase-40303
Prolyl endopeptidase0808
Receptor-type tyrosine-protein phosphatase S0202
Polyunsaturated fatty acid lipoxygenase ALOX15B0101
G-protein coupled receptor 350121123
Canalicular multispecific organic anion transporter 109012
Beta-lactamase0202
Cysteinyl leukotriene receptor 20437
Cysteinyl leukotriene receptor 1011415
Voltage-dependent L-type calcium channel subunit alpha-1D011012
Voltage-dependent L-type calcium channel subunit alpha-1S010011
Transient receptor potential cation channel subfamily A member 10088
Vitamin D-binding protein0202
15-hydroxyprostaglandin dehydrogenase [NAD(+)]0101
Zinc finger protein mex-50011
Chain B, SARS CORONAVIRUS MAIN PROTEINASE0101
Poly(ADP-ribose) glycohydrolase0101
Chain A, TRYPSIN0101
Chain H, Thrombin heavy chain0101
Chain H, Thrombin heavy chain0101
Chain A, PROTEIN (TRYPSIN)0101
Chain A, PROTEIN (TRYPSIN)0101
Chain A, PROTEIN (TRYPSIN)0101
Chain A, PROTEIN (TRYPSIN)0101
Chain B, PROTEIN (UROKINASE-TYPE PLASMINOGEN ACTIVATOR)0101
Chain B, PROTEIN (UROKINASE-TYPE PLASMINOGEN ACTIVATOR)0101
Chain B, PROTEIN (UROKINASE-TYPE PLASMINOGEN ACTIVATOR)0101
Chain A, PROTEIN (TRYPSIN)0202
Chain A, TRYPSIN IVA0101
Chain A, trypsin II, anionic0101
Chain A, Trypsin II, anionic0101
Chain A, Trypsin II, anionic0101
Chain T, Trypsin II, anionic0101
Chain A, trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain T, Trypsin0101
Chain A, PROTEIN (TRYPSIN)0202
Coagulation factor X0101
Acrosin0202
Suppressor of tumorigenicity 14 protein0303
Chain A, Integrase0101
Chain A, Integrase0101
Chain A, T4 LYSOZYME0011
Chain A, GCN4P10011
Chain B, GCN4P10011
Chain C, GCN4P10011
Chain A, T4 LYSOZYME0011
Chain A, T4 LYSOZYME0011
Chain A, Replicase polyprotein 1ab0101
Chain A, 3C-like proteinase0101
Chain A, GTPase KRas, isoform 2B0011
Chain A, GTPase KRas, isoform 2B0011
GTPase KRas0011
Aryl hydrocarbon receptor0022
Chain A, Oxygen-insensitive Nad(p)h Nitroreductase0101
Chain B, Oxygen-insensitive Nad(p)h Nitroreductase0101
Alpha-glucosidase MAL120404
Serine racemase0404
Chain A, Kemp eliminase KE59 R1 7/10H0101
Chain A, Kemp eliminase KE59 R13 3/11H0101
Chain A, Kemp eliminase KE59 R13 3/11H0101
P2Y purinoceptor 120819
Guanylate cyclase soluble subunit beta-20011
Guanylate cyclase soluble subunit alpha-20011
Guanylate cyclase soluble subunit alpha-10011
Guanylate cyclase soluble subunit beta-10011
Amiloride-sensitive amine oxidase [copper-containing]0102
Telomerase reverse transcriptase0303
Neuraminidase0505
Aldo-keto reductase family 1 member C3016016
Aldo-keto reductase family 1 member C2 010010
Sodium- and chloride-dependent GABA transporter 30909
Sodium- and chloride-dependent GABA transporter 20606
Chain A, D-MALTODEXTRIN BINDING PROTEIN0011
Chain A, Limit Dextrinase0011
Chain A, Solute-binding protein0011
Chain A, Solute-binding protein0011
Chain B, SusD0011
Chain A, SusD0011
Chain A, SusD0011
Chain A, Alpha-hemolysin0011
Chain B, Alpha-hemolysin0011
Chain C, Alpha-hemolysin0011
Chain D, Alpha-hemolysin0011
Chain E, Alpha-hemolysin0011
Chain F, Alpha-hemolysin0011
Chain G, Alpha-hemolysin0011
Chain A, Betaine ABC transporter permease and substrate binding protein0011
Chain A, Osmoprotection protein (ProX)0011
Chain A, Glycine betaine/carnitine/choline-binding protein0022
Chain A, Glycine betaine/carnitine/choline-binding protein0022
Chain A, Glycine betaine/carnitine/choline-binding protein0022
Chain A, Glycine betaine/carnitine/choline-binding protein0022
galanin receptor type 30303
hexokinase-4 isoform 1210021
glucokinase regulatory protein210021
Transcription factor p6509011
Sodium/bile acid cotransporter09110
Ubiquitin-like modifier activating enzyme 20202
SUMO1 activating enzyme subunit 10202
SUMO-conjugating enzyme UBC90202
DNA polymerase beta0505
DNA polymerase beta0303
Zinc finger protein GLI10202
Oxysterols receptor LXR-beta0113
Oxysterols receptor LXR-alpha0113
Env polyprotein 0033
Phosphodiesterase isozyme 4 0101
Transmembrane prolyl 4-hydroxylase0246
Non-structural protein 1 0202
Neuropeptide Y receptor type 10517
Neuropeptide Y receptor type 20303
Neuropeptide Y receptor type 40101
Neuropeptide Y receptor type 50101
NPY-Y2 receptor 0101
Neuropeptide FF receptor 10112
Neuropeptide FF receptor 20224
carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 10303
MBT domain-containing protein 10404
Lethal(3)malignant brain tumor-like protein 40404
Lethal(3)malignant brain tumor-like protein 10404
STAT3, partial0314
signal transducer and activator of transcription 1-alpha/beta isoform alpha0314
transcription factor p65 isoform 10022
Pancreatic triacylglycerol lipase011012
Carbonyl reductase [NADPH] 10608
Beta-hydroxyacyl-ACP dehydratase precursor (Fatty acid synthesis protein)0909
Chain A, Avidin0011
Chain A, Protein (streptavidin)0011
Chain B, Protein (streptavidin)0011
Chain A, Streptavidin0011
Chain D, Streptavidin0011
Chain A, Streptavidin0011
Chain D, Streptavidin0011
Chain A, Streptavidin0011
Chain D, Streptavidin0011
Chain A, Streptavidin Complex With Biotin0011
Chain D, Circularly Permuted Core-streptavidin E51/a460011
Chain A, Core-streptavidin0011
Chain D, Core-streptavidin0011
Chain A, Core-streptavidin0011
Chain D, Core-streptavidin0011
Chain A, Core-streptavidin0011
Chain D, Core-streptavidin0011
Chain A, Core-streptavidin0011
Chain D, Core-streptavidin0011
Chain A, Avidin0011
Chain A, Streptavidin0011
Chain B, Streptavidin0011
Chain A, Streptavidin0011
Chain B, Streptavidin0011
green fluorescent protein, partial0101
insulin-degrading enzyme isoform 10011
Liver carboxylesterase0202
DNA topoisomerase 109320
Chain A, Protein kinase C, iota0101
G1/S-specific cyclin-E20202
Protein kinase C gamma type010212
Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform0101
G1/S-specific cyclin-D10808
G1/S-specific cyclin-E10303
cAMP-dependent protein kinase catalytic subunit alpha 0202
NAD-dependent protein deacetylase sirtuin-20516
NAD-dependent protein deacetylase sirtuin-10419
Serine/threonine-protein kinase LMTK30101
Peptidylglycine alpha-amidating monooxygenase0003
MSRA protein0101
Sclerostin0101
Neuromedin-B receptor0303
Gastrin-releasing peptide receptor0213
Beta-lactamase04010
Chain H, Proteasome component PUP10101
Chain I, Proteasome component PUP30101
Chain K, Proteasome component PRE20101
Chain L, Proteasome component C50101
Chain K, Proteasome component PRE20101
Chain L, Proteasome component C50101
26S proteasome non-ATPase regulatory subunit 110202
26S proteasome non-ATPase regulatory subunit 120202
26S proteasome non-ATPase regulatory subunit 140202
26S proteasome non-ATPase regulatory subunit 30202
Chymotrypsinogen A013014
Cathepsin B0606
Cathepsin G0404
Lysosomal protective protein0303
Chymotrypsinogen B0505
26S proteasome regulatory subunit 6A0202
Chymase0202
Proteasome subunit beta type-80101
26S proteasome regulatory subunit 70202
Lon protease homolog, mitochondrial0101
26S proteasome non-ATPase regulatory subunit 80202
26S proteasome non-ATPase regulatory subunit 70202
26S proteasome non-ATPase regulatory subunit 40202
26S proteasome complex subunit SEM10202
26S proteasome regulatory subunit 40202
26S proteasome regulatory subunit 80202
26S proteasome regulatory subunit 10B0202
Nuclear factor NF-kappa-B p100 subunit 0505
26S proteasome non-ATPase regulatory subunit 20202
26S proteasome non-ATPase regulatory subunit 60202
Proteasomal ubiquitin receptor ADRM10202
ATP-dependent Clp protease proteolytic subunit0112
NACHT, LRR and PYD domains-containing protein 3 0606
26S proteasome non-ATPase regulatory subunit 10202
26S proteasome non-ATPase regulatory subunit 130202
Multidrug resistance-associated protein 60001
Solute carrier organic anion transporter family member 1A50008
Endothelin receptor type B0808
Endothelin-1 receptor4408
Endothelin-1 receptor0303
Solute carrier organic anion transporter family member 1B20106
Angiotensin-converting enzyme 021123
B2 bradykinin receptor0101
B1 bradykinin receptor0101
Gamma-aminobutyric acid 0448
Gamma-aminobutyric acid receptor subunit alpha-60448
Gamma-aminobutyric acid receptor subunit gamma-20448
Gamma-aminobutyric acid receptor subunit delta0448
Gamma-aminobutyric acid receptor subunit alpha-20448
Gamma-aminobutyric acid receptor subunit alpha-30448
Gamma-aminobutyric acid receptor subunit gamma-30448
Gamma-aminobutyric acid receptor subunit beta-10448
Gamma-aminobutyric acid receptor subunit alpha-107411
Gamma-aminobutyric acid receptor subunit beta-30448
Gamma-aminobutyric acid receptor subunit alpha-50448
Gamma-aminobutyric acid receptor subunit pi0448
Gamma-aminobutyric acid receptor subunit alpha-40448
Gamma-aminobutyric acid receptor subunit theta0448
Gamma-aminobutyric acid receptor subunit gamma-10448
Pannexin-10202
Genome polyprotein 08311
Nuclear hormone receptor family member daf-120011
oxysterols receptor LXR-beta isoform 10011
Thymidine phosphorylase0014
Thymidylate kinase0303
Thymidine kinase0003
Thymidylate kinase0303
Taste receptor type 2 member 100035
cAMP-dependent protein kinase type I-alpha regulatory subunit0011
cAMP-dependent protein kinase type II-beta regulatory subunit0011
cAMP-dependent protein kinase catalytic subunit beta isoform 10011
cAMP-dependent protein kinase catalytic subunit beta isoform 30011
Solute carrier family 12 member 20202
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform0101
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform0303
Nucleoside diphosphate kinase B0022
Serine/threonine-protein kinase mTOR 0202
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform0404
Potassium channel subfamily K member 30202
Potassium channel subfamily K member 90202
Integrin alpha-50101
UDP-glucuronosyltransferase 2B7014132
UDP-glucuronosyltransferase 2B10 012113
Alpha-2A adrenergic receptor0606
Matrix metalloproteinase-9013013
Chain A, Nitrile Hydratase alpha subunit0101
Chain B, Nitrile Hydratase beta subunit0101
Methyl-accepting chemotaxis protein NahY0066
Vpr240024
Leukotriene B4 receptor 20427
RNA polymerase beta subunit (EC 2.7.7.6), partial0202
Lipoxygenase 0101
Neuraminidase0101
Interstitial collagenase011112
Tyrosine-protein phosphatase non-receptor type 70303
Dual specificity protein phosphatase 30404
Hyaluronidase-10303
BiP isoform A0101
Lysosomal alpha-glucosidase0303
Aldo-keto reductase family 1 member A10202
Aldo-keto reductase family 1 member C40606
Aldo-keto reductase family 1 member C10909
Chain A, Glycogen Phosphorylase0101
Chain A, Glycogen phosphorylase, liver form0022
Chain A, glycogen phosphorylase, liver form0022
Chain A, Glycogen phosphorylase, liver form0022
Chain A, Glycogen phosphorylase, liver form0022
Chain A, Chitinase0101
Glycogen phosphorylase, liver form0202
Glycogen phosphorylase, muscle form0101
Chitotriosidase-10415
Adenosine receptor A2b0115
Palmitoleoyl-protein carboxylesterase NOTUM0235
Endochitinase B10415
electroneutral potassium-chloride cotransporter KCC20112
TSHR protein5005
LacZ protein (plasmid)0033
XBP10303
type-1 angiotensin II receptor0303
apelin receptor0404
DNA damage-inducible transcript 3 protein0303
Chain A, Vitamin D Nuclear Receptor0011
Vitamin D3 receptor0011
Vitamin D-binding protein0011
Vitamin D3 receptor04513
Vitamin D3 receptor0113
Retinoic acid receptor RXR-alpha031115
Vitamin D3 receptor0022
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial0213
Vitamin D3 receptor0112
Transporter010010
Vitamin D3 receptor A0022
Calpain-90202
Calpain-1 catalytic subunit0101
Cathepsin D0202
Calpain-1 catalytic subunit0404
Pro-cathepsin H0101
Calpain-2 catalytic subunit0303
Calpain-1 catalytic subunit0202
Falcipain 2B 0101
Cysteine proteinase falcipain 2a 0202
Cathepsin K0303
DNA topoisomerase 0101
Type-2 restriction enzyme ScaI0101
Deoxyribonuclease-2-alpha0101
Tyrosyl-DNA phosphodiesterase 20101
Deoxyribonuclease-10101
Type-2 restriction enzyme PstI0101
Type-2 restriction enzyme EcoRI0101
DNA ligase0202
Heterogeneous nuclear ribonucleoprotein A10022
Type-2 restriction enzyme BamHI0101
Somatostatin receptor type 10404
Type-2 restriction enzyme HindIII0101
Ribonuclease pancreatic0101
DNA topoisomerase 10203
DNA topoisomerase 10101
DNA topoisomerase type IB small subunit 0011
NEDD8-activating enzyme E1 regulatory subunit0112
NEDD8-activating enzyme E1 catalytic subunit0011
DNA polymerase kappa0202
DNA polymerase iota0202
DNA polymerase eta0202
N-acylethanolamine-hydrolyzing acid amidase0707
Transient receptor potential cation channel subfamily V member 40549
Cytochrome P450 2C11 0303
Heat sensitive channel TRPV30224
Transient receptor potential cation channel subfamily V member 40358
G-protein coupled receptor 550146
G-protein coupled receptor 60011
Inhibin alpha chain0101
Transient receptor potential cation channel, subfamily V, member 30011
Chain A, Beta-lactoglobulin0011
Chain A, Beta-lactoglobulin0011
UDP-3-O-acyl-N-acetylglucosamine deacetylase0011
NADH-ubiquinone oxidoreductase chain 10202
Transient receptor potential cation channel subfamily M member 80101
Chain A, angiotensin converting enzyme0101
Chain A, angiotensin converting enzyme0101
Neprilysin0404
Neprilysin0404
EEF1AKMT4-ECE2 readthrough transcript protein0303
Leukotriene A-4 hydrolase0101
Endothelin-converting enzyme 10404
Succinyl-diaminopimelate desuccinylase0505
Beta-lactamase TEM011021
Beta-lactamase 0303
Sodium channel protein type 1 subunit alpha113014
Sodium channel protein type 2 subunit alpha116118
Sodium channel protein type 3 subunit alpha112013
Frizzled-80011
kallikrein-5 preproprotein0101
Dihydroxyacetone phosphate acyltransferase0003
Oxytocin receptor0022
Cytochrome P450 2E10617
Chain A, serum paraoxonase0101
Proteasome subunit beta type-20101
Proteasome subunit beta type-10101
Glutathione S-transferase omega-10404
Sodium/hydrogen exchanger 10303
Sodium/hydrogen exchanger 30101
Sodium/hydrogen exchanger 30101
Sodium/hydrogen exchanger 20101
Glutathione reductase, mitochondrial017020
Glutathione reductase0202
Solute carrier family 22 member 50002
Solute carrier family 22 member 50203
Solute carrier family 22 member 160001
Solute carrier family 22 member 210001
Solute carrier family 22 member 50002
Toll-like receptor 40202
Potassium channel subfamily K member 100101
Chain A, Protein kinase CK2, alpha Subunit0101
Chain A, PROTEIN KINASE CK2, alpha SUBUNIT0101
Chain A, Protein Kinase Ck2, Alpha Subunit0101
Serine/threonine-protein kinase Sgk10101
Casein kinase II subunit alpha 0202
Casein kinase II subunit beta0202
Cyclin-A10505
Single-stranded DNA cytosine deaminase7007
Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase0022
Non-lysosomal glucosylceramidase0101
Arginase 0303
Chain A, Neutrophil gelatinase-associated lipocalin0011
3-dehydroquinate synthase0102
Potassium-transporting ATPase subunit beta0203
Potassium-transporting ATPase alpha chain 10203
Autoinducer 2-binding periplasmic protein LuxP0303
Solute carrier family 22 member 708013
Solute carrier family 22 member 11011018
Solute carrier family 22 member 8015019
Solute carrier family 22 member 707011
Beta-lactamase 0005
Metallo-beta-lactamase VIM-19 0008
Beta-lactamase0005
Beta-lactamase07018
Beta-lactamase0005
Beta-lactamase0106
Metallo-beta-lactamase VIM-20008
Beta-lactamase 0008
Beta-lactamase 0006
Beta-lactamase 02011
Glutathione peroxidase 10101
Microsomal glutathione S-transferase 10101
Beta-lactamase 0004
Beta-lactamase 0006
Beta-lactamase IMP-1 0006
Beta-lactamase 0006
MecA 0202
Chain A, Carbonic anhydrase II0101
prostaglandin E2 receptor EP2 subtype1005
Prostaglandin E synthase0707
Cytochrome c oxidase subunit 10101
Cytochrome c oxidase subunit 20101
Catechol O-methyltransferase0101
Cytochrome c oxidase subunit 20404
Quinolone resistance protein NorA0405
Prostaglandin G/H synthase 10505
Indoleamine 2,3-dioxygenase 1010010
Bifunctional epoxide hydrolase 2017017
Prostaglandin G/H synthase 2011012
Prostaglandin G/H synthase 10101
Cyclooxygenase-2 0202
Beta-lactamase OXA-100002
DNA (cytosine-5)-methyltransferase 1 isoform b0101
Solute carrier family 22 member 808011
Beta-lactamase OXA-10305
Beta-lactamase 0105
Caspase-20022
Retinoic acid receptor RXR-alpha0235
Ileal sodium/bile acid cotransporter0303
Bile acid receptor0011
30S ribosomal protein S608110
30S ribosomal protein S708110
50S ribosomal protein L1508110
50S ribosomal protein L1008110
50S ribosomal protein L1108110
50S ribosomal protein L7/L1208110
50S ribosomal protein L1908110
50S ribosomal protein L108110
50S ribosomal protein L2008110
50S ribosomal protein L2708110
50S ribosomal protein L2808110
50S ribosomal protein L2908110
50S ribosomal protein L3108110
50S ribosomal protein L31 type B08110
50S ribosomal protein L3208110
50S ribosomal protein L3308110
50S ribosomal protein L3408110
50S ribosomal protein L3508110
50S ribosomal protein L3608110
30S ribosomal protein S1008110
30S ribosomal protein S1108110
30S ribosomal protein S1208110
30S ribosomal protein S1308110
30S ribosomal protein S1608110
30S ribosomal protein S1808110
30S ribosomal protein S1908110
30S ribosomal protein S2008110
30S ribosomal protein S208110
30S ribosomal protein S308110
30S ribosomal protein S408110
30S ribosomal protein S508110
30S ribosomal protein S808110
30S ribosomal protein S908110
50S ribosomal protein L1308110
50S ribosomal protein L1408110
50S ribosomal protein L1608110
50S ribosomal protein L2308110
30S ribosomal protein S1508110
50S ribosomal protein L1708110
50S ribosomal protein L2108110
50S ribosomal protein L3008110
50S ribosomal protein L608110
30S ribosomal protein S1408110
30S ribosomal protein S1708110
30S ribosomal protein S108110
50S ribosomal protein L1808110
50S ribosomal protein L208110
50S ribosomal protein L308110
50S ribosomal protein L2408110
50S ribosomal protein L408110
50S ribosomal protein L2208110
50S ribosomal protein L508110
30S ribosomal protein S2108110
50S ribosomal protein L2508110
50S ribosomal protein L36 208110
Methionine--tRNA ligase, mitochondrial0011
calcineurin A1, putative0022
hepatocyte nuclear factor 4-alpha isoform 20303
perilipin-50808
perilipin-10808
protein AF-9 isoform a0004
melanocortin receptor 40213
CAAX prenyl protease0002
bcl-2-related protein A10606
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a0808
hexokinase HKDC10112
DNA repair protein RAD52 homolog isoform a0005
Synaptojanin-20202
Synaptojanin-10202
Peroxisomal N(1)-acetyl-spermine/spermidine oxidase0101
Spermine oxidase0202
1,3-beta-D-glucan synthase catalytic subunit 0101
Dihydrofolate reductase 0505
Riboflavin-binding protein0235
Histidine-rich protein PFHRP-II0708
Spike glycoprotein0213
DNA ligase 10101
Calcium-dependent protein kinase 10011
DNA ligase A0101
Phosphoethanolamine N-methyltransferase0101
Cysteine proteinase falcipain 2a 0101
Lethal(3)malignant brain tumor-like protein 30303
Chloroquine resistance transporter0303
NADPH oxidase 10505
Snq2p00014
Adenylate cyclase type 1 0404
Major prion protein0112
Cys-loop ligand-gated ion channel0101
Sphingomyelin phosphodiesterase0303
Adenylate cyclase type 30404
Adenylate cyclase type 20415
Adenylate cyclase type 40404
Pleiotropic ABC efflux transporter of multiple drugs014028
Adenylate cyclase type 80404
Gastrin/cholecystokinin type B receptor0707
Adenylate cyclase type 60404
Adenylyl cyclase 7 0404
Acetylcholinesterase 0101
Carboxylic ester hydrolase 0101
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 70005
Chain A, Putative Glycine Betaine-binding Abc Transporter Protein0011
Chain A, PUTATIVE GLYCINE BETAINE-BINDING ABC TRANSPORTER PROTEIN0011
Chain A, Choline-binding protein0011
Solute carrier family 22 member 10709
Solute carrier family 22 member 20506
Sodium- and chloride-dependent creatine transporter 10101
High affinity choline transporter 10101
Chain A, Glycogen phosphorylase, muscle form0101
Chain A, Glycogen phosphorylase, muscle form0101
nuclear receptor subfamily 0 group B member 10606
steroidogenic factor 10606
3-oxoacyl-acyl-carrier protein reductase 0808
Dipeptidase 10101
Potassium-transporting ATPase alpha chain 10202
Potassium-transporting ATPase subunit beta0202
Solute carrier family 22 member 40404
Platelet glycoprotein VI0236
Estrogen receptor 10303
estrogen receptor beta isoform 10606
DNA gyrase subunit B0202
DNA gyrase subunit A0202
DNA gyrase subunit B07010
DNA gyrase subunit A012017
DNA gyrase subunit B012117
DNA topoisomerase 4 subunit A0202
DNA topoisomerase 4 subunit B0204
DNA topoisomerase 4 subunit A0608
DNA gyrase subunit A07010
Multidrug resistance protein MdtK0022
DNA gyrase subunit B08010
DNA gyrase subunit A010012
Enoyl-[acyl-carrier-protein] reductase [NADH]0207
DNA topoisomerase 4 subunit A0202
DNA topoisomerase 4 subunit B0202
Neutral alpha-glucosidase AB0101
Sodium-dependent noradrenaline transporter0505
Sodium-dependent serotonin transporter0505
Sodium-dependent dopamine transporter0606
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, Proto-oncogene Tyrosine-protein Kinase Src0303
Chain A, N5-carboxyaminoimidazole ribonucleotide mutase0011
Chain B, N5-carboxyaminoimidazole ribonucleotide mutase0011
Chain A, N5-carboxyaminoimidazole ribonucleotide mutase0011
Chain B, N5-carboxyaminoimidazole ribonucleotide mutase0011
Beta-lactamase0303
3-dehydroquinate dehydratase0011
ATP-citrate synthase 0102
Ribonuclease T0002
Cell death-related nuclease 40002
3-dehydroquinate dehydratase0011
Prolyl 4-hydroxylase0808
Alpha-ketoglutarate-dependent dioxygenase FTO0606
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1010013
General amino-acid permease GAP10001
Beta-lactamase 0303
Beta-lactamase0101
Beta-lactamase 0101
Beta-lactamase 0202
Short transient receptor potential channel 30101
Transient receptor potential cation channel subfamily V member 4 0112
Short transient receptor potential channel 4 0101
Short transient receptor potential channel 50101
Short transient receptor potential channel 70101
Short transient receptor potential channel 60101
mu opioid receptor, partial0011
LAP40022
MEP20022
delta-type opioid receptor0123
kappa-type opioid receptor isoform 10101
Beta-galactosidase0011
Histamine H3 receptor0527
Histamine H4 receptor0347
Type IV secretion-like conjugative transfer relaxase protein TraI 0202
Peroxisome proliferator-activated receptor alpha0358
Trypanothione reductase0101
Envelope glycoprotein0044
Translocator protein0202
Alpha-1B adrenergic receptor 0044
Alpha-1A adrenergic receptor010414
Alpha-2B adrenergic receptor0507
Alpha-2C adrenergic receptor0507
Alpha-2A adrenergic receptor0507
Amine oxidase [flavin-containing] A 010011
Sigma intracellular receptor 20101
Intermediate conductance calcium-activated potassium channel protein 40101
Heme oxygenase 1 0606
Heme oxygenase 20707
C-X-C chemokine receptor type 10505
Malate dehydrogenase, cytoplasmic0808
Transitional endoplasmic reticulum ATPase0202
Cytochrome P450 1440055
Steroid C26-monooxygenase0055
Mycocyclosin synthase0033
Lanosterol 14-alpha demethylase0044
Nuclear receptor subfamily 1 group I member 3 0404
Sterol 14-alpha demethylase0033
Indoleamine 2,3-dioxygenase 20707
14-alpha sterol demethylase 0034
Endothelin receptor type B47011
D(2) dopamine receptor0303
D(3) dopamine receptor0303
5-hydroxytryptamine receptor 1A0505
Chain A, CHIMERA OF IG KAPPA CHAIN: HUMAN CONSTANT REGION AND MOUSE VARIABLE REGION0011
Chain B, CHIMERA OF IG GAMMA-1 CHAIN: HUMAN CONSTANT REGION AND MOUSE VARIABLE REGION0011
Chain H, Fab M82G2, Heavy chain0011
Chain L, Fab M82G2, Light chain0011
Chain H, Fab M82g2, Heavy Chain0011
Chain L, Fab M82g2, Light Chain0011
Fatty acid-binding protein, heart0303
Muscarinic acetylcholine receptor M20134
Cytochrome P450 2D10606
Cytochrome P450 2D260707
Cytochrome P450 2D30707
Cytochrome P450 2D40707
Histone acetyltransferase p3000505
Histone acetyltransferase KAT2B0303
Histone acetyltransferase KAT50202
5-hydroxytryptamine receptor 1F0718
Tubulin alpha-1A chain0539
Tubulin beta chain0538
Tubulin beta-4A chain06514
Tubulin beta chain06514
Tubulin alpha-3C chain06514
Tubulin alpha-1B chain06514
Tubulin alpha-4A chain06514
Tubulin beta-4B chain06514
Vesicular acetylcholine transporter0101
Tubulin beta-3 chain07515
Tubulin beta-2A chain06514
Tubulin polymerization-promoting protein0011
Tubulin beta-8 chain06514
Tubulin beta-2B chain0518
Tubulin alpha-3E chain06514
Tubulin alpha-1A chain06514
Similar to alpha-tubulin isoform 1 0417
Similar to alpha-tubulin isoform 1 0406
CREB-binding protein3306
Tubulin alpha-1C chain06514
Tubulin beta-6 chain06514
Tubulin beta-2B chain06514
Tubulin beta-1 chain06514
Adenylate cyclase type 80011
Relaxin receptor 10011
Nuclear receptor subfamily 1 group I member 20066
B2 bradykinin receptor0606
Dihydrofolate reductase0404
Beta-galactosidase0203
Ectonucleotide pyrophosphatase/phosphodiesterase family member 20707
PH domain leucine-rich repeat-containing protein phosphatase 20101
Chymotrypsin-C0202
RNA-directed RNA polymerase 0226
Exportin-10202
NAD-dependent histone deacetylase SIR20204
Acetylcholinesterase017118
Prolyl endopeptidase0202
Growth hormone secretagogue receptor type 10011
Growth hormone secretagogue receptor type 10426
N-arachidonyl glycine receptor0213
Sodium- and chloride-dependent creatine transporter 10101
ATP-binding cassette sub-family C member 90224
ATP-binding cassette sub-family C member 80325
ATP-sensitive inward rectifier potassium channel 110426
ATP-sensitive inward rectifier potassium channel 80011
G protein-coupled receptor GPR350033
G-protein coupled receptor 350022
toll-like receptor 90202
hypothetical protein SA14220101
Phospholipase A20415
Neuronal proto-oncogene tyrosine-protein kinase Src 0101
Glutathione S-transferase P0404
Microtubule-associated protein tau0719
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 0101
Sarcoplasmic/endoplasmic reticulum calcium ATPase 20303
Thioredoxin reductase 1, cytoplasmic0506
Thioredoxin reductase 30303
Sortase A0202
Sarcoplasmic/endoplasmic reticulum calcium ATPase 30303
Cysteine protease 0101
Thioredoxin reductase 2, mitochondrial0303
Lymphocyte antigen 960011
Multidrug resistance-associated protein 50304
RPL19A0011
transactivating tegument protein VP16 [Human herpesvirus 1]0606
COUP transcription factor 2 isoform a0101
Eukaryotic initiation factor 4A-I0101
Peptidyl-prolyl cis-trans isomerase FKBP1A0628
Peptidyl-prolyl cis-trans isomerase FKBP30101
Peptidyl-prolyl cis-trans isomerase FKBP40101
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 10415
Hypoxia-inducible factor 1-alpha0628
Endothelial PAS domain-containing protein 10415
Peptidyl-prolyl cis-trans isomerase FKBP140101
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 40101
Smoothened homolog0101
Sonic hedgehog protein0101
Sonic hedgehog protein0112
Smoothened homolog0213
D-alanine--D-alanine ligase0101
UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase 0101
chaperonin GroEL3003
Glycogen phosphorylase, muscle form0202
Histone-lysine N-methyltransferase SETD70505
Histone-lysine N-methyltransferase EHMT10808
LMP1 [Human herpesvirus 4]0005
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]0404
nuclear receptor coactivator 3 isoform a0404
Thymidine kinase 2, mitochondrial0101
Thymidine kinase0203
Thymidylate synthase0406
Thymidine kinase0101
Probable deoxycytidylate deaminase0002
Cytidine deaminase0307
Enoyl-[acyl-carrier-protein] reductase [NADH] 0303
Deoxynucleoside kinase0101
Cdk-related protein kinase 60101
Protein kinase domain-containing protein0101
Mitogen-activated protein kinase 0101
Proline--tRNA ligase0101
Calcium-dependent protein kinase 40202
Lysine--tRNA ligase 0101
Uridine-cytidine kinase 1 0002
Ribonucleoside-diphosphate reductase large subunit0102
Ribonucleoside-diphosphate reductase subunit M20001
2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase0101
2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase0022
Ribonucleoside-diphosphate reductase subunit M2 B0001
neutrophil cytosol factor 10505
Solute carrier family 2, facilitated glucose transporter member 30101
Solute carrier family 2, facilitated glucose transporter member 40101
Deoxycytidine kinase0001
Alpha-tocopherol transfer protein0011
Serine protease hepsin0101
RAD510202
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 10101
Growth factor receptor-bound protein 20102
Pantothenate synthetase0303
Growth factor receptor-bound protein 2 0101
Chain A, Aldehyde Dehydrogenase, Mitochondrial0101
Retinal dehydrogenase 20101
Retinal dehydrogenase 10404
Aldehyde dehydrogenase, mitochondrial0314
Aldehyde dehydrogenase X, mitochondrial0101
Aldehyde dehydrogenase family 1 member A30101
Interleukin-20011
Glandular kallikrein0101
Cell division protein FtsZ0012
6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase 0101
Dihydrofolate reductase0809
Potassium voltage-gated channel subfamily E member 10101
Thromboxane-A synthase0103
Prostacyclin synthase0101
Acetylcholinesterase0101
G-protein coupled receptor 8405611
Chain A, Odorant binding protein0011
Chain B, Odorant binding protein0011
Lysine-specific demethylase 6A0101
Lysine-specific demethylase 4A0303
Lysine-specific demethylase 5C0303
Lysine-specific demethylase 2B0101
Deoxyhypusine hydroxylase0202
Lysine-specific demethylase 2A0303
Retinoic acid receptor RXR-beta0268
Retinoic acid receptor RXR-gamma0268
Lysine--tRNA ligase0101
Beta-glucuronidase0101
Glucose-6-phosphate 1-dehydrogenase 0101
NPC1-like intracellular cholesterol transporter 10112
Solute carrier organic anion transporter family member 1A20108
Solute carrier organic anion transporter family member 1A30308
ATP-binding cassette sub-family C member 110002
Solute carrier organic anion transporter family member 1A10002
Thymidine kinase 2 0202
AAA family ATPase 0002
AAA family ATPase 0001
Sterol O-acyltransferase 10202
Sodium-dependent neutral amino acid transporter B(0)AT20202
Collagenase 30808
Alpha-1A adrenergic receptor0527
Trace amine-associated receptor 10022
Trace amine-associated receptor 10044
Trace amine-associated receptor 10077
Taste receptor type 2 member 460033
Fatty acid synthase0606
Alpha-1-acid glycoprotein 10002
Nicotinamide phosphoribosyltransferase0011
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial0202
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial0202
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial0202
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial0202
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Acetylcholinesterase0101
Interleukin-80303
UDP-glucuronosyltransferase 1A70215
UDP-glucuronosyltransferase 1A100216
NAD0101
NAD0102
ATP phosphoribosyltransferase0101
Proprotein convertase subtilisin/kexin type 70202
Estrogen-related receptor gamma0112
UDP-glucose 4-epimerase0303
Chain A, DigA160022
Chain A, DigA160022
Sodium/potassium-transporting ATPase subunit alpha-1 010011
Sodium/potassium-transporting ATPase subunit beta-1010011
Sodium/potassium-transporting ATPase subunit alpha-30708
Sodium/potassium-transporting ATPase subunit beta-20708
Sodium/potassium-transporting ATPase subunit alpha-2010011
Sodium/potassium-transporting ATPase subunit alpha-10303
Potassium-transporting ATPase alpha chain 20102
Sodium/potassium-transporting ATPase subunit beta-30708
Sodium/potassium-transporting ATPase subunit gamma0708
Sodium/potassium-transporting ATPase subunit alpha-40708
Solute carrier organic anion transporter family member 4C10306
Sodium/potassium-transporting ATPase subunit alpha-20202
Sodium/potassium-transporting ATPase subunit alpha-3 0202
Sodium/potassium-transporting ATPase subunit beta-1 0202
Sodium/potassium-transporting ATPase subunit alpha-40202
Solute carrier organic anion transporter family member 4C10002
Solute carrier organic anion transporter family member 1A40001
ADP-ribose glycohydrolase MACROD20101
Neuronal acetylcholine receptor subunit alpha-50123
fatty acid synthase0303
Chain A, HTH-type transcriptional regulator qacR0011
Chain B, HTH-type transcriptional regulator qacR0011
Chain A, PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN (PROBABLY DEOR-FAMILY)0011
Chain B, PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN (PROBABLY DEOR-FAMILY)0011
Chain A, GLUTAMATE RECEPTOR SUBUNIT 20303
Chain A, Glutamate Receptor Subunit 20303
Chain B, Glutamate Receptor Subunit 20303
Chain A, Glutamate receptor 20101
Chain A, Glutamate receptor 20101
Chain A, Glutamate receptor0101
Chain A, Sex Hormone-Binding Globulin0011
Progesterone receptor0101
Glucocorticoid receptor0326
Sex hormone-binding globulin0101
Androgen receptor0134
Neuropeptide FF receptor 20002
Equilibrative nucleoside transporter 20101
Histamine H1 receptor 0101
Cereblon isoform 40909
Insulin-like growth factor-binding protein 50011
Protein cereblon020122
DNA dC->dU-editing enzyme APOBEC-3A isoform a0101
Thromboxane A2 receptor 0327
Prostaglandin F2-alpha receptor0202
Prostaglandin F2-alpha receptor0224
Prostaglandin F2-alpha receptor0011
Solute carrier organic anion transporter family member 2A10202
Prostaglandin E2 receptor EP4 subtype0112
Prostaglandin E2 receptor EP2 subtype0112
Solute carrier family 22 member 70002
Sodium channel protein type 10 subunit alpha0303
Histamine N-methyltransferase0104
Calcium release-activated calcium channel protein 10303
Protein orai-20101
Protein orai-30101
Ornithine transcarbamylase, mitochondrial0202
Nociceptin receptor0314
Chain A, limonene-1,2-epoxide hydrolase0101
Chain A, Epoxide hydrolase0101
LANA0001
kelch-like ECH-associated protein 10003
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta0303
3',5'-cyclic-AMP phosphodiesterase 0606
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha0303
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma0303
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta0303
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma0303
Exopolyphosphatase PRUNE10101
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A0404
Phosphodiesterase 0404
polypyrimidine tract-binding protein 1 isoform a1001
bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferase0404
Carbamate kinase0101
C-X-C chemokine receptor type 20404
Gasdermin-D0202
Monoglyceride lipase0606
Gasdermin-D0202
hypothetical protein CAALFM_CR05890CA0005
H3 histone acetyltransferase0005
Photosystem II protein D10101
Kinesin-like protein KIF110101
Nucleotide-binding oligomerization domain-containing protein 20202
Chain A, PFV integrase0101
Chain A, PFV integrase0101
Chain A, PFV integrase0101
Integrase 0011
Cholinesterase0606
Acetylcholine receptor subunit epsilon0325
Acyl-CoA:cholesterol acyltransferase 0404
Carboxylic ester hydrolase 010010
M18 aspartyl aminopeptidase0303
cathepsin L10202
Potassium voltage-gated channel subfamily E member 1011011
Potassium voltage-gated channel subfamily KQT member 1012012
Monoacylglycerol lipase ABHD60101
N-acetyltransferase Eis0303
Arrestin, beta 10101
MPI protein0303
hexokinase0303
hexokinase-1 isoform HKI0011
phosphomannomutase 20101
fructose-bisphosphate aldolase A4004
phosphoethanolamine/phosphocholine phosphatase isoform 10202
Sulfhydryl oxidase 10101
Macrophage migration inhibitory factor016016
Insulin-degrading enzyme0101
Toxin B0101
Methionine aminopeptidase 20101
Structural capsid protein 0101
UDP-glucuronosyltransferase 2B170012
Eyes absent homolog 20202
Chain A, POL POLYPROTEIN0101
Chain A, POL POLYPROTEIN0101
Chain B, POL POLYPROTEIN0101
Chain A, POL POLYPROTEIN0101
Chain B, POL POLYPROTEIN0101
Chain A, Pol Polyprotein0101
Chain B, Pol Polyprotein0101
Gag-Pol polyprotein0707
Gag-Pol polyprotein0606
Microsomal triglyceride transfer protein large subunit0202
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 0101
Fructose-1,6-bisphosphatase 1 0002
Reverse transcriptase 0224
Cholesterol 24-hydroxylase0426
Mitochondrial 2-oxodicarboxylate carrier0101
Chain A, Protein (peroxisome Proliferator Activated Receptor (ppar-delta))0101
Oxoeicosanoid receptor 10101
N-methyl-D-aspartate receptor 0101
Chain A, Casein kinase II subunit alpha0101
acetyl-CoA acetyltransferase/HMG-CoA reductase0101
unnamed protein product0202
heat shock 70kDa protein 1A0202
Aldehyde oxidase 10101
dual specificity protein phosphatase 30202
mothers against decapentaplegic homolog 3 isoform 10101
heat shock cognate 71 kDa protein isoform 10202
heat shock cognate 71 kDa protein isoform 20202
Nucleophosmin0101
Glutathione S-transferase Mu 10101
Mitogen-activated protein kinase kinase kinase 80101
DNA primase0202
Tyrosine-protein kinase Lyn 0101
Polypeptide N-acetylgalactosaminyltransferase 20224
ELAV-like protein 30303
Tyrosine-protein kinase Fgr0101
Glutathione S-transferase0101
Translin-associated protein X0101
Cysteine protease ATG4B0202
likely tRNA 2'-phosphotransferase0202
D(2) dopamine receptor isoform long1001
E3 ubiquitin-protein ligase XIAP0303
Macrophage-expressed gene 1 protein0202
Nociceptin receptor010518
Nociceptin receptor0303
Cytosol aminopeptidase0303
Opioid receptor, delta 1b 0202
Opioid receptor homologue0202
Proenkephalin-B0011
Mu-type opioid receptor0202
V-type proton ATPase subunit B, brain isoform0101
RISC-loading complex subunit TARBP20011
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI0404
Apoptosis regulator Bcl-20404
Glucose-6-phosphate 1-dehydrogenase0202
6-phosphogluconate dehydrogenase, decarboxylating0707
Chain A, Troponin C, slow skeletal and cardiac muscles0011
Chain A, Peptidyl-prolyl cis-trans isomerase NIMA-interacting 10011
Chain A, POLYMERASE PA0101
Chain A, Polymerase Pa0101
Chain A, Polymerase Pa0101
Chain A, Polymerase Pa0101
Chain A, Polymerase Pa0101
galactokinase4004
NAD kinase0213
Polymerase acidic protein0325
Plasminogen activator inhibitor 10303
CPG DNA methylase0202
Phosphoglycerate mutase 10202
Signal transducer and activator of transcription 1-alpha/beta0011
Matrix metalloproteinase-140202
BH3-interacting domain death agonist0101
Bcl-2-like protein 10404
Bcl-2-related protein A10101
Dual specificity tyrosine-phosphorylation-regulated kinase 1A0202
3-oxoacyl-[acyl-carrier-protein] reductase 0101
Bcl-2-like protein 20101
Bcl2-associated agonist of cell death 0101
Bcl-2-like protein 100101
Adenylate cyclase 0101
Solute carrier family 22 member 40102
Serine/threonine-protein kinase B-raf 0202
Motilin receptor0011
low molecular weight phosphotyrosine protein phosphatase isoform c0202
Motilin receptor0112
Chitinase B0101
Low molecular weight phosphotyrosine protein phosphatase0505
Flavin reductase (NADPH)0022
ERAP2 protein0002
M17 leucyl aminopeptidase0101
M1-family alanyl aminopeptidase0101
leucyl-cystinyl aminopeptidase [Mus musculus]0002
Tyrosine-protein phosphatase non-receptor type 110708
Sodium/bile acid cotransporter0002
Solute carrier organic anion transporter family member0001
Solute carrier organic anion transporter family member 1C10303
Chain A, GLUTATHIONE TRANSFERASE A1-10101
Chain A, Glutathione S-transferase P1-10101
Chain A, Glutathione S-transferase P1-10101
Chain B, Glutathione S-transferase P1-10101
Hematopoietic prostaglandin D synthase0202
Glutathione S-transferase A10101
14 kDa phosphohistidine phosphatase0303
3-oxo-5-alpha-steroid 4-dehydrogenase 1 0505
Voltage-dependent calcium channel subunit alpha-2/delta-10303
Voltage-dependent T-type calcium channel subunit alpha-1I0415
Taste receptor type 2 member 380049
5-hydroxytryptamine receptor 5A0011
Sodium/hydrogen exchanger 20101
Chain H, IGG1-KAPPA DB3 FAB (HEAVY CHAIN)0101
Chain L, IGG1-KAPPA DB3 FAB (LIGHT CHAIN)0101
Chain H, IGG1-KAPPA DB3 FAB (HEAVY CHAIN)0101
Chain L, IGG1-KAPPA DB3 FAB (LIGHT CHAIN)0101
Chain H, IGG1-KAPPA DB3 FAB (HEAVY CHAIN)0101
Chain L, IGG1-KAPPA DB3 FAB (LIGHT CHAIN)0101
Acetylcholine receptor subunit delta0101
Acetylcholine receptor subunit alpha0101
Acetylcholine receptor subunit gamma0101
Acetylcholine receptor subunit beta0101
Regulatory protein E20022
DNA topoisomerase 20001
DNA topoisomerase 2-alpha 0001
Ubiquitin carboxyl-terminal hydrolase isozyme L30101
Ubiquitin carboxyl-terminal hydrolase isozyme L10101
Potassium voltage-gated channel subfamily D member 30303
NPC1-like intracellular cholesterol transporter 10101
Potassium voltage-gated channel subfamily KQT member 30049
Potassium voltage-gated channel subfamily KQT member 201410
UDP-glucuronosyltransferase 2B110011
Potassium voltage-gated channel subfamily KQT member 20011
Potassium voltage-gated channel subfamily KQT member 3 0011
UDP-glucuronosyltransferase 2B40011
UDP-glucuronosyltransferase 2A10011
UDP-glucuronosyltransferase 2A20011
UDP-glucuronosyltransferase 1A50011
UDP-glucuronosyltransferase 2B150011
Potassium voltage-gated channel subfamily KQT member 40034
UDP-glucuronosyltransferase 2A30011
UDP-glucuronosyltransferase 2B280011
UDP-glucuronosyltransferase 1A80016
Potassium voltage-gated channel subfamily KQT member 50035
Potassium voltage-gated channel subfamily KQT member 2 0011
Chain E, cAMP-dependent protein kinase, alpha-catalytic subunit0202
Chain I, cAMP-dependent protein kinase inhibitor, alpha form0202
Chain B, Rho-associated protein kinase 10202
Chain A, Rho-associated protein kinase 10202
Chain A, Rho-associated protein kinase 10202
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit0202
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit0202
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit0202
Chain I, cAMP-dependent protein kinase inhibitor alpha0202
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit0202
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit0202
Chain I, cAMP-dependent protein kinase inhibitor alpha0202
Chain A, Rho-associated protein kinase 10202
cAMP-dependent protein kinase catalytic subunit alpha isoform Calpha10001
cAMP-dependent protein kinase catalytic subunit alpha 0314
C-C motif chemokine 20202
Cell division control protein 42 homolog0202
Ras-related C3 botulinum toxin substrate 10213
Rho-associated protein kinase 20202
Cathepsin B0101
procathepsin L isoform 1 preproprotein0202
fructose-bisphosphate aldolase0101
Caspase-40505
Caspase-50505
Transcriptional activator protein LuxR0404
Extracellular calcium-sensing receptor0011
Fatty acid-binding protein, liver0224
Peroxisome proliferator-activated receptor alpha0022
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 10101
3-oxo-5-alpha-steroid 4-dehydrogenase 10202
3-oxo-5-alpha-steroid 4-dehydrogenase 20404
3-oxo-5-alpha-steroid 4-dehydrogenase 20404
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase0101
Sphingosine 1-phosphate receptor 10011
RCG53912, isoform CRA_a 0001
Sphingosine kinase 1 0001
Sphingosine kinase 20304
Sphingosine kinase 10203
Chain B, Cell division protein kinase 60101
Potassium voltage-gated channel subfamily D member 20303
Lanosterol 14-alpha demethylase0124
Lanosterol 14-alpha demethylase0011
Sterol 14-alpha demethylase0112
corticotropin-releasing hormone receptor 20224
corticotropin releasing factor-binding protein0224
Voltage-dependent T-type calcium channel subunit alpha-1G0426
Voltage-dependent T-type calcium channel subunit alpha-1H0415
Voltage-dependent L-type calcium channel subunit beta-10101
Voltage-dependent calcium channel subunit alpha-2/delta-10101
Voltage-dependent N-type calcium channel subunit alpha-1B0101
Prostaglandin D2 receptor 20314
Chain A, Uracil Phosphoribosyltransferase0101
Potassium voltage-gated channel subfamily C member 10202
Gastrin/cholecystokinin type B receptor 0101
Serine hydroxymethyltransferase, mitochondrial0303
Acid-sensing ion channel 30202
Arylacetamide deacetylase0104
Arylacetamide deacetylase0002
Arylacetamide deacetylase0002
Chain A, Dihydrofolate reductase0011
Dihydrofolate reductase09414
Folylpolyglutamate synthase, mitochondrial0104
Multidrug resistance associated protein0103
Chain A, probable fosfomycin resistance protein0011
Chain B, probable fosfomycin resistance protein0011
DNA polymerase catalytic subunit0101
DNA polymerase catalytic subunit0101
DNA polymerase alpha catalytic subunit0202
DNA polymerase delta catalytic subunit0101
UDP-N-acetylglucosamine 1-carboxyvinyltransferase0202
UDP-N-acetylglucosamine 1-carboxyvinyltransferase0202
Menin0112
Lecithin retinol acyltransferase0101
Protein Rev 0022
Fucose-binding lectin PA-IIL0202
CD209 antigen0303
Steroid hormone receptor ERR10303
NADP-dependent malic enzyme, mitochondrial0002
Corticosteroid 11-beta-dehydrogenase isozyme 10314
Holo-[acyl-carrier-protein] synthase0101
Dopamine beta-hydroxylase 0405
Dopamine beta-hydroxylase0101
Chain A, Type Iii Chloramphenicol Acetyltransferase0101
Sterol O-acyltransferase 10022
Lipopolysaccharide heptosyltransferase 10101
PA-I galactophilic lectin0134
Jacalin0011
Chain A, ACETYLCHOLINESTERASE0101
Chain A, Acetylcholinesterase0101
Galanin receptor type 30011
Galanin receptor type 10213
L-selectin0101
P-selectin0101
E-selectin0101
Toll-like receptor 2 0101
Sodium- and chloride-dependent GABA transporter 1012116
Sodium- and chloride-dependent taurine transporter0202
Sodium- and chloride-dependent betaine transporter0808
Toll-like receptor 70112
Small conductance calcium-activated potassium channel protein 20303
Small conductance calcium-activated potassium channel protein 10303
Putative nucleoside diphosphate kinase0011
Cholesteryl ester transfer protein0415
Cyclin-dependent kinase 100066
Chain A, DEOXYNUCLEOSIDE KINASE0101
Chain A, Estrogen receptor 1 (alpha)0101
Chain A, Transthyretin0011
Chain A, Transthyretin0011
Alpha-mannosidase0101
Maltase-glucoamylase, intestinal0303
Steroid hormone receptor ERR20101
Ornithine decarboxylase0202
Solute carrier family 2, facilitated glucose transporter member 40101
Cystic fibrosis transmembrane conductance regulator0011
Alpha-glucosidase MAL320101
Tissue alpha-L-fucosidase0101
DNA (cytosine-5)-methyltransferase 3-like0303
DNA (cytosine-5)-methyltransferase 3A0404
Glucagon-like peptide 1 receptor0011
Glucagon-like peptide 1 receptor0336
Glucagon receptor0011
Glucagon receptor0011
Asialoglycoprotein receptor 10112
Chain A, Slr1257 protein0011
Chain A, Glucosamine--fructose-6-phosphate aminotransferase [isomerizing]0101
Bifunctional aspartokinase/homoserine dehydrogenase 10101
Excitatory amino acid transporter 3 0001
Glutamate racemase0001
Metabotropic glutamate receptor 80314
Glutamate racemase0001
Protein-glutamine gamma-glutamyltransferase 20404
Chain A, Glutamine Binding Protein0011
Asc-type amino acid transporter 10202
Chain A, Protein (aspartate Aminotransferase)0022
Chain A, Aspartate Aminotransferase0022
Glutathione reductase0102
ATP synthase subunit beta, mitochondrial0101
ATP synthase subunit delta, mitochondrial0101
ATP synthase subunit gamma, mitochondrial0101
ATP synthase subunit epsilon, mitochondrial0101
Cholesteryl ester transfer protein0101
Chain B, EUKARYOTIC TRANSLATION INITIATION FACTOR 4E0011
Sodium- and chloride-dependent glycine transporter 10202
Large neutral amino acids transporter small subunit 1010011
Sodium- and chloride-dependent glycine transporter 20101
High mobility group protein B10033
High mobility group protein B10001
Corticosteroid 11-beta-dehydrogenase isozyme 20112
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferase0101
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferase0101
Glutamine synthetase 0101
Cytochrome P450 71B10102
Glutamine synthetase 0101
2-dehydro-3-deoxyphosphooctonate aldolase0101
Polycomb protein SUZ120202
Histone-lysine N-methyltransferase EZH20404
guanine nucleotide-binding protein subunit alpha-150224
trace amine-associated receptor 10224
Ricin0202
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase0011
Purine nucleoside phosphorylase 0024
Chain A, Probable hydrogenase nickel incorporation protein hypB0011
Chain B, Probable hydrogenase nickel incorporation protein hypB0011
Chain A, ELONGATION FACTOR TU (EF-TU)0011
Chain A, Elongation Factor G0011
Chain A, ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 30011
Chain A, Eukaryotic peptide chain release factor GTP-binding subunit0011
Chain A, ras-related C3 botulinum toxin substrate 1 isoform Rac1b0022
Chain A, ras-related C3 botulinum toxin substrate 1 isoform Rac1b0022
Chain A, interferon-inducible GTPase0011
Chain A, interferon-inducible GTPase0011
Chain A, Elongation factor 20011
Chain A, Guanine nucleotide-binding protein G(i), alpha-1 subunit0011
Ras-related protein Rab-7a0022
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT50101
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 90404
Chain A, Hypoxanthine Phosphoribosyltransferase0101
Chain A, HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE0101
Chain A, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE0011
Chain B, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE0011
Chain A, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE0011
Chain A, Xanthine phosphoribosyltransferase0011
Histidine triad nucleotide-binding protein 10011
Chain A, Uracil Phosphoribosyltransferase0011
Chain B, Uracil Phosphoribosyltransferase0011
Chain C, Uracil Phosphoribosyltransferase0011
Chain A, PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR0101
Chain E, C-amp-dependent Protein Kinase0101
Chain I, Protein Kinase Inhibitor Peptide0101
Chain E, C-amp-dependent Protein Kinase0101
Chain E, C-amp-dependent Protein Kinase0101
Chain I, Protein Kinase Inhibitor Peptide0101
cAMP-dependent protein kinase type II-alpha regulatory subunit0202
cAMP-dependent protein kinase catalytic subunit beta 0202
cAMP-dependent protein kinase type II-beta regulatory subunit0202
5-hydroxytryptamine receptor 2A0213
AP-2 complex subunit sigma0101
Genome polyprotein 0303
Zinc finger protein 6640101
Sodium-dependent dopamine transporter0202
STE240002
DNA repair and recombination protein RAD54-like isoform 10001
Tryptophan 2,3-dioxygenase0304
Chain A, Dual specificity tyrosine-phosphorylation-regulated kinase 1A0101
Glycogen synthase kinase-3 beta 0202
CDC-like kinase 1, isoform CRA_c0001
[Tau protein] kinase 0202
dual specificity protein kinase CLK41001
Dual specificity protein kinase CLK20101
Dual specificity protein kinase CLK30101
Dual specificity protein kinase CLK40101
Dual specificity tyrosine-phosphorylation-regulated kinase 30101
Cyclin-T10101
Dual specificity protein kinase CLK10101
Cyclin-H0101
Mitogen-activated protein kinase 10202
Serine/threonine-protein kinase haspin0101
Dual specificity tyrosine-phosphorylation-regulated kinase 40101
Tyrosine-protein kinase JAK1 0101
Tyrosine-protein kinase JAK30101
Chain E, Fibrin beta chain0202
Cyclin-dependent kinase 5, regulatory subunit 1 (p35)0001
CDK50001
major prion protein preproprotein Prp precursor0101
Chain A, TYROSINE PHOSPHATASE0101
Chain A, Tyrosine Phosphatase0101
calpain II, partial0101
SUMO-10101
Valosin-containing protein0202
neuropeptide Y receptor type 10011
neuropeptide Y receptor type 20011
small ubiquitin-related modifier 2 isoform b precursor0101
enteropeptidase precursor1001
4-(cytidine 5'-phospho)-2-C-methyl-D-erithritol kinase1001
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D0101
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D0101
M1-family alanyl aminopeptidase0303
BZLF20202
Protein arginine N-methyltransferase 50314
Protein arginine N-methyltransferase 10606
Platelet glycoprotein 40101
Chain A, CARBONIC ANHYDRASE II0011
Chain A, Protein (female-specific Histamine Binding Protein 2)0011
Histamine N-methyltransferase 0202
Equilibrative nucleoside transporter 40001
Histamine H4 receptor0224
Histamine H4 receptor 0101
Chain A, HISTIDINE-BINDING PROTEIN0011
Histidine-binding periplasmic protein0011
Cystine/glutamate transporter0303
Chain A, TGF-beta receptor type I0101
Chain A, TGF-beta receptor type I0101
N-glycosylase/DNA lyase0404
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Chain A, Carbonic anhydrase 20101
Cyclic GMP-AMP synthase0202
Toll-like receptor 90101
Oleandomycin glycosyltransferase0001
2-5A-dependent ribonuclease0202
Chain A, Purine-nucleoside Phosphorylase0101
Chain C, Xanthine dehydrogenase/oxidase0011
Dehydrogenase/reductase SDR family member 90101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM0101
potassium voltage-gated channel subfamily KQT member 20022
NAD-dependent protein deacetylase 0202
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase0101
Prostacyclin receptor0112
Beta-lactamase 0001
Metallo-beta-lactamase type 20001
Beta-lactamase 0203
Chain A, Cell Division Protein Kinase 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, Cell Division Protein Kinase 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, CELL DIVISION PROTEIN KINASE 20101
Chain A, Cell Division Protein Kinase 20101
Chain A, PROTEIN (PROTEASE)0101
Chain B, PROTEIN (PROTEASE)0101
Chain A, PROTEIN (PROTEASE)0101
Chain B, PROTEIN (PROTEASE)0101
Chain A, HIV-1 PROTEASE0101
Chain B, HIV-1 PROTEASE0101
Chain A, HIV-II PROTEASE0101
Chain B, HIV-II PROTEASE0101
Chain A, POL polyprotein0011
Chain B, POL polyprotein0011
Chain A, POL polyprotein0011
Chain B, POL polyprotein0011
Chain A, POL polyprotein0011
Chain B, POL polyprotein0011
Chain A, POL polyprotein0011
Chain B, POL polyprotein0011
Chain A, protease RETROPEPSIN0101
Chain B, protease RETROPEPSIN0101
Chain A, protease RETROPEPSIN0101
Chain B, protease RETROPEPSIN0101
Chain A, protease RETROPEPSIN0101
Chain B, protease RETROPEPSIN0101
Chain A, POL polyprotein0202
Chain B, POL polyprotein0202
Chain A, POL polyprotein0202
Chain B, POL polyprotein0202
Chain A, HIV-1 protease0101
Chain B, HIV-1 protease0101
Chain A, Pol polyprotein0101
Chain B, Pol polyprotein0101
Chain A, Pol polyprotein0101
Chain B, Pol polyprotein0101
Chain A, Pol polyprotein0101
Chain B, Pol polyprotein0101
Chain A, Pol polyprotein0101
Chain B, Pol polyprotein0101
Chain A, Hiv-1 Protease0101
Chain B, Hiv-1 Protease0101
Chain A, Hiv-1 Protease0101
Chain B, Hiv-1 Protease0101
Chain A, Hiv-1 Protease0101
Chain B, Hiv-1 Protease0101
Gag-Pol polyprotein0505
Gag-Pol polyprotein0202
Gag polyprotein0101
Gag-Pol polyprotein0404
Gag-Pol polyprotein0404
Protease 0101
Phenol oxidase 0101
Integrin beta-20112
Intercellular adhesion molecule 10112
Trp operon repressor0022
Integrin alpha-L0123
Peptide deformylase 1A, chloroplastic/mitochondrial0101
Peptide deformylase 0101
Chain A, membrane-associated prostaglandin E synthase-20101
Phospholipase A2, major isoenzyme0202
C-X-C chemokine receptor type 30505
Prostaglandin D2 receptor 0202
Dehydrogenase/reductase SDR family member 90101
Chain A, ADENOSINE DEAMINASE0101
Chain A, ADENOSINE DEAMINASE0101
Chain B, Pulmonary surfactant-associated protein D0101
Chain A, Pulmonary surfactant-associated protein D0101
Sodium/myo-inositol cotransporter 20101
Beta-adrenergic receptor kinase 10303
Chain A, BETA-SPECTRIN0011
Chain A, Phospholipase C Delta-10011
Chain A, Inositol 1,4,5-trisphosphate receptor type 10011
Inositol-trisphosphate 3-kinase A0101
Inositol 1,4,5-trisphosphate receptor type 1 0022
Inositol 1,4,5-trisphosphate receptor type 20101
Inositol 1,4,5-trisphosphate receptor type 30112
Inositol polyphosphate-5-phosphatase A0101
Inositol 1,4,5-trisphosphate receptor type 10112
citrate synthase 2, partial0011
Chain A, Acetylcholinesterase0101
Chain A, meta-Cleavage product hydrolase0101
Free fatty acid receptor 30033
Fatty acid synthase 0101
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, isoform CRA_a0011
Protein disulfide-isomerase0101
3-oxoacyl-[acyl-carrier-protein] synthase 3 0101
Formamidopyrimidine-DNA glycosylase0101
Endonuclease III-like protein 10101
Putative FAD-containing monooxygenase MymA0101
Dihydrofolate reductase0303
Endonuclease 8-like 10101
Beta-2 adrenergic receptor0112
Beta-3 adrenergic receptor0011
Beta-1 adrenergic receptor0314
Taste receptor type 2 member 390011
Taste receptor type 2 member 400011
Taste receptor type 2 member 410011
Taste receptor type 2 member 430011
Taste receptor type 2 member 450011
Taste receptor type 2 member 300011
Taste receptor type 2 member 190011
Taste receptor type 2 member 200011
Taste receptor type 2 member 500011
Taste receptor type 2 member 600022
Taste receptor type 2 member 420011
Taste receptor type 2 member 140023
Taste receptor type 2 member 130022
Taste receptor type 2 member 90022
Taste receptor type 2 member 80011
Taste receptor type 2 member 70011
Taste receptor type 2 member 50011
Taste receptor type 2 member 40022
Taste receptor type 2 member 30011
Taste receptor type 2 member 10011
Ornithine decarboxylase0002
Retinoic acid receptor alpha0224
Retinoic acid receptor gamma0224
Retinoic acid receptor beta0224
Cellular retinoic acid-binding protein 20022
Retinoic acid receptor RXR-beta0224
Retinoic acid receptor RXR-gamma0224
Cellular retinoic acid-binding protein 10203
Cellular retinoic acid-binding protein 10022
Voltage-dependent L-type calcium channel subunit alpha-1C0101
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 20011
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 10011
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 40011
P2X purinoceptor 70404
P2X purinoceptor 70101
3-oxoacyl-[acyl-carrier-protein] synthase 30101
Gap junction alpha-1 protein0101
Gap junction beta-2 protein0101
Acyl-protein thioesterase 10101
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial0101
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial0202
Cytochrome P450 26A10101
Steroid 21-hydroxylase0101
Cholesterol side-chain cleavage enzyme, mitochondrial 0101
Cytochrome P450 2A20101
Cytochrome P450 11B1, mitochondrial 0303
Cytochrome P450 7A1 0101
Gonadotropin-releasing hormone receptor0314
Cytochrome P450 4F20303
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial0101
Cytochrome P450 7A10101
Lanosterol 14-alpha demethylase 0202
P2X purinoceptor0101
p2X7 purinoceptor 0101
Calcium/calmodulin-dependent protein kinase type II subunit beta0101
Calcium/calmodulin-dependent protein kinase type II subunit gamma0101
Calcium/calmodulin-dependent protein kinase type II subunit delta0101
Tyrosinase0112
Uncharacterized protein YOR062C0101
Tyrosinase 0101
Leukotriene C4 synthase0202
Leukotriene C4 synthase0001
Prostaglandin E synthase 20101
Chain A, Lectin0011
Chain A, Lectin0011
Chain A, Lectin0011
Chain A, Lectin0011
Chain A, ERYTHRINA CRISTA-GALLI LECTIN0011
Chain A, ERYTHRINA CRISTA-GALLI LECTIN0011
Chain A, cellulase0011
Chain A, cellulase0011
Chain A, Galectin-30011
Chain A, Anti-tumor lectin0101
Galectin-30101
Galectin-90022
Galectin-80022
Beta-galactoside-binding lectin0101
Galectin-10124
Galectin-30112
Galectin-30125
Galectin-70022
Alpha 1,4 galactosyltransferase0001
Capsid protein 0123
Alpha-crystallin B chain0011
WD repeat-containing protein 50303
Histone-lysine N-methyltransferase 2A0303
Cytosolic endo-beta-N-acetylglucosaminidase0303
Actin0101
matrix metalloproteinase 1, partial0011
Dihydroorotate dehydrogenase (quinone), mitochondrial0202
Dihydroorotate dehydrogenase (quinone), mitochondrial0617
Dihydroorotate dehydrogenase (quinone), mitochondrial0202
Protein delta homolog 10134
Chain A, AMINOPEPTIDASE0202
Chain A, AMINOPEPTIDASE0202
Chain A, Leucine Aminopeptidase0101
Gonadotropin-releasing hormone receptor0101
Alkaline phosphatase, placental type0101
Alkaline phosphatase, tissue-nonspecific isozyme 0303
Intestinal-type alkaline phosphatase0202
Synaptic vesicle glycoprotein 2A0303
integrase, partial0303
lens epithelium-derived growth factor p750303
SLC16A10 protein0004
Monocarboxylate transporter 100004
CAAX prenyl protease 2 isoform 20001
Isocitrate dehydrogenase [NADP] cytoplasmic0112
Potassium channel subfamily K member 180101
Dipeptidyl peptidase 90101
Dipeptidyl peptidase IV0101
Prolyl endopeptidase FAP0101
Prolyl endopeptidase FAP0101
Dipeptidyl peptidase 80101
Dipeptidyl peptidase 90101
Dipeptidyl peptidase 20101
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial0101
Dual specificity tyrosine-phosphorylation-regulated kinase 1A0101
Renin0303
Sterol O-acyltransferase 10404
inositol monophosphatase 12002
Chain A, protease0101
Chain B, protease0101
Chain A, protease0011
Chain B, protease0011
Chain A, protease0011
Chain B, protease0011
Chain A, protease0011
Chain B, protease0011
Chain A, protease0011
Chain B, protease0011
Chain A, protease0011
Chain B, protease0011
Chain A, Protease0101
Chain B, Protease0101
Chain A, Protease0101
Chain B, Protease0101
Chain A, Protease0101
Chain B, Protease0101
Chain A, PROTEASE RETROPEPSIN0101
Chain B, PROTEASE RETROPEPSIN0101
Chain A, Protease Retropepsin0101
Chain B, Protease Retropepsin0101
Chain A, Protease Retropepsin0101
Chain B, Protease Retropepsin0101
Gag-Pol polyprotein0202
CAAX prenyl protease 1 homolog0101
Plasmepsin V 0202
Potassium channel subfamily K member 90101
5-hydroxytryptamine receptor 2C0011
Type-1 angiotensin II receptor0213
Chain A, Antigen Cd11a (p180)0101
Queuine tRNA-ribosyltransferase0101
histidine kinase 0101
Chemotaxis protein CheA0101
Protein polybromo-10011
DNA topoisomerase 10101
Melatonin receptor type 1C0112
NADH-cytochrome b5 reductase 3 0202
Monoglyceride lipase0303
Neutral cholesterol ester hydrolase 10101
Monoacylglycerol lipase ABHD60101
5-hydroxytryptamine receptor 1E0607
Sodium-dependent dopamine transporter0101
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase, chloroplast0101
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase, chloroplast0101
Lysophosphatidic acid receptor 60011
Lysophosphatidic acid receptor 4 0011
Lysophosphatidic acid receptor 10022
Lysophosphatidic acid receptor 40011
Lysophosphatidic acid receptor 50011
Lysophosphatidic acid receptor 20011
Lysophosphatidic acid receptor 30011
Chain A, Retinoic acid receptor RXR-alpha0011
Chain A, Peroxisome proliferator-activated receptor gamma0011
Carboxylic ester hydrolase 0202
Chain A, Phosphoenolpyruvate carboxykinase0101
D-aspartate oxidase 0101
D-aspartate oxidase0101
Serine racemase0303
Alpha-mannosidase 2C10112
Phosphatidylcholine 2-acylhydrolase 0101
Acidic phospholipase A2 beta0101
Phospholipase A20101
Phospholipase A2, membrane associated0202
Phospholipase A2, membrane associated0203
Acidic phospholipase A2 20303
histone-lysine N-methyltransferase NSD2 isoform 10001
C-C chemokine receptor type 50101
C-C chemokine receptor type 50101
Receptor-type tyrosine-protein phosphatase F0404
Tyrosine-protein phosphatase non-receptor type 60505
Cysteinyl leukotriene receptor 10303
REST corepressor 10101
Chain A, Fructose-1,6-bisphosphatase0101
Uracil nucleotide/cysteinyl leukotriene receptor0011
Uracil nucleotide/cysteinyl leukotriene receptor0011
Prostate-specific antigen0101
Calmodulin-domain protein kinase 10101
Neuronal acetylcholine receptor subunit alpha-20202
Transcription factor SOX-180101
Myc proto-oncogene protein0203
Melatonin receptor type 1A0224
Melatonin receptor type 1C0224
Melatonin receptor type 1B0224
Large neutral amino acids transporter small subunit 1 0202
UDP-glucose 6-dehydrogenase0101
UDP-glucose 6-dehydrogenase0101
UDP-glucuronosyltransferase 1A1 0101
Lactoperoxidase0101
Chain A, Methionyl-tRNA synthetase0011
Chain A, Methionyl-tRNA synthetase0011
Chain A, Aminopeptidase0101
Chain A, Methionine aminopeptidase0101
S-ribosylhomocysteine lyase0101
Adenylate cyclase type 50001
G-protein coupled receptor homolog US280011
G protein-coupled receptor0011
Chain B, DIHYDROFOLATE REDUCTASE0011
Chain B, DIHYDROFOLATE REDUCTASE0011
Chain B, DIHYDROFOLATE REDUCTASE0011
Thymidylate synthase 0101
Thymidylate synthase 0101
ATP-binding cassette sub-family C member 30102
Dihydrofolate reductase0304
Dihydrofolate reductase0101
Dihydrofolate reductase0405
Thymidylate synthase0102
Bifunctional dihydrofolate reductase-thymidylate synthase0303
Dihydrofolate reductase0303
Thymidylate synthase0202
Folate receptor beta0101
Folate receptor alpha0101
Histidine decarboxylase0145
Reduced folate transporter0202
Bifunctional dihydrofolate reductase-thymidylate synthase0304
Bifunctional dihydrofolate reductase-thymidylate synthase0101
Trifunctional purine biosynthetic protein adenosine-30101
Dihydrofolate reductase 0303
Dihydrofolate reductase0405
Proton-coupled folate transporter0101
Cytochrome P450 2A1307512
Chain A, Discoidin-20011
Chain A, Discoidin-20011
Galectin-20011
Galectin-40011
Ribonuclease HI0202
T cell receptor, partial1001
luteinizing hormone receptor1001
Apoptotic peptidase activating factor 10101
caspase-9 isoform alpha precursor0101
caspase-3 isoform a preproprotein0101
Dihydrolipoyl dehydrogenase, mitochondrial0102
Dihydrolipoyl dehydrogenase 0102
Xaa-Pro dipeptidase0002
P2Y purinoceptor 10011
5-hydroxytryptamine receptor 3B0707
Chain A, Histamine N-methyltransferase0202
Chain A, Histamine N-methyltransferase0202
Chain A, Histamine N-methyltransferase0202
Chain A, Histamine N-methyltransferase0202
Thioredoxin reductase 0101
G-protein coupled receptor 0101
Cytochrome P450 1A20101
methionyl-tRNA synthetase, putative0101
Chain A, PROGESTERONE RECEPTOR0101
Glucocorticoid receptor 0101
Tegument protein VP160011
Glucocorticoid receptor0112
Progesterone receptor0011
Glucocorticoid receptor0101
Multidrug transporter MdfA0202
Nuclear receptor corepressor 10303
Nuclear receptor corepressor 20303
Protein E60202
Islet amyloid polypeptide0101
Low molecular weight phosphotyrosine protein phosphatase0101
DNA-3-methyladenine glycosylase0101
C-terminal-binding protein 13003
Solute carrier family 22 member 120101
Solute carrier family 22 member 120404
Class A sortase SrtA 0101
Acyl-CoA desaturase 10404
Mu-type opioid receptor0101
DNA gyrase subunit B0202
Melanocortin receptor 30011
Melanocortin receptor 30123
Melanocortin receptor 50112
Melanocortin receptor 40123
Melanocyte-stimulating hormone receptor0213
Melanocyte-stimulating hormone receptor0112
5-hydroxytryptamine receptor 1B0202
Chain A, Inosine-5'-Monophosphate Dehydrogenase 20101
Inosine-5'-monophosphate dehydrogenase0102
Toll-like receptor 20202
Peroxisome proliferator-activated receptor delta0439
Dynamin-10101
Carboxypeptidase B20202
Prostaglandin E synthase0101
potassium voltage-gated channel subfamily KQT member 1 isoform 10011
potassium voltage-gated channel subfamily E member 10011
potassium voltage-gated channel subfamily KQT member 4 isoform a0011
potassium voltage-gated channel subfamily KQT member 30011
Glycogen synthase kinase-3 beta0101
solute carrier family 12 member 2 isoform 10101
Solute carrier family 12 member 50101
Nitric oxide synthase, endothelial 0101
Papain0001
Formyl peptide receptor-related sequence 10011
fMet-Leu-Phe receptor0325
N-formyl peptide receptor 20022
FML2_HUMAN 0011
Chain A, Venom Allergen 20011
Muscarinic acetylcholine receptor 0011
Muscarinic acetylcholine receptor 0101
Tyrosine 3-monooxygenase0101
Chain A, PROTEIN (5-AMINOLAEVULINIC ACID DEHYDRATASE)0101
N(G),N(G)-dimethylarginine dimethylaminohydrolase 10002
N(G),N(G)-dimethylarginine dimethylaminohydrolase 10001
Chain B, Exotoxin A0011
Chain B, Exotoxin A0011
Chain B, Exotoxin A0011
Hormone-sensitive lipase0101
Chain A, Hth-type Transcriptional Regulator Ttgr0011
Chain A, Hth-type Transcriptional Regulator Ttgr0011
Chain A, Mitogen-activated protein kinase 140101
Chain A, Mitogen-activated protein kinase 140101
Chain A, Mitogen-activated protein kinase 140101
Chain A, Mitogen-activated protein kinase 140101
Chain A, Mitogen-activated protein kinase 140101
Chain A, Mitogen-activated protein kinase 140101
Chain A, Mitogen-activated protein kinase 140101
Chain A, Mitogen-activated protein kinase 140101
Chain A, Mitogen-activated protein kinase 140101
G protein-activated inward rectifier potassium channel 20011
G protein-activated inward rectifier potassium channel 40011
G protein-activated inward rectifier potassium channel 10011
Chain A, ASPARTYLPROTEASE0101
Chain B, ASPARTYLPROTEASE0101
Neuromedin-K receptor0033
Substance-K receptor0246
Neuromedin-K receptor0639
Substance-K receptor0303
Substance-K receptor0303
Neuromedin-K receptor0112
Neurotensin receptor type 10011
Neurotensin receptor type 20113
Myelin basic protein0011
Neurotensin receptor type 10112
Neurotensin receptor type 10225
Neurotensin receptor type 20213
Sortilin0101
Chain B, Hiv-1 Reverse Transcriptase0101
Chain A, Hiv-1 Reverse Transcriptase0101
Chain A, Hiv-1 Reverse Transcriptase0101
Chain A, Hiv-1 Reverse Transcriptase0101
Chain B, Hiv-1 Reverse Transcriptase0101
Chain A, Reverse transcriptase/ribonuclease H0101
Gag-Pol polyprotein0101
Imidazoleglycerol-phosphate dehydratase0101
Ryanodine receptor 10101
Exoribonuclease H 0101
Cardiac ryanodine receptor 2 0101
Hydroxycarboxylic acid receptor 30011
Hydroxycarboxylic acid receptor 20011
Hydroxycarboxylic acid receptor 20224
Hydroxycarboxylic acid receptor 20112
Chain A, NAD-dependent deacetylase0101
NAD-dependent protein deacetylase HST20101
NAD(+) hydrolase SARM10404
NAD-dependent protein deacetylase sirtuin-60303
Equilibrative nucleoside transporter 10101
Anoctamin-10101
Neuronal acetylcholine receptor subunit alpha-40101
Acetylcholine receptor subunit beta-like 20202
Acetylcholine-binding protein0112
Neuronal acetylcholine receptor subunit beta-30112
Neuronal acetylcholine receptor subunit alpha-60112
Liver carboxylesterase B-10101
Soluble acetylcholine receptor0101
Integrin beta0011
Glycoprotein IIb0011
Voltage-dependent L-type calcium channel subunit alpha-1C0101
Voltage-dependent L-type calcium channel subunit alpha-1S0101
Voltage-dependent L-type calcium channel subunit alpha-1D0101
Voltage-dependent L-type calcium channel subunit alpha-1F0101
Voltage-dependent L-type calcium channel subunit beta-40202
Voltage-dependent P/Q-type calcium channel subunit alpha-1A0202
Voltage-dependent calcium channel gamma-3 subunit0202
Voltage-dependent L-type calcium channel subunit beta-30202
Voltage-dependent calcium channel subunit alpha-2/delta-10405
Voltage-dependent calcium channel gamma-7 subunit0202
Voltage-dependent L-type calcium channel subunit beta-10202
Voltage-dependent calcium channel gamma-1 subunit0202
Voltage-dependent L-type calcium channel subunit beta-20202
Voltage-dependent R-type calcium channel subunit alpha-1E0202
Voltage-dependent calcium channel subunit alpha-2/delta-40202
Voltage-dependent calcium channel subunit alpha-2/delta-30202
Voltage-dependent calcium channel gamma-8 subunit0202
Voltage-dependent calcium channel gamma-6 subunit0202
Voltage-dependent calcium channel subunit alpha-2/delta-20404
Voltage-dependent calcium channel gamma-4 subunit0202
Voltage-dependent calcium channel gamma-5 subunit0202
Voltage-dependent calcium channel gamma-2 subunit0202
Sodium/iodide cotransporter0101
Lysine-specific demethylase 4C0606
G-protein coupled receptor 550101
Platelet-activating factor receptor0101
Nitric oxide synthase, inducible0202
Nitric oxide synthase, brain0202
Snake venom metalloproteinase BaP10101
Nociceptin receptor0134
Chain A, Gyrase0011
DNA gyrase subunit B0101
DNA gyrase subunit B0101
Cell division inhibitor SulA0001
Heat shock protein HSP 900101
DNA topoisomerase 4 subunit B0101
DNA topoisomerase 0101
Microtubule-associated proteins 1A/1B light chain 3B0213
Microtubule-associated proteins 1A/1B light chain 3A0213
Ras-related C3 botulinum toxin substrate 10101
Chain A, G protein-coupled receptor kinase 60011
Phosphotyrosine protein phosphatase 0101
Hemagglutinin [Cleaved into: Hemagglutinin HA1 chain; Hemagglutinin HA2 chain]0011
Receptor-type tyrosine-protein phosphatase C0101
Receptor-type tyrosine-protein phosphatase alpha0202
Receptor-type tyrosine-protein phosphatase epsilon0202
M-phase inducer phosphatase 20202
Chain A, Adipocyte Lipid-binding Protein0011
Chain A, MUSCLE FATTY ACID BINDING PROTEIN0022
Chain A, MUSCLE FATTY ACID BINDING PROTEIN0022
Chain A, MUSCLE FATTY ACID BINDING PROTEIN0022
putative potassium channel subunit0011
Glutathione hydrolase 1 proenzyme 0011
Bifunctional cytochrome P450/NADPH--P450 reductase0011
Bombesin receptor subtype-30011
Interleukin-6 receptor subunit alpha0101
Thyrotropin-releasing hormone receptor0101
Glycine receptor subunit alpha-40101
Leukotriene B4 receptor 10101
Chain A, ARGINASE 10101
Chain A, Arginase 10101
Chain A, ARGINASE 10101
Chain A, L-ARGININE\\:GLYCINE AMIDINOTRANSFERASE0101
Solute carrier family 2, facilitated glucose transporter member 90224
Neuraminidase 0202
Neuraminidase 0202
Acyl-CoA desaturase 10101
Neuraminidase 0202
Neuraminidase 0202
Neuraminidase0101
Neuraminidase0101
Chain H, Igg2b-kappa 40-50 Fab (heavy Chain)0101
Chain L, Igg2b-kappa 40-50 Fab (light Chain)0101
Chain A, Na, K-ATPase alpha subunit0011
Kruppel-like factor 50101
Sodium/potassium-transporting ATPase subunit alpha-1 0101
Sodium/potassium-transporting ATPase subunit beta-30101
Protoporphyrinogen oxidase0101
Chain A, Pyruvate kinase, M2 isozyme0101
Chain A, Phosphonopyruvate hydrolase0101
Chain A, Phosphoenolpyruvate-protein phosphotransferase0101
Chain A, CITRATE SYNTHASE0011
Chain B, CITRATE SYNTHASE0011
Phosphoenolpyruvate carboxykinase, cytosolic [GTP]0101
Lysine-specific demethylase 6B0303
Prolyl 4-hydroxylase subunit alpha-10202
Peptidyl-prolyl cis-trans isomerase A 0101
Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial0101
Lysine-specific demethylase 5D0101
Lysine-specific demethylase 5B0101
Lysine-specific demethylase 3A0101
L-lactate dehydrogenase C chain0101
Malate dehydrogenase, mitochondrial0101
L-lactate dehydrogenase A chain0101
L-lactate dehydrogenase B chain0202
Malate dehydrogenase, cytoplasmic0101
L-lactate dehydrogenase B chain0101
L-lactate dehydrogenase A chain0101
L-lactate dehydrogenase0101
L-lactate dehydrogenase0101
L-lactate dehydrogenase B chain0101
L-lactate dehydrogenase0101
L-lactate dehydrogenase 0101
Complement C50011
Bifunctional epoxide hydrolase 20101
Bifunctional epoxide hydrolase 20101
MCOLN3 protein0011
transient receptor potential cation channel, subfamily N, member 10011
Alpha-1B adrenergic receptor0606
Alpha-2A adrenergic receptor0303
Microphthalmia-associated transcription factor0002
metallo beta-lactamase0101
metallo-beta-lactamase IMP-10101
Type 1 InsP3 receptor isoform S2 1001
Beta-tubulin 0101
Genome polyprotein0101
Chain A, Fatty acid-binding protein, adipocyte0101
Type II pantothenate kinase0001
Type III pantothenate kinase0001
Chain A, cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A0101
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A 0202
Photosystem I iron-sulfur center 0001
Pyrroline-5-carboxylate reductase 1, mitochondrial0101
Rhodopsin kinase GRK10101
G protein-coupled receptor kinase 50202
G protein-coupled receptor kinase 50101
Beta-adrenergic receptor kinase 10001
Transcriptional activator Myb0101
Dual specificity mitogen-activated protein kinase kinase 2 0101
Dual specificity mitogen-activated protein kinase kinase 1 0101
Beta-lactamase 10001
Protein tyrosine phosphatase type IVA 30101
Protein S100-B0112
Protein S100-B0011
Diamine acetyltransferase 10102
Protein tyrosine phosphatase type IVA 20101
Protein tyrosine phosphatase type IVA 10101
Adenosine deaminase 0101
Aldehyde oxidase 10101
Aldehyde oxidase 10101
Chain A, Immunoglobulin0011
Chain B, Immunoglobulin0011
Glutamate carboxypeptidase 20202
N-acetylated-alpha-linked acidic dipeptidase 20101
Retinoid isomerohydrolase 0101
Retinoid isomerohydrolase 0101
Retinoid isomerohydrolase0101
fMet-Leu-Phe receptor0202
Myeloblastin0101
Chain A, PROTEIN (CATECHOL OXIDASE)0101
Sodium/glucose cotransporter 10314
Sodium/glucose cotransporter 20314
Sodium/glucose cotransporter 1 0101
Sodium/glucose cotransporter 20101
Solute carrier family 5 member 40101
Protein kinase C alpha type0101
Proto-oncogene vav0011
Protein kinase C delta type0112
Chain A, Alkaline Phosphatase0101
Chain A, ALKALINE PHOSPHATASE0101
Fe(3+)-Zn(2+) purple acid phosphatase0202
Chain E, THERMOLYSIN0101
Chain E, Thermolysin0101
Neprilysin0404
Acetylcholinesterase0101
Complement C1s subcomponent0101
Ubiquitin carboxyl-terminal hydrolase 10303
WD repeat-containing protein 480303
CDGSH iron-sulfur domain-containing protein 10202
Peroxisome proliferator-activated receptor gamma0101
Carnitine O-palmitoyltransferase 2, mitochondrial0202
CDGSH iron-sulfur domain-containing protein 20202
Peroxisomal sarcosine oxidase0001
Chloride channel isoform 1 0011
Cytochrome P450 4B10202
Cytochrome P450 2A70202
Cytochrome P450 2F10202
Transcriptional enhancer factor TEF-10112
Cytochrome P450 2C180303
Cytochrome P450 4F80202
Cytochrome P450 4A110202
Cytochrome P450 4F30202
Transcriptional enhancer factor TEF-30101
Transcriptional enhancer factor TEF-40101
Cytochrome P450 4A220202
Vitamin D 25-hydroxylase0202
Cytochrome P450 2U10202
Cytochrome P450 2W10202
Cytochrome P450 2S10202
Transcriptional enhancer factor TEF-50101
Vasoactive intestinal polypeptide receptor 10101
Pituitary adenylate cyclase-activating polypeptide type I receptor0213
C-X-C chemokine receptor type 40101
Atypical chemokine receptor 30011
C-X-C chemokine receptor type 40204
Regulatory protein E20011
Regulatory protein E20011
Calcium-activated potassium channel subunit alpha-10101
Sodium/potassium/calcium exchanger 40112
Sodium/potassium/calcium exchanger 20112
Proto-oncogene tyrosine-protein kinase Src0202
Receptor protein-tyrosine kinase 0202
Caspase-80101
Beta-casein0202
luciferase0001
Glutamine synthetase0011
Pannexin-10101
Histamine H2 receptor0101
Glutamate 5-kinase0001
Nuclear receptor subfamily 2 group E member 10044
Free fatty acid receptor 20011
Thyroid peroxidase0101
Puromycin-sensitive aminopeptidase0101
Chain A, PUTRESCINE-BINDING PROTEIN0011
Chain A, S-ADENOSYLMETHIONINE DECARBOXYLASE ALPHA CHAIN0101
Chain B, S-ADENOSYLMETHIONINE DECARBOXYLASE BETA CHAIN0101
Chain A, S-ADENOSYLMETHIONINE DECARBOXYLASE ALPHA CHAIN0101
Chain B, S-ADENOSYLMETHIONINE DECARBOXYLASE BETA CHAIN0101
S-adenosylmethionine decarboxylase proenzyme0001
tyrosine-protein phosphatase non-receptor type 22 isoform 10101
Bifunctional dihydrofolate reductase-thymidylate synthase0101
Beta-hexosaminidase subunit alpha0102
Beta-hexosaminidase subunit beta0101
Dihydrofolate reductase0202
Bifunctional dihydrofolate reductase-thymidylate synthase0202
Bifunctional dihydrofolate reductase-thymidylate synthase0202
Multidrug and toxin extrusion protein 10101
Cytidine deaminase0101
5-lipoxygenase 0101
Thyrotropin releasing hormone degrading enzyme0101
Chain A, dATP pyrophosphohydrolase0101
Chain A, Adenylate cyclase type 50101
Chain B, Adenylate cyclase type 20101
Monocarboxylate transporter 20002
C-terminal-binding protein 20101
Chain A, APH(2')-Id0101
glucose-6-phosphate dehydrogenase0101
Chymotrypsin-like elastase family member 10101
Epoxide hydrolase 1 0101
Malate dehydrogenase0404
Solute carrier family 2, facilitated glucose transporter member 20101
Solute carrier family 2, facilitated glucose transporter member 4 0101
Aldo-keto reductase family 1 member A10202
Aldo-keto reductase family 1 member A10202
Oligo-1,6-glucosidase IMA10101
Aldo-keto reductase family 1 member B10101
Heat shock factor protein 10101
ELAV-like protein 10101
Probable maltase-glucoamylase 20101
Aldo-keto reductase family 1 member C210202
N0101
DNA-directed RNA polymerase subunit alpha0101
DNA-directed RNA polymerase subunit omega0101
DNA-directed RNA polymerase subunit beta'0101
DNA-directed RNA polymerase subunit beta0101
Multidrug resistance protein 1a0001
Advanced glycosylation end product-specific receptor0011
Advanced glycosylation end product-specific receptor0011
Dihydroorotate dehydrogenase 0202
Carbon monoxide dehydrogenase small chain0011
Dual specificity protein phosphatase 10101
Dual specificity protein phosphatase 60101
Dipeptidyl peptidase 40011
Chain A, Glutamate Receptor 20101
Chain A, Glutamate Receptor 20101
Prolyl 4-hydroxylase, beta polypeptide0001
Gastric inhibitory polypeptide receptor0101
Voltage-gated sodium channel Nav1.5 cardiac isoform 0101
Vascular endothelial growth factor receptor 30202
Vascular endothelial growth factor receptor 20202
Chromaffin granule amine transporter0101
Synaptic vesicular amine transporter0202
Chain A, Troponin C, slow skeletal and cardiac muscles0011
Aryl hydrocarbon receptor0101
N1L 0101
NAD(P)H dehydrogenase [quinone] 10003
Chain A, PLASMA RETINOL-BINDING PROTEIN PRECURSOR0011
Retinol-binding protein 40011
Beta-lactoglobulin0011
DNA (cytosine-5)-methyltransferase 3B0202
NS5 0134
Polymerase basic protein 20011
RNA-directed RNA polymerase catalytic subunit0011
Genome polyprotein0011
Chain A, 6,7-Dimethyl-8-ribityllumazine Synthase0011
Chain B, 6,7-Dimethyl-8-ribityllumazine Synthase0011
Chain H, Immunoglobulin Igg1 Heavy chain0011
Chain L, Immunoglobulin Igg1 Lambda Light Chain0011
Chain A, DODECIN0011
Chain A, DODECIN0011
Chain C, DODECIN0011
Chain E, DODECIN0011
DNA-directed RNA polymerase subunit beta0101
NH(3)-dependent NAD(+) synthetase0202
DNA-directed RNA polymerase subunit beta0101
Scavenger receptor class B member 10101
Diacylglycerol kinase alpha0101
Chain A, HIV-1 PROTEASE0101
Chain B, HIV-1 PROTEASE0101
Chain A, Endothiapepsin0101
Chain A, Endothiapepsin0101
Acetylcholine receptor subunit epsilon0101
Cholinesterase0101
Prostaglandin G/H synthase 20101
Cytochrome c oxidase subunit 10101
Transporter0101
Sodium-dependent serotonin transporter0101
Retina-specific copper amine oxidase0202
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B0202
Phosphodiesterase 0101
Thrombin 0011
Transcription factor AP-10202
UDP-galactopyranose mutase0011
UDP-galactopyranose mutase0011
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial0101
Dihydroorotate dehydrogenase (fumarate)0101
Acyl carrier protein, mitochondrial0101
Dihydroorotate dehydrogenase 0303
Eukaryotic elongation factor 2 kinase0101
M-phase inducer phosphatase 10202
Receptor-type tyrosine-protein phosphatase eta0101
RuvB-like 10202
Neuromedin-U receptor 20011
Chain A, CARBONIC ANHYDRASE II (CA II)0101
Chain A, ADENINE-N6-DNA-METHYLTRANSFERASE TAQI0011
Chain A, Adenine-n6-dna-methyltransferase Taqi0011
Chain A, Histamine N-Methyltransferase0101
Chain A, Histamine N-Methyltransferase0101
Chain A, Modification Methylase Rsri0011
Chain A, Modification Methylase Rsri0011
Chain A, Ermc' Methyltransferase0101
Chain A, Ermc' Rrna Methyltransferase0101
Chain A, Uroporphyrin-III C-methyltransferase0101
Chain B, ADENINE-N6-DNA-METHYLTRANSFERASE TAQI0011
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase0011
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase0011
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase0011
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase0011
tRNA (cytosine(38)-C(5))-methyltransferase0112
Histone-lysine N-methyltransferase SUV39H10202
Adenosylhomocysteinase0001
Protein arginine N-methyltransferase 30101
Indolethylamine N-methyltransferase0101
Histone-lysine N-methyltransferase NSD20101
Adenosylhomocysteinase0001
rRNA adenine N-6-methyltransferase0101
tRNA (guanine-N(1)-)-methyltransferase0011
Histone-lysine N-methyltransferase SETDB10101
Retinoblastoma-binding protein 50101
tRNA (guanine-N(1)-)-methyltransferase0011
N6-adenosine-methyltransferase catalytic subunit0101
Histone-arginine methyltransferase CARM10101
Histone-lysine N-methyltransferase KMT5C0101
Histone-lysine N-methyltransferase EZH10101
Methylosome protein 500112
Protein dpy-30 homolog0101
Histamine N-methyltransferase0001
Histone-lysine N-methyltransferase SUV39H20101
tRNA (guanine-N(1)-)-methyltransferase0011
N-lysine methyltransferase SMYD20101
Protein arginine N-methyltransferase 70101
Set1/Ash2 histone methyltransferase complex subunit ASH20101
Met repressor 0022
Histone H3K27 methylase0001
Protein-L-isoaspartate(D-aspartate) O-methyltransferase0101
Catechol O-methyltransferase0001
Aspartate-semialdehyde dehydrogenase0101
RmtA0101
Chain A, Lysr-type Regulatory Protein0011
Chain A, Lysr-type Regulatory Protein0011
Chain A, Lysr-type Regulatory Protein0011
Chain A, 146aa long hypothetical transcriptional regulator0011
Chain A, Anthranilate phosphoribosyltransferase0101
Chain A, Anthranilate phosphoribosyltransferase0101
Chain A, Anthranilate phosphoribosyltransferase0101
Chain B, Anthranilate phosphoribosyltransferase0101
Chain C, Anthranilate phosphoribosyltransferase0101
Chain A, Anthranilate phosphoribosyltransferase0101
Anthranilate phosphoribosyltransferase0101
Tyrosine-protein phosphatase YopH0101
Ubiquitin-like domain-containing CTD phosphatase 10101
Bromodomain testis-specific protein0101
Tau-tubulin kinase 10101
Tau-tubulin kinase 20101
Chain A, Erk20101
Mitogen-activated protein kinase 20101
Mitogen-activated protein kinase 14 0112
5-hydroxytryptamine receptor 1D0101
Transient receptor potential cation channel subfamily M member 10101
Transforming growth factor beta-1 proprotein0101
Mothers against decapentaplegic homolog 3 0101
Adenosine receptor A30101
Collagenase ColH0101
Chain A, Porphobilinogen Synthase0101
Chain A, Porphobilinogen Synthase0101
Chain A, Porphobilinogen Synthase0101
Type-1 angiotensin II receptor0101
Chain A, Shikimate kinase0011
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferase0101
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferase0101
photoreceptor-specific nuclear receptor0101
Cholecystokinin receptor type A0101
Eukaryotic translation initiation factor 4E0011
Peptidyl-prolyl cis-trans isomerase FKBP1A0101
Peptidyl-prolyl cis-trans isomerase FKBP1B0022
Programmed cell death protein 40112
epidermal growth factor receptor isoform a precursor0101
Laccase 0101
Somatostatin receptor type 50101
Somatostatin receptor type 10101
Somatostatin receptor type 20101
Somatostatin receptor type 30101
Somatostatin receptor type 50101
Somatostatin receptor type 4 0101
Chain A, Mitogen-activated protein kinase 140011
Chain A, Mitogen-activated protein kinase 140011
Chain A, Mitogen-activated protein kinase 140011
Chain A, Mitogen-activated protein kinase 140011
Chain A, Mitogen-activated protein kinase 140011
Chain A, Mitogen-activated protein kinase 140011
Chain A, Mitogen-activated protein kinase 140011
Tyrosine-protein kinase ABL10101
Platelet-derived growth factor receptor beta0202
Cyclin-C0112
Vascular endothelial growth factor receptor 20101
RuvB-like 20112
Sulfate anion transporter 10001
C-X-C chemokine receptor type 5 isoform 10101
C-C chemokine receptor type 60101
Endoglycoceramidase II 0001
alternatively spliced Trp40011
5-hydroxytryptamine receptor 1E0101
sphingosine 1-phosphate receptor 30101
D(3) dopamine receptor0101
5-hydroxytryptamine receptor 7 0101
D(4) dopamine receptor0101
D(1B) dopamine receptor0101
Chain A, Mineralocorticoid receptor0101
Chain A, Mineralocorticoid receptor0101
Nuclear receptor subfamily 1 group D member 10011
Cathepsin B0101
Chain A, Ribosomal protein S6 kinase alpha-10101
Chain X, Tyrosine-protein kinase Lyn0101
Chain A, Dual specificity protein kinase TTK0011
Chain A, Dual specificity protein kinase TTK0011
Zinc finger protein GLI20101
Thymidine kinase, cytosolic 0104
Glycine receptor subunit beta0101
Mast/stem cell growth factor receptor Kit0101
Platelet-derived growth factor receptor alpha 0101
Serine/threonine-protein kinase ULK30011
Bromodomain-containing protein 90011
Serine/threonine-protein kinase 30011
Bromodomain-containing protein 70011
Solute carrier family 13 member 30101
Chain A, MALTOPORIN0011
Chain B, MALTOPORIN0011
Metallo-beta-lactamase type 20202
ATP-dependent 6-phosphofructokinase0101
Dihydropteroate synthase0101
Protein argonaute-20022
Chain A, Glutathione S-transferase0101
Fibroblast growth factor 10011
D(2) dopamine receptor0101
Chain A, Carbonic anhydrase 20101
Carboxypeptidase M0101
5-hydroxytryptamine receptor 1B0101
Chain A, ACETYLCHOLINESTERASE0101
Chain A, liver Carboxylesterase I0101
Gastrotropin0011
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform0202
Splicing factor 3B subunit 30101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D0101
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B0101
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4B0101
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase0101
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase0101
cGMP-specific 3',5'-cyclic phosphodiesterase0123
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma0101
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha0101
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'0101
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma0101
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta0101
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta0101
Chain A, CES1 protein0101
Lysosomal acid glucosylceramidase0011
Phospholipase D1 0101
Phospholipase D10101
Emopamil-binding protein-like0202
7-dehydrocholesterol reductase0112
Corticotropin releasing hormone receptor 20101
Lysine-specific demethylase 4B0101
ATP-dependent molecular chaperone HSC820101
Heat-shock protein0101
Putative heat shock protein HSP 90-alpha A40101
Chain A, Prostatic Acid Phosphatase0101
Metallo-beta-lactamase L1 type 30101
Beta-lactamase 0101
NS3 protease 0203
Cathepsin L20101
Cathepsin S0102
NS3 protease 0101
Cathepsin F0101
Chymotrypsin-like elastase family member 10101
Peroxisome proliferator-activated receptor delta0011
Indoleamine 2,3-dioxygenase 20101
Stromal interaction molecule 10101
cGMP-gated cation channel alpha-10011
Tetracycline resistance protein, class B0001
Neutrophil collagenase0202
Ras guanyl-releasing protein 30011
Solute carrier family 22 member 30001
Solute carrier family 22 member 40001
Sodium channel protein type 11 subunit alpha0101
Sodium channel protein type 5 subunit alpha0101
Sodium channel protein type 8 subunit alpha0101
DNA-binding protein Ikaros0001
DNA damage-binding protein 10112
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 0101
Chain A, ykoF0011
Chain B, ykoF0011
Chain A, ThiT0011
Thiamine transporter ThiT0011
Transketolase0011
Thiamine-binding periplasmic protein0011
1-deoxy-D-xylulose-5-phosphate synthase0011
1-deoxy-D-xylulose-5-phosphate synthase0011
neurotensin receptor type 10011
Mucosa-associated lymphoid tissue lymphoma translocation protein 10101
Neprilysin0101
Urease subunit alpha0101
Urease subunit beta 0101
E3 ubiquitin-protein ligase Mdm2 isoform a0011
Thymidine phosphorylase0001
Thymidine kinase 0204
Thymidine kinase0103
Thymidine phosphorylase0101
Chain A, ODORANT-BINDING PROTEIN0101
Chain A, ODORANT-BINDING PROTEIN0101
Chain B, Odorant-binding Protein0101
Chain A, ODORANT-BINDING PROTEIN0101
Chain A, ODORANT-BINDING PROTEIN0101
Chain A, ODORANT-BINDING PROTEIN0101
Chain X, Thyroid hormone receptor beta-10022
Chain X, Thyroid hormone receptor beta-10022
Proliferating cell nuclear antigen0202
Malate dehydrogenase, mitochondrial0101
Monocarboxylate transporter 80001
Solute carrier organic anion transporter family member 1C10001
Chain A, Carbonic anhydrase 10101
Carbonic anhydrase 20101
Acrosin0101
Chain A, RIO-type serine/threonine-protein kinase Rio10011
REST corepressor 30202
Chain A, X-ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp.PCC6803 in complex with trehalose0101
Chain A, X-ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp.PCC6803 in complex with cellobiose0101
Chain A, X-ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp.PCC6803 in complex with maltose0101
Trehalose-phosphatase0101
Chain A, Nuclear Receptor ROR-beta0101
Nuclear receptor ROR-alpha0101
Nuclear receptor ROR-beta0101
Chain A, PAPAIN1001
Thialysine N-epsilon-acetyltransferase0001
Solute carrier organic anion transporter family member 4A10001
Chain A, Dihydrofolate Reductase0011
Chain A, Dihydrofolate reductase0101
Chain A, dihydrofolate reductase (DHFR)0101
Chain A, Dihydrofolate reductase0101
Chain A, Dihydrofolate reductase0101
Dihydrofolate reductase 0102
Dihydrofolate reductase type 10102
Dihydrofolate reductase0101
Dihydrofolate reductase0101
Dihydrofolate reductase type 1 from Tn40030101
Bifunctional dihydrofolate reductase-thymidylate synthase0101
Dihydrofolate reductase0101
Dihydrofolate reductase0101
Dihydrofolate reductase 0101
Dihydrofolate reductase 0101
Chain A, CARBONIC ANHYDRASE II0101
5-hydroxytryptamine receptor 4 0001
Strictosidine synthase0001
Chain A, Trp Rna-binding Attenuation Protein0011
Chain K, Trp Rna-binding Attenuation Protein0011
Chain B, tryptophanyl-tRNA synthetase0011
Chain C, Tryptophanyl-tRNA synthetase II0011
Tryprostatin B synthase0001
Chain A, Purine nucleoside phosphorylase0101
Chain A, Purine nucleoside phosphorylase DeoD-type0101
MSH0001
Chain A, CHORISMATE MUTASE0101
Chain A, TYROSYL-tRNA SYNTHETASE0011
Chain A, Glutamate Receptor, Ionotropic Kainate 10011
Chain A, Glutamate Receptor, Ionotropic Kainate 10011
Cadherin-10101
Adenomatous polyposis coli protein0101
Catenin beta-10202
Transcription factor 7-like 20101
Chain A, Uracil-DNA Glycosylase0101
Coagulation factor XIII A chain0101
Fatty-acid amide hydrolase 20101
Monoglyceride lipase0101
CAD protein0001
Chain A, Cytidine Deaminase0101
P2Y purinoceptor 140011
Chain A, orotidine 5'-monophosphate decarboxylase0101
Chain B, orotidine 5'-monophosphate decarboxylase0101
Chain A, orotidine 5'-monophosphate decarboxylase0101
Chain A, orotidine monophosphate decarboxylase0101
Chain A, orotidine monophosphate decarboxylase0101
Chain B, orotidine monophosphate decarboxylase0101
Chain B, PyrR bifunctional protein0011
Uridine 5'-monophosphate synthase0101
Orotidine 5'-phosphate decarboxylase 0101
P2Y purinoceptor 40011
N-acetyllactosaminide alpha-1,3-galactosyltransferase0101
P2Y purinoceptor 2 0112
P2Y purinoceptor 20011
P2Y purinoceptor 40011
Ubiquitin carboxyl-terminal hydrolase 20101
Basic phospholipase A2 10101
Hemagglutinin0011
Basic phospholipase A2 PLA-A0101
Acidic phospholipase A2 EC-I0101
Ubiquitin carboxyl-terminal hydrolase 70101
Ubiquitin carboxyl-terminal hydrolase 470101
Sentrin-specific protease 10101
Valacyclovir hydrolase0001
Chain A, Arginase 10101
HD2 type histone deacetylase HDA106 0303
Aldo-keto reductase family 1 member A10101
Aldo-keto reductase family 1 member B70101
D-alanyl-D-alanine dipeptidase0101
Protein mono-ADP-ribosyltransferase PARP140101
Protein mono-ADP-ribosyltransferase PARP100112
Protein mono-ADP-ribosyltransferase PARP160011
Protein mono-ADP-ribosyltransferase PARP120101
Poly [ADP-ribose] polymerase 20224
Protein mono-ADP-ribosyltransferase PARP40112
Protein mono-ADP-ribosyltransferase PARP30123
Glycoprotein0101
Catechol O-methyltransferase0101
Adenosylhomocysteinase0101
Sterol 14-alpha-demethylase0011
14-alpha sterol demethylase 0011
14-alpha sterol demethylase 0011
Chain A, Histone deacetylase-like amidohydrolase0101
Chain A, Histone deacetylase-like amidohydrolase0101
Histone deacetylase 80101
Histone deacetylase 0101
Gli10101
protein Wnt-3a precursor0101
Histone deacetylase 10202
Protein Tat0011
Leukotriene A-4 hydrolase0101
Apoptosis regulator BAX 0011
Histone deacetylase 10101
Histone deacetylase 0101
Renin0101
Histone deacetylase 30101
Histone deacetylase-like amidohydrolase0213
Histone deacetylase 0101
Histone deacetylase 70101
Histone deacetylase 6 0101
Histone deacetylase 40101
Histone deacetylase 0101
Histone deacetylase 60101
Histone deacetylase 0101
metabotropic glutamate receptor 5 precursor0101
Vitamin K epoxide reductase complex subunit 1-like protein 10101
Vitamin K epoxide reductase complex subunit 10101
Vitamin K epoxide reductase complex subunit 1-like protein 10101
Vitamin K epoxide reductase complex subunit 1 0202
Protein-serine O-palmitoleoyltransferase porcupine0101
cGMP-specific 3',5'-cyclic phosphodiesterase0101
Alkaline phosphatase, tissue-nonspecific isozyme 0101
Ectonucleoside triphosphate diphosphohydrolase 10001
twin arginine protein translocation system - TatA protein0001
Chain A, Human Adenosine A2A receptor/T4 lysozyme chimera0011
Chain A, Adenosine receptor A2a0011
Chain A, Adenosine receptor A2a0011
Hexokinase-40101
Butyrophilin subfamily 3 member A10012
Farnesyl diphosphate synthase0101
Geranylgeranyl pyrophosphate synthase0202
H0101
Amine oxidase [flavin-containing]0101
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]